[
{
"trial": {
"nct": "NCT00223080",
"brief_title": "HIV Vaccine Trial in Thai Adults",
"official_title": "A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults",
"conditions": [
"HIV Infection"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"18 Years",
"30 Years"
],
"arms": [
{
"label": "Vaccine",
"type": "ACTIVE_COMPARATOR",
"description": "ALVAC-HIV vCP1521 + AIDSVAX will both be administered by the intramuscular route (preferably in the deltoid region) on weeks 0, 4, 12, and 24.",
"interventions": [
"Biological: ALVAC-HIV vCP1521 + AIDSVAX"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "ALVAC Placebo + AIDSVAX Placebo will be administered at week 12 and 24. ALVAC Placebo only was additionally administered at week 0 and 4.",
"interventions": [
"Other: ALVAC Placebo + AIDSVAX Placebo"
]
}
],
"interventions": [
{
"name": "ALVAC-HIV vCP1521 + AIDSVAX",
"type": "BIOLOGICAL",
"description": "Combined dose of 600 \u03bcg (300 \u03bcg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 \u03bcg/mL",
"other_names": [
"ALVAC-HIV (vCP1521) >106 CCID50 per 1 mL dose",
"AIDSVAX\u00ae B/E",
"Bivalent HIV gp120 vaccine subtype B (MN), and E (A244)"
]
},
{
"name": "ALVAC Placebo + AIDSVAX Placebo",
"type": "OTHER",
"description": "ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection",
"other_names": [
"ALVAC carrier lyophilized product without virus",
"Aluminum hydroxide adjuvant"
]
}
],
"ae_time_frame": "For serious adverse events - anytime after the first vaccination until final follow-up at week 184. For other adverse events - total post-injection reaction severity",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Vaccine",
"description": "ALVAC-HIV vCP1521 + AIDSVAX will both be administered by the intramuscular route (preferably in the deltoid region) on weeks 0, 4, 12, and 24. ALVAC-HIV vCP1521 + AIDSVAX: Combined dose of 600 \u03bcg (300 \u03bcg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 \u03bcg/mL"
},
{
"id": "EG001",
"title": "Placebo",
"description": "ALVAC Placebo + AIDSVAX Placebo will be administered at week 12 and 24. ALVAC Placebo only was additionally administered at week 0 and 4. ALVAC Placebo + AIDSVAX Placebo: ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection"
}
]
},
"coder_1": {
"nct": "NCT00223080",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ALVAC-HIV (canarypox vector) prime plus AIDSVAX B/E gp120 in aluminium hydroxide; placebo was ALVAC carrier without virus plus aluminium hydroxide."
},
"coder_2": {
"nct": "NCT00223080",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ALVAC prime, AIDSVAX gp120 boost in aluminium hydroxide; placebo is ALVAC carrier without virus and without aluminium hydroxide"
}
},
{
"trial": {
"nct": "NCT00224484",
"brief_title": "Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old",
"official_title": "A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2-AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.",
"conditions": [
"Herpes Simplex"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"10 Years",
"17 Years"
],
"arms": [
{
"label": "GD2-AS04 GROUP",
"type": "EXPERIMENTAL",
"description": "Female subjects aged 10-17 years, who received 3 doses of gD2-AS04 vaccine, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.",
"interventions": [
"Biological: GSK208141"
]
},
{
"label": "HAVRIX GROUP",
"type": "ACTIVE_COMPARATOR",
"description": "Female subjects aged 10-17 years, who received 3 doses of Havrix, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.",
"interventions": [
"Biological: Havrix (investigational formulation)"
]
},
{
"label": "SALINE GROUP",
"type": "PLACEBO_COMPARATOR",
"description": "Female subjects aged 10-17 years, who received 3 doses of a saline solution, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "GSK208141",
"type": "BIOLOGICAL",
"description": "3 intramuscular doses",
"other_names": [
"Herpes simplex vaccine",
"gD2-AS04 vaccine"
]
},
{
"name": "Havrix (investigational formulation)",
"type": "BIOLOGICAL",
"description": "3 intramuscular doses",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "3 intramuscular doses",
"other_names": []
}
],
"ae_time_frame": "Serious Adverse Events: -Group GD2-AS04, Group Havrix and Group Saline: during the active study period (Month 0 - 12). -GD2-AS04 (ESFU) Group and Pooled Group: during the combined active study period and the ESFU period (Month 0 - 18). Other Adverse Events: -Solicited local/general symptoms: during  [\u2026]",
"ae_description": "The solicited local and general symptoms were only collected for those subjects who filled in their symptom sheets. Other Adverse Events were not collected during the ESFU period, hence resulting in zero participants at risk for GD2-AS04 (ESFU) Group and Pooled Group.",
"ae_groups": [
{
"id": "EG000",
"title": "Group GD2-AS04",
"description": "Female subjects aged 10-17 years, who received 3 doses of gD2-AS04 vaccine, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."
},
{
"id": "EG001",
"title": "Group Havrix",
"description": "Female subjects aged 10-17 years, who received 3 doses of Havrix\u2122 vaccine, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."
},
{
"id": "EG002",
"title": "Group Saline",
"description": "Female subjects aged 10-17 years, who received 3 doses of a saline solution, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."
},
{
"id": "EG003",
"title": "GD2-AS04 (ESFU) Group",
"description": "Female subjects aged 10-17 years, who received 3 doses of gD2-AS04 vaccine, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule."
},
{
"id": "EG004",
"title": "Pooled Group",
"description": "Pooled group of subjects 10-17 years of age from Havrix and Saline groups, included in the Extended Safety Follow Up (ESFU) period."
}
]
},
"coder_1": {
"nct": "NCT00224484",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"herpes_simplex",
"hepatitis_a"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "gD2-AS04 (EG000) and Havrix (EG001, the trial's active control) each against saline (EG002); left out EG003 (same gD2 participants in extended follow-up) and EG004 (pools Havrix and saline)."
},
"coder_2": {
"nct": "NCT00224484",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"herpes_simplex"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "gD2-AS04 vs saline, active study period; Havrix group left out (active control); ESFU groups left out (EG004 pools Havrix and saline participants)"
}
},
{
"trial": {
"nct": "NCT00303069",
"brief_title": "V710 First-In-Man (FIM) Study (V710-001)",
"official_title": "A Sequential-Panel, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine in Healthy Adults 18 to 55 Years of Age",
"conditions": [
"Staphylococcal Infections"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"18 Years",
"55 Years"
],
"arms": [
{
"label": "V710 5 \u03bcg",
"type": "EXPERIMENTAL",
"description": "V710 S. aureus vaccine",
"interventions": [
"Biological: V710"
]
},
{
"label": "V710 30 \u03bcg",
"type": "EXPERIMENTAL",
"description": "V710 S. aureus vaccine",
"interventions": [
"Biological: V710"
]
},
{
"label": "V710 90 \u03bcg",
"type": "EXPERIMENTAL",
"description": "V710 S. aureus vaccine",
"interventions": [
"Biological: V710"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Placebo",
"interventions": [
"Biological: Comparator: Placebo"
]
}
],
"interventions": [
{
"name": "V710",
"type": "BIOLOGICAL",
"description": "Single dose of V710 (at dosages of 5 \u03bcg, 30 \u03bcg, or 90 \u03bcg) intramuscularly",
"other_names": []
},
{
"name": "Comparator: Placebo",
"type": "BIOLOGICAL",
"description": "Single dose of saline placebo intramuscularly",
"other_names": []
}
],
"ae_time_frame": "Following vaccination, all subjects in this study were followed for all clinical adverse experiences for 14 days postvaccination, and for vaccine-related serious adverse experiences and deaths for 84 days postvaccination (entire duration of the study).",
"ae_description": "Specific systemic AEs: fatigue, headache, myalgia, and nausea for 14 days (D) postvaccination (PV). Injection-site AEs including maximum intensity/size for 5D PV. Elevated body temperatures for 5D PV. Subjects in Panel A (N=36) were actively followed for laboratory (lab) AEs for 7D PV. Any lab abnor [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "V710 5 \u03bcg",
"description": "V710 5 \u03bcg single dose at baseline."
},
{
"id": "EG001",
"title": "V710 30 \u03bcg",
"description": "V710 30 \u03bcg single dose at baseline."
},
{
"id": "EG002",
"title": "V710 90 \u03bcg",
"description": "V710 90 \u03bcg single dose at baseline."
},
{
"id": "EG003",
"title": "Placebo",
"description": "Saline placebo single dose at baseline."
}
]
},
"coder_1": {
"nct": "NCT00303069",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled V710 doses against saline; V710 (IsdB protein) is formulated on Merck's aluminium adjuvant."
},
"coder_2": {
"nct": "NCT00303069",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V710 recombinant protein; adjuvant not stated in record"
}
},
{
"trial": {
"nct": "NCT00339040",
"brief_title": "Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children",
"official_title": "Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age",
"conditions": [
"HIV Infections",
"Sexually Transmitted Diseases"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"7 Years",
"12 Years"
],
"arms": [
{
"label": "Arm A: QHPV",
"type": "ACTIVE_COMPARATOR",
"description": "QHPV at week 0, 8, 24, 96.",
"interventions": [
"Biological: Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)"
]
},
{
"label": "Arm B: Placebo/QHPV",
"type": "OTHER",
"description": "Placebo at week 0, 8, 24; QHPV at week 96, 104, 120.",
"interventions": [
"Other: Placebo/QHPV"
]
}
],
"interventions": [
{
"name": "Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)",
"type": "BIOLOGICAL",
"description": "QHPV at week 0, 8, 24 and 96.",
"other_names": [
"QHPV"
]
},
{
"name": "Placebo/QHPV",
"type": "OTHER",
"description": "Placebo at week 0, 8, 24 and QHPV at week 96, 104, 120.",
"other_names": []
}
],
"ae_time_frame": "Adverse events were reported from the time when participants started to receive study treatment until study completion and before August 10, 2009 (primary completion date).",
"ae_description": "Expedited adverse event (AE) reporting followed Intensive Division of AIDS (DAIDS) Reporting Level, which included AEs resulting in death, congenital anomalies, fetal losses, significant disabilities, requiring hospitalization, and \\>=grade 3 AEs defined by the \"DAIDS Table for Grading the Severity  [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "Arm A QHPV",
"description": "Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96."
},
{
"id": "EG001",
"title": "Arm B Placebo/QHPV",
"description": "Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120."
}
]
},
"coder_1": {
"nct": "NCT00339040",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Placebo arm crossed over to QHPV at week 96 and the AE groups run to study completion; no group covers only the placebo-controlled period."
},
"coder_2": {
"nct": "NCT00339040",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HIV-infected children; arm B got open-label QHPV from week 96, and tables do not split periods, so groups may include post-crossover events"
}
},
{
"trial": {
"nct": "NCT00382408",
"brief_title": "A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001",
"official_title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001",
"conditions": [
"Respiratory Tract Diseases"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"17 Years",
null
],
"arms": [
{
"label": "Vaccine",
"type": "EXPERIMENTAL",
"description": "Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).",
"interventions": [
"Biological: DR-5001"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).",
"interventions": [
"Other: Placebo"
]
}
],
"interventions": [
{
"name": "DR-5001",
"type": "BIOLOGICAL",
"description": "All randomized subjects received a single tablet of both Type-4 and Type-7 ADV vaccines on Day 0. Both vaccine tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "All randomized subjects received a single tablet each of the placebos matching Type-4 and Type-7 ADV vaccines on Day 0. Both placebo tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.",
"other_names": []
}
],
"ae_time_frame": "Day 0 (vaccination day) - Day 56",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Placebo",
"description": "Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."
},
{
"id": "EG001",
"title": "Vaccine",
"description": "Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."
}
]
},
"coder_1": {
"nct": "NCT00382408",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target is adenovirus types 4 and 7 (other). Oral live adenovirus 4/7 tablets (live replicating, enteric; coded live_attenuated as the nearest live-vaccine category). Placebo tablets, composition not given."
},
"coder_2": {
"nct": "NCT00382408",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Oral enteric tablets of live adenovirus types 4 and 7 (not attenuated); target adenovirus respiratory disease."
}
},
{
"trial": {
"nct": "NCT00437021",
"brief_title": "MVA Post-Event: Administration Timing and Boost Study",
"official_title": "Evaluation of IMVAMUNE\u00ae Smallpox Vaccine With Respect to Safety and Optimization of Immune Responses by Different Vaccination Regimens in Vaccinia-Na\u00efve Adults",
"conditions": [
"Smallpox"
],
"phases": [
"PHASE1",
"PHASE2"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"18 Years",
"38 Years"
],
"arms": [
{
"label": "Group A",
"type": "EXPERIMENTAL",
"description": "Standard dose IMVAMUNE\u00ae vaccine or placebo on Days 0 and 7.",
"interventions": [
"Biological: MVA Smallpox Vaccine",
"Other: Placebo"
]
},
{
"label": "Group B",
"type": "EXPERIMENTAL",
"description": "Standard dose IMVAMUNE\u00ae vaccine or placebo on Days 0 and 28.",
"interventions": [
"Biological: MVA Smallpox Vaccine",
"Other: Placebo"
]
},
{
"label": "Group C",
"type": "ACTIVE_COMPARATOR",
"description": "Dryvax\u00ae vaccine or placebo on Day 0. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.",
"interventions": [
"Biological: Live vaccinia virus vaccine",
"Other: Placebo"
]
},
{
"label": "Group D",
"type": "EXPERIMENTAL",
"description": "Standard dose IMVAMUNE\u00ae vaccine or placebo on Day 0 and Dryvax\u00ae vaccine or placebo on Day 7. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.",
"interventions": [
"Biological: Live vaccinia virus vaccine",
"Biological: MVA Smallpox Vaccine",
"Other: Placebo"
]
},
{
"label": "Group E",
"type": "EXPERIMENTAL",
"description": "Dryvax\u00ae vaccine and standard dose IMVAMUNE\u00ae vaccine or 2 placebos on Day 0. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.",
"interventions": [
"Biological: Live vaccinia virus vaccine",
"Biological: MVA Smallpox Vaccine",
"Other: Placebo"
]
},
{
"label": "Group F",
"type": "EXPERIMENTAL",
"description": "Standard dose IMVAMUNE\u00ae vaccine or placebo on Day 0.",
"interventions": [
"Biological: MVA Smallpox Vaccine",
"Other: Placebo"
]
}
],
"interventions": [
{
"name": "Live vaccinia virus vaccine",
"type": "BIOLOGICAL",
"description": "Dryvax\u00ae Vaccinia Vaccine (\\~10\\^5 \\[plaque forming units (pfu)/dose\\] given via scarification, titer 10\\^8 pfu per mL after reconstitution).",
"other_names": []
},
{
"name": "MVA Smallpox Vaccine",
"type": "BIOLOGICAL",
"description": "IMVAMUNE\u00ae Vaccinia Vaccine delivered by subcutaneous (SC) route at titer 1X10\\^8 Tissue Culture Infections Dose50 per 0.5 mL dose.",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "0.9 percent (weight/volume) sodium chloride injection, United States Pharmacopeia \\[Sterile Saline Placebo (SSP)\\].",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "Physiologic normal saline for injection.",
"other_names": []
}
],
"ae_time_frame": "AEs collected include solicited AEs, unsolicited AEs, and SAEs. Solicited AEs were collected daily for 15 days post each vaccination. Unsolicited AEs were collected from the first vaccination through 28 days after the last vaccination. SAEs were collected from the first vaccination to study completi [\u2026]",
"ae_description": "Participants were analyzed \"as treated\" according to the study product they received. One participant enrolled in Group B was randomized to Placebo B but was actually administered two doses IMVAMUNE on Days 0 and 28. For AE results, this participant is counted among those at risk in Group B: Two Dos [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "Group A: Two Doses IMVAMUNE, Days 0, 7",
"description": "Standard dose IMVAMUNE\u00ae vaccine on Days 0 and 7."
},
{
"id": "EG001",
"title": "Group B: Two Doses IMVAMUNE, Days 0, 28",
"description": "Standard dose IMVAMUNE\u00ae vaccine on Days 0 and 28."
},
{
"id": "EG002",
"title": "Group C: One Dose Dryvax, Day 0",
"description": "Dryvax\u00ae vaccine on Day 0. This arm was discontinued from original protocol. Participants already enrolled in this group continued follow-up per protocol."
},
{
"id": "EG003",
"title": "Group D: IMVAMUNE, Day 0 + Dryvax, Day 7",
"description": "Standard dose IMVAMUNE\u00ae vaccine on Day 0 and Dryvax\u00ae vaccine on Day 7. This arm was discontinued from original protocol. Participants already enrolled in this group continued follow-up per protocol."
},
{
"id": "EG004",
"title": "Group E: IMVAMUNE + Dryvax, Day 0",
"description": "Dryvax\u00ae vaccine and standard dose IMVAMUNE\u00ae vaccine on Day 0. This arm was discontinued from original protocol. Participants already enrolled in this group continued follow-up per protocol."
},
{
"id": "EG005",
"title": "Group F: IMVAMUNE, Day 0",
"description": "Standard dose IMVAMUNE\u00ae vaccine on Day 0."
},
{
"id": "EG006",
"title": "Placebo A",
"description": "Placebo participants from Group A. Placebo administered corresponding to method for active drug administration in Group A."
},
{
"id": "EG007",
"title": "Placebo B",
"description": "Placebo participants from Group B. Placebo administered corresponding to method for active drug administration in Group B."
},
{
"id": "EG008",
"title": "Placebo D",
"description": "Placebo participants from Group D. Placebo administered corresponding to method for active drug administration in Group D."
},
{
"id": "EG009",
"title": "Placebo E",
"description": "Placebo participants from Group E. Placebo administered corresponding to method for active drug administration in Group E."
},
{
"id": "EG010",
"title": "Placebo F",
"description": "Placebo participants from Group F. Placebo administered corresponding to method for active drug administration in Group F."
}
]
},
"coder_1": {
"nct": "NCT00437021",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006",
"EG007",
"EG008",
"EG009",
"EG010"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"smallpox_mpox"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "IMVAMUNE (MVA against smallpox) and Dryvax (live vaccinia) groups, by schedule, pooled vs saline placebo subgroups of each schedule (no Placebo C group reported). Groups D and E got both MVA and Dryvax."
},
"coder_2": {
"nct": "NCT00437021",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006",
"EG007",
"EG008",
"EG009",
"EG010"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"smallpox_mpox"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled regimens A, B, D, E, F with their placebo groups (saline). Group C (Dryvax) has no placebo group reported so is left out. D and E include Dryvax and IMVAMUNE; their placebos replaced both."
}
},
{
"trial": {
"nct": "NCT00485134",
"brief_title": "Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection",
"official_title": "Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection",
"conditions": [
"Shigellosis"
],
"phases": [
"PHASE1",
"PHASE2"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"18 Years",
"45 Years"
],
"arms": [
{
"label": "Stage 1: Group A, Dolphin 240 \u00b5g",
"type": "EXPERIMENTAL",
"description": "240 \u00b5g Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 \u03bcg of lipopolysaccharides (LPS). 230 \u03bcL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).",
"interventions": [
"Biological: 240 \u00b5g Shigella flexneri 2a Invaplex 50 vaccine"
]
},
{
"label": "Stage 1: Group B, Dolphin 480 \u00b5g",
"type": "EXPERIMENTAL",
"description": "480 \u00b5g Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 \u03bcg of LPS. 230 \u03bcL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).",
"interventions": [
"Biological: 480 \u00b5g Shigella flexneri 2a Invaplex 50 vaccine"
]
},
{
"label": "Stage 1: Group C, Dolphin 690 \u00b5g",
"type": "EXPERIMENTAL",
"description": "690 Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 \u03bcg of LPS. 230 \u03bcL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).",
"interventions": [
"Biological: 690 Shigella flexneri 2a Invaplex 50 vaccine"
]
},
{
"label": "Stage 1: Group D, Pipette 240 \u00b5g",
"type": "OTHER",
"description": "240 \u00b5g Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 \u03bcg of LPS. These subjects received 200 \u03bcL the vaccine via electronic pipette. This group is for lot bridging only, not included in dose-finding study.",
"interventions": [
"Biological: 240 \u00b5g Shigella flexneri 2a Invaplex 50 vaccine"
]
},
{
"label": "Stage 2: Immunized / Challenge",
"type": "OTHER",
"description": "The selected dose was to be administered with the Dolphin\u2122 using the vaccination schedule from stage 1. Immunized and challenged with Shigella challenge strain approximately 42 days after receiving the last vaccination following a 90-minute fast.",
"interventions": [
"Other: Shigella challenge strain"
]
},
{
"label": "Stage 2: Controls",
"type": "PLACEBO_COMPARATOR",
"description": "A control was to be administered with the DolphinTM using the vaccination schedule from Stage 1. Non-immunized and challenged with Shigella challenge strain approximately 42 days after receiving the last vaccination following a 90-minute fast.",
"interventions": [
"Other: Shigella challenge strain"
]
}
],
"interventions": [
{
"name": "240 \u00b5g Shigella flexneri 2a Invaplex 50 vaccine",
"type": "BIOLOGICAL",
"description": "Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 \u03bcg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.",
"other_names": []
},
{
"name": "480 \u00b5g Shigella flexneri 2a Invaplex 50 vaccine",
"type": "BIOLOGICAL",
"description": "Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 \u03bcg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.",
"other_names": []
},
{
"name": "690 Shigella flexneri 2a Invaplex 50 vaccine",
"type": "BIOLOGICAL",
"description": "Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 \u03bcg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.",
"other_names": []
},
{
"name": "Shigella challenge strain",
"type": "OTHER",
"description": "300 colony forming units (CFU) of Shigella challenge strain, Shigella flexneri 2a strain 2457T",
"other_names": [
"Shigella challenge material"
]
}
],
"ae_time_frame": "Subjects Participating in Stages 1 and 2 who Experienced Surveyed Signs and Symptoms Post-vaccination",
"ae_description": "Group D was not included in findings due to they were for lot bridging only and not for dose-finding study.",
"ae_groups": [
{
"id": "EG000",
"title": "Stage 1: Group A, Dolphin 240 \u00b5g",
"description": "240 \u00b5g Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 \u03bcg of LPS. 230 \u03bcL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (Dolphin\u2122). 240 \u00b5g Shigella flexneri 2a Invaplex 50 vaccine: Vaccines were administered intranas [\u2026]"
},
{
"id": "EG001",
"title": "Stage 1: Group B, Dolphin 480 \u00b5g",
"description": "480 \u00b5g Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 \u03bcg of LPS. 230 \u03bcL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (Dolphin\u2122). 480 \u00b5g Shigella flexneri 2a Invaplex 50 vaccine: Vaccines were administered intranas [\u2026]"
},
{
"id": "EG002",
"title": "Stage 1: Group C, Dolphin 690 \u00b5g",
"description": "690 \u00b5g Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 \u03bcg of LPS. 230 \u03bcL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (Dolphin\u2122). 690 \u00b5g Shigella flexneri 2a Invaplex 50 vaccine: Vaccines were administered intranas [\u2026]"
},
{
"id": "EG003",
"title": "Stage 2: Immunized",
"description": "The selected dose was to be administered with the Dolphin\u2122 using the vaccination schedule from stage 1. Immunized and challenged with Shigella challenge strain approximately 42 days after receiving the last vaccination following a 90-minute fast. Some individuals were randomly selected for the challenge phase. Shigella challenge strain: 800 colony forming units (CFU) of Shigella challenge strain,  [\u2026]"
},
{
"id": "EG004",
"title": "Stage 2: Controls",
"description": "A control was to be administered with the Dolphin\u2122 using the vaccination schedule from Stage 1. Non-immunized and challenged with Shigella challenge strain approximately 42 days after receiving the last vaccination following a 90-minute fast. Some individuals were randomly selected for the challenge phase. Shigella challenge strain: 800 colony forming units (CFU) of Shigella challenge strain, Shig [\u2026]"
}
]
},
"coder_1": {
"nct": "NCT00485134",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "Shigella challenge ~42 days after last dose"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took Stage 2 immunized vs controls (control given by the same nasal device; placebo described as sterile saline). Stage 1 dose groups left out: no Stage 1 placebo group is reported. Invaplex 50 (Ipa proteins with LPS) coded protein, no added adjuvant."
},
"coder_2": {
"nct": "NCT00485134",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Stage 1 dose groups contain vaccine and saline recipients together; stage 2 controls are described as non-immunized and challenged, not a stated placebo."
}
},
{
"trial": {
"nct": "NCT00596271",
"brief_title": "Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX\u00ae 1440",
"official_title": "Safety and Immunogenicity of Concomitant Vaccination With IC51 and HARVIX\u00ae 1440 in Healthy Subjects. A Single-blind Randomized, Controlled Phase 3 Study",
"conditions": [
"Japanese Encephalitis"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "SINGLE",
"ages": [
"18 Years",
null
],
"arms": [
{
"label": "IC51 and Placebo",
"type": "ACTIVE_COMPARATOR",
"description": "6 mcg i.m. IC51 with 2 injections (day 0 and 28)and placebo 0.5 mL with 1 injection (day 0)",
"interventions": [
"Biological: IC51",
"Other: Placebo"
]
},
{
"label": "HAVRIX and placebo",
"type": "ACTIVE_COMPARATOR",
"description": "HAVRIX with 1 injection (day 0) and placebo 0.5 mL with 2 injections (day 0 and 28)",
"interventions": [
"Biological: HAVRIX",
"Other: Placebo"
]
},
{
"label": "IC51 and HAVRIX",
"type": "ACTIVE_COMPARATOR",
"description": "IC51 6 mcg i.m. with 2 injections (day 0 and 28) and HAVRIX with 1 injection (day 0)",
"interventions": [
"Biological: IC51",
"Biological: HAVRIX"
]
}
],
"interventions": [
{
"name": "IC51",
"type": "BIOLOGICAL",
"description": "",
"other_names": [
"Japanese Encephalitis purified inactivated vaccine"
]
},
{
"name": "HAVRIX",
"type": "BIOLOGICAL",
"description": "",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "",
"other_names": []
}
],
"ae_time_frame": "",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "IC51 and Placebo",
"description": "6 mcg i.m. IC51 with 2 injections (day 0 and 28)and placebo 0.5 mL with 1 injection (day 0)"
},
{
"id": "EG001",
"title": "HAVRIX and Placebo",
"description": "HAVRIX with 1 injection (day 0) and placebo 0.5 mL with 2 injections (day 0 and 28)"
},
{
"id": "EG002",
"title": "IC51 and HAVRIX",
"description": "IC51 6 mcg i.m. with 2 injections (day 0 and 28) and HAVRIX with 1 injection (day 0)"
}
]
},
"coder_1": {
"nct": "NCT00596271",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Havrix (hepatitis A vaccine)"
}
],
"targets": [
"japanese_encephalitis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took IC51+Havrix vs Havrix+placebo (placebo in place of both IC51 doses). EG000 (IC51+placebo) left out: its only clean match (Havrix vs placebo on IC51) would reuse EG002. IC51 (Ixiaro) is inactivated JE vaccine on aluminium hydroxide."
},
"coder_2": {
"nct": "NCT00596271",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"japanese_encephalitis",
"hepatitis_a"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "IC51 and Havrix concomitant study; every arm gets a vaccine, placebo only for blinding."
}
},
{
"trial": {
"nct": "NCT00686075",
"brief_title": "A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants",
"official_title": "A Phase 1/2a, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-old Children and in 2 Month-old Infants",
"conditions": [
"Healthy"
],
"phases": [
"PHASE1",
"PHASE2"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"2 Months",
"23 Months"
],
"arms": [
{
"label": "MEDI-534, Cohort 1",
"type": "EXPERIMENTAL",
"description": "Participants aged 6 to less than (\\<) 24 months will receive MEDI-534, 10\\^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.",
"interventions": [
"Biological: MEDI-534, Cohort 1"
]
},
{
"label": "Placebo, Cohort 1",
"type": "PLACEBO_COMPARATOR",
"description": "Participants aged 6 to \\<24 months will receive placebo matched to MEDI-534, 10\\^5 TCID50 by intranasal route at Month 0, 2, and 4.",
"interventions": [
"Other: Placebo, Cohort 1"
]
},
{
"label": "MEDI-534, Cohort 2",
"type": "EXPERIMENTAL",
"description": "Participants aged 6 to \\<24 months will receive MEDI-534, 10\\^6 TCID50 by intranasal route at Month 0, 2, and 4.",
"interventions": [
"Biological: MEDI-534, Cohort 2"
]
},
{
"label": "Placebo, Cohort 2",
"type": "PLACEBO_COMPARATOR",
"description": "Participants aged 6 to \\<24 months will receive placebo matched to MEDI-534, 10\\^6 TCID50 by intranasal route at Month 0, 2, and 4.",
"interventions": [
"Other: Placebo, Cohort 2"
]
},
{
"label": "MEDI-534, Cohort 3",
"type": "EXPERIMENTAL",
"description": "Participants aged 2 months will receive MEDI-534, 10\\^4 TCID50 by intranasal route at Month 0, 2, and 4.",
"interventions": [
"Biological: MEDI-534, Cohort 3"
]
},
{
"label": "Placebo, Cohort 3",
"type": "PLACEBO_COMPARATOR",
"description": "Participants aged 2 months will receive placebo matched to MEDI-534, 10\\^4 TCID50 by intranasal route at Month 0, 2, and 4.",
"interventions": [
"Other: Placebo, Cohort 3"
]
},
{
"label": "MEDI-534, Cohort 4",
"type": "EXPERIMENTAL",
"description": "Participants aged 2 months will receive MEDI-534, 10\\^5 TCID50 by intranasal route at Month 0, 2, and 4.",
"interventions": [
"Biological: MEDI-534, Cohort 4"
]
},
{
"label": "Placebo, Cohort 4",
"type": "PLACEBO_COMPARATOR",
"description": "Participants aged 2 months will receive placebo matched to MEDI-534, 10\\^5 TCID50 by intranasal route at Month 0, 2, and 4.",
"interventions": [
"Other: Placebo, Cohort 4"
]
},
{
"label": "MEDI-534, Cohort 5",
"type": "EXPERIMENTAL",
"description": "Participants aged 2 months will receive MEDI-534, 10\\^6 TCID50 by intranasal route at Month 0, 2, and 4.",
"interventions": [
"Biological: MEDI-534, Cohort 5"
]
},
{
"label": "Placebo, Cohort 5",
"type": "PLACEBO_COMPARATOR",
"description": "Participants aged 2 months will receive placebo matched to MEDI-534, 10\\^6 TCID50 by intranasal route at Month 0, 2, and 4.",
"interventions": [
"Other: Placebo, Cohort 5"
]
}
],
"interventions": [
{
"name": "MEDI-534, Cohort 1",
"type": "BIOLOGICAL",
"description": "Participants aged 6 to less than (\\<) 24 months will receive MEDI-534, 10\\^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.",
"other_names": []
},
{
"name": "Placebo, Cohort 1",
"type": "OTHER",
"description": "Participants aged 6 to \\<24 months will receive placebo matched to MEDI-534, 10\\^5 TCID50 by intranasal route at Month 0, 2, and 4.",
"other_names": []
},
{
"name": "MEDI-534, Cohort 2",
"type": "BIOLOGICAL",
"description": "Participants aged 6 to \\<24 months will receive MEDI-534, 10\\^6 TCID50 by intranasal route at Month 0, 2, and 4.",
"other_names": []
},
{
"name": "Placebo, Cohort 2",
"type": "OTHER",
"description": "Participants aged 6 to \\<24 months will receive placebo matched to MEDI-534, 10\\^6 TCID50 by intranasal route at Month 0, 2, and 4.",
"other_names": []
},
{
"name": "MEDI-534, Cohort 3",
"type": "BIOLOGICAL",
"description": "Participants aged 2 months will receive MEDI-534, 10\\^4 TCID50 by intranasal route at Month 0, 2, and 4.",
"other_names": []
},
{
"name": "Placebo, Cohort 3",
"type": "OTHER",
"description": "Participants aged 2 months will receive placebo matched to MEDI-534, 10\\^4 TCID50 by intranasal route at Month 0, 2, and 4.",
"other_names": []
},
{
"name": "MEDI-534, Cohort 4",
"type": "BIOLOGICAL",
"description": "Participants aged 2 months will receive MEDI-534, 10\\^5 TCID50 by intranasal route at Month 0, 2, and 4.",
"other_names": []
},
{
"name": "Placebo, Cohort 4",
"type": "OTHER",
"description": "Participants aged 2 months will receive placebo matched to MEDI-534, 10\\^5 TCID50 by intranasal route at Month 0, 2, and 4.",
"other_names": []
},
{
"name": "MEDI-534, Cohort 5",
"type": "BIOLOGICAL",
"description": "Participants aged 2 months will receive MEDI-534, 10\\^6 TCID50 by intranasal route at Month 0, 2, and 4.",
"other_names": []
},
{
"name": "Placebo, Cohort 5",
"type": "OTHER",
"description": "Participants aged 2 months will receive placebo matched to MEDI-534, 10\\^6 TCID50 by intranasal route at Month 0, 2, and 4.",
"other_names": []
}
],
"ae_time_frame": "Day 0 to Day 365",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "MEDI-534, Cohort 1",
"description": "Participants aged 6 to less than (\\<) 24 months received MEDI-534, 10\\^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4."
},
{
"id": "EG001",
"title": "Placebo, Cohort 1",
"description": "Participants aged 6 to \\<24 months received placebo matched to MEDI-534, 10\\^5 TCID50 by intranasal route at Month 0, 2, and 4."
},
{
"id": "EG002",
"title": "MEDI-534, Cohort 2",
"description": "Participants aged 6 to \\<24 months received MEDI-534, 10\\^6 TCID50 by intranasal route at Month 0, 2, and 4."
},
{
"id": "EG003",
"title": "Placebo, Cohort 2",
"description": "Participants aged 6 to \\<24 months received placebo matched to MEDI-534, 10\\^6 TCID50 by intranasal route at Month 0, 2, and 4."
},
{
"id": "EG004",
"title": "MEDI-534, Cohort 3",
"description": "Participants aged 2 months received MEDI-534, 10\\^4 TCID50 by intranasal route at Month 0, 2, and 4."
},
{
"id": "EG005",
"title": "Placebo, Cohort 3",
"description": "Participants aged 2 months received placebo matched to MEDI-534, 10\\^4 TCID50 by intranasal route at Month 0, 2, and 4."
},
{
"id": "EG006",
"title": "MEDI-534, Cohort 4",
"description": "Participants aged 2 months received MEDI-534, 10\\^5 TCID50 by intranasal route at Month 0, 2, and 4."
},
{
"id": "EG007",
"title": "Placebo, Cohort 4",
"description": "Participants aged 2 months received placebo matched to MEDI-534, 10\\^5 TCID50 by intranasal route at Month 0, 2, and 4."
},
{
"id": "EG008",
"title": "MEDI-534, Cohort 5",
"description": "Participants aged 2 months received MEDI-534, 10\\^6 TCID50 by intranasal route at Month 0, 2, and 4."
},
{
"id": "EG009",
"title": "Placebo, Cohort 5",
"description": "Participants aged 2 months received placebo matched to MEDI-534, 10\\^6 TCID50 by intranasal route at Month 0, 2, and 4."
}
]
},
"coder_1": {
"nct": "NCT00686075",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"live_attenuated",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"live_attenuated",
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG007",
"EG009"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv",
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MEDI-534 is a live attenuated chimeric bovine/human PIV3 that also carries RSV F, so both platforms listed; other target = parainfluenza virus type 3. Five dose/age cohorts pooled."
},
"coder_2": {
"nct": "NCT00686075",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG007",
"EG009"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv",
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MEDI-534 live attenuated chimeric RSV/PIV3; other=parainfluenza 3; all cohorts pooled"
}
},
{
"trial": {
"nct": "NCT00696709",
"brief_title": "A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)",
"official_title": "A Phase I, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults",
"conditions": [
"Herpes Zoster"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"50 Years",
"59 Years"
],
"arms": [
{
"label": "Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine",
"type": "EXPERIMENTAL",
"description": "Participants received an 0.65 mL subcutaneous injection of heat-treated varicella zoster virus (VZV) vaccine A; 4-dose regimen administered \\~30 days apart.",
"interventions": [
"Biological: Comparator: V212"
]
},
{
"label": "Part 1: Gamma- Irradiated VZV Vaccine A",
"type": "EXPERIMENTAL",
"description": "Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine A; 4-dose regimen administered \\~30 days apart.",
"interventions": [
"Biological: Comparator: V212"
]
},
{
"label": "Part 1: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants received a 4-dose placebo regimen administered \\~30 days apart.",
"interventions": [
"Biological: Comparator: Placebo"
]
},
{
"label": "Part 2: Gamma- Irradiated VZV Vaccine B",
"type": "EXPERIMENTAL",
"description": "Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine B; 4-dose regimen administered \\~30 days apart.",
"interventions": [
"Biological: Comparator: V212"
]
},
{
"label": "Part 2: Gamma- Irradiated VZV Vaccine C",
"type": "EXPERIMENTAL",
"description": "Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine C; 4-dose regimen administered \\~30 days apart.",
"interventions": [
"Biological: Comparator: V212"
]
}
],
"interventions": [
{
"name": "Comparator: V212",
"type": "BIOLOGICAL",
"description": "0.65 mL subcutaneous injection of heat-treated Varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \\~30 days apart",
"other_names": []
},
{
"name": "Comparator: Placebo",
"type": "BIOLOGICAL",
"description": "Placebo; 4-dose regimen administered \\~30 days apart.",
"other_names": []
}
],
"ae_time_frame": "Up to ~28 days Postdose 4 (up to ~118 days)",
"ae_description": "All participants who received at least one dose of vaccine and who had any safety follow-up were included in the safety evaluation, based on the actual vaccination received. Participants were excluded from the safety analysis population if they received an incorrect vaccination.",
"ae_groups": [
{
"id": "EG000",
"title": "Part 1 Heat-treated VZV Vaccine",
"description": "Participants received an 0.65 mL subcutaneous injection of heat-treated varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \\~30 days apart."
},
{
"id": "EG001",
"title": "Gamma-irradiated VZV Vaccine A",
"description": "Participants received an 0.65 mL subcutaneous injection of heat-treated varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \\~30 days apart."
},
{
"id": "EG002",
"title": "Placebo",
"description": "Participants received a 4-dose placebo regimen administered \\~30 days apart."
},
{
"id": "EG003",
"title": "Part 2 Gamma-irradiated VZV Vaccine B",
"description": "Participants received an 0.65 mL subcutaneous injection of heat-treated varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \\~30 days apart."
},
{
"id": "EG004",
"title": "Gamma-irradiated VZV Vaccine C",
"description": "Participants received an 0.65 mL subcutaneous injection of heat-treated varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \\~30 days apart."
}
]
},
"coder_1": {
"nct": "NCT00696709",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Part 1 only (heat-treated and gamma-irradiated V212 vs placebo). Part 2 groups EG003 and EG004 left out: Part 2 had no placebo arm. V212 is inactivated VZV without adjuvant."
},
"coder_2": {
"nct": "NCT00696709",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V212 inactivated VZV; adjuvant none assumed (unadjuvanted product); Part 1 and Part 2 vaccine groups pooled, one placebo group"
}
},
{
"trial": {
"nct": "NCT00736476",
"brief_title": "Efficacy and Safety of an H.Pylori Vaccine in H.Pylori-Negative Adults",
"official_title": "Phase I/II, Randomized, Observer-blind, Placebo-controlled, Single-Center Study of the Tolerability, Immunogenicity, and Efficacy of an Novartis' Investigational H. Pylori Vaccine in H. Pylori-Negative Adults",
"conditions": [
"Helicobacter Pylori Infection"
],
"phases": [
"PHASE1"
],
"model": "SINGLE_GROUP",
"masking": "SINGLE",
"ages": [
"18 Years",
"40 Years"
],
"arms": [
{
"label": "1",
"type": "EXPERIMENTAL",
"description": "",
"interventions": [
"Biological: H.pylori vaccines"
]
},
{
"label": "2",
"type": "PLACEBO_COMPARATOR",
"description": "",
"interventions": [
"Biological: Placebo Vaccine"
]
}
],
"interventions": [
{
"name": "H.pylori vaccines",
"type": "BIOLOGICAL",
"description": "1 dose of H.pylori vaccine at 0, 1, and 2 months",
"other_names": []
},
{
"name": "Placebo Vaccine",
"type": "BIOLOGICAL",
"description": "Placebo Vaccine at 0, 1, and 2 months",
"other_names": []
}
],
"ae_time_frame": "Throughout the study period (12-14 months)",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Group I (HP Vaccine)",
"description": "Subjects received three injections of HP Vaccine at 0, 1, and 2 months."
},
{
"id": "EG001",
"title": "Group II (Placebo)",
"description": "Subjects received three injections of Placebo at 0, 1, and 2 months"
}
]
},
"coder_1": {
"nct": "NCT00736476",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target is Helicobacter pylori (preventive, in H. pylori-negative adults). Platform 'other': the record names only an investigational Novartis H. pylori vaccine, composition and adjuvant not given. Placebo composition not stated."
},
"coder_2": {
"nct": "NCT00736476",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target H. pylori. Platform assumed protein antigens; adjuvant not stated."
}
},
{
"trial": {
"nct": "NCT00751777",
"brief_title": "Traveler's Diarrhea (TD) Automated Process",
"official_title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Two Vaccination Regimen With an LT Vaccine Patch in Healthy Adults",
"conditions": [
"Prevention of Travelers' Diarrhea"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"64 Years"
],
"arms": [
{
"label": "Group 1: 37.5 \u00b5g LT patch",
"type": "EXPERIMENTAL",
"description": "80 subjects will receive a two vaccination regimen with a LT patch.",
"interventions": [
"Biological: heat-labile enterotoxin of E. coli (LT)"
]
},
{
"label": "Group 2: 0 \u00b5g LT patch (placebo)",
"type": "PLACEBO_COMPARATOR",
"description": "40 subjects will receive a two vaccination regimen with a placebo patch.",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "heat-labile enterotoxin of E. coli (LT)",
"type": "BIOLOGICAL",
"description": "Travelers' Diarrhea Vaccine System",
"other_names": [
"TD Vaccine System"
]
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Travelers' Diarrhea Vaccine System",
"other_names": [
"TD Vaccine System"
]
}
],
"ae_time_frame": "",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Group 1: 37.5 \u00b5g LT Patch",
"description": "heat-labile enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"
},
{
"id": "EG001",
"title": "Group 2: 0 \u00b5g LT Patch (Placebo)",
"description": "Placebo: Travelers' Diarrhea Vaccine System"
}
]
},
"coder_1": {
"nct": "NCT00751777",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Transcutaneous ETEC heat-labile toxin (LT) patch vs the same patch with 0 ug LT; no separate adjuvant. AE time frame not given."
},
"coder_2": {
"nct": "NCT00751777",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "E. coli LT transcutaneous patch (ETEC travelers' diarrhea); LT is the antigen, no separate adjuvant stated; placebo patch with 0 ug LT"
}
},
{
"trial": {
"nct": "NCT00808028",
"brief_title": "A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents",
"official_title": "A Randomized, Single-blind, Placebo-controlled, Phase 2 Trial Of The Safety, Immunogenicity, And Tolerability Of Meningococcal Serogroup B (Mnb) Rlp2086 Vaccine At Doses Of 60 Mug, 120 Mug, And 200 Mug In Healthy Adolescents Aged 11 To 18 Years",
"conditions": [
"Meningitis, Meningococcal"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "SINGLE",
"ages": [
"11 Years",
"18 Years"
],
"arms": [
{
"label": "1",
"type": "EXPERIMENTAL",
"description": "dose level 1 rLP2086 vaccine",
"interventions": [
"Biological: meningococcal B rLP2086 vaccine."
]
},
{
"label": "2",
"type": "EXPERIMENTAL",
"description": "dose level 2 rLP2086 vaccine",
"interventions": [
"Biological: meningococcal B rLP2086 vaccine."
]
},
{
"label": "3",
"type": "EXPERIMENTAL",
"description": "dose level 3 rLP2086 vaccine",
"interventions": [
"Biological: meningococcal B rLP2086 vaccine."
]
},
{
"label": "4",
"type": "PLACEBO_COMPARATOR",
"description": "normal saline (placebo)",
"interventions": [
"Other: normal saline (placebo)"
]
}
],
"interventions": [
{
"name": "meningococcal B rLP2086 vaccine.",
"type": "BIOLOGICAL",
"description": "vaccine, 0.5 mL, 0 - 2 - 6 to 9 months",
"other_names": []
},
{
"name": "meningococcal B rLP2086 vaccine.",
"type": "BIOLOGICAL",
"description": "vaccine, 0.5 mL, 0 - 2 - 6 to 9 months",
"other_names": []
},
{
"name": "meningococcal B rLP2086 vaccine.",
"type": "BIOLOGICAL",
"description": "vaccine, 0.5 mL, 0 - 2 - 6 to 9 months",
"other_names": []
},
{
"name": "normal saline (placebo)",
"type": "OTHER",
"description": "vaccine, 0.5 mL, 0 - 2 - 6 to 9 months",
"other_names": []
}
],
"ae_time_frame": "AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Control- Stage 1",
"description": "Given on a 0, 2-, 6-month schedule in Stage 1"
},
{
"id": "EG001",
"title": "rLP2086 60 mcg- Stage 1",
"description": "Given on a 0, 2-, 6-month schedule in Stage 1"
},
{
"id": "EG002",
"title": "rLP2086 120 mcg- Stage 1",
"description": "Given on a 0, 2-, 6-month schedule in Stage 1"
},
{
"id": "EG003",
"title": "rLP2086 200 mcg- Stage 1",
"description": "Given on a 0, 2-, 6-month schedule in Stage 1"
},
{
"id": "EG004",
"title": "Control-Stage 1 Follow-up",
"description": "Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1"
},
{
"id": "EG005",
"title": "rLP2086 60 mcg- Stage 1 Follow up",
"description": "Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1"
},
{
"id": "EG006",
"title": "rLP2086 120 mcg- Stage 1 Follow up",
"description": "Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1"
},
{
"id": "EG007",
"title": "rLP2086 200 mcg- Stage 1 Follow up",
"description": "Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1"
},
{
"id": "EG008",
"title": "Control-Stage 2",
"description": "Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1 and further up to 48 months in Stage 2"
},
{
"id": "EG009",
"title": "rLP2086 120 mcg- Stage 2",
"description": "Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1 and further up to 48 months in Stage 2"
},
{
"id": "EG010",
"title": "rLP2086 200 mcg- Stage 2",
"description": "Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1 and further up to 48 months in Stage 2"
}
]
},
"coder_1": {
"nct": "NCT00808028",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Groups repeat participants by period; took the Stage 1 vaccination-period groups EG000-EG003, which hold every randomized participant once. Stage 1 follow-up (EG004-EG007) and Stage 2 (EG008-EG010, no 60 mcg arm) left out. rLP2086 holds aluminium phosphate."
},
"coder_2": {
"nct": "NCT00808028",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "took Stage 1 follow-up groups (EG004-007, up to 6 months, all four randomized arms counted once); Stage 1 (EG000-003) and Stage 2 (EG008-010, to 48 months, only 120 and 200 mcg and control) are overlapping views of the same participants; Stage 2 left out since it drops the 60 mcg arm; rLP2086 holds aluminium phosphate (known for the product)"
}
},
{
"trial": {
"nct": "NCT00920218",
"brief_title": "Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A",
"official_title": "Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A",
"conditions": [
"Herpes Zoster"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"18 Years",
null
],
"arms": [
{
"label": "GSK 1437173A F1 Group",
"type": "EXPERIMENTAL",
"description": "Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 1 (F1) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.",
"interventions": [
"Biological: Herpes Zoster Vaccine 1437173A"
]
},
{
"label": "GSK 1437173A F2 Group",
"type": "EXPERIMENTAL",
"description": "Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 2 (F2) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.",
"interventions": [
"Biological: Herpes Zoster Vaccine 1437173A"
]
},
{
"label": "Placebo-GSK 1437173A F1 Group",
"type": "EXPERIMENTAL",
"description": "Male or female subjects, 18 years of age or older at the time of the first vaccination, received 1 dose of the placebo followed by 2 doses of GSK 1437173A F1 vaccine. For some safety analyses, this Group was split into Placebo 1D Group (results following placebo administration) and GSK 1437173A 2D Group (results following HZV administration). All vaccines were administered intramuscularly in the upper deltoid region of non-dominant arm according  [\u2026]",
"interventions": [
"Biological: Herpes Zoster Vaccine 1437173A",
"Biological: Placebo vaccine (saline)"
]
},
{
"label": "Placebo Group",
"type": "PLACEBO_COMPARATOR",
"description": "Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of placebo, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.",
"interventions": [
"Biological: Placebo vaccine (saline)"
]
}
],
"interventions": [
{
"name": "Herpes Zoster Vaccine 1437173A",
"type": "BIOLOGICAL",
"description": "Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.",
"other_names": []
},
{
"name": "Placebo vaccine (saline)",
"type": "BIOLOGICAL",
"description": "1 or 3 doses of Placebo (saline) injected intramuscularly.",
"other_names": []
}
],
"ae_time_frame": "Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6); Unsolicited AEs: during the 30-day post-vaccination period (Days 0-29); SAEs: during the entire study period (Day 0 - Month 15).",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "GSK 1437173A F1 Group",
"description": "Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 1 (F1) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule."
},
{
"id": "EG001",
"title": "GSK 1437173A F2 Group",
"description": "Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 2 (F2) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule."
},
{
"id": "EG002",
"title": "Placebo-GSK 1437173A F1 Group",
"description": "Male or female subjects, 18 years of age or older at the time of the first vaccination, received 1 dose of the placebo followed by 2 doses of GSK 1437173A F1 vaccine. For some safety analyses, this Group was split into Placebo 1D Group (results following placebo administration) and GSK 1437173A 2D Group (results following HZV administration). All vaccines were administered intramuscularly in the u [\u2026]"
},
{
"id": "EG003",
"title": "Placebo Group",
"description": "Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of placebo, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule."
}
]
},
"coder_1": {
"nct": "NCT00920218",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "gE/AS01 formulations pooled; EG002 (saline then two F1 doses) counted as a vaccine group with a different schedule. Placebo is saline."
},
"coder_2": {
"nct": "NCT00920218",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "left out EG002 (placebo then two vaccine doses, mixes arms); gE/AS01"
}
},
{
"trial": {
"nct": "NCT00953927",
"brief_title": "A Study of MVA85A in Healthy Infants",
"official_title": "Phase II Double-blinded Randomized Controlled Evaluation of MVA85A/AERAS-485 for Safety, Immunogenicity and Prevention of Tuberculosis in BCG-vaccinated, HIV-negative Infants",
"conditions": [
"Tuberculosis"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"126 Days",
"182 Days"
],
"arms": [
{
"label": "Investigational Vaccine",
"type": "EXPERIMENTAL",
"description": "MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.",
"interventions": [
"Biological: MVA85A/AERAS-485"
]
},
{
"label": "Control Group",
"type": "PLACEBO_COMPARATOR",
"description": "Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.",
"interventions": [
"Biological: Candida Skin Test Antigen"
]
}
],
"interventions": [
{
"name": "MVA85A/AERAS-485",
"type": "BIOLOGICAL",
"description": "Attenuated virus MVA vector with insertion. Single dose vaccine, 1 x 10\\^8 pfu.",
"other_names": [
"Manufactured by IDT of Germany."
]
},
{
"name": "Candida Skin Test Antigen",
"type": "BIOLOGICAL",
"description": "1 test, administered once as a placebo control.",
"other_names": [
"Candin(R)",
"Manufactured by Allermed Laboratories of USA."
]
}
],
"ae_time_frame": "",
"ae_description": "Two subjects within the control group were randomized but did not receive control vaccination.",
"ae_groups": [
{
"id": "EG000",
"title": "Investigational Vaccine",
"description": "MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests."
},
{
"id": "EG001",
"title": "Control Group",
"description": "Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests."
}
]
},
"coder_1": {
"nct": "NCT00953927",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MVA85A vs Candida skin test antigen (Candin), which the record calls a placebo control but is an active antigen product, neither inert nor adjuvant alone."
},
"coder_2": {
"nct": "NCT00953927",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "BCG-vaccinated infants"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "control is Candida skin test antigen (Candin) that the record calls a placebo control; composition not given in record"
}
},
{
"trial": {
"nct": "NCT00985166",
"brief_title": "A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)",
"official_title": "Administration of Frozen Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine to Healthy Children at 4 to 6 Years of Age",
"conditions": [
"Measles",
"Mumps",
"Rubella",
"Varicella"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"4 Years",
"6 Years"
],
"arms": [
{
"label": "1",
"type": "EXPERIMENTAL",
"description": "ProQuad + Placebo",
"interventions": [
"Biological: ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)",
"Biological: Comparator: Placebo"
]
},
{
"label": "2",
"type": "ACTIVE_COMPARATOR",
"description": "M-M-R II + Placebo",
"interventions": [
"Biological: Comparator: M-M-R II",
"Biological: Comparator: Placebo"
]
},
{
"label": "3",
"type": "ACTIVE_COMPARATOR",
"description": "M-M-R II + Varivax",
"interventions": [
"Biological: Comparator: M-M-R II",
"Biological: Comparator: Varivax"
]
}
],
"interventions": [
{
"name": "ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)",
"type": "BIOLOGICAL",
"description": "A Single 0.5 mL subcutaneous injection at Day 1",
"other_names": [
"ProQuad"
]
},
{
"name": "Comparator: M-M-R II",
"type": "BIOLOGICAL",
"description": "A Single 0.5 mL subcutaneous injection at Day 1",
"other_names": []
},
{
"name": "Comparator: Varivax",
"type": "BIOLOGICAL",
"description": "A Single 0.5 mL subcutaneous injection at Day 1",
"other_names": []
},
{
"name": "Comparator: Placebo",
"type": "BIOLOGICAL",
"description": "A Single 0.5 mL subcutaneous placebo injection at Day 1",
"other_names": []
}
],
"ae_time_frame": "",
"ae_description": "The number of participants listed as \"at risk\" is the number of participants with follow-up. 0/0 indicates that subjects in this treatment group did not receive the indicated vaccine.",
"ae_groups": [
{
"id": "EG000",
"title": "ProQuad\u2122 + Placebo",
"description": "ProQuad\u2122 (measles, mumps, rubella, and varicella vaccine) + placebo administered concomitantly at separate injection sites on Day 1."
},
{
"id": "EG001",
"title": "M-M-R\u2122 II + Placebo",
"description": "M-M-R\u2122 II + placebo administered concomitantly at separate injection sites on Day 1."
},
{
"id": "EG002",
"title": "M-M-R\u2122 II + VARIVAX\u2122",
"description": "VARIVAX\u2122 + M-M-R\u2122 II administered concomitantly at separate injection sites on Day 1."
}
]
},
"coder_1": {
"nct": "NCT00985166",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "M-M-R II"
}
],
"targets": [
"varicella"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Clean comparison is Varivax vs placebo, both with M-M-R II (EG002 vs EG001). EG000 (ProQuad + placebo) left out: ProQuad replaces M-M-R II, an active comparison."
},
"coder_2": {
"nct": "NCT00985166",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"measles_mumps_rubella",
"varicella"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ProQuad vs MMR II plus placebo or Varivax: active controls; placebo only given as a concomitant filler."
}
},
{
"trial": {
"nct": "NCT00993447",
"brief_title": "Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America",
"official_title": "Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America",
"conditions": [
"Dengue",
"Dengue Hemorrhagic Fever",
"Dengue Virus",
"Dengue Fever"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "SINGLE",
"ages": [
"9 Years",
"16 Years"
],
"arms": [
{
"label": "CYD Dengue Vaccine Group",
"type": "EXPERIMENTAL",
"description": "Sanofi pasteur's CYD Dengue vaccine group (Dengvaxia\u00ae)",
"interventions": [
"Biological: CYD Dengue Vaccine"
]
},
{
"label": "Control Vaccine Group",
"type": "SHAM_COMPARATOR",
"description": "",
"interventions": [
"Biological: Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis"
]
}
],
"interventions": [
{
"name": "CYD Dengue Vaccine",
"type": "BIOLOGICAL",
"description": "0.5 mL, Subcutaneous at Day 0, 6 and 12 months",
"other_names": [
"Dengvaxia\u00ae"
]
},
{
"name": "Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis",
"type": "BIOLOGICAL",
"description": "NaCl: 0.5 mL, Intramuscular at Day 0 and 6 months; Adacel\u00ae: 0.5 mL, Intramuscular at 12 months",
"other_names": [
"ADACEL\u00ae",
"NaCl"
]
}
],
"ae_time_frame": "Adverse event data were collected from Day 0 (post vaccination) up to Day 28 after each vaccination.",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Dengue Vaccine Group",
"description": "Participants received the 5555 formulation of Sanofi Pasteur's CYD dengue vaccine as first (Day 0), second (Day 0 + 6 months), and third (Day 0 + 12 months) injections."
},
{
"id": "EG001",
"title": "Control Group",
"description": "Participants received a placebo (NaCl) as first (Day 0) and second (Day 0 + 6 months) injections and ADACEL vaccine as a third (Day 0 + 12 months) injection."
}
]
},
"coder_1": {
"nct": "NCT00993447",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control got NaCl at months 0 and 6 but Adacel at month 12, and the AE groups span all three injections, so the control group isn't a clean placebo group."
},
"coder_2": {
"nct": "NCT00993447",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control group got NaCl placebo at doses 1 and 2 and Adacel at 12 months; the tables report the group as a whole, so the last dose is an active control mixed in."
}
},
{
"trial": {
"nct": "NCT01011335",
"brief_title": "Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial",
"official_title": "A Randomized, Multi-Center Trial to Evaluate the Safety & Immunogenicity of Staphylococcus Aureus Toxoids, rAT and rLukS-PV, in Healthy Volunteers",
"conditions": [
"Staphylococcus Aureus"
],
"phases": [
"PHASE1",
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"55 Years"
],
"arms": [
{
"label": "Active Vaccine",
"type": "EXPERIMENTAL",
"description": "Monovalent rAT or Monovalent rLukS-PV or Bivalent rLukS-PV / rAT",
"interventions": [
"Biological: Monovalent rAT",
"Biological: Monovalent rLukS-PV",
"Biological: Bivalent rLukS-PV / rAT"
]
},
{
"label": "Placebo with Alum",
"type": "PLACEBO_COMPARATOR",
"description": "",
"interventions": [
"Biological: Placebo with adjuvant"
]
},
{
"label": "Saline Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "Monovalent rAT",
"type": "BIOLOGICAL",
"description": "10, 25, 50 or 100 \u03bcg",
"other_names": []
},
{
"name": "Monovalent rLukS-PV",
"type": "BIOLOGICAL",
"description": "10, 25, 50 or 100 \u03bcg",
"other_names": []
},
{
"name": "Bivalent rLukS-PV / rAT",
"type": "BIOLOGICAL",
"description": "10, 25 or 50 \u03bcg",
"other_names": []
},
{
"name": "Placebo with adjuvant",
"type": "BIOLOGICAL",
"description": "Placebo with adjuvant",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Placebo saline",
"other_names": []
}
],
"ae_time_frame": "",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Monovalent rAT 10\u00b5g Dose",
"description": ""
},
{
"id": "EG001",
"title": "Monovalent rAT 25\u00b5g Dose",
"description": ""
},
{
"id": "EG002",
"title": "Monovalent rAT 50\u00b5g Dose",
"description": ""
},
{
"id": "EG003",
"title": "Monovalent rAT 100\u00b5g Dose",
"description": ""
},
{
"id": "EG004",
"title": "Monovalent rLukS 10\u00b5g Dose",
"description": ""
},
{
"id": "EG005",
"title": "Monovalent rLukS 25\u00b5g Dose",
"description": ""
},
{
"id": "EG006",
"title": "Monovalent rLukS 50\u00b5g Dose",
"description": ""
},
{
"id": "EG007",
"title": "Monovalent rLukS 100\u00b5g Dose",
"description": ""
},
{
"id": "EG008",
"title": "Bivalent rAT/rLukS 10\u00b5g Dose",
"description": ""
},
{
"id": "EG009",
"title": "Bivalent rAT/rLukS 25\u00b5g Dose",
"description": ""
},
{
"id": "EG010",
"title": "Bivalent rAT/rLukS 50\u00b5g Dose",
"description": ""
},
{
"id": "EG011",
"title": "Alum Placebo",
"description": ""
},
{
"id": "EG012",
"title": "Normal Saline Placebo",
"description": ""
}
]
},
"coder_1": {
"nct": "NCT01011335",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG010",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG011",
"EG012"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two placebo groups pooled: EG011 is alum placebo, EG012 is saline; placebo_content set to adjuvant for the alum group. Vaccine's alum not stated outright, inferred from the 'placebo with adjuvant' arm. Recombinant toxoids rAT and rLukS-PV."
},
"coder_2": {
"nct": "NCT01011335",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG010",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG011"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took alum placebo (EG011) as the matched control; saline placebo group EG012 left out as a second placebo. Vaccine adjuvant inferred as alum from the alum placebo arm; record does not state it."
}
},
{
"trial": {
"nct": "NCT01067781",
"brief_title": "Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch",
"official_title": "A Phase 2, Gender-Stratified, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Two Vaccination Regimen With the Travelers' Diarrhea Vaccine System in Healthy Adults",
"conditions": [
"Diarrhea"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"18 Years",
"64 Years"
],
"arms": [
{
"label": "1",
"type": "EXPERIMENTAL",
"description": "Two vaccination regimen with an LT patch (no swabbing)",
"interventions": [
"Biological: Heat-Labile Enterotoxin of E. coli (LT)"
]
},
{
"label": "2",
"type": "EXPERIMENTAL",
"description": "Two vaccination regimen with an LT patch (with swabbing)",
"interventions": [
"Biological: Heat-Labile Enterotoxin of E. coli (LT)"
]
},
{
"label": "3",
"type": "PLACEBO_COMPARATOR",
"description": "Two vaccination regimen with a placebo patch (no swabbing)",
"interventions": [
"Biological: Placebo"
]
},
{
"label": "4",
"type": "PLACEBO_COMPARATOR",
"description": "Two vaccination regimen with a placebo patch (with swabbing)",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "Heat-Labile Enterotoxin of E. coli (LT)",
"type": "BIOLOGICAL",
"description": "Travelers' Diarrhea Vaccine System",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Travelers' Diarrhea Vaccine System",
"other_names": []
}
],
"ae_time_frame": "",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Group 1: 37.5\u03bcg LT, No Swab",
"description": "Two vaccination regimen with an LT patch (no swabbing) Heat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"
},
{
"id": "EG001",
"title": "Group 2: 37.5\u03bcg LT, Swab",
"description": "Two vaccination regimen with an LT patch (with swabbing) Heat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"
},
{
"id": "EG002",
"title": "Group 3: 0\u03bcg LT, No Swab",
"description": "Two vaccination regimen with a placebo patch (no swabbing) Placebo: Travelers' Diarrhea Vaccine System"
},
{
"id": "EG003",
"title": "Group 4: 0\u03bcg LT, Swab",
"description": "Two vaccination regimen with a placebo patch (with swabbing) Placebo: Travelers' Diarrhea Vaccine System"
}
]
},
"coder_1": {
"nct": "NCT01067781",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "skin swabbing before patch"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Transcutaneous patch of E. coli heat-labile enterotoxin (LT) against ETEC travelers' diarrhea. Split by skin swabbing, which both sides of each pair got. Placebo patch composition not given."
},
"coder_2": {
"nct": "NCT01067781",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG002",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "transcutaneous patch, with or without skin swab"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "LT patch for travelers' diarrhea (ETEC); LT is antigen and adjuvant, adjuvant coded unknown."
}
},
{
"trial": {
"nct": "NCT01150123",
"brief_title": "Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women",
"official_title": "A Phase Ib Randomized, Observer-Blind, Controlled, Single Center, Dose-Ranging Study of a Group B Streptococcus Vaccine in Healthy Women 18-40 Years of Age",
"conditions": [
"Group B Streptococcus"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "SINGLE",
"ages": [
"18 Years",
"40 Years"
],
"arms": [
{
"label": "5 \u00b5g_No Adj",
"type": "EXPERIMENTAL",
"description": "Subjects received either 1 or 2 doses of active vaccine (5 \u00b5g) without any adjuvant",
"interventions": [
"Biological: Group B streptococcus (GBS) vaccine- low dose"
]
},
{
"label": "20 \u00b5g_No Adj",
"type": "EXPERIMENTAL",
"description": "Subjects received either 1 or 2 doses of active vaccine (20 \u00b5g) without any adjuvant.",
"interventions": [
"Biological: Group B streptococcus (GBS) vaccine- High dose"
]
},
{
"label": "5 \u00b5g_Alum",
"type": "EXPERIMENTAL",
"description": "Subjects received either 1 or 2 doses of active vaccine (5 \u00b5g) with Alum adjuvant.",
"interventions": [
"Biological: Group B streptococcus (GBS) vaccine- low dose"
]
},
{
"label": "20 \u00b5g_Alum",
"type": "EXPERIMENTAL",
"description": "Subjects received either 1 or 2 doses of active vaccine (5 \u00b5g) with Alum adjuvant.",
"interventions": [
"Biological: Group B streptococcus (GBS) vaccine- High dose"
]
},
{
"label": "5 \u00b5g_MF59-H",
"type": "EXPERIMENTAL",
"description": "Subjects received either 1 or 2 doses of active vaccine (5 \u00b5g) adjuvanted with 4.87 mg of MF59",
"interventions": [
"Biological: Group B streptococcus (GBS) vaccine- low dose"
]
},
{
"label": "20 \u00b5g_MF59-H",
"type": "EXPERIMENTAL",
"description": "Subjects received either 1 or 2 doses of active vaccine (20 \u00b5g) adjuvanted with 4.87 mg of MF59",
"interventions": [
"Biological: Group B streptococcus (GBS) vaccine- High dose"
]
},
{
"label": "5 \u00b5g_MF59-F",
"type": "EXPERIMENTAL",
"description": "Subjects received either 1 or 2 doses of active vaccine (5 \u00b5g) adjuvanted with 9.75 mg of MF59",
"interventions": [
"Biological: Group B streptococcus (GBS) vaccine- low dose"
]
},
{
"label": "20 \u00b5g_MF59-F",
"type": "EXPERIMENTAL",
"description": "Subjects received either 1 or 2 doses of active vaccine (20 \u00b5g) adjuvanted with 9.75 mg of MF59",
"interventions": [
"Biological: Group B streptococcus (GBS) vaccine- High dose"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Subjects received 2 injections of placebo administered 1 month apart",
"interventions": [
"Biological: Placebo- Saline"
]
}
],
"interventions": [
{
"name": "Group B streptococcus (GBS) vaccine- low dose",
"type": "BIOLOGICAL",
"description": "",
"other_names": []
},
{
"name": "Group B streptococcus (GBS) vaccine- High dose",
"type": "BIOLOGICAL",
"description": "",
"other_names": []
},
{
"name": "Placebo- Saline",
"type": "BIOLOGICAL",
"description": "",
"other_names": []
}
],
"ae_time_frame": "Day 1 through Day 721",
"ae_description": "All Solicited AEs are classified as systematic assessment and all unsolicited AEs are classified as non-systematic assessment. Safety analysis was done on As treated set.",
"ae_groups": [
{
"id": "EG000",
"title": "5\u00b5g-1 Inj - No Adj",
"description": "Subjects received single active vaccine injection (5 \u00b5g) without any adjuvant followed by a placebo administered 1 month apart"
},
{
"id": "EG001",
"title": "5\u00b5g-2 Inj - No Adj",
"description": "Subjects received two identical active vaccine injections (5 \u00b5g) without any adjuvant administered 1 month apart"
},
{
"id": "EG002",
"title": "20 \u00b5g-1 Inj - No Adj",
"description": "Subjects received single active vaccine injection (20 \u00b5g) without any adjuvant followed by a placebo administered 1 month apart"
},
{
"id": "EG003",
"title": "20 \u00b5g-2 Inj - No Adj",
"description": "Subjects received two identical active vaccine injections (20 \u00b5g) without any adjuvant administered 1 month apart"
},
{
"id": "EG004",
"title": "5\u00b5g-1 Inj - Alum",
"description": "Subjects received single active vaccine injection (5 \u00b5g) with adjuvant followed by a placebo administered 1 month apart"
},
{
"id": "EG005",
"title": "5\u00b5g-2 Inj - Alum",
"description": "Subjects received two identical active vaccine injections (5 \u00b5g) with adjuvant administered 1 month apart"
},
{
"id": "EG006",
"title": "20 \u00b5g-1 Inj - Alum",
"description": "Subjects received single active vaccine injection (20 \u00b5g) with adjuvant followed by a placebo administered 1 month apart"
},
{
"id": "EG007",
"title": "20 \u00b5g-2 Inj- Alum",
"description": "Subjects received two identical active vaccine injections (20 \u00b5g) with adjuvant administered 1 month apart"
},
{
"id": "EG008",
"title": "Placebo - Group 1",
"description": "Subjects received two injections of placebo administered 1 month apart"
},
{
"id": "EG009",
"title": "5\u00b5g-1 Inj - MF59_H",
"description": "Subjects received single active vaccine injection (5 \u00b5g) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart"
},
{
"id": "EG010",
"title": "5\u00b5g-2 Inj - MF59_H",
"description": "Subjects received two identical active vaccine injections (5 \u00b5g) of adjuvanted with 4.87 mg of MF59 administered 1 month apart"
},
{
"id": "EG011",
"title": "20 \u00b5g-1 Inj - MF59_H",
"description": "Subjects received single active vaccine injection (20 \u00b5g) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart"
},
{
"id": "EG012",
"title": "20 \u00b5g-2 Inj - MF59_H",
"description": "Subjects received two identical active vaccine injections (20 \u00b5g) adjuvanted with 4.87 mg of MF59 administered 1 month apart"
},
{
"id": "EG013",
"title": "5\u00b5g-1 Inj - MF59_F",
"description": "Subjects received single active vaccine injection (5 \u00b5g) of adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart"
},
{
"id": "EG014",
"title": "5\u00b5g-2 Inj - MF59_F",
"description": "Subjects received two identical active vaccine injections (5 \u00b5g) adjuvanted with 9.75 mg of MF59 administered 1 month apart"
},
{
"id": "EG015",
"title": "20 \u00b5g-1 Inj - MF59_F",
"description": "Subjects received single active vaccine injection (20 \u00b5g) adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart"
},
{
"id": "EG016",
"title": "20 \u00b5g-2 Inj- MF59_F",
"description": "Subjects received two identical active vaccine injections (20 \u00b5g) adjuvanted with 9.75 mg of MF59 administered 1 month apart"
},
{
"id": "EG017",
"title": "Placebo - Group 2",
"description": "Subjects received two injections of placebo administered 1 month apart"
}
]
},
"coder_1": {
"nct": "NCT01150123",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG010",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG011",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG012",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG013",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG014",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG015",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG016",
"platforms": [
"other"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG008",
"EG017"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Platform 'other': the record doesn't say what the GBS vaccine is (protein or conjugate). Doses, 1 or 2 injections, and no-adjuvant/alum/MF59 formulations pooled with both saline placebo groups."
},
"coder_2": {
"nct": "NCT01150123",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"polysaccharide"
],
"adjuvant": "other"
},
{
"id": "EG010",
"platforms": [
"polysaccharide"
],
"adjuvant": "other"
},
{
"id": "EG011",
"platforms": [
"polysaccharide"
],
"adjuvant": "other"
},
{
"id": "EG012",
"platforms": [
"polysaccharide"
],
"adjuvant": "other"
},
{
"id": "EG013",
"platforms": [
"polysaccharide"
],
"adjuvant": "other"
},
{
"id": "EG014",
"platforms": [
"polysaccharide"
],
"adjuvant": "other"
},
{
"id": "EG015",
"platforms": [
"polysaccharide"
],
"adjuvant": "other"
},
{
"id": "EG016",
"platforms": [
"polysaccharide"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG008",
"EG017"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All dose, schedule and adjuvant groups pooled against both saline placebo groups. Platform (CPS conjugate) from product knowledge; record only says GBS vaccine."
}
},
{
"trial": {
"nct": "NCT01193920",
"brief_title": "Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age",
"official_title": "A Phase Ib/II Randomized, Observer-Blind, Controlled, Single Centre Study of a Trivalent Group B Streptococcus Vaccine in Healthy Non-Pregnant Women Leading Into a Dose-Ranging Study in Pregnant Women in South Africa",
"conditions": [
"Streptococcal Infections"
],
"phases": [
"PHASE1",
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"40 Years"
],
"arms": [
{
"label": "1: GBS Trivalent Vaccine with aluminium - 20/20/20 \u03bcg",
"type": "EXPERIMENTAL",
"description": "Non-pregnant women who received two injections of 20/20/20 \u03bcg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.",
"interventions": [
"Biological: Group B Streptococcus Trivalent Vaccine - 20/20/20 \u03bcg"
]
},
{
"label": "2: Placebo - Sterile saline",
"type": "PLACEBO_COMPARATOR",
"description": "Non-Pregnant Women who received two injection of saline solution.",
"interventions": [
"Other: Saline solution"
]
},
{
"label": "3: GBS Trivalent Vaccine - 0.5/0.5/0.5 \u00b5g",
"type": "EXPERIMENTAL",
"description": "Pregnant women who received one injection of 0.5/0.5/0.5 \u03bcg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.",
"interventions": [
"Biological: Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 \u03bcg"
]
},
{
"label": "4: GBS Trivalent Vaccine - 2.5/2.5/2.5 \u00b5g",
"type": "EXPERIMENTAL",
"description": "Pregnant Women who received one injection of 2.5/2.5/2.5 \u03bcg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.",
"interventions": [
"Biological: Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 \u03bcg"
]
},
{
"label": "5: GBS Trivalent Vaccine - 5/5/5 \u00b5g",
"type": "EXPERIMENTAL",
"description": "Pregnant women who received one injection of 5/5/5 \u03bcg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.",
"interventions": [
"Biological: Group B Streptococcus Trivalent Vaccine - 5/5/5 \u03bcg"
]
},
{
"label": "6: Placebo - Sterile saline",
"type": "PLACEBO_COMPARATOR",
"description": "Pregnant Women who received one injection of saline solution.",
"interventions": [
"Other: saline solution"
]
}
],
"interventions": [
{
"name": "Group B Streptococcus Trivalent Vaccine - 20/20/20 \u03bcg",
"type": "BIOLOGICAL",
"description": "Subjects received two injections of 20/20/20 \u03bcg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.",
"other_names": []
},
{
"name": "Saline solution",
"type": "OTHER",
"description": "Subjects received two injection of saline solution.",
"other_names": []
},
{
"name": "Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 \u03bcg",
"type": "BIOLOGICAL",
"description": "Subjects received one injection of 0.5/0.5/0.5 \u03bcg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.",
"other_names": []
},
{
"name": "Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 \u03bcg",
"type": "BIOLOGICAL",
"description": "Subjects received one injection of 2.5/2.5/2.5 \u03bcg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.",
"other_names": []
},
{
"name": "Group B Streptococcus Trivalent Vaccine - 5/5/5 \u03bcg",
"type": "BIOLOGICAL",
"description": "Subjects received one injection of 5/5/5 \u03bcg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.",
"other_names": []
},
{
"name": "saline solution",
"type": "OTHER",
"description": "Subjects received one injection of saline solution.",
"other_names": []
}
],
"ae_time_frame": "Solicited AEs were collected from day 1 to 7 after vaccination; unsolicited AEs and SAEs were collected from day 1 to day 361.",
"ae_description": "Analyses was done on the Safety Population. Solicited AEs were collected through systematic assessment, unsolicited AEs were collected through non-systematic assesment.",
"ae_groups": [
{
"id": "EG000",
"title": "Non-pregnant 20/20/20 \u03bcg +Aluminum Hydroxide",
"description": "Non-pregnant women who received two injections of 20/20/20 \u03bcg dose of trivalent GBS vaccine with aluminum"
},
{
"id": "EG001",
"title": "Non-pregnant/Placebo",
"description": "Non-pregnant women received two injections of saline solution"
},
{
"id": "EG002",
"title": "Pregnant 0.5/0.5/0.5 \u03bcg",
"description": "Pregnant women who received one injection of 0.5/0.5/0.5 \u03bcg dose of non adjuvanted trivalent GBS vaccine"
},
{
"id": "EG003",
"title": "Pregnant 2.5/2.5/2.5 \u03bcg",
"description": "Pregnant women who received one injection of 2.5/2.5/2.5 \u03bcg dose of non adjuvanted trivalent GBS vaccine"
},
{
"id": "EG004",
"title": "Pregnant 5/5/5 \u03bcg",
"description": "Pregnant women who received one injection of 5/5/5 \u03bcg dose of non adjuvanted trivalent GBS vaccine"
},
{
"id": "EG005",
"title": "Pregnant/Placebo",
"description": "Pregnant women who received one injection of saline solution"
},
{
"id": "EG006",
"title": "Infants 0.5/0.5/0.5 \u03bcg",
"description": "Infants born from women who received one injection of 0.5/0.5/0.5 \u03bcg dose of non adjuvanted trivalent GBS vaccine"
},
{
"id": "EG007",
"title": "Infants 2.5/2.5/2.5 \u03bcg",
"description": "Infants born from women who received one injection of 2.5/2.5/2.5 \u03bcg dose of non adjuvanted trivalent GBS vaccine"
},
{
"id": "EG008",
"title": "Infants 5/5/5 \u03bcg",
"description": "Infants born from women who received one injection of 5/5/5 \u03bcg dose of non adjuvanted trivalent GBS vaccine"
},
{
"id": "EG009",
"title": "Infants / Placebo",
"description": "Infants born from women who received one injection of saline solution"
}
]
},
"coder_1": {
"nct": "NCT01193920",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "pregnancy and antenatal care"
},
{
"vaccine_groups": [
{
"id": "EG006",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG009"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Non-pregnant women (alum, 2 doses) and pregnant women (unadjuvanted, 1 dose) kept as separate comparisons since pregnancy and its care differ; infants of the pregnant women are the offspring comparison. Platform 'other': trivalent GBS vaccine, type not stated (likely capsular polysaccharide conjugate). Placebo is saline."
},
"coder_2": {
"nct": "NCT01193920",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG006",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG009"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Non-pregnant and pregnant women pooled; infants of pregnant women are the offspring comparison. Platform (CRM197 conjugate) from product knowledge."
}
},
{
"trial": {
"nct": "NCT01254630",
"brief_title": "A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)",
"official_title": "A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy",
"conditions": [
"Herpes Zoster"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"18 Years",
null
],
"arms": [
{
"label": "V212-STM",
"type": "EXPERIMENTAL",
"description": "Participants with STM receiving chemotherapy randomized to receive V212 vaccine given as a 4-dose regimen administered \\~30 days apart.",
"interventions": [
"Biological: V212"
]
},
{
"label": "V212-HM",
"type": "EXPERIMENTAL",
"description": "Participants with HM randomized to receive V212 vaccine given as a 4-dose regimen administered \\~30 days apart.",
"interventions": [
"Biological: V212"
]
},
{
"label": "Placebo-STM",
"type": "PLACEBO_COMPARATOR",
"description": "Participants with STM receiving chemotherapy randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered \\~30 days apart.",
"interventions": [
"Biological: Placebo"
]
},
{
"label": "Placebo-HM",
"type": "PLACEBO_COMPARATOR",
"description": "Participants with HM randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered \\~30 days apart.",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "V212",
"type": "BIOLOGICAL",
"description": "V212 viral antigen for HZ, 0.5 mL subcutaneous (SC) injection per dose, in a four dose regimen, approximately 30 days apart.",
"other_names": [
"Inactivated Varicella-Zoster (VZV) vaccine"
]
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Vaccine stabilizer for V212 with no virus antigen, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart.",
"other_names": []
}
],
"ae_time_frame": "Adverse events were collected up to approximately 5 years after vaccination 1.",
"ae_description": "The All Subjects as Treated population included all participants who received \u22651 dose of vaccination or placebo and had safety follow-up. Three participants in the STM population were cross-treated, these participants were excluded from the safety analyses.",
"ae_groups": [
{
"id": "EG000",
"title": "V212-STM",
"description": "Participants with STM receiving chemotherapy randomized to receive V212 vaccine given as a 4-dose regimen administered \\~30 days apart."
},
{
"id": "EG001",
"title": "V212-HM",
"description": "Participants with HM randomized to receive V212 vaccine given as a 4-dose regimen administered \\~30 days apart."
},
{
"id": "EG002",
"title": "Placebo-STM",
"description": "Participants with STM receiving chemotherapy randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered \\~30 days apart."
},
{
"id": "EG003",
"title": "Placebo-HM",
"description": "Participants with HM randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered \\~30 days apart."
}
]
},
"coder_1": {
"nct": "NCT01254630",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Pooled solid-tumour and haematologic-malignancy strata. V212 is inactivated VZV (heat-inactivated Zostavax), no adjuvant; placebo is the vaccine stabilizer without antigen."
},
"coder_2": {
"nct": "NCT01254630",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Solid tumor and hematologic malignancy strata pooled."
}
},
{
"trial": {
"nct": "NCT01511419",
"brief_title": "Safety Trial of Live Attenuated Influenza (H7N3) Vaccine",
"official_title": "Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Mallard/Netherlands/00/95 (H7N3) Influenza Vaccine",
"conditions": [
"Influenza",
"Avian Influenza"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"49 Years"
],
"arms": [
{
"label": "LAIV H7N3",
"type": "EXPERIMENTAL",
"description": "Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs. Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine. Dose: \u22657.5 log egg infectious dose (EID) 50/0.5 ml dose; 0.25 ml/nare. Route of administration: Intranasal aerosol. Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28.",
"interventions": [
"Biological: LAIV H7N3"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine. Dose: 0.5 ml; 0.25 ml/nare Route of administration: Intranasal aerosol Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28",
"interventions": [
"Biological: placebo"
]
}
],
"interventions": [
{
"name": "LAIV H7N3",
"type": "BIOLOGICAL",
"description": "2 doses of vaccine",
"other_names": [
"A/17/mallard/Netherlands/00/95 (H7N3)"
]
},
{
"name": "placebo",
"type": "BIOLOGICAL",
"description": "2 doses of placebo",
"other_names": []
}
],
"ae_time_frame": "Up to 56 days following dosing",
"ae_description": "For the assessment of safety, subjects were assessed for adverse reactions twice daily (early morning and late afternoon) for 7 days. An ear, nose, and throat (ENT) examination was performed on Days 7, 28, 35, and 56. Blood and urine specimens were also collected on Days 7, 28 (prior to administrati [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "LAIV H7N3: Dose 1",
"description": "Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs. Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine. Dose: \u22657.5 log EID50/0.5 ml dose; 0.25 ml/nare. Route of administration: Intranasal aerosol."
},
{
"id": "EG001",
"title": "Placebo: Dose 1",
"description": "Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine. Dose: 0.5 ml; 0.25 ml/nare Route of administration: Intranasal aerosol"
},
{
"id": "EG002",
"title": "LAIV H7N3: Dose 2",
"description": "Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs. Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine. Dose: \u22657.5 log EID50/0.5 ml dose; 0.25 ml/nare. Route of administration: Intranasal aerosol."
},
{
"id": "EG003",
"title": "Placebo: Dose 2",
"description": "Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine. Dose: 0.5 ml; 0.25 ml/nare Route of administration: Intranasal aerosol"
}
]
},
"coder_1": {
"nct": "NCT01511419",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Groups are reported per dose for the same participants; took the dose-1 groups (all randomized participants), left out dose-2 groups EG002, EG003. Placebo is saline passed through eggs like the vaccine."
},
"coder_2": {
"nct": "NCT01511419",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Dose 1 and dose 2 groups report the same participants; took the dose 2 groups, which run to day 56."
}
},
{
"trial": {
"nct": "NCT01662440",
"brief_title": "Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects",
"official_title": "A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Separately According to 1 of 2 Different Preexposure Prophylaxis Schedules to Healthy Adult Subjects.",
"conditions": [
"Rabies",
"Japanese Encephalitis"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"65 Years"
],
"arms": [
{
"label": "R/JE - Conv",
"type": "ACTIVE_COMPARATOR",
"description": "Subjects received Rabies and Japanese Encephalitis (JE) vaccines following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm.",
"interventions": [
"Biological: Rabies",
"Biological: Japanese Encephalitis",
"Other: Placebo"
]
},
{
"label": "R/JE - Acc",
"type": "EXPERIMENTAL",
"description": "Subjects received Rabies and JE vaccines following the accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg; and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm.",
"interventions": [
"Biological: Rabies",
"Biological: Japanese Encephalitis",
"Other: Placebo"
]
},
{
"label": "R - Conv",
"type": "ACTIVE_COMPARATOR",
"description": "Subjects received Rabies vaccine following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and placebo on days 1, 8 and 29 in the left arm.",
"interventions": [
"Biological: Rabies",
"Other: Placebo"
]
},
{
"label": "JE - Conv",
"type": "ACTIVE_COMPARATOR",
"description": "Subjects received JE vaccine following the conventional schedule, ie, placebo on days 1, 4, 8 and 29 in the right arm or leg; and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm.",
"interventions": [
"Biological: Japanese Encephalitis",
"Other: Placebo"
]
}
],
"interventions": [
{
"name": "Rabies",
"type": "BIOLOGICAL",
"description": "Subjects received three doses of Rabies, whole virus vaccine (inactivated, Germany).",
"other_names": []
},
{
"name": "Japanese Encephalitis",
"type": "BIOLOGICAL",
"description": "Subjects received two doses of Japanese Encephalitis vaccine.",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "Subjects received either two, three, four or five doses of normal saline, 0.9% w/v sodium chloride depending on the vaccine group.",
"other_names": []
}
],
"ae_time_frame": "Solicited AEs were collected for 7 days after each vaccination. All unsolicited AEs, serious adverse events (SAEs), AEs leading to study and/or treatment withdrawal were collected through day 57. From day 57 to day 366 vaccine-related SAEs were collected.",
"ae_description": "Solicited adverse events were collected by systematic assessment, unsolicited AEs by non-systematic assessment. SAEs analysis was done one the unsolicited safety set, other AEs analysis was done on the overall safety set.",
"ae_groups": [
{
"id": "EG000",
"title": "R/JE - Conv",
"description": "Subjects received Rabies and JE vaccines, conventional schedule, i.e. Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm."
},
{
"id": "EG001",
"title": "R/JE - Acc",
"description": "Subjects received Rabies and JE vaccines, accelerated schedule, i.e. Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg; and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm."
},
{
"id": "EG002",
"title": "R - Conv",
"description": "Subjects received Rabies vaccine, conventional schedule, i.e. Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and placebo on days 1, 8 and 29 in the left arm."
},
{
"id": "EG003",
"title": "JE - Conv",
"description": "Subjects received JE vaccine, conventional schedule, i.e. placebo on days 1, 4, 8 and 29 in the right arm or leg; and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm."
}
]
},
"coder_1": {
"nct": "NCT01662440",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "JE vaccine on days 1 and 29"
}
],
"targets": [
"rabies"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "R/JE-Conv (EG000) vs JE-Conv (EG003) differ only in rabies vaccine (Rabipur-type, inactivated) vs saline. EG000 can serve one comparison; the alternative was JE vs saline on rabies (EG000 vs EG002). EG001 (accelerated schedule) and EG002 left out."
},
"coder_2": {
"nct": "NCT01662440",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "rabies vaccine, conventional schedule"
}
],
"targets": [
"rabies",
"japanese_encephalitis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "JE vaccine plus rabies vs placebo plus rabies, conventional schedule. EG001 (accelerated) has no matched placebo; EG003 left out because EG000 is used once (it could instead pair for rabies vs placebo with JE background)."
}
},
{
"trial": {
"nct": "NCT01734811",
"brief_title": "Efficacy and Safety Evaluation in Recurrent Wheezing Attacks",
"official_title": "Randomized Double-blind Placebo-controlled, Parallel, Multi Centre Clinical Trial of Sublingual Bacterial Vaccine in Children With Recurrent Bronchospasm (Wheezing Attacks) for the Evaluation of Efficacy, Security and Clinical Impact.",
"conditions": [
"Bronchospasm; Bronchiolitis",
"Bronchospasm; Bronchitis"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"12 Months",
"36 Months"
],
"arms": [
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "The subjects will receive daily placebo spray (2 puff of 100 \u00b5L) for 6 months, followed by other 6 months of observation",
"interventions": [
"Biological: Biological vaccine"
]
},
{
"label": "Biological vaccine",
"type": "EXPERIMENTAL",
"description": "The subjects will receive daily biological vaccines pray (2 puff of 100 \u00b5L) of for 6 months, followed by other 6 months of observation",
"interventions": [
"Biological: Biological vaccine"
]
}
],
"interventions": [
{
"name": "Biological vaccine",
"type": "BIOLOGICAL",
"description": "daily spray (2 puff of 100 \u00b5L) for six months",
"other_names": []
}
],
"ae_time_frame": "Up to 12 months.",
"ae_description": "Adverse Events were registered throughout the trial. Grading was according to EAACI guidelines.",
"ae_groups": [
{
"id": "EG000",
"title": "Placebo",
"description": "The subjects will receive daily placebo spray (2 puff of 100 \u00b5L) for 6 months, followed by other 6 months of observation Biological vaccine: daily spray (2 puff of 100 \u00b5L) for six months"
},
{
"id": "EG001",
"title": "Biological Vaccine",
"description": "The subjects will receive daily biological vaccines pray (2 puff of 100 \u00b5L) of for 6 months, followed by other 6 months of observation Biological vaccine: daily spray (2 puff of 100 \u00b5L) for six months"
}
]
},
"coder_1": {
"nct": "NCT01734811",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": true,
"pregnant": false,
"patients": true,
"note": "Sublingual bacterial vaccine spray in toddlers with recurrent wheezing (bronchiolitis/bronchitis); target 'other' = recurrent wheezing attacks/respiratory infections. Platform 'other': polybacterial preparation, composition not given in the record. Judged a preventive vaccine rather than an immune stimulant; off_target because it is a bacterial vaccine given against wheezing attacks."
},
"coder_2": {
"nct": "NCT01734811",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Sublingual bacterial vaccine against respiratory infections causing wheezing; platform not stated in record. Target other: bacterial respiratory pathogens."
}
},
{
"trial": {
"nct": "NCT01877655",
"brief_title": "A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)",
"official_title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)",
"conditions": [
"Cytomegalovirus (CMV)-Positive Recipients",
"Allogeneic, Hematopoietic Cell Transplant (HCT)"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
null
],
"arms": [
{
"label": "ASP0113",
"type": "EXPERIMENTAL",
"description": "Participants received 1 mL of 5 mg/mL of ASP0113 via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).",
"interventions": [
"Biological: ASP0113"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants received 1 mL of 5 mg/mL of matching placebo via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).",
"interventions": [
"Drug: Placebo"
]
}
],
"interventions": [
{
"name": "ASP0113",
"type": "BIOLOGICAL",
"description": "Intramuscular injection",
"other_names": []
},
{
"name": "Placebo",
"type": "DRUG",
"description": "Intramuscular injection",
"other_names": []
}
],
"ae_time_frame": "All cause-Mortality: Baseline up to 5.5 years post transplant. Adverse Events: From first dose of study drug up to 30 days after last dose of study drug (Day 365).",
"ae_description": "Treatment Emergent Adverse Event (TEAE) was defined as an adverse event observed after the first dose of study drug injection through Day 365 and within 30 days of the last dose of study drug. Drug-related TEAE was defined as any TEAE with at least possible relationship to study treatment as assesse [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "Placebo",
"description": "Participants received 1 mL of 5 mg/mL of matching placebo via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0)."
},
{
"id": "EG001",
"title": "ASP0113 5mg",
"description": "Participants received 1 mL of 5 mg/mL of ASP0113 via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0)."
}
]
},
"coder_1": {
"nct": "NCT01877655",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"dna"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Record calls ASP0113 a 'therapeutic vaccine' but it is given to CMV-seropositive HCT recipients to prevent CMV reactivation disease (protective efficacy), like zoster vaccines in VZV carriers, so kept as preventive. Platform (plasmid DNA) and adjuvant (poloxamer CRL1005 with benzalkonium chloride) from what is known of ASP0113, not in the record."
},
"coder_2": {
"nct": "NCT01877655",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Described as therapeutic vaccine in already CMV-seropositive transplant recipients"
}
},
{
"trial": {
"nct": "NCT01974206",
"brief_title": "A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor",
"official_title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor",
"conditions": [
"Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
null
],
"arms": [
{
"label": "ASP0113",
"type": "EXPERIMENTAL",
"description": "Participants received 1 mL of 5 mg/mL of ASP0113 via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0).",
"interventions": [
"Biological: ASP0113"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants received 1 mL of 5 mg/mL of placebo via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0).",
"interventions": [
"Drug: Placebo"
]
}
],
"interventions": [
{
"name": "ASP0113",
"type": "BIOLOGICAL",
"description": "intramuscular injection",
"other_names": []
},
{
"name": "Placebo",
"type": "DRUG",
"description": "intramuscular injection",
"other_names": []
}
],
"ae_time_frame": "Day 1 to Day 380",
"ae_description": "Treatment Emergent Adverse Event (TEAE) was defined as an adverse event observed after the first study drug injection Day 1 through Day 380. No AEs were collected / reported during the long-term follow-up period.",
"ae_groups": [
{
"id": "EG000",
"title": "Placebo",
"description": "Participants received 1 mL of 5 mg/mL of placebo via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0)."
},
{
"id": "EG001",
"title": "ASP0113",
"description": "Participants received 1 mL of 5 mg/mL of ASP0113 via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0)."
}
]
},
"coder_1": {
"nct": "NCT01974206",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"dna"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ASP0113 in CMV-seronegative kidney recipients of seropositive organs. Platform (plasmid DNA) and adjuvant (poloxamer CRL1005 with benzalkonium chloride) from what is known of ASP0113, not in the record."
},
"coder_2": {
"nct": "NCT01974206",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"dna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ASP0113 DNA vaccine in CMV-seronegative kidney transplant recipients; judged preventive since participants not yet infected"
}
},
{
"trial": {
"nct": "NCT02046148",
"brief_title": "Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women",
"official_title": "A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women",
"conditions": [
"GBS Disease",
"Streptococcus Agalactiae"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"40 Years"
],
"arms": [
{
"label": "GBS Group",
"type": "EXPERIMENTAL",
"description": "Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Group B Streptococcus (GBS) trivalent vaccine, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum).",
"interventions": [
"Biological: GBS trivalent vaccine"
]
},
{
"label": "Placebo Group",
"type": "ACTIVE_COMPARATOR",
"description": "Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Placebo, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum).",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "GBS trivalent vaccine",
"type": "BIOLOGICAL",
"description": "Intramuscular injection - Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus and conjugated to the Corynebacterium diphtheriae CRM197 carrier protein",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Intramuscular injection - Normal saline",
"other_names": []
}
],
"ae_time_frame": "Solicited and Unsolicited AEs within the 31-day post-vaccination period for maternal subjects; SAEs from Study Day 1 to Day 180 postpartum for maternal subjects and from Birth up to Day 180 of age for Infants.",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "GBS Group",
"description": "Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Group B Streptococcus (GBS) trivalent vaccine, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum)."
},
{
"id": "EG001",
"title": "Placebo Group",
"description": "Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Placebo, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum)."
}
]
},
"coder_1": {
"nct": "NCT02046148",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Maternal groups only (control is normal saline despite 'Active Comparator' label); no separate infant groups are reported, though the time frame includes infant SAEs, so no offspring comparison. Adjuvant not stated."
},
"coder_2": {
"nct": "NCT02046148",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Pregnant women groups only; infants not reported as separate groups. Adjuvant none by default for conjugate; not stated in record."
}
},
{
"trial": {
"nct": "NCT02075203",
"brief_title": "Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents",
"official_title": "A Randomized, Placebo Controlled, Partially Blinded Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents",
"conditions": [
"Tuberculosis"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"12 Years",
"17 Years"
],
"arms": [
{
"label": "AERAS-404 (15 mcgH4/500 nmol IC31)",
"type": "EXPERIMENTAL",
"description": "2 doses on Study Days 0 and 56",
"interventions": [
"Biological: AERAS-404"
]
},
{
"label": "Bacillus Calmette-Gu\u00e9rin (BCG)",
"type": "ACTIVE_COMPARATOR",
"description": "1 Dose on Study Day 0",
"interventions": [
"Biological: Bacillus Calmette-Gu\u00e9rin (BCG)"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "2 Doses on Study Days 0 and 56",
"interventions": [
"Drug: Placebo"
]
}
],
"interventions": [
{
"name": "AERAS-404",
"type": "BIOLOGICAL",
"description": "The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as \u03b1-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a le [\u2026]",
"other_names": [
"H4",
"H4:IC31"
]
},
{
"name": "Placebo",
"type": "DRUG",
"description": "Saline",
"other_names": [
"0.9% Saline"
]
},
{
"name": "Bacillus Calmette-Gu\u00e9rin (BCG)",
"type": "BIOLOGICAL",
"description": "BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Gu\u00e9rin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg [\u2026]",
"other_names": [
"BCG",
"BCG SSI"
]
}
],
"ae_time_frame": "Unsolicited AEs: 28 days post each vaccination Solicited AEs: 7 days post each vaccination (with diary cards used for 7 days after each vaccination for Safety and Immunogenicity Cohort only) Solicited and unsolicited injection site reaction AEs: BCG Group - 84 days post vaccination; H4:IC31/Placebo  [\u2026]",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "AERAS-404 (15 mcgH4/500 Nmol IC31)",
"description": "2 doses on Study Days 0 and 56 AERAS-404: The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as \u03b1-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subje [\u2026]"
},
{
"id": "EG001",
"title": "Bacillus Calmette-Guerin (BCG)",
"description": "1 Dose on Study Day 0 Bacillus Calmette-Gu\u00e9rin (BCG): BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Gu\u00e9rin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the D [\u2026]"
},
{
"id": "EG002",
"title": "Placebo",
"description": "2 Doses on Study Days 0 and 56 Placebo: Saline"
}
]
},
"coder_1": {
"nct": "NCT02075203",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two vaccines against one saline placebo: H4:IC31 (IC31 adjuvant) and BCG revaccination, both tested for preventing infection; BCG kept as a vaccine group despite the 'Active Comparator' label. Placebo follows H4:IC31's 2-dose schedule; BCG is one dose."
},
"coder_2": {
"nct": "NCT02075203",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BCG group left out: active comparator with no matching placebo group. IC31 adjuvant has no aluminium."
}
},
{
"trial": {
"nct": "NCT02094586",
"brief_title": "A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults",
"official_title": "Phase 3 Randomized, Double-blind, Placebo-Controlled 3-Lot Study in Healthy Volunteers to Assess Immunogenicity, & Acceptability of a Single-dose of Live Oral Cholera Vaccine, Vibrio Cholerae O1 Serotype Inaba Vaccine Strain CVD 103-HgR",
"conditions": [
"Cholera"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"45 Years"
],
"arms": [
{
"label": "PXVX0200 Lot A",
"type": "EXPERIMENTAL",
"description": "PXVX0200 (Lot P700-1CA03) Single dose; liquid suspension after reconstitution with buffer; \\> 2x10\\^8 CFU in a liquid suspension",
"interventions": [
"Biological: PXVX0200 Lot A"
]
},
{
"label": "PXVX0200 Lot B",
"type": "EXPERIMENTAL",
"description": "PXVX0200 (Lot P700-3CA03) Single dose; liquid suspension after reconstitution with buffer; \\> 2x10\\^8 CFU in a liquid suspension",
"interventions": [
"Biological: PXVX0200 Lot B"
]
},
{
"label": "PXVX0200 Lot C",
"type": "EXPERIMENTAL",
"description": "PXVX0200 (Lot P700-6BA03) Single dose; liquid suspension after reconstitution with buffer; \\> 2x10\\^8 CFU in a liquid suspension",
"interventions": [
"Biological: PXVX0200 Lot C"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Placebo physiological saline",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "PXVX0200 Lot A",
"type": "BIOLOGICAL",
"description": "Lot P700-1CA03",
"other_names": []
},
{
"name": "PXVX0200 Lot B",
"type": "BIOLOGICAL",
"description": "Lot P700-3CA03",
"other_names": []
},
{
"name": "PXVX0200 Lot C",
"type": "BIOLOGICAL",
"description": "Lot P700-6BA03",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Placebo",
"other_names": []
}
],
"ae_time_frame": "Unsolicited AEs, serious adverse events (SAEs), medically attended events, and new onset of chronic medical conditions were assessed for 180 days post-vaccination.",
"ae_description": "Totals presented are the number of subjects with at least one AE. Analysis of all cause mortality, SAEs and other serious events were performed for the safety population (N=2789) and not the randomized population. Only the SAEs were analyzed per lot while the analysis for the AEs was not completed f [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "PXVX0200 Lot A",
"description": "PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 1x10\\^9 CFU in a liquid suspension"
},
{
"id": "EG001",
"title": "PXVX0200 Lot B",
"description": "PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 1x10\\^9 CFU in a liquid suspension"
},
{
"id": "EG002",
"title": "PXVX0200 Lot C",
"description": "PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 1x10\\^9 CFU in a liquid suspension"
},
{
"id": "EG003",
"title": "All PXVX0200 Lots",
"description": "All PXVX0200 Lots"
},
{
"id": "EG004",
"title": "Placebo",
"description": "Placebo physiological saline"
}
]
},
"coder_1": {
"nct": "NCT02094586",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cholera"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the pooled 'All PXVX0200 Lots' group (EG003) rather than lots A-C (EG000-EG002): the same participants, and per the AE description only SAEs were analysed per lot."
},
"coder_2": {
"nct": "NCT02094586",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cholera"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Three lots; 'All PXVX0200 Lots' group duplicates them and is excluded"
}
},
{
"trial": {
"nct": "NCT02117570",
"brief_title": "A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.",
"official_title": "A Phase 2, Placebo-controlled, Randomised, Observer-blinded Trial To Evaluate The Safety, Tolerability And Immunogenicity Of A Clostridium Difficile Vaccine Administered As A 3-dose Regimen In Healthy Adults Aged 50 To 85 Years",
"conditions": [
"Clostridium Difficile Associated Disease"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"50 Years",
"85 Years"
],
"arms": [
{
"label": "High dose of C. difficile vaccine",
"type": "EXPERIMENTAL",
"description": "",
"interventions": [
"Biological: Clostridium difficile vaccine"
]
},
{
"label": "Low dose of C. difficile vaccine",
"type": "EXPERIMENTAL",
"description": "",
"interventions": [
"Biological: Clostridium difficile vaccine"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "Clostridium difficile vaccine",
"type": "BIOLOGICAL",
"description": "0.5 mL intramuscular injection on day 1, day 8, and day 30.",
"other_names": []
},
{
"name": "Clostridium difficile vaccine",
"type": "BIOLOGICAL",
"description": "0.5 mL intramuscular injection on day 1, day 8, and day 30.",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Placebo (0.9 percent saline) given as a 0.5 mL intramuscular injection on day 1, day 8, and day 30.",
"other_names": []
}
],
"ae_time_frame": "Adverse events (AEs) were assessed from informed consent through and including Visit 6 (Month 2). Serious AEs (SAEs) were assessed from informed consent through and including Visit 9.",
"ae_description": "The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study.",
"ae_groups": [
{
"id": "EG000",
"title": "Placebo (50-64 Year Age Cohort)",
"description": "Participants were vaccinated with placebo at each vaccination visit (Days 1, 8, and 30) for a total of 3 vaccinations."
},
{
"id": "EG001",
"title": "Clostridium Difficile Vaccine, 100 \u00b5g (50-64 Year Age Cohort)",
"description": "Participants were vaccinated with C difficile vaccine, 100 \u00b5g, at each vaccination visit (Days 1, 8, and 30) for a total of 3 vaccinations."
},
{
"id": "EG002",
"title": "Clostridium Difficile Vaccine, 200 \u00b5g (50-64 Year Age Cohort)",
"description": "Participants were vaccinated with C difficile vaccine, 200 \u00b5g, at each vaccination visit (Days 1, 8, and 30) for a total of 3 vaccinations."
},
{
"id": "EG003",
"title": "Placebo (65-85 Year Age Cohort)",
"description": "Participants were vaccinated with placebo at each vaccination visit (Days 1, 8, and 30) for a total of 3 vaccinations."
},
{
"id": "EG004",
"title": "Clostridium Difficile Vaccine, 100 \u00b5g (65-85 Year Age Cohort)",
"description": "Participants were vaccinated with C difficile vaccine, 100 \u00b5g, at each vaccination visit (Days 1, 8, and 30) for a total of 3 vaccinations."
},
{
"id": "EG005",
"title": "Clostridium Difficile Vaccine, 200 \u00b5g (65-85 Year Age Cohort)",
"description": "Participants were vaccinated with C difficile vaccine, 200 \u00b5g, at each vaccination visit (Days 1, 8, and 30) for a total of 3 vaccinations."
}
]
},
"coder_1": {
"nct": "NCT02117570",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pfizer C. difficile toxoid vaccine, two doses, two age cohorts pooled. Aluminium hydroxide from what is known of the product, not stated in the record."
},
"coder_2": {
"nct": "NCT02117570",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG000",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two age cohorts pooled"
}
},
{
"trial": {
"nct": "NCT02289820",
"brief_title": "A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults",
"official_title": "A Phase 1b Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults",
"conditions": [
"Respiratory Syncytial Virus (RSV)"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"60 Years",
"99 Years"
],
"arms": [
{
"label": "MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1",
"type": "EXPERIMENTAL",
"description": "Participants will receive a single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.",
"interventions": [
"Biological: MEDI7510"
]
},
{
"label": "MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2",
"type": "EXPERIMENTAL",
"description": "Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.",
"interventions": [
"Biological: MEDI7510",
"Biological: IIV"
]
},
{
"label": "MEDI7510 (120 mcg sF + 5 mcg GLA), Cohort 3",
"type": "EXPERIMENTAL",
"description": "Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.",
"interventions": [
"Biological: MEDI7510"
]
},
{
"label": "MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4",
"type": "EXPERIMENTAL",
"description": "Participants will receive a single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.",
"interventions": [
"Biological: MEDI7510"
]
},
{
"label": "Inactivated Influenza Vaccine (IIV)",
"type": "ACTIVE_COMPARATOR",
"description": "Participants will receive a single dose of IIV by intramuscular injection in contralateral arms on Day 1.",
"interventions": [
"Biological: IIV"
]
}
],
"interventions": [
{
"name": "MEDI7510",
"type": "BIOLOGICAL",
"description": "RSV sF antigen plus adjuvant",
"other_names": []
},
{
"name": "IIV",
"type": "BIOLOGICAL",
"description": "Marketed Inactivated Influenza Vaccine",
"other_names": []
}
],
"ae_time_frame": "AEs and SAEs were collected from time of signature of informed consent throughout the treatment period and including the follow-up period through the Day 29 visit and day of last subject contact (Day 361 visit), respectively",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1",
"description": "Participants received single dose of MEDI7510 (120 microgram \\[mcg\\] respiratory syncytial virus \\[RSV\\] soluble fusion protein \\[sF\\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1."
},
{
"id": "EG001",
"title": "Inactivated Influenza Vaccine (IIV)",
"description": "Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1."
},
{
"id": "EG002",
"title": "MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2",
"description": "Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1."
},
{
"id": "EG003",
"title": "MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2",
"description": "Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1."
},
{
"id": "EG004",
"title": "MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3",
"description": "Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1."
},
{
"id": "EG005",
"title": "MEDI7510 (120 mcg sF + 5 mcg GLA)+ IIV, Cohort 3",
"description": "Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1."
},
{
"id": "EG006",
"title": "MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4",
"description": "Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1."
}
]
},
"coder_1": {
"nct": "NCT02289820",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "MEDI7510 RSV sF + GLA-SE vaccine"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MEDI7510 has no placebo: the IIV-alone arm (EG001) is not called placebo. In cohorts 2 and 3 participants were randomized to MEDI7510+IIV or MEDI7510+placebo, so the clean comparison is IIV vs placebo on a MEDI7510 background, the two cohorts' GLA doses pooled. Cohorts 1 and 4 (MEDI7510 alone) and EG001 left out."
},
"coder_2": {
"nct": "NCT02289820",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"rsv",
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo only given with MEDI7510 in place of IIV; no group with placebo in place of MEDI7510 against a MEDI7510-free group; IIV arm is an active control"
}
},
{
"trial": {
"nct": "NCT02374814",
"brief_title": "Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis",
"official_title": "Immunogenicity of a Two vs Three Dose, Intradermal (ID) vs Intramuscular (IM) Administration of a Licensed Rabies Vaccine for Pre-Exposure Vaccination",
"conditions": [
"Rabies"
],
"phases": [
"PHASE4"
],
"model": "PARALLEL",
"masking": "NONE",
"ages": [
"18 Years",
"60 Years"
],
"arms": [
{
"label": "Rabies vaccine IM 3 dose",
"type": "ACTIVE_COMPARATOR",
"description": "Intramuscular injection: 1mL at 0, 7 and 21 days. An additional 1 mL intramuscular dose at day 365",
"interventions": [
"Drug: Rabies vaccine"
]
},
{
"label": "Rabies vaccine ID 3 dose",
"type": "EXPERIMENTAL",
"description": "Intradermal injection: 0.1mL at 0, 7 and 21 days. A single intramuscular 1 mL dose at day 365",
"interventions": [
"Drug: Rabies vaccine"
]
},
{
"label": "Rabies vaccine IM 2 dose",
"type": "EXPERIMENTAL",
"description": "Intramuscular injection: 1mL at 0, 7 days. An additional 1 mL intramuscular dose at day 365",
"interventions": [
"Drug: Rabies vaccine"
]
},
{
"label": "Rabies vaccine ID 2 dose",
"type": "EXPERIMENTAL",
"description": "Intradermal injection: 0.1mL at 0, 7 days. A single intramuscular 1 mL dose at day 365",
"interventions": [
"Drug: Rabies vaccine"
]
},
{
"label": "Placebo IM 1 dose",
"type": "PLACEBO_COMPARATOR",
"description": "Albumin and saline comparator, Intramuscular injection: 1mL",
"interventions": [
"Drug: Placebo"
]
},
{
"label": "Placebo ID 1 dose",
"type": "PLACEBO_COMPARATOR",
"description": "Albumin and saline comparator, Intradermal injection: 0.1mL",
"interventions": [
"Drug: Placebo"
]
}
],
"interventions": [
{
"name": "Rabies vaccine",
"type": "DRUG",
"description": "Compare dose schedule and route of administration",
"other_names": [
"Rabavert"
]
},
{
"name": "Placebo",
"type": "DRUG",
"description": "Placebo",
"other_names": [
"Albumin"
]
}
],
"ae_time_frame": "372 days for all groups (1-4) receiving rabies vaccine; 7 days for groups 5-6 receiving control",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Rabies Vaccine IM 3 Dose",
"description": "Intramuscular injection: 1mL at 0, 7 and 21 days. An additional 1 mL intramuscular dose at day 365"
},
{
"id": "EG001",
"title": "Rabies Vaccine ID 3 Dose",
"description": "Intradermal injection: 0.1mL at 0, 7 and 21 days. A single intramuscular 1 mL dose at day 365"
},
{
"id": "EG002",
"title": "Rabies Vaccine IM 2 Dose",
"description": "Intramuscular injection: 1mL at 0, 7 days. An additional 1 mL intramuscular dose at day 365"
},
{
"id": "EG003",
"title": "Rabies Vaccine ID 2 Dose",
"description": "Intradermal injection: 0.1mL at 0, 7 days. A single intramuscular 1 mL dose at day 365"
},
{
"id": "EG004",
"title": "Placebo IM 1 Dose",
"description": "Albumin and saline comparator Intramuscular injection: 1ml"
},
{
"id": "EG005",
"title": "Placebo ID 1 Dose",
"description": "Albumin and saline comparator Intradermal injection: 0.1ml"
}
]
},
"coder_1": {
"nct": "NCT02374814",
"eligible": false,
"exclusion_reason": "other",
"comparisons": [],
"targets": [
"rabies"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo groups (albumin and saline, one dose) were followed for AEs 7 days, vaccine groups (3-4 doses) 372 days, so the groups do not cover the same period; open label."
},
"coder_2": {
"nct": "NCT02374814",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG004",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rabies"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Licensed rabies vaccine, product not named, so adjuvant unknown. Placebo (albumin and saline) groups followed 7 days only, vaccine groups 372 days; open-label masking"
}
},
{
"trial": {
"nct": "NCT02377349",
"brief_title": "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix\u2122 Vaccine in Pregnant Women",
"official_title": "Immunogenicity and Safety Study of GSK Biologicals' dTpa Vaccine, Boostrix\u2122 (263855) in Pregnant Women",
"conditions": [
"Diphtheria-Tetanus-acellular Pertussis Vaccines"
],
"phases": [
"PHASE4"
],
"model": "CROSSOVER",
"masking": "TRIPLE",
"ages": [
"18 Years",
"45 Years"
],
"arms": [
{
"label": "dTpa Group",
"type": "EXPERIMENTAL",
"description": "This group will consist of pregnant women who will receive a single dose of Boostrix\u2122 at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of the placebo post-delivery (within 72 hours).",
"interventions": [
"Biological: Boostrix\u2122",
"Drug: Saline placebo"
]
},
{
"label": "Control Group",
"type": "PLACEBO_COMPARATOR",
"description": "This group will consist of pregnant women who will receive a single dose of placebo at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of Boostrix\u2122 post-delivery (within 72 hours).",
"interventions": [
"Biological: Boostrix\u2122",
"Drug: Saline placebo"
]
}
],
"interventions": [
{
"name": "Boostrix\u2122",
"type": "BIOLOGICAL",
"description": "One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.",
"other_names": []
},
{
"name": "Saline placebo",
"type": "DRUG",
"description": "One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.",
"other_names": []
}
],
"ae_time_frame": "For the Mothers' Groups: Solicited local and general AEs were reported during Days 0 - 7 following each dose. Unsolicited AEs were reported during Days 0 - 30 following each dose. SAEs were reported during the entire study period (Day 0 up to Month 2). For the Infants' Groups: unsolicited AEs and SA [\u2026]",
"ae_description": "No solicited symptoms were assessed for the Infants' Groups and Household Group.",
"ae_groups": [
{
"id": "EG000",
"title": "dTpa Group-Mother",
"description": "This group consisted of pregnant women who received a single dose of Boostrix at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and received a dose of the placebo post-delivery (within 72 hours)."
},
{
"id": "EG001",
"title": "Control Group-Mother",
"description": "This group consisted of pregnant women who received a single dose of placebo at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and received a dose of Boostrix post-delivery (within 72 hours)."
},
{
"id": "EG002",
"title": "dTpa Group - Infant",
"description": "This group consisted of infants born to mothers (from dTpa Group Mother) who received a dose of Boostrix during pregnancy."
},
{
"id": "EG003",
"title": "Control Group-Infant",
"description": "This group consisted of infants born to mothers (from Control Group Mother) who received a dose of placebo during pregnancy"
},
{
"id": "EG004",
"title": "Household Group",
"description": "This group consisted of eligible household contacts of the infants born to pregnant women enrolled in Spain who received a single dose of Boostrix anytime during the study."
}
]
},
"coder_1": {
"nct": "NCT02377349",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Crossover at delivery: the mother groups cover the pregnancy dose and the post-delivery dose (control mothers got Boostrix after delivery), so they are left out. Infant groups compared by their mothers' pregnancy dose (offspring); control infants' mothers got Boostrix within 72 h of birth. Household group EG004 not randomized, left out. Boostrix holds aluminium salts."
},
"coder_2": {
"nct": "NCT02377349",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": true,
"background": "none"
}
],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Only the infants' groups are used: mothers were crossed over (placebo in pregnancy, Boostrix after delivery) and the tables give one group each across both doses, mixing the arms. Infants of vaccinated vs placebo mothers. Household group left out. Boostrix holds aluminium salts."
}
},
{
"trial": {
"nct": "NCT02388165",
"brief_title": "Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation",
"official_title": "A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 4 ANTIGEN VACCINE (SA4AG) IN ADULTS UNDERGOING ELECTIVE OPEN POSTERIOR SPINAL FUSION PROCEDURES WITH MULTILEVEL INSTRUMENTATION",
"conditions": [
"Staphylococcal Vaccine"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"18 Years",
"85 Years"
],
"arms": [
{
"label": "SA4Ag",
"type": "ACTIVE_COMPARATOR",
"description": "Staphylococcus aureus 4-antigen Vaccine",
"interventions": [
"Biological: Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Diluent (sterile water) for Placebo",
"interventions": [
"Other: Placebo"
]
}
],
"interventions": [
{
"name": "Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine",
"type": "BIOLOGICAL",
"description": "SA4Ag vaccine reconstituted in 0.5mL water for injection. Administered via IM injection, once 10 to 60 days prior to surgery",
"other_names": [
"Vaccine"
]
},
{
"name": "Placebo",
"type": "OTHER",
"description": "Vaccine excipients reconstituted in 0.5mL water for injections. Administered via IM injection given 10 to 60 days prior to surgery",
"other_names": []
}
],
"ae_time_frame": "SAE and non-SAE: From vaccination up to Day 180 (190-240 days after vaccination). Local and systemic reactions: within 10 days after vaccination (systematic assessment).",
"ae_description": "Safety population: included all participants who had received investigational product in this study. The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant  [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "Staphylococcus Aureus 4-antigen (SA4Ag)",
"description": "Participants randomized to SA4Ag received a single dose of 0.5 mL SA4Ag vaccine intramuscularly, 10 to 60 days prior to their scheduled surgery. Participants were followed from vaccination up to 6 months after their spinal surgical procedure."
},
{
"id": "EG001",
"title": "Placebo",
"description": "Participants randomized to this arm received placebo containing the vaccine excipients reconstituted in 0.5mL water for injection. It was administered via intramuscular injection, 10 to 60 days prior to scheduled surgery. Participants were followed from vaccination up to 6 months after their spinal surgical procedure."
}
]
},
"coder_1": {
"nct": "NCT02388165",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "SA4Ag: two capsular polysaccharide conjugates plus ClfA and MntC proteins, lyophilized and reconstituted in water, unadjuvanted as known for the product. Placebo is excipients in water. Patients scheduled for spinal fusion surgery."
},
"coder_2": {
"nct": "NCT02388165",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Adults having elective spinal fusion. Placebo is vaccine excipients in water. SA4Ag has recombinant proteins and conjugated polysaccharides; adjuvant not stated."
}
},
{
"trial": {
"nct": "NCT02492958",
"brief_title": "SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults",
"official_title": "A Phase 1/2a Placebo-controlled, Randomized, Double-blind, Sponsor-unblinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of Staphylococcus Aureus 4-antigen Vaccine (sa4ag) In Japanese Adults",
"conditions": [
"Staphylococcal Infections"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"20 Years",
"85 Years"
],
"arms": [
{
"label": "SA4Ag",
"type": "EXPERIMENTAL",
"description": "Staphylococcus aureus 4-antigen vaccine",
"interventions": [
"Biological: Staphylococcus aureus 4-antigen vaccine"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "a lyophile match to the vaccine, consisting of excipients of SA4Ag formulation minus the active ingredients",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "Staphylococcus aureus 4-antigen vaccine",
"type": "BIOLOGICAL",
"description": "a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm",
"other_names": [
"SA4Ag"
]
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm",
"other_names": []
}
],
"ae_time_frame": "",
"ae_description": "The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant or one participant may have experienced both a serious and non-serious event during the study.",
"ae_groups": [
{
"id": "EG000",
"title": "Placebo (20 to <65 Years)",
"description": "Participants aged from 20 years to less than (\\<) 65 years, received a single dose of placebo matched to Staphylococcus aureus 4-antigen (SA4Ag) vaccine intramuscularly on Day 1. Participants were followed up to Month 12."
},
{
"id": "EG001",
"title": "SA4Ag (20 to <65 Years)",
"description": "Participants aged from 20 years to \\<65 years, received a single 0.5 milliliter (mL) dose of SA4Ag vaccine intramuscularly on Day 1. Participants were followed up to Month 12."
},
{
"id": "EG002",
"title": "Placebo (65 to <86 Years)",
"description": "Participants aged from 65 years to \\<86 years, received a single dose of placebo matched to SA4Ag vaccine intramuscularly on Day 1. Participants were followed up to Month 12."
},
{
"id": "EG003",
"title": "SA4Ag (65 to <86 Years)",
"description": "Participants aged from 65 years to \\<86 years, received a single 0.5 mL dose of SA4Ag vaccine intramuscularly on Day 1. Participants were followed up to Month 12."
}
]
},
"coder_1": {
"nct": "NCT02492958",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000",
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two age strata pooled. SA4Ag (polysaccharide conjugates plus proteins) unadjuvanted as known for the product; placebo is its excipients."
},
"coder_2": {
"nct": "NCT02492958",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG000",
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two age cohorts pooled; placebo is excipients lyophile"
}
},
{
"trial": {
"nct": "NCT02531802",
"brief_title": "Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh",
"official_title": "A Randomized, Double-blind, Placebo-controlled, Dose-Escalation Study Evaluating the Safety, Tolerability, and Immunogenicity of an Oral Inactivated ETEC Vaccine (ETVAX) Alone and Together With dmLT Adjuvant in Descending Age Groups in Bangladesh",
"conditions": [
"Escherichia Coli Diarrhea"
],
"phases": [
"PHASE1",
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"6 Months",
"45 Years"
],
"arms": [
{
"label": "Adult: ETVAX (Full)",
"type": "EXPERIMENTAL",
"description": "Adult arm (18-45 year olds) receiving the full dose of ETVAX vaccine (10\\^11 inactivated E. coli bacteria) added to bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Biological: ETVAX",
"Other: Bicarbonate Buffer"
]
},
{
"label": "Adult: ETVAX (Full) + 10 ug dmLT",
"type": "EXPERIMENTAL",
"description": "Adult arm (18-45 year olds) receiving the full dose of ETVAX vaccine (10\\^11 inactivated E. coli bacteria) with 10 ug dmLT added to bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Biological: ETVAX",
"Biological: dmLT",
"Other: Bicarbonate Buffer"
]
},
{
"label": "Adult: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Adult arm (18-45 year olds) receiving a placebo on days 0 and 14",
"interventions": [
"Other: Bicarbonate Buffer"
]
},
{
"label": "24-59 months: ETVAX (1/4)",
"type": "EXPERIMENTAL",
"description": "24-59 month old children receiving a quarter adult dose (2.5 x 10\\^10 inactivated E. coli bacteria) of ETVAX vaccine in bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Biological: ETVAX",
"Other: Bicarbonate Buffer"
]
},
{
"label": "24-59 months: ETVAX (1/2)",
"type": "EXPERIMENTAL",
"description": "24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\\^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Biological: ETVAX",
"Other: Bicarbonate Buffer"
]
},
{
"label": "24-59 months: ETVAX (full)",
"type": "EXPERIMENTAL",
"description": "24-59 month old children receiving a full adult dose of ETVAX vaccine (10\\^11 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Biological: ETVAX",
"Other: Bicarbonate Buffer"
]
},
{
"label": "24-59 months: ETVAX (1/2) + 2.5 ug dmLT",
"type": "EXPERIMENTAL",
"description": "24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\\^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Biological: ETVAX",
"Biological: dmLT",
"Other: Bicarbonate Buffer"
]
},
{
"label": "24-59 months: ETVAX (1/2) + 5 ug dmLT",
"type": "EXPERIMENTAL",
"description": "24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\\^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Biological: ETVAX",
"Biological: dmLT",
"Other: Bicarbonate Buffer"
]
},
{
"label": "24-59 months: ETVAX (1/2) + 10 ug dmLT",
"type": "EXPERIMENTAL",
"description": "24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\\^10 inactivated E. coli bacteria) plus 10 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Biological: ETVAX",
"Biological: dmLT",
"Other: Bicarbonate Buffer"
]
},
{
"label": "24-59 months: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "24-59 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Other: Bicarbonate Buffer"
]
},
{
"label": "12-23 months: ETVAX (1/4)",
"type": "EXPERIMENTAL",
"description": "12-23 month old children receiving a quarter adult dose of ETVAX vaccine (2.5 x 10\\^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Biological: ETVAX",
"Other: Bicarbonate Buffer"
]
},
{
"label": "12-23 months: ETVAX (1/2)",
"type": "EXPERIMENTAL",
"description": "12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\\^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Biological: ETVAX",
"Other: Bicarbonate Buffer"
]
},
{
"label": "12-23 months: ETVAX (1/2) + 2.5 ug dmLT",
"type": "EXPERIMENTAL",
"description": "12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\\^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Biological: ETVAX",
"Biological: dmLT",
"Other: Bicarbonate Buffer"
]
},
{
"label": "12-23 months: ETVAX (1/2) + 5 ug dmLT",
"type": "EXPERIMENTAL",
"description": "12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\\^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Biological: ETVAX",
"Biological: dmLT",
"Other: Bicarbonate Buffer"
]
},
{
"label": "12-23 months: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "12-23 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Other: Bicarbonate Buffer"
]
},
{
"label": "6-11 months: ETVAX (1/8)",
"type": "EXPERIMENTAL",
"description": "6-11 month old children receiving an eighth of an adult dose of ETVAX vaccine in bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Biological: ETVAX",
"Other: Bicarbonate Buffer"
]
},
{
"label": "6-11 months: ETVAX (1/4)",
"type": "EXPERIMENTAL",
"description": "6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10\\^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Biological: ETVAX",
"Other: Bicarbonate Buffer"
]
},
{
"label": "6-11 months: ETVAX (1/2)",
"type": "EXPERIMENTAL",
"description": "6-11 month old children receiving a half of an adult dose of ETVAX vaccine (5 x 10\\^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Biological: ETVAX",
"Other: Bicarbonate Buffer"
]
},
{
"label": "6-11 months: ETVAX (1/4) + 2.5 ug dmLT",
"type": "EXPERIMENTAL",
"description": "6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10\\^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Biological: ETVAX",
"Biological: dmLT",
"Other: Bicarbonate Buffer"
]
},
{
"label": "6-11 month olds: ETVAX (1/4) + 5 ug dmLT",
"type": "EXPERIMENTAL",
"description": "6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10\\^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Biological: ETVAX",
"Biological: dmLT",
"Other: Bicarbonate Buffer"
]
},
{
"label": "6-11 month olds: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "6-11 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14",
"interventions": [
"Other: Bicarbonate Buffer"
]
}
],
"interventions": [
{
"name": "ETVAX",
"type": "BIOLOGICAL",
"description": "Varying dosages of liquid ETVAX vaccine (Batch BX1003574). A full dose consisted of: * Hybrid protein between the B-subunit of the E. coli heat-labile enterotoxin and the B-subunit of the cholera toxin (LCTBA): 1 mg * E. coli ETEX 21 formalin inactivated: 1.3 mg colonization factor 1 (CFA/I) * E. coli ETEX 22 formalin inactivated: 6.4 mg coli surface antigen 3 (CS3) * E. coli ETEX 23 formalin inactivated: 1.1 mg coli surface antigen 5 (CS5) * E.  [\u2026]",
"other_names": []
},
{
"name": "dmLT",
"type": "BIOLOGICAL",
"description": "Varying dosages of dmLT, a derivative of wild-type enterotoxigenic Escherichia coli LT that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.",
"other_names": [
"double mutant heat labile toxin, LT(R192G/L211A)"
]
},
{
"name": "Bicarbonate Buffer",
"type": "OTHER",
"description": "Sodium bicarbonate buffer dissolved in 150 ml of potable water",
"other_names": []
}
],
"ae_time_frame": "6 months \u00b1 14 days after the first dose for unsolicited adverse events, 7 days for solicited events (fever, vomiting, loose stools, diarrhea, acute systemic allergic reaction; plus nausea and abdominal pain/stomach ache for adults/children 24-59 months)",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Adult: ETVAX (Full)",
"description": "Adult arm (18-45 year olds) receiving the full dose of ETVAX vaccine (10\\^11 inactivated E. coli bacteria) added to bicarbonate buffer solution administered orally on Day 0 and 14"
},
{
"id": "EG001",
"title": "Adult: ETVAX (Full) + 10 ug dmLT",
"description": "Adult arm (18-45 year olds) receiving the full dose of ETVAX vaccine (10\\^11 inactivated E. coli bacteria) with 10 ug dmLT added to bicarbonate buffer solution administered orally on Day 0 and 14"
},
{
"id": "EG002",
"title": "Adult: Placebo",
"description": "Adult arm (18-45 year olds) receiving a placebo on days 0 and 14 Bicarbonate Buffer: Sodium bicarbonate buffer dissolved in 150 ml of potable water"
},
{
"id": "EG003",
"title": "24-59 Months: ETVAX (1/4)",
"description": "24-59 month old children receiving a quarter adult dose (2.5 x 10\\^10 inactivated E. coli bacteria) of ETVAX vaccine in bicarbonate buffer solution administered orally on Day 0 and 14"
},
{
"id": "EG004",
"title": "24-59 Months: ETVAX (1/2)",
"description": "24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\\^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14"
},
{
"id": "EG005",
"title": "24-59 Months: ETVAX (Full)",
"description": "24-59 month old children receiving a full adult dose of ETVAX vaccine (10\\^11 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14"
},
{
"id": "EG006",
"title": "24-59 Months: ETVAX (1/2) + 2.5 ug dmLT",
"description": "24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\\^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14"
},
{
"id": "EG007",
"title": "24-59 Months: ETVAX (1/2) + 5 ug dmLT",
"description": "24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\\^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14"
},
{
"id": "EG008",
"title": "24-59 Months: ETVAX (1/2) + 10 ug dmLT",
"description": "24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\\^10 inactivated E. coli bacteria) plus 10 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14"
},
{
"id": "EG009",
"title": "24-59 Months: Placebo",
"description": "24-59 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14 Bicarbonate Buffer: Sodium bicarbonate buffer dissolved in 150 ml of potable water"
},
{
"id": "EG010",
"title": "12-23 Months: ETVAX (1/4)",
"description": "12-23 month old children receiving a quarter adult dose of ETVAX vaccine (2.5 x 10\\^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14"
},
{
"id": "EG011",
"title": "12-23 Months: ETVAX (1/2)",
"description": "12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\\^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14"
},
{
"id": "EG012",
"title": "12-23 Months: ETVAX (1/2) + 2.5 ug dmLT",
"description": "12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\\^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14"
},
{
"id": "EG013",
"title": "12-23 Months: ETVAX (1/2) + 5 ug dmLT",
"description": "12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10\\^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14"
},
{
"id": "EG014",
"title": "12-23 Months: Placebo",
"description": "12-23 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14 Bicarbonate Buffer: Sodium bicarbonate buffer dissolved in 150 ml of potable water"
},
{
"id": "EG015",
"title": "6-11 Months: ETVAX (1/8)",
"description": "6-11 month old children receiving an eighth of an adult dose of ETVAX vaccine in bicarbonate buffer solution administered orally on Day 0 and 14"
},
{
"id": "EG016",
"title": "6-11 Months: ETVAX (1/4)",
"description": "6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10\\^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14"
},
{
"id": "EG017",
"title": "6-11 Months: ETVAX (1/2)",
"description": "6-11 month old children receiving a half of an adult dose of ETVAX vaccine (5 x 10\\^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14"
},
{
"id": "EG018",
"title": "6-11 Months: ETVAX (1/4) + 2.5 ug dmLT",
"description": "6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10\\^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14"
},
{
"id": "EG019",
"title": "6-11 Month Olds: ETVAX (1/4) + 5 ug dmLT",
"description": "6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10\\^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14"
},
{
"id": "EG020",
"title": "6-11 Month Olds: Placebo",
"description": "6-11 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14 Bicarbonate Buffer: Sodium bicarbonate buffer dissolved in 150 ml of potable water"
}
]
},
"coder_1": {
"nct": "NCT02531802",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG007",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG008",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG010",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG011",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG012",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG013",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG015",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG016",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG017",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG018",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG019",
"platforms": [
"inactivated"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002",
"EG009",
"EG014",
"EG020"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ETVAX: formalin-inactivated ETEC bacteria plus LCTBA toxoid (coded inactivated, like killed oral cholera). dmLT groups coded as adjuvanted formulations (adjuvant other), not as a separate active product. Placebo is the bicarbonate buffer. All age cohorts pooled."
},
"coder_2": {
"nct": "NCT02531802",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG011",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG015",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG016",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG017",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG006",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG007",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG008",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG012",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG013",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG018",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG019",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002",
"EG009",
"EG014",
"EG020"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ETVAX (inactivated ETEC + LCTBA protein), groups with dmLT adjuvant marked other; age cohorts pooled; placebo is bicarbonate buffer"
}
},
{
"trial": {
"nct": "NCT02547974",
"brief_title": "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults.",
"official_title": "An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults.",
"conditions": [
"Respiratory Disorders"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"18 Years",
"70 Years"
],
"arms": [
{
"label": "GSK3277513A F1 Group",
"type": "EXPERIMENTAL",
"description": "Subjects, 18 - 40 years, receiving two doses of the non adjuvanted GSK Biologicals' NTHi Mcat investigational vaccine (GSK3277513A ) containing formulation 1 (F1) of PD, PE-PilA and UspA2 during Step 1 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.",
"interventions": [
"Biological: Formulation 1 (plain): NTHi/Mcat vaccine GSK3277513A"
]
},
{
"label": "GSK3277513A F2 Group",
"type": "EXPERIMENTAL",
"description": "Subjects, 50 - 70 years, receiving two doses of the GSK Biologicals' NTHi-Mcat investigational vaccine(GSK3277513A) containing formulation 2 (F2) (adjuvanted) of PD, PE-PilA and UspA2 during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.",
"interventions": [
"Biological: Formulation 2 (adjuvanted): NTHi/Mcat vaccine GSK3277513A"
]
},
{
"label": "GSK3277513A F3 Group",
"type": "EXPERIMENTAL",
"description": "Subjects, 50 - 70 years, receiving two doses of the GSK Biologicals' NTHi-Mcat investigational vaccine(GSK3277513A) containing formulation 3 (F3) (adjuvanted) of PD, PE-PilA and UspA2 during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.",
"interventions": [
"Biological: Formulation 3 (adjuvanted): NTHi/Mcat vaccine GSK3339036A"
]
},
{
"label": "Placebo Group",
"type": "PLACEBO_COMPARATOR",
"description": "Subjects, 18 - 40 years, receiving two doses of placebo (saline solution) during Step 1 of the study and subjects, 50 - 70 years, receiving two doses of placebo (saline solution) during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.",
"interventions": [
"Drug: Placebo"
]
}
],
"interventions": [
{
"name": "Formulation 1 (plain): NTHi/Mcat vaccine GSK3277513A",
"type": "BIOLOGICAL",
"description": "2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule",
"other_names": []
},
{
"name": "Formulation 2 (adjuvanted): NTHi/Mcat vaccine GSK3277513A",
"type": "BIOLOGICAL",
"description": "2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule",
"other_names": []
},
{
"name": "Formulation 3 (adjuvanted): NTHi/Mcat vaccine GSK3339036A",
"type": "BIOLOGICAL",
"description": "2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule",
"other_names": []
},
{
"name": "Placebo",
"type": "DRUG",
"description": "2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule",
"other_names": []
}
],
"ae_time_frame": "Solicited symptoms:within the 7-day post-vaccination period and Unsolicited AEs: during 30 days post- vaccination period. SAEs: during the whole study period (from Day 0 to Day 420)",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "GSK3277513A F1 Group",
"description": "Subjects, 18 - 40 years, receiving two doses of the non adjuvanted GSK Biologicals' NTHi Mcat investigational vaccine (GSK3277513A ) containing formulation 1 (F1) of PD, PE-PilA and UspA2 during Step 1 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be per [\u2026]"
},
{
"id": "EG001",
"title": "GSK3277513A F2 Group",
"description": "Subjects, 50 - 70 years, receiving two doses of the GSK Biologicals' NTHi-Mcat investigational vaccine(GSK3277513A) containing formulation 2 (F2) (adjuvanted) of PD, PE-PilA and UspA2 during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be perform [\u2026]"
},
{
"id": "EG002",
"title": "GSK3277513A F3 Group",
"description": "Subjects, 50 - 70 years, receiving two doses of the GSK Biologicals' NTHi-Mcat investigational vaccine(GSK3277513A) containing formulation 3 (F3) (adjuvanted) of PD, PE-PilA and UspA2 during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be perform [\u2026]"
},
{
"id": "EG003",
"title": "PLACEBO Group",
"description": "Subjects, 18 - 40 years, receiving two doses of placebo (saline solution) during Step 1 of the study and subjects, 50 - 70 years, receiving two doses of placebo (saline solution) during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed."
}
]
},
"coder_1": {
"nct": "NCT02547974",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target: non-typeable H. influenzae and Moraxella catarrhalis (PD, PE-PilA, UspA2 proteins). F1 is stated non-adjuvanted; F2/F3 are 'adjuvanted' with the adjuvant not named. Placebo group pools 18-40 and 50-70 year steps."
},
"coder_2": {
"nct": "NCT02547974",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "NTHi/Mcat vaccine (COPD exacerbation target); F2/F3 adjuvanted with AS01E-type adjuvant (not aluminium) per product knowledge"
}
},
{
"trial": {
"nct": "NCT02561195",
"brief_title": "A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years",
"official_title": "A PHASE 2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF TWO 3-DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS",
"conditions": [
"Clostridium Difficile Associated Disease"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"65 Years",
"85 Years"
],
"arms": [
{
"label": "Low-dose C. difficile Vaccine (accelerated schedule)",
"type": "EXPERIMENTAL",
"description": "",
"interventions": [
"Biological: Clostridium difficile Vaccine"
]
},
{
"label": "High-dose C. difficile Vaccine (accelerated schedule)",
"type": "EXPERIMENTAL",
"description": "",
"interventions": [
"Biological: Clostridium difficile Vaccine"
]
},
{
"label": "Placebo (accelerated schedule)",
"type": "PLACEBO_COMPARATOR",
"description": "",
"interventions": [
"Biological: Placebo"
]
},
{
"label": "Low-dose C. difficile Vaccine (non-accelerated schedule)",
"type": "EXPERIMENTAL",
"description": "",
"interventions": [
"Biological: Clostridium difficile Vaccine"
]
},
{
"label": "High-Dose C. difficile Vaccine (non-accelerated schedule)",
"type": "EXPERIMENTAL",
"description": "",
"interventions": [
"Biological: Clostridium difficile Vaccine"
]
},
{
"label": "Placebo (non-accelerated schedule)",
"type": "PLACEBO_COMPARATOR",
"description": "",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "Clostridium difficile Vaccine",
"type": "BIOLOGICAL",
"description": "0.5 mL intramuscular injection.",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "0.5 mL intramuscular injection",
"other_names": []
}
],
"ae_time_frame": "AEs: From Vaccination 1 up to 1 month after Vaccination 3 (up to Month 2 for day regimen and Month 7 for month regimen); from Vaccination 4 up to 36 months (after Vaccination 4) SAEs: From Vaccination 1 through 6 months after Vaccination 3 (Month 7 for day regimen and Month 12 for month regimen); fr [\u2026]",
"ae_description": "SAEs and AEs were grouped by system organ class and preferred term. AEs included AEs collected in the e-diary (local and systemic reactions; systematic assessment) and AEs collected on the case report form at each visit (nonsystematic assessment). Safety population: all participants who received at  [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen",
"description": "Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination"
},
{
"id": "EG001",
"title": "Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen",
"description": "Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination."
},
{
"id": "EG002",
"title": "Placebo: Day 1, 8 and 30 Regimen",
"description": "Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination."
},
{
"id": "EG003",
"title": "Clostridium Difficile Vaccine(100 mcg): Month 0, 1 and 6 Regimen",
"description": "Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination."
},
{
"id": "EG004",
"title": "Clostridium Difficile Vaccine(200 mcg): Month 0, 1 and 6 Regimen",
"description": "Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination."
},
{
"id": "EG005",
"title": "Placebo: Month 0, 1 and 6 Regimen",
"description": "Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination."
},
{
"id": "EG006",
"title": "100mcg Clostridium Difficile Vaccine to Placebo:Day 1, 8 and 30 Regimen",
"description": "Eligible participants who received the first 3 doses of Clostridium difficile vaccine at the 100 mcg dose level received placebo intramuscularly as the fourth dose in extension stage at visit 9 (340 to 380 Days after vaccination 3). Participants were followed up to 36 months after the last vaccination."
},
{
"id": "EG007",
"title": "100mcg Clostridium Difficile Vaccine to 100mcg Clostridium Difficile Vaccine:Day 1, 8 and 30 Regimen",
"description": "Eligible participants who received the first 3 doses of Clostridium difficile vaccine at the 100 mcg dose level received a fourth dose of Clostridium difficile vaccine intramuscularly at the 100 mcg dose level in extension stage at visit 9 (340 to 380 Days after vaccination 3). Participants were followed up to 36 months after the last vaccination."
},
{
"id": "EG008",
"title": "200mcg Clostridium Difficile Vaccine to Placebo:Day 1, 8 and 30 Regimen",
"description": "Eligible participants who received the first 3 doses of Clostridium difficile vaccine at the 200 mcg dose level received placebo as the fourth dose in extension stage at visit 9 (340 to 380 Days after vaccination 3). Participants were followed up to 36 months after the last vaccination."
},
{
"id": "EG009",
"title": "200mcg Clostridium Difficile Vaccine to 200mcg Clostridium Difficile Vaccine:Day 1, 8 and 30 Regimen",
"description": "Eligible participants who received the first 3 doses of Clostridium difficile vaccine at the 200 mcg dose level received fourth dose of Clostridium difficile vaccine intramuscularly at the 200 mcg dose level in extension stage at visit 9 (340 to 380 Days after vaccination 3). Participants were followed up to 36 months after the last vaccination."
},
{
"id": "EG010",
"title": "100mcg Clostridium Difficile Vaccine to Placebo:Month 0, 1 and 6 Regimen",
"description": "Eligible participants who received the first 3 doses of Clostridium difficile vaccine at the 100 mcg dose level received placebo intramuscularly as the fourth dose in extension stage at visit 9 (340 to 380 Days after vaccination 3). Participants were followed up to 36 months after the last vaccination."
},
{
"id": "EG011",
"title": "100mcg Clostridium Difficile Vaccine to 100mcg Clostridium Difficile Vaccine:Month 0,1 and 6 Regimen",
"description": "Eligible participants who received the first 3 doses of Clostridium difficile vaccine at the 100 mcg dose level received fourth dose of Clostridium difficile vaccine intramuscularly at the 100 mcg dose level in extension stage at visit 9 (340 to 380 Days after vaccination 3). Participants were followed up to 36 months after the last vaccination."
},
{
"id": "EG012",
"title": "200mcg Clostridium Difficile Vaccine to Placebo:Month 0, 1 and 6 Regimen",
"description": "Eligible participants who received the first 3 doses of Clostridium difficile vaccine at the 200 mcg dose level received placebo as the fourth dose in extension stage at visit 9 (340 to 380 Days after vaccination 3). Participants were followed up to 36 months after the last vaccination."
},
{
"id": "EG013",
"title": "200mcg Clostridium Difficile Vaccine to 200mcg Clostridium Difficile Vaccine:Month 0,1 and 6 Regimen",
"description": "Eligible participants who received the first 3 doses of Clostridium difficile vaccine at the 200 mcg dose level received fourth dose of Clostridium difficile vaccine intramuscularly at the 200 mcg dose level in extension stage at visit 9 (340 to 380 Days after vaccination 3). Participants were followed up to 36 months after the last vaccination."
}
]
},
"coder_1": {
"nct": "NCT02561195",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG002",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took stage 1 groups (both schedules, both doses, saline placebo). Left out EG006-EG013: extension-stage fourth dose re-randomized among vaccine recipients only. Toxoid vaccine; adjuvant not stated."
},
"coder_2": {
"nct": "NCT02561195",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "First randomization groups only (EG000-EG005); EG006-EG013 are re-randomized booster/placebo subsets of the same participants. Pfizer toxoid vaccine, aluminium hydroxide per product knowledge."
}
},
{
"trial": {
"nct": "NCT02612909",
"brief_title": "A Safety and Immunogenicity Study of IVACFLU-A/H5N1",
"official_title": "A Phase 2/3 Double Blinded, Randomized, Placebo-controlled Study in Healthy Adult Volunteers in Vietnam to Examine the Safety and Immunogenicity of an Inactivated A/H5N1 Influenza Vaccine (IVACFLU-A/H5N1) Produced by IVAC",
"conditions": [
"Avian Influenza"
],
"phases": [
"PHASE2",
"PHASE3"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"18 Years",
"60 Years"
],
"arms": [
{
"label": "Phase 2: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.",
"interventions": [
"Biological: Placebo"
]
},
{
"label": "Phase 2: Vaccine (15 mcg)",
"type": "ACTIVE_COMPARATOR",
"description": "Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.",
"interventions": [
"Biological: IVACFLU-A/H5N1 vaccine"
]
},
{
"label": "Phase 2: Vaccine (30 mcg)",
"type": "ACTIVE_COMPARATOR",
"description": "Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.",
"interventions": [
"Biological: IVACFLU-A/H5N1 vaccine"
]
},
{
"label": "Phase 3: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.",
"interventions": [
"Biological: Placebo"
]
},
{
"label": "Phase 3: Vaccine",
"type": "EXPERIMENTAL",
"description": "Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.",
"interventions": [
"Biological: IVACFLU-A/H5N1 vaccine"
]
}
],
"interventions": [
{
"name": "IVACFLU-A/H5N1 vaccine",
"type": "BIOLOGICAL",
"description": "Monovalent A/H5N1 influenza vaccine (MIV), whole virion inactivated, purified by sucrose gradient on ultracentrifuge. The vaccine was produced in eggs, inactivated with formaldehyde, and formulated with aluminum hydroxide 0.6 mg/0.5 mL with no preservative.",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Includes 4.500mg sodium chloride, 0.685 mg sodium phosphate dibasic dihydrate, and 0.186 mg sodium phosphate monobasic dihydrate.",
"other_names": [
"Sterile Phosphate Buffered Saline (PBS)"
]
}
],
"ae_time_frame": "21 days for non-serious adverse events, 90 days for serious adverse events",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Phase 2: Placebo",
"description": "Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days."
},
{
"id": "EG001",
"title": "Phase 2: Vaccine (15 mcg)",
"description": "Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days."
},
{
"id": "EG002",
"title": "Phase 2: Vaccine (30 mcg)",
"description": "Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days."
},
{
"id": "EG003",
"title": "Phase 3: Placebo",
"description": "Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days."
},
{
"id": "EG004",
"title": "Phase 3: Vaccine",
"description": "Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days."
}
]
},
"coder_1": {
"nct": "NCT02612909",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Whole-virion inactivated H5N1 on aluminium hydroxide; phase 2 and phase 3 parts pooled; placebo PBS."
},
"coder_2": {
"nct": "NCT02612909",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "H5N1 whole-virion vaccine, no adjuvant named; phase 2 and phase 3 cohorts pooled"
}
},
{
"trial": {
"nct": "NCT02646371",
"brief_title": "Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a",
"official_title": "Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a",
"conditions": [
"Shigellosis"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"18 Years",
"50 Years"
],
"arms": [
{
"label": "Flexyn2a",
"type": "ACTIVE_COMPARATOR",
"description": "2 doses of 10 \u03bcg of Flexyn2a will be injected intramuscularly 4 weeks apart",
"interventions": [
"Biological: Flexyn2a"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "2 doses of TBS solution will be injected intramuscularly 4 weeks apart",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "Flexyn2a",
"type": "BIOLOGICAL",
"description": "2 doses of 10 \u03bcg of Flexyn2a will be injected intramuscularly 4 weeks apart",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "2 doses of TBS solution will be injected intramuscularly 4 weeks apart",
"other_names": []
}
],
"ae_time_frame": "",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Flexyn2a - Vaccination",
"description": "In the Flexyn2a treatment arm - 34 subjects received the first Flexyn2a vaccine and 34 subjects received the second Flexyn2a vaccine."
},
{
"id": "EG001",
"title": "Placebo - Vaccination",
"description": "In the control treatment (Placebo) arm - 34 subjects received the first Placebo vaccine and 30 subjects received the second Placebo vaccine."
}
]
},
"coder_1": {
"nct": "NCT02646371",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Flexyn2a, an S. flexneri 2a O-polysaccharide bioconjugate; adjuvant not stated. Placebo TBS. Groups are the vaccination phase; both arms were later challenged with S. flexneri 2a."
},
"coder_2": {
"nct": "NCT02646371",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Shigella flexneri 2a bioconjugate vaccine vs TBS buffer; no adjuvant named in the record"
}
},
{
"trial": {
"nct": "NCT02712424",
"brief_title": "DAR-901 TB Booster Vaccine to Prevent TB in Adolescents",
"official_title": "A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study of the Prevention of Infection With Mycobacterium Tuberculosis Among Adolescents Who Have Previously Received BCG",
"conditions": [
"Tuberculosis"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"13 Years",
"15 Years"
],
"arms": [
{
"label": "DAR-901",
"type": "ACTIVE_COMPARATOR",
"description": "0.1 mL intradermal injection of 1 mg DAR-901",
"interventions": [
"Biological: DAR-901"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "0.1 mL intradermal injection of sterile saline for human use",
"interventions": [
"Biological: Sterile saline placebo"
]
}
],
"interventions": [
{
"name": "DAR-901",
"type": "BIOLOGICAL",
"description": "",
"other_names": []
},
{
"name": "Sterile saline placebo",
"type": "BIOLOGICAL",
"description": "",
"other_names": []
}
],
"ae_time_frame": "3 years",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "DAR-901",
"description": "0.1 mL intradermal injection of 1 mg DAR-901 DAR-901"
},
{
"id": "EG001",
"title": "Placebo",
"description": "0.1 mL intradermal injection of sterile saline for human use Sterile saline placebo"
}
]
},
"coder_1": {
"nct": "NCT02712424",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "prior BCG"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "DAR-901 composition not given in the record (it is described elsewhere as a whole-cell inactivated mycobacterial vaccine), so platform other and adjuvant unknown. Participants previously received BCG."
},
"coder_2": {
"nct": "NCT02712424",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "DAR-901 inactivated whole-cell mycobacterium booster; no adjuvant named"
}
},
{
"trial": {
"nct": "NCT02756208",
"brief_title": "A Safety and Immunogenicity Trial of IHV01",
"official_title": "A Phase I Safety and Immunogenicity Trial of IHV01 in HIV-1 Uninfected Volunteers",
"conditions": [
"HIV Infection"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"45 Years"
],
"arms": [
{
"label": "300 ug FLSC vaccine",
"type": "EXPERIMENTAL",
"description": "Subjects will be vaccinated with 300 ug FLSC vaccine (highest vaccine dose) on study days 0, 28, 56 and 168.",
"interventions": [
"Biological: 300 ug FLSC vaccine"
]
},
{
"label": "150 ug FLSC vaccine",
"type": "EXPERIMENTAL",
"description": "Subjects will be vaccinated with 150 ug FLSC vaccine (middle vaccine dose) on study days 0, 28, 56 and 168.",
"interventions": [
"Biological: 150 ug FLSC vaccine"
]
},
{
"label": "75 ug FLSC vaccine",
"type": "EXPERIMENTAL",
"description": "Subjects will be vaccinated with 75 ug FLSC vaccine (lowest vaccine dose) on study days 0, 28, 56 and 168.",
"interventions": [
"Biological: 75 ug FLSC vaccine"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Subjects will be vaccinated with placebo (control group) on study days 0, 28, 56 and 168.",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "300 ug FLSC vaccine",
"type": "BIOLOGICAL",
"description": "FLSC vaccine 300 ug (1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168",
"other_names": [
"Full length single chain gp120-CD4 complex vaccine"
]
},
{
"name": "150 ug FLSC vaccine",
"type": "BIOLOGICAL",
"description": "FLSC vaccine 150 ug (0.5 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168",
"other_names": [
"Full length single chain gp120-CD4 complex vaccine"
]
},
{
"name": "75 ug FLSC vaccine",
"type": "BIOLOGICAL",
"description": "FLSC vaccine 75 ug (0.25 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168",
"other_names": [
"Full length single chain gp120-CD4 complex vaccine"
]
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Placebo sterile saline (0.25 - 1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168",
"other_names": [
"sterile saline"
]
}
],
"ae_time_frame": "1 year",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "300 ug FLSC Vaccine",
"description": "Highest dose vaccine group"
},
{
"id": "EG001",
"title": "150 ug FLSC Vaccine",
"description": "Middle dose vaccine group"
},
{
"id": "EG002",
"title": "75 ug FLSC Vaccine",
"description": "Lowest dose vaccine group"
},
{
"id": "EG003",
"title": "Placebo",
"description": "Control group"
}
]
},
"coder_1": {
"nct": "NCT02756208",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "IHV01 (full-length single-chain gp120-CD4 complex) in HIV-uninfected adults; adjuvant not stated; placebo saline."
},
"coder_2": {
"nct": "NCT02756208",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "IHV01 (FLSC) gp120-CD4 fusion protein; aluminium adjuvant by product knowledge, not stated in record; saline placebo"
}
},
{
"trial": {
"nct": "NCT02852005",
"brief_title": "Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205",
"official_title": "A Phase 1 Clinical Trial to Evaluate the Immunogenicity of AIDSVAX B/E Bivalent gp120 Vaccine and MVA/HIV62B in Healthy, HIV-1-Uninfected Adult Participants Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205",
"conditions": [
"HIV Infections"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"55 Years"
],
"arms": [
{
"label": "Group 1: MVA/HIV62B + Placebo",
"type": "EXPERIMENTAL",
"description": "Participants who received 3 sequential administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive placebo in their right deltoid at Months 0 and 4.",
"interventions": [
"Biological: MVA/HIV62B vaccine",
"Biological: Placebo"
]
},
{
"label": "Group 2: MVA/HIV62B + AIDSVAX B/E",
"type": "EXPERIMENTAL",
"description": "Participants who received 3 sequential administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.",
"interventions": [
"Biological: MVA/HIV62B vaccine",
"Biological: AIDSVAX B/E vaccine"
]
},
{
"label": "Group 3: MVA/HIV62B + Placebo",
"type": "EXPERIMENTAL",
"description": "Participants who received 2 sequential priming administrations of JS7 DNA plasmid followed by 2 sequential boost administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive placebo in their right deltoid at Months 0 and 4.",
"interventions": [
"Biological: MVA/HIV62B vaccine",
"Biological: Placebo"
]
},
{
"label": "Group 4: MVA/HIV62B + AIDSVAX B/E",
"type": "EXPERIMENTAL",
"description": "Participants who received 2 sequential priming administrations of JS7 DNA plasmid followed by 2 sequential boost administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.",
"interventions": [
"Biological: MVA/HIV62B vaccine",
"Biological: AIDSVAX B/E vaccine"
]
},
{
"label": "Group 5: Placebo + AIDSVAX B/E",
"type": "EXPERIMENTAL",
"description": "Participants who received 2 sequential priming administrations of JS7 DNA plasmid followed by 2 sequential boost administrations of MVA/HIV62B in HVTN 205 will receive placebo in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.",
"interventions": [
"Biological: AIDSVAX B/E vaccine",
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "MVA/HIV62B vaccine",
"type": "BIOLOGICAL",
"description": "1\u00d710\\^8 TCID50 dose to be administered as a 1 mL intramuscular (IM) injection in the deltoid",
"other_names": []
},
{
"name": "AIDSVAX B/E vaccine",
"type": "BIOLOGICAL",
"description": "600 mcg/mL dose to be administered as a 1 mL IM injection in the deltoid",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Sodium Chloride for Injection USP, 0.9% to be administered as a 1 mL IM injection in the deltoid",
"other_names": []
}
],
"ae_time_frame": "Serious adverse events are collected throughout the study (months 0-10). Non-serious adverse events are collected through 30 days after each vaccination (at months 0 and 4).",
"ae_description": "This table shows the number of participants reporting AEs by MedDRA preferred term and severity grade. The table was not grouped by the vaccine products because no vaccine related AE occurred.",
"ae_groups": [
{
"id": "EG000",
"title": "Group 1: Boost",
"description": "MVA/HIV62B mo(0,4) post HVTN 205 MMM"
},
{
"id": "EG001",
"title": "Group 2: Boost",
"description": "MVA/HIV62B + AIDSVAX B/E mo(0,4) post HVTN 205 MMM"
},
{
"id": "EG002",
"title": "Group 3: Boost",
"description": "MVA/HIV62B mo(0,4) post HVTN 205 DDMM"
},
{
"id": "EG003",
"title": "Group 4: Boost",
"description": "MVA/HIV62B + AIDSVAX B/E mo(0,4) post HVTN 205 DDMM"
},
{
"id": "EG004",
"title": "Group 5: Boost",
"description": "AIDSVAX B/E mo(0,4) post HVTN 205 DDMM"
}
]
},
"coder_1": {
"nct": "NCT02852005",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG000",
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "MVA/HIV62B boost; all previously vaccinated in HVTN 205"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AIDSVAX B/E vs saline, both arms boosted with MVA/HIV62B; pooled the two prior-regimen strata (MMM: EG001 vs EG000; DDMM: EG003 vs EG002). Left out EG004 (placebo + AIDSVAX), whose MVA-vs-placebo partner EG003 is already used. AIDSVAX adjuvant not stated."
},
"coder_2": {
"nct": "NCT02852005",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "every arm gets MVA/HIV62B and/or AIDSVAX; placebo only in place of one component"
}
},
{
"trial": {
"nct": "NCT02873286",
"brief_title": "RSV-MVA-BN Vaccine Phase II Trial in \u2265 55 Year Old Adults",
"official_title": "A Randomized, Single-blind, Placebo Controlled, Dose-ranging Phase II Trial in \u2265 55 Year Old Adults to Evaluate the Safety and Immunogenicity of the Recombinant MVA-BN-RSV Vaccine",
"conditions": [
"Respiratory Syncytial Virus Infections"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "SINGLE",
"ages": [
"55 Years",
null
],
"arms": [
{
"label": "Group 1 - Single Low Dose / Booster",
"type": "EXPERIMENTAL",
"description": "First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)",
"interventions": [
"Biological: MVA-BN-RSV",
"Other: Placebo"
]
},
{
"label": "Group 2 - Two Low Doses",
"type": "EXPERIMENTAL",
"description": "First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)",
"interventions": [
"Biological: MVA-BN-RSV"
]
},
{
"label": "Group 3 - Single High Dose / Booster",
"type": "EXPERIMENTAL",
"description": "First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)",
"interventions": [
"Biological: MVA-BN-RSV",
"Other: Placebo"
]
},
{
"label": "Group 4 - Two High Doses",
"type": "EXPERIMENTAL",
"description": "First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)",
"interventions": [
"Biological: MVA-BN-RSV"
]
},
{
"label": "Group 5 - Placebo",
"type": "EXPERIMENTAL",
"description": "First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)",
"interventions": [
"Other: Placebo"
]
}
],
"interventions": [
{
"name": "MVA-BN-RSV",
"type": "BIOLOGICAL",
"description": "MVA-mBN294B",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "Tris Buffered Saline, sterile",
"other_names": []
}
],
"ae_time_frame": "108 weeks for participants of both study parts and 30 weeks for participants of the main study only",
"ae_description": "Serious adverse events were to be reported during the entire study, non-serious adverse events within 4 weeks after each vaccination. Percentages of participants are based on MedDRA Preferred Terms.",
"ae_groups": [
{
"id": "EG000",
"title": "Group 1 - Single Low Dose / Booster",
"description": "First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)"
},
{
"id": "EG001",
"title": "Group 2 - Two Low Doses",
"description": "First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)"
},
{
"id": "EG002",
"title": "Group 3 - Single High Dose / Booster",
"description": "First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)"
},
{
"id": "EG003",
"title": "Group 4 - Two High Doses",
"description": "First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)"
},
{
"id": "EG004",
"title": "Group 5 - Placebo",
"description": "First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)"
}
]
},
"coder_1": {
"nct": "NCT02873286",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MVA-BN-RSV vs TBS placebo. Took the two-dose groups; left out EG000/EG002, whose groups include a week-56 booster phase and follow-up to 108 weeks without placebo (placebo followed 30 weeks)."
},
"coder_2": {
"nct": "NCT02873286",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MVA-BN-RSV dose groups pooled; whole follow-up of 108 weeks includes week 56 booster in groups 1 and 3"
}
},
{
"trial": {
"nct": "NCT02918006",
"brief_title": "A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine",
"official_title": "Phase 2 Randomized, Controlled, Human Influenza A (H1N1) Challenge Study Following Administration of an Oral H1N1 HA Adenoviral-Vector Based Seasonal Influenza Vaccine and dsRNA Adjuvant to Healthy Adult Volunteers",
"conditions": [
"Influenza"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"49 Years"
],
"arms": [
{
"label": "Oral Vaccine (VXA-A1.1)",
"type": "EXPERIMENTAL",
"description": "Oral enteric coated vaccine tablets. Placebo (saline solution) IM injection will also be administered in this arm.",
"interventions": [
"Biological: VXA-A1.1",
"Other: Saline Solution for Placebo IM Injection"
]
},
{
"label": "QIV IM Injection",
"type": "ACTIVE_COMPARATOR",
"description": "A commercially available QIV will be administered at the approved dose level as the active comparator. Oral placebo tablets will also be administered in this arm.",
"interventions": [
"Biological: Fluzone\u00ae",
"Other: Placebo Tablets"
]
},
{
"label": "Oral and IM Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Two forms or placebos (saline IM injection and oral placebo tablets) will be administered in this arm.",
"interventions": [
"Other: Placebo Tablets",
"Other: Saline Solution for Placebo IM Injection"
]
}
],
"interventions": [
{
"name": "VXA-A1.1",
"type": "BIOLOGICAL",
"description": "Enteric coated oral vaccine tablet",
"other_names": [
"Oral H1N1 Ad5 Tableted Vaccine"
]
},
{
"name": "Fluzone\u00ae",
"type": "BIOLOGICAL",
"description": "Fluzone Quadravalent (Fluzone\u00ae) influenza vaccine (QIV) suspension for intramuscular (IM) injection",
"other_names": [
"Fluzone Quadravalent"
]
},
{
"name": "Placebo Tablets",
"type": "OTHER",
"description": "Placebo tablets similar in size, color and number to the active oral tablet vaccine drug product",
"other_names": [
"Enteric Coated Placebo Tablets"
]
},
{
"name": "Saline Solution for Placebo IM Injection",
"type": "OTHER",
"description": "",
"other_names": [
"0.9% Sodium Chloride Injection, USP"
]
}
],
"ae_time_frame": "Systemic and local solicited adverse events were collected daily through Day 8 post-vaccination Unsolicited AEs were recorded through 120 days post-vaccination (90 days in Part A and 30 days post challenge in Part B) SAEs and AESIs/NOCIs are recorded through Day 365",
"ae_description": "Systemic and local solicited adverse events were graded on a scale of 0 (absent), 1 (mild), 2 (moderate) and 3 (severe) Systemic events include: diarrhea, nausea, vomiting, abdominal pain, malaise, anorexia, headache, myalgia and fever. Local events include injection site reactions of: pain, tendern [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "Oral Vaccine (VXA-A1.1)",
"description": "Oral enteric coated vaccine tablets. Placebo (saline solution) IM injection was also administered in this arm. VXA-A1.1: Enteric coated oral vaccine tablet Saline Solution for Placebo IM Injection"
},
{
"id": "EG001",
"title": "QIV IM Injection",
"description": "A commercially available QIV was administered at the approved dose level as the active comparator. Oral placebo tablets were also administered in this arm. Fluzone\u00ae: Fluzone Quadravalent (Fluzone\u00ae) influenza vaccine (QIV) suspension for intramuscular (IM) injection Placebo Tablets: Placebo tablets similar in size, color and number to the active oral tablet vaccine drug product"
},
{
"id": "EG002",
"title": "Oral and IM Placebo",
"description": "Two forms of placebo (saline IM injection and oral placebo tablets) were administered in this arm. Placebo Tablets: Placebo tablets similar in size, color and number to the active oral tablet vaccine drug product Saline Solution for Placebo IM Injection"
}
]
},
"coder_1": {
"nct": "NCT02918006",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "H1N1 influenza challenge after vaccination"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Oral Ad5 HA vector tablet with dsRNA adjuvant (VXA-A1.1) and Fluzone Quadrivalent (QIV with oral placebo) each vs oral placebo tablets plus IM saline. Placebo tablets' composition not given (IM placebo was saline)."
},
"coder_2": {
"nct": "NCT02918006",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Oral adenoviral-vector vaccine with dsRNA adjuvant vs oral placebo tablet plus saline IM; QIV group EG001 left out as active control"
}
},
{
"trial": {
"nct": "NCT02962908",
"brief_title": "A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine",
"official_title": "A Randomised, Double-blind, Placebo-controlled, Single-centre Phase IIb Trial as Part of the EU-funded UNISEC Project to Assess the Immunogenicity and Safety of Different Formulations and Dosing Regimens of FLU-v Vaccine in Healthy Adults",
"conditions": [
"Influenza"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"60 Years"
],
"arms": [
{
"label": "Group 1",
"type": "EXPERIMENTAL",
"description": "(n=74): FLU-v on Day 0 and Day 21",
"interventions": [
"Biological: FLU-v"
]
},
{
"label": "Group 2",
"type": "EXPERIMENTAL",
"description": "(n=74): adjuvanted FLU-v on Day 0, saline (0.5mL) on Day 21",
"interventions": [
"Biological: adjuvanted FLU-v",
"Biological: Saline"
]
},
{
"label": "Group 3",
"type": "PLACEBO_COMPARATOR",
"description": "(n=37): saline solution (0.5ml) on Day 0 and Day 21",
"interventions": [
"Biological: Saline"
]
},
{
"label": "Group 4",
"type": "PLACEBO_COMPARATOR",
"description": "(n=37): Adjuvanted placebo on Day 0, saline (0.5mL) on Day 21",
"interventions": [
"Biological: Saline",
"Biological: Adjuvanted placebo"
]
}
],
"interventions": [
{
"name": "FLU-v",
"type": "BIOLOGICAL",
"description": "Subcutaneous injection in the upper arm with 500 ug of FLU-v as 0.5ml suspension in 0.01M HCl and 0.01M NaOH",
"other_names": []
},
{
"name": "adjuvanted FLU-v",
"type": "BIOLOGICAL",
"description": "Subcutaneous injection in the upper arm with 500ug of FLU-v emulsified in 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection",
"other_names": []
},
{
"name": "Saline",
"type": "BIOLOGICAL",
"description": "Subcutaneous injection in the upper arm with 0.5ml of saline",
"other_names": [
"NaCl"
]
},
{
"name": "Adjuvanted placebo",
"type": "BIOLOGICAL",
"description": "Subcutaneous injection in the upper arm with an emulsion made with 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection",
"other_names": []
}
],
"ae_time_frame": "From vaccination to study completion (approx. 7 months)",
"ae_description": "Solicited Adverse Events were collected for 21 days after each vaccination. Subjects had to fill in the AEs diary card daily and return to the clinic on the next scheduled visit. Unsolicited Adverse Events and Severe Adverse Events were collected at any time during the study directly to the PI or st [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "2x Non-adjuvanted FLU-v",
"description": "FLU-v on Day 0 and Day 21 FLU-v: Subcutaneous injection in the upper arm with 500 ug of FLU-v as 0.5ml suspension in 0.01M HCl and 0.01M NaOH"
},
{
"id": "EG001",
"title": "1x Adjuvanted FLU-v",
"description": "adjuvanted FLU-v on Day 0, saline (0.5mL) on Day 21 adjuvanted FLU-v: Subcutaneous injection in the upper arm with 500ug of FLU-v emulsified in 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection Saline: Subcutaneous injection in the upper arm with 0.5ml of saline"
},
{
"id": "EG002",
"title": "Non-adjuvanted Placebo",
"description": "saline solution (0.5ml) on Day 0 and Day 21 Saline: Subcutaneous injection in the upper arm with 0.5ml of saline"
},
{
"id": "EG003",
"title": "Adjuvanted Placebo",
"description": "Adjuvanted placebo on Day 0, saline (0.5mL) on Day 21 Saline: Subcutaneous injection in the upper arm with 0.5ml of saline Adjuvanted placebo: Subcutaneous injection in the upper arm with an emulsion made with 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection"
}
]
},
"coder_1": {
"nct": "NCT02962908",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two matched designs kept apart because their placebos differ: unadjuvanted FLU-v x2 vs saline x2, and Montanide ISA-51-adjuvanted FLU-v + saline vs adjuvant-only placebo + saline. Platform 'other': the record does not say what FLU-v is (believed a synthetic peptide mix, which would be protein)."
},
"coder_2": {
"nct": "NCT02962908",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two comparisons by placebo type: unadjuvanted FLU-v vs saline; Montanide ISA-51 FLU-v vs Montanide placebo."
}
},
{
"trial": {
"nct": "NCT02998996",
"brief_title": "Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose\u2122 FLU",
"official_title": "A Phase I/II, Randomised, Placebo-controlled, Partially-blinded, Parallel-group Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose\u2122 FLU",
"conditions": [
"Influenza, Human"
],
"phases": [
"PHASE1",
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"39 Years"
],
"arms": [
{
"label": "Immunose\u2122 FLU 1%,",
"type": "EXPERIMENTAL",
"description": "15 \u00b5g haemagglutinin(HA)/strain and 1% Endocine\u2122",
"interventions": [
"Biological: 15 \u00b5g HA/strain and 1% Endocine\u2122"
]
},
{
"label": "Immunose\u2122 FLU 2%,",
"type": "EXPERIMENTAL",
"description": "15 \u00b5g HA/strain and 2% Endocine\u2122",
"interventions": [
"Biological: 15 \u00b5g HA/strain and 2% Endocine\u2122"
]
},
{
"label": "Influenza antigen,",
"type": "EXPERIMENTAL",
"description": "15 \u00b5g HA/strain",
"interventions": [
"Biological: 15 \u00b5g HA/strain"
]
},
{
"label": "Saline (NaCl),",
"type": "PLACEBO_COMPARATOR",
"description": "Placebo",
"interventions": [
"Biological: Placebo, Saline"
]
},
{
"label": "i.m. comparator,",
"type": "ACTIVE_COMPARATOR",
"description": "15 \u00b5g HA/strain",
"interventions": [
"Biological: intramuscular comparator"
]
},
{
"label": "i.n. comparator",
"type": "ACTIVE_COMPARATOR",
"description": "",
"interventions": [
"Biological: intranasal comparator"
]
}
],
"interventions": [
{
"name": "15 \u00b5g HA/strain and 1% Endocine\u2122",
"type": "BIOLOGICAL",
"description": "intranasal administration",
"other_names": []
},
{
"name": "15 \u00b5g HA/strain and 2% Endocine\u2122",
"type": "BIOLOGICAL",
"description": "intranasal administration",
"other_names": []
},
{
"name": "15 \u00b5g HA/strain",
"type": "BIOLOGICAL",
"description": "intranasal administration",
"other_names": []
},
{
"name": "intramuscular comparator",
"type": "BIOLOGICAL",
"description": "intramuscular administration",
"other_names": []
},
{
"name": "intranasal comparator",
"type": "BIOLOGICAL",
"description": "intranasal administration",
"other_names": []
},
{
"name": "Placebo, Saline",
"type": "BIOLOGICAL",
"description": "intranasal administration",
"other_names": []
}
],
"ae_time_frame": "From first dose of IMP until the subject's last visit to the clinic (Visit 4 for Group 1 to 4 and Visit 3 for Group 5 and 6). In addition to collection of AEs at the clinic visits, solicited and unsolicited AEs were collected using a diary for 10 days after each dose administration. SAEs and AEs of  [\u2026]",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Immunose\u2122 FLU 1%,",
"description": "15 \u00b5g haemagglutinin(HA)/strain and 1% Endocine\u2122 15 \u00b5g HA/strain and 1% Endocine\u2122: intranasal administration"
},
{
"id": "EG001",
"title": "Immunose\u2122 FLU 2%,",
"description": "15 \u00b5g HA/strain and 2% Endocine\u2122 15 \u00b5g HA/strain and 2% Endocine\u2122: intranasal administration"
},
{
"id": "EG002",
"title": "Influenza Antigen,",
"description": "15 \u00b5g HA/strain 15 \u00b5g HA/strain: intranasal administration"
},
{
"id": "EG003",
"title": "Saline (NaCl),",
"description": "Placebo Placebo, Saline: intranasal administration"
},
{
"id": "EG004",
"title": "i.m. Comparator,",
"description": "15 \u00b5g HA/strain intramuscular comparator: intramuscular administration"
},
{
"id": "EG005",
"title": "i.n. Comparator",
"description": "intranasal comparator: intranasal administration"
}
]
},
"coder_1": {
"nct": "NCT02998996",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal HA antigen with 1% or 2% Endocine or alone vs intranasal saline. EG004 (i.m. comparator) and EG005 (i.n. comparator) left out: active comparators on a different schedule. Platform 'other': 15 ug HA/strain influenza antigen, record does not say split (inactivated) or subunit (protein)."
},
"coder_2": {
"nct": "NCT02998996",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal split-antigen assumed inactivated; left out i.m. and i.n. comparator groups (active controls)."
}
},
{
"trial": {
"nct": "NCT03014089",
"brief_title": "Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects",
"official_title": "A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region",
"conditions": [
"Zika Virus"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"18 Years",
"49 Years"
],
"arms": [
{
"label": "mRNA-1325",
"type": "EXPERIMENTAL",
"description": "",
"interventions": [
"Biological: mRNA-1325"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "0.9% sodium chloride",
"interventions": [
"Other: Placebo"
]
}
],
"interventions": [
{
"name": "mRNA-1325",
"type": "BIOLOGICAL",
"description": "Escalating dose levels",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "",
"other_names": []
}
],
"ae_time_frame": "Baseline up to Day 392",
"ae_description": "The Safety set included all participants in Randomized Set who received at least 1 dose of study drug (mRNA-1325 or placebo). Adverse Events reported in the Adverse Events section below include unsolicited AEs and solicited ARs. All AEs considered an SAE were collected till end of study (Day 392). T [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "mRNA-1325 10 mcg",
"description": "Participants received mRNA-1325 10 mcg IM injection on Days 1 and 29."
},
{
"id": "EG001",
"title": "mRNA-1325 25 mcg",
"description": "Participants received placebo matched to mRNA-1325 as an IM injection on Days 1 and 29."
},
{
"id": "EG002",
"title": "mRNA-1325 100 mcg",
"description": "Participants received mRNA-1325 25 mcg as an IM injection on Days 1 and 29."
},
{
"id": "EG003",
"title": "Placebo",
"description": "Participants received mRNA-1325 100 mcg as an IM injection on Days 1 and 29."
}
]
},
"coder_1": {
"nct": "NCT03014089",
"eligible": false,
"exclusion_reason": "other",
"comparisons": [],
"targets": [
"zika"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AE group titles and descriptions conflict on which group got placebo: titles put placebo at EG003, descriptions at EG001 (EG001 'mRNA-1325 25 mcg' described as placebo, EG003 'Placebo' described as 100 mcg). The placebo group cannot be identified from the record."
},
"coder_2": {
"nct": "NCT03014089",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zika"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Group titles and descriptions are shifted by one; used titles (EG003 Placebo)."
}
},
{
"trial": {
"nct": "NCT03090191",
"brief_title": "Clostridium Difficile Vaccine Efficacy Trial",
"official_title": "A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER",
"conditions": [
"Clostridium Difficile Infection"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"50 Years",
null
],
"arms": [
{
"label": "Clostridium difficile vaccine",
"type": "EXPERIMENTAL",
"description": "",
"interventions": [
"Biological: Clostridium difficile vaccine"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "Clostridium difficile vaccine",
"type": "BIOLOGICAL",
"description": "Toxoid-based Clostridium difficile vaccine",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Normal saline solution (0.9% sodium chloride)",
"other_names": []
}
],
"ae_time_frame": "Local reactions and systemic events (included in other AEs): within 7 days after each dose (systematic assessment); SAEs: from Day 1 up to 6 months after last dose of vaccination (up to 12 months); other AEs: from Day 1 up to 1 month after last dose of vaccination (up to 7 months); All-Cause mortali [\u2026]",
"ae_description": "Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. Cause of death was unknown. Safety analysi [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "Clostridium Difficile Vaccine",
"description": "Participants who received Clostridium difficile vaccine 200 microgram total toxoid per dose intramuscularly at Months 0, 1 and 6."
},
{
"id": "EG001",
"title": "Placebo",
"description": "Participants who received placebo (normal saline solution of 0.9 percent \\[%\\] sodium chloride) intramuscularly at Months 0, 1 and 6."
}
]
},
"coder_1": {
"nct": "NCT03090191",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Toxoid-based C. difficile vaccine, adjuvant not stated; placebo normal saline."
},
"coder_2": {
"nct": "NCT03090191",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Aluminium hydroxide formulation from product knowledge."
}
},
{
"trial": {
"nct": "NCT03170609",
"brief_title": "A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age",
"official_title": "A PHASE 1/2, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY ADULTS 18 TO 49 YEARS OF AGE",
"conditions": [
"Group B Streptococcal Infections"
],
"phases": [
"PHASE2"
],
"model": "SEQUENTIAL",
"masking": "DOUBLE",
"ages": [
"18 Years",
"49 Years"
],
"arms": [
{
"label": "Lowest dose formulation a",
"type": "EXPERIMENTAL",
"description": "Multivalent group B streptococcus vaccine",
"interventions": [
"Biological: Multivalent group B streptococcus vaccine"
]
},
{
"label": "Middle dose formulation a",
"type": "EXPERIMENTAL",
"description": "Multivalent group B streptococcus vaccine",
"interventions": [
"Biological: Multivalent group B streptococcus vaccine"
]
},
{
"label": "Highest dose formulation a",
"type": "EXPERIMENTAL",
"description": "Multivalent group B streptococcus vaccine",
"interventions": [
"Biological: Multivalent group B streptococcus vaccine"
]
},
{
"label": "Lowest dose formulation b",
"type": "EXPERIMENTAL",
"description": "Multivalent group B streptococcus vaccine",
"interventions": [
"Biological: Multivalent group B streptococcus vaccine"
]
},
{
"label": "Middle dose formulation b",
"type": "EXPERIMENTAL",
"description": "Multivalent group B streptococcus vaccine",
"interventions": [
"Biological: Multivalent group B streptococcus vaccine"
]
},
{
"label": "Highest dose formulation b",
"type": "EXPERIMENTAL",
"description": "Multivalent group B streptococcus vaccine",
"interventions": [
"Biological: Multivalent group B streptococcus vaccine"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Saline control",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "Multivalent group B streptococcus vaccine",
"type": "BIOLOGICAL",
"description": "Various formulations at three dose levels",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Saline Control",
"other_names": []
}
],
"ae_time_frame": "Local reactions and systemic events: within 14 days after vaccination on Day 1 and all AEs other than local reactions and systemic events: within 6 Months after vaccination on Day 1",
"ae_description": "The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.Safety p [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "GBS6 5 Microgram With Aluminum Phosphate",
"description": "Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."
},
{
"id": "EG001",
"title": "GBS6 5 Microgram Without Aluminum Phosphate",
"description": "Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."
},
{
"id": "EG002",
"title": "GBS6 10 Microgram With Aluminum Phosphate",
"description": "Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."
},
{
"id": "EG003",
"title": "GBS6 10 Microgram Without Aluminum Phosphate",
"description": "Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."
},
{
"id": "EG004",
"title": "GBS6 20 Microgram With Aluminum Phosphate",
"description": "Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months"
},
{
"id": "EG005",
"title": "GBS6 20 Microgram Without Aluminum Phosphate",
"description": "Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."
},
{
"id": "EG006",
"title": "Placebo",
"description": "Participants were randomized to receive placebo (saline control) intramuscularly on Day 1 and were followed up to 6 months."
}
]
},
"coder_1": {
"nct": "NCT03170609",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Platform 'other': record calls GBS6 only a multivalent GBS vaccine (believed a capsular polysaccharide-CRM197 conjugate, which would be polysaccharide). Adjuvant per group: with or without aluminium phosphate. Placebo saline."
},
"coder_2": {
"nct": "NCT03170609",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "GBS6 CRM197 conjugate; with or without aluminium phosphate."
}
},
{
"trial": {
"nct": "NCT03180801",
"brief_title": "Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model",
"official_title": "Phase IIb Study of the Efficacy of FLU-v, a Broad Spectrum Influenza Vaccine in an H1N1 Influenza Healthy Human Challenge Model",
"conditions": [
"Influenza"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"55 Years"
],
"arms": [
{
"label": "Group 1 adjuvanted placebo",
"type": "PLACEBO_COMPARATOR",
"description": "0.5ml adjuvanted placebo on Day -43 and on Day -22 followed by influenza challenge on day 0",
"interventions": [
"Biological: adjuvanted placebo",
"Other: Influenza challenge"
]
},
{
"label": "Group 2 adjuvanted FLU-v one dose",
"type": "EXPERIMENTAL",
"description": "0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22 followed by influenza challenge on day 0",
"interventions": [
"Biological: adjuvanted FLU-v",
"Biological: adjuvanted placebo",
"Other: Influenza challenge"
]
},
{
"label": "Group 3 adjuvanted FLU-v two doses",
"type": "EXPERIMENTAL",
"description": "0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22 followed by influenza challenge on day 0",
"interventions": [
"Biological: adjuvanted FLU-v",
"Other: Influenza challenge"
]
}
],
"interventions": [
{
"name": "adjuvanted FLU-v",
"type": "BIOLOGICAL",
"description": "Subcutaneous injection in the upper arm with 500mcg of FLU-v as 0.5ml emulsion in 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51",
"other_names": []
},
{
"name": "adjuvanted placebo",
"type": "BIOLOGICAL",
"description": "Subcutaneous injection in the upper arm with 0.5ml emulsion made of 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51",
"other_names": []
},
{
"name": "Influenza challenge",
"type": "OTHER",
"description": "On day 0, administration with an intranasal sprayer of 1ml of PBS containing 10(7) TCID50 of Influenza A 2009 H1N1 human virus manufactured under GMP in certified Vero cells.",
"other_names": []
}
],
"ae_time_frame": "From the date of first administration of vaccine to the date of inoculation with the challenge virus (TEAEs).",
"ae_description": "Treatment Emergent AEs are all AEs that occur in the period between the first administration of the vaccine and the end of the study independently of their intensity and if they are related or not to the vaccine.",
"ae_groups": [
{
"id": "EG000",
"title": "Group 1 Adjuvanted Placebo",
"description": "0.5ml adjuvanted placebo on Day -43 and on Day -22"
},
{
"id": "EG001",
"title": "Group 2 Adjuvanted FLU-v One Dose",
"description": "0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22"
},
{
"id": "EG002",
"title": "Group 3 Adjuvanted FLU-v Two Doses",
"description": "0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22"
}
]
},
"coder_1": {
"nct": "NCT03180801",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AEs counted only until the influenza challenge. Placebo is Montanide ISA-51 emulsion. Platform 'other': record does not say what FLU-v is (believed synthetic peptides, which would be protein)."
},
"coder_2": {
"nct": "NCT03180801",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo holds Montanide ISA-51; AE period before challenge."
}
},
{
"trial": {
"nct": "NCT03281876",
"brief_title": "A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.",
"official_title": "An Observer-blind Study to Evaluate the Efficacy, Safety, Reactogenicity and Immunogenicity of the GSK Biologicals' Investigational Vaccine GSK3277511A When Administered to COPD Patients",
"conditions": [
"Respiratory Disorders"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"40 Years",
"80 Years"
],
"arms": [
{
"label": "GSK3277511A Group",
"type": "EXPERIMENTAL",
"description": "Healthy males and females, 40 to 80 years of age, who received two doses of the adjuvanted GSK3277511A investigational vaccine containing surface protein D (PD), protein E- type IV pilus assembly protein (PE-PilA,) and ubiquitous surface protein A2 (UspA2) at Day 1 and Day 61.",
"interventions": [
"Biological: NTHi Mcat investigational vaccine (GSK3277511A)"
]
},
{
"label": "CONTROL Group",
"type": "PLACEBO_COMPARATOR",
"description": "Healthy males and females, 40 to 80 years of age, who received two doses of placebo vaccine at Day 1 and Day 61.",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "NTHi Mcat investigational vaccine (GSK3277511A)",
"type": "BIOLOGICAL",
"description": "Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.",
"other_names": []
}
],
"ae_time_frame": "Solicited AEs reported during the 7-day follow-up period and Unsolicited AEs reported during the 30-day follow-up period after any vaccination. SAEs reported from first vaccination (Day 1) up to Study end (at Day 451 - an average of 15 months).",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "GSK3277511A Group",
"description": "Healthy males and females, 40 to 80 years of age, who received two doses of the adjuvanted GSK3277511A investigational vaccine containing surface protein D (PD), protein E- type IV pilus assembly protein (PE-PilA,) and ubiquitous surface protein A2 (UspA2), administered at Day 1 and Day 61"
},
{
"id": "EG001",
"title": "Control Group",
"description": "Healthy males and females, 40 to 80 years of age, who received two doses of placebo, administered at Day 1 and Day 61."
}
]
},
"coder_1": {
"nct": "NCT03281876",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Target 'other': non-typeable H. influenzae and Moraxella catarrhalis (COPD exacerbations). Record says the vaccine is adjuvanted but not with what. COPD patients (arm text says 'healthy', title says COPD)."
},
"coder_2": {
"nct": "NCT03281876",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "NTHi/Moraxella vaccine in COPD patients; adjuvant (AS01E) from product knowledge."
}
},
{
"trial": {
"nct": "NCT03300050",
"brief_title": "Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine",
"official_title": "A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Health [\u2026]",
"conditions": [
"Influenza",
"Vaccine"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"18 Years",
"39 Years"
],
"arms": [
{
"label": "Group 1: cH8/1N1 LAIV and cH5/1N1 IIV + adjuvant",
"type": "EXPERIMENTAL",
"description": "Participants received 0.5 mL cH8/1N1 LAIV administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL AS03-adjuvanted cH5/1N1 IIV administered as an intramuscular injection on Day 85.",
"interventions": [
"Biological: cH8/1N1 LAIV",
"Biological: AS03-adjuvanted cH5/1N1 IIV"
]
},
{
"label": "Group 2: cH8/1N1 LAIV and cH5/1N1 IIV",
"type": "EXPERIMENTAL",
"description": "Participants received 0.5 mL cH8/1N1 LAIV administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL cH5/1N1 IIV administered as an intramuscular injection on Day 85.",
"interventions": [
"Biological: cH8/1N1 LAIV",
"Biological: cH5/1N1 IIV"
]
},
{
"label": "Group 3: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants received 0.5 mL of normal saline administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL phosphate buffered saline (PBS) administered as an intramuscular injection on Day 85.",
"interventions": [
"Biological: Normal saline",
"Biological: Phosphate buffered saline (PBS)"
]
},
{
"label": "Group 4: cH8/1N1 IIV + adjuvant and cH5/1N1 IIV + adjuvant",
"type": "EXPERIMENTAL",
"description": "Participants received 0.5 mL AS03-adjuvanted cH8/1N1 IIV administered as an intramuscular injection on Day 1 followed by 0.5 mL AS03-adjuvanted cH5/1N1 IIV administered as an intramuscular injection on Day 85.",
"interventions": [
"Biological: AS03-adjuvanted cH5/1N1 IIV",
"Biological: AS03-adjuvanted cH8/1N1 IIV"
]
},
{
"label": "Group 5: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants received 0.5 mL PBS administered as an intramuscular injection on Day 1 followed by 0.5 mL PBS administered as an intramuscular injection on Day 85.",
"interventions": [
"Biological: Phosphate buffered saline (PBS)"
]
}
],
"interventions": [
{
"name": "cH8/1N1 LAIV",
"type": "BIOLOGICAL",
"description": "Live-attenuated influenza virus vaccine (LAIV) expressing chimeric hemagglutinin (HA) with the H8 head and H1 stalk and neuraminidase (NA) subtype 1 (N1) (cH8/1N1): HA head, A/mallard/Sweden/24/2002 (H8N4); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1) containing the backbone of the cold-adapted/temperature sensitive of the Russian LAIV A/Leningrad/134/17/1957 (Len17 IDCDCRG46D). Administered intranasally as drops at a do [\u2026]",
"other_names": []
},
{
"name": "AS03-adjuvanted cH5/1N1 IIV",
"type": "BIOLOGICAL",
"description": "Chimeric H5 head with H1 stalk plus N1 (cH5/1N1) split virion inactivated influenza virus vaccine (IIV) plus AS03 adjuvant: HA head, A/Vietnam/1203/2004 (H5N1); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1). Administered intramuscularly at a dose of 15 \u03bcg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS).",
"other_names": [
"cH5/1N1 IIV + AS03 adjuvant"
]
},
{
"name": "cH5/1N1 IIV",
"type": "BIOLOGICAL",
"description": "Chimeric H5 head with H1 stalk plus N1 (cH5/1N1) split virion inactivated influenza virus vaccine (IIV): HA head, A/Vietnam/1203/2004 (H5N1); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1). Administered intramuscularly at a dose of 15 \u03bcg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS).",
"other_names": []
},
{
"name": "AS03-adjuvanted cH8/1N1 IIV",
"type": "BIOLOGICAL",
"description": "Chimeric H8 head with H1 stalk plus N1 (cH8/1N1) inactivated influenza vaccine plus AS03 adjuvant: HA head, A/mallard/Sweden/24/2002 (H8N4); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1). Administered intramuscularly at a dose of 15 \u03bcg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS).",
"other_names": [
"cH8/1N1 IIV + AS03 adjuvant"
]
},
{
"name": "Normal saline",
"type": "BIOLOGICAL",
"description": "Administered intranasally as 0.25 mL nasal drops per nostril",
"other_names": []
},
{
"name": "Phosphate buffered saline (PBS)",
"type": "BIOLOGICAL",
"description": "Administered intramuscularly as 0.5 mL injection",
"other_names": []
}
],
"ae_time_frame": "All-cause mortality and serious adverse events were recorded through the end of study, 588 days (21 months). Other adverse events were collected through 28 days after each vaccination (Days 1 to 28 and Days 85 to 113)",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Group 1: cH8/1N1 LAIV and cH5/1N1 IIV + Adjuvant",
"description": "Participants received 0.5 mL cH8/1N1 live-attenuated influenza virus vaccine (LAIV) administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL AS03-adjuvanted cH5/1N1 inactivated influenza virus vaccine (IIV) administered as an intramuscular injection on Day 85."
},
{
"id": "EG001",
"title": "Group 2: cH8/1N1 LAIV and cH5/1N1 IIV",
"description": "Participants received 0.5 mL cH8/1N1 LAIV administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL cH5/1N1 IIV administered as an intramuscular injection on Day 85."
},
{
"id": "EG002",
"title": "Group 3: Placebo",
"description": "Participants received 0.5 mL normal saline administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL phosphate buffered saline (PBS) administered as an intramuscular injection on Day 85."
},
{
"id": "EG003",
"title": "Group 4: cH8/1N1 IIV + Adjuvant and cH5/1N1 IIV + Adjuvant",
"description": "Participants received 0.5 mL AS03-adjuvanted cH8/1N1 IIV administered as an intramuscular injection on Day 1 followed by 0.5 mL AS03-adjuvanted cH5/1N1 IIV administered as an intramuscular injection on Day 85."
},
{
"id": "EG004",
"title": "Group 5: Placebo",
"description": "Participants received 0.5 mL PBS administered as an intramuscular injection on Day 1 followed by 0.5 mL PBS administered as an intramuscular injection on Day 85."
}
]
},
"coder_1": {
"nct": "NCT03300050",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated",
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"live_attenuated",
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002",
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two schedules (intranasal LAIV then IM IIV; IM IIV twice) each with a route-matched saline/PBS placebo, pooled as one design. AS03 is in the second dose of EG000 and both doses of EG003."
},
"coder_2": {
"nct": "NCT03300050",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated",
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"live_attenuated",
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two comparisons: LAIV-prime groups vs intranasal-then-IM placebo; IIV-only AS03 group vs IM PBS placebo."
}
},
{
"trial": {
"nct": "NCT03301051",
"brief_title": "Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults",
"official_title": "A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults 18-64 Years of Age",
"conditions": [
"Virus Diseases",
"RNA Virus Infections",
"Respiratory Tract Diseases",
"Respiratory Tract Infections",
"Influenza"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"64 Years"
],
"arms": [
{
"label": "Quadrivalent VLP Vaccine",
"type": "EXPERIMENTAL",
"description": "Participants received one intramuscular (IM) injection of 0.5 mL of 30 \u03bcg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.",
"interventions": [
"Biological: Quadrivalent VLP Vaccine"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants received one IM injection of 0.5 mL of placebo on Day 0.",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "Quadrivalent VLP Vaccine",
"type": "BIOLOGICAL",
"description": "Single dose of a 30 \u00b5g/strain of Quadrivalent VLP Vaccine",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Single dose of a Placebo",
"other_names": []
}
],
"ae_time_frame": "Day 0 (post-vaccination) up to ~8 months",
"ae_description": "SAS. The unsolicited serious adverse events (SAEs), unsolicited non-serious adverse events (NSAEs), and all deaths were reported.",
"ae_groups": [
{
"id": "EG000",
"title": "Quadrivalent VLP Vaccine",
"description": "Participants received one IM injection of 0.5 mL of 30 \u03bcg/strain of the Quadrivalent VLP Influenza Vaccine or placebo on Day 0."
},
{
"id": "EG001",
"title": "Placebo",
"description": "Participants received one IM injection of 0.5 mL of placebo on Day 0."
}
]
},
"coder_1": {
"nct": "NCT03301051",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Plant-derived quadrivalent VLP; adjuvant not stated. EG000's description says 'vaccine or placebo', read as a template slip given its title."
},
"coder_2": {
"nct": "NCT03301051",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Plant-derived VLP, unadjuvanted."
}
},
{
"trial": {
"nct": "NCT03325075",
"brief_title": "Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants",
"official_title": "A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of VAL-181388 in Healthy Adults in a Non-endemic Chikungunya Region",
"conditions": [
"Chikungunya Virus"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"18 Years",
"49 Years"
],
"arms": [
{
"label": "VAL-181388",
"type": "EXPERIMENTAL",
"description": "",
"interventions": [
"Biological: VAL-181388"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "",
"interventions": [
"Other: Placebo"
]
}
],
"interventions": [
{
"name": "VAL-181388",
"type": "BIOLOGICAL",
"description": "Escalating dose levels",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "Saline",
"other_names": []
}
],
"ae_time_frame": "Through 1 year following the last vaccination",
"ae_description": "The safety analysis set included all participants who received at least 1 dose of study drug (VAL-181388 or placebo).",
"ae_groups": [
{
"id": "EG000",
"title": "Part A - VAL-181388 Dose A: Vaccination 1",
"description": "Participants received first IM injection of VAL-181388 Dose A."
},
{
"id": "EG001",
"title": "Part A - VAL-181388 Dose A: Vaccination 2",
"description": "Participants received second IM injection of VAL-181388 Dose A."
},
{
"id": "EG002",
"title": "Part A - VAL-181388 Dose B: Vaccination 1",
"description": "Participants received first IM injection of VAL-181388 Dose B."
},
{
"id": "EG003",
"title": "Part A - VAL-181388 Dose B: Vaccination 2",
"description": "Participants received second IM injection of VAL-181388 Dose B."
},
{
"id": "EG004",
"title": "Part A - VAL-181388 Dose C: Vaccination 1",
"description": "Participants received first IM injection of VAL-181388 Dose C."
},
{
"id": "EG005",
"title": "Part A - VAL-181388 Dose C: Vaccination 2",
"description": "Participants received second IM injection of VAL-181388 Dose C."
},
{
"id": "EG006",
"title": "Part A - Placebo: Vaccination 1",
"description": "Participants received first IM injection of VAL-181388 matched placebo."
},
{
"id": "EG007",
"title": "Part A - Placebo: Vaccination 2",
"description": "Participants received second IM injection of VAL-181388 matched placebo."
},
{
"id": "EG008",
"title": "Part B - VAL-181388 Dose A",
"description": "Participants who received VAL-181388 Dose A in Part A, were followed up for longer-term safety and immune persistence in Part B."
},
{
"id": "EG009",
"title": "Part B - VAL-181388 Dose B",
"description": "Participants who received VAL-181388 Dose B in Part A, were followed up for longer-term safety and immune persistence in Part B."
},
{
"id": "EG010",
"title": "Part B - VAL-181388 Dose C",
"description": "Participants who received VAL-181388 Dose C in Part A, were followed up for longer-term safety and immune persistence in Part B."
},
{
"id": "EG011",
"title": "Part B - Placebo",
"description": "Participants who received VAL-181388 matched placebo in Part A, were followed up for longer-term safety and immune persistence in Part B."
}
]
},
"coder_1": {
"nct": "NCT03325075",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG008",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG009",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG010",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG011"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AE groups report the same people by period: Part A after vaccination 1 (EG000/002/004 vs EG006), after vaccination 2 (EG001/003/005 vs EG007), and Part B long-term follow-up (EG008-010 vs EG011). Took Part B, the longest placebo-controlled follow-up; the vaccination-1 set is the alternative if all participants are needed. Platform 'other': record does not name it (VAL-181388 believed an mRNA vaccine)."
},
"coder_2": {
"nct": "NCT03325075",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG008",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG009",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG011"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took Part B groups (longest follow-up, each participant once); Part A groups are by vaccination number of the same participants."
}
},
{
"trial": {
"nct": "NCT03334695",
"brief_title": "An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults",
"official_title": "An Exploratory, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-Old Adults",
"conditions": [
"Healthy"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"18 Years",
"50 Years"
],
"arms": [
{
"label": "Group 1: Ad26.RSV.preF",
"type": "EXPERIMENTAL",
"description": "Participants will receive single intramuscular injection of 1\\*10\\^11 virus particles (vp) of Ad26.RSV.preF during Day -90 to Day -28. On Day 0, intranasal challenge with respiratory syncytial virus (RSV)-A Memphis 37b virus will occur for all participants.",
"interventions": [
"Biological: Ad26.RSV.preF"
]
},
{
"label": "Group 2: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants will receive single intramuscular injection of placebo as sterile 0.9 percent (%) saline for injection during Day -90 to Day -28. On Day 0, intranasal challenge with RSV-A Memphis 37b virus will occur for all participants.",
"interventions": [
"Drug: Placebo"
]
}
],
"interventions": [
{
"name": "Ad26.RSV.preF",
"type": "BIOLOGICAL",
"description": "Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\\*10\\^11 vp in single-use vials.",
"other_names": [
"JNJ-64400141"
]
},
{
"name": "Placebo",
"type": "DRUG",
"description": "Placebo will be administered as sterile 0.9% saline for injection.",
"other_names": []
}
],
"ae_time_frame": "Up to 6 months post-vaccination and up to 6 months post-challenge",
"ae_description": "The full analysis set (FAS) included all participants who were randomized and received at least one dose of study vaccine, regardless of the occurrence of protocol deviations.",
"ae_groups": [
{
"id": "EG000",
"title": "Post-dose: Ad26.RSV.preF (1x10^11 vp)",
"description": "Participants received a single intramuscular injection of 1\\*10\\^11 vp (viral particles) of Ad26.RSV.preF on Day -28."
},
{
"id": "EG001",
"title": "Post-dose: Placebo",
"description": "Participants received a single intramuscular injection of matching placebo on Day -28."
},
{
"id": "EG002",
"title": "Post-challenge: Challenge After Ad26.RSV.preF",
"description": "Participants undergone intranasal challenge with RSV-A Memphis 37b virus on Day 0, after receiving single intramuscular doses of 1x1011 vp of Ad26.RSV.preF on Day -28."
},
{
"id": "EG003",
"title": "Post-challenge: Challenge After Placebo",
"description": "Participants undergone intranasal challenge with RSV-A Memphis 37b virus on Day 0, after receiving single intramuscular doses of placebo on Day -28."
}
]
},
"coder_1": {
"nct": "NCT03334695",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the post-dose groups (EG000/EG001); left out the post-challenge groups (EG002/EG003), the same participants after an RSV challenge given to all."
},
"coder_2": {
"nct": "NCT03334695",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "challenge with RSV-A virus for all"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Post-challenge groups (EG002/EG003) take the longest follow-up and count each randomized participant once; post-dose groups EG000/EG001 report the same participants for the pre-challenge period."
}
},
{
"trial": {
"nct": "NCT03408262",
"brief_title": "Clinical Trial of HIV Vaccine Combinations in Healthy Men and Women",
"official_title": "A Phase I Single-Blind Randomised Trial Investigating Immunisation Strategies Using Ad4-EnvCN54, MVA-CN54 and CN54gp140/MPLA Combinations in Order to Maximise Antibody Responses to Human Immunodeficiency Virus",
"conditions": [
"Human Immunodeficiency Virus"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "SINGLE",
"ages": [
"18 Years",
"50 Years"
],
"arms": [
{
"label": "Group A",
"type": "ACTIVE_COMPARATOR",
"description": "Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo",
"interventions": [
"Biological: CN54gp140/MPLA"
]
},
{
"label": "Group B",
"type": "EXPERIMENTAL",
"description": "Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo",
"interventions": [
"Biological: Ad4-EnvCN54",
"Biological: CN54gp140/MPLA"
]
},
{
"label": "Group C",
"type": "EXPERIMENTAL",
"description": "Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo",
"interventions": [
"Biological: Ad4-EnvCN54",
"Biological: CN54gp140/MPLA"
]
},
{
"label": "Group D",
"type": "EXPERIMENTAL",
"description": "Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo",
"interventions": [
"Biological: Ad4-EnvCN54",
"Biological: CN54gp140/MPLA"
]
},
{
"label": "Group E",
"type": "ACTIVE_COMPARATOR",
"description": "Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54",
"interventions": [
"Biological: MVA-CN54",
"Biological: CN54gp140/MPLA"
]
},
{
"label": "Group F",
"type": "EXPERIMENTAL",
"description": "Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54",
"interventions": [
"Biological: Ad4-EnvCN54",
"Biological: MVA-CN54",
"Biological: CN54gp140/MPLA"
]
},
{
"label": "Group G",
"type": "EXPERIMENTAL",
"description": "Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54",
"interventions": [
"Biological: Ad4-EnvCN54",
"Biological: MVA-CN54",
"Biological: CN54gp140/MPLA"
]
},
{
"label": "Group H",
"type": "EXPERIMENTAL",
"description": "Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54",
"interventions": [
"Biological: Ad4-EnvCN54",
"Biological: MVA-CN54",
"Biological: CN54gp140/MPLA"
]
}
],
"interventions": [
{
"name": "Ad4-EnvCN54",
"type": "BIOLOGICAL",
"description": "Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54",
"other_names": []
},
{
"name": "MVA-CN54",
"type": "BIOLOGICAL",
"description": "Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54",
"other_names": []
},
{
"name": "CN54gp140/MPLA",
"type": "BIOLOGICAL",
"description": "Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant",
"other_names": [
"CN54-M"
]
}
],
"ae_time_frame": "12 months",
"ae_description": "All adverse events were recorded. Grades were defined as 1 (mild), 2 (moderate), 3 (severe) or 4 (life threatening).",
"ae_groups": [
{
"id": "EG000",
"title": "Group A",
"description": "Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo CN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"
},
{
"id": "EG001",
"title": "Group B",
"description": "Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Ad4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54 CN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"
},
{
"id": "EG002",
"title": "Group C",
"description": "Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Ad4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54 CN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"
},
{
"id": "EG003",
"title": "Group D",
"description": "Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Ad4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54 CN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"
},
{
"id": "EG004",
"title": "Group E",
"description": "Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 MVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54 CN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"
},
{
"id": "EG005",
"title": "Group F",
"description": "Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Ad4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54 MVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 iso [\u2026]"
},
{
"id": "EG006",
"title": "Group G",
"description": "Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Ad4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54 MVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isol [\u2026]"
},
{
"id": "EG007",
"title": "Group H",
"description": "Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Ad4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54 MVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isola [\u2026]"
}
]
},
"coder_1": {
"nct": "NCT03408262",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "CN54gp140/MPLA protein vaccine"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group gets CN54gp140/MPLA; Group A (oral and IM placebo) is placebo for Ad4-EnvCN54 and/or MVA-CN54 given to the other groups (E: MVA only; B-D: Ad4; F-H: both)."
},
"coder_2": {
"nct": "NCT03408262",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets CN54gp140/MPLA; placebo replaces only vector components."
}
},
{
"trial": {
"nct": "NCT03450915",
"brief_title": "A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine",
"official_title": "A Pivotal Multi-center, Randomized, Modified Double-blind, Placebo-controlled Phase 3 Trial to Assess the Safety and Clinical Efficacy of M-001 Influenza Vaccine Administered Intra-muscularly Twice in Older Adults and Elderly (\u226550 Years).",
"conditions": [
"Influenza"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"50 Years",
null
],
"arms": [
{
"label": "M-001",
"type": "EXPERIMENTAL",
"description": "Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.",
"interventions": [
"Biological: M-001"
]
},
{
"label": "Saline",
"type": "PLACEBO_COMPARATOR",
"description": "Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.",
"interventions": [
"Biological: Saline"
]
}
],
"interventions": [
{
"name": "M-001",
"type": "BIOLOGICAL",
"description": "A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.",
"other_names": [
"Multimeric-001"
]
},
{
"name": "Saline",
"type": "BIOLOGICAL",
"description": "0.9% sodium chloride (NaCl)",
"other_names": []
}
],
"ae_time_frame": "4 months",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "M-001",
"description": "Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21. M-001: A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses."
},
{
"id": "EG001",
"title": "Saline",
"description": "Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21. Saline: 0.9% sodium chloride (NaCl)"
}
]
},
"coder_1": {
"nct": "NCT03450915",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M-001 recombinant multi-epitope protein; record states no adjuvant either way."
},
"coder_2": {
"nct": "NCT03450915",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M-001 is unadjuvanted per product knowledge."
}
},
{
"trial": {
"nct": "NCT03500679",
"brief_title": "A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older",
"official_title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Immunogenicity of the ExPEC4V (JNJ-63871860) Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Subjects Aged 18 Years and Older",
"conditions": [
"Healthy"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"18 Years",
null
],
"arms": [
{
"label": "Group 1: ExPEC4V (JNJ-63871860)",
"type": "EXPERIMENTAL",
"description": "Participants will receive vaccination of ExPEC4V dose as an intramuscular (IM) injection into deltoid muscle on Days 1 and 181. The ExPEC4V doses contain polysaccharide antigen (4:4:4:8 microgram \\[mcg\\]) from the ExPEC4V serotypes O1A, O2, O6A, and O25B.",
"interventions": [
"Biological: ExPEC4V"
]
},
{
"label": "Group 2: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants will receive placebo matching to ExPEC4V as an IM injection on Days 1 and 181.",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "ExPEC4V",
"type": "BIOLOGICAL",
"description": "Participants will receive ExPEC4V vaccine as an IM injection on Days 1 and 181.",
"other_names": [
"JNJ-63871860"
]
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Participants will receive placebo as an IM injection on Days 1 and 181.",
"other_names": []
}
],
"ae_time_frame": "Up to Day 360",
"ae_description": "The full analysis set (FAS) included all randomized participants with at least one study vaccine administration documented regardless of the occurrence of protocol deviations.",
"ae_groups": [
{
"id": "EG000",
"title": "ExPEC4V",
"description": "Participants received a single 0.5 milliliter (mL) dose of ExPEC4V vaccine as an intramuscular (IM) injection into the deltoid muscle on Day 1 and Day 181."
},
{
"id": "EG001",
"title": "Placebo",
"description": "Participants received placebo matching to ExPEC4V as an IM injection into the deltoid muscle on Day 1 and Day 181."
}
]
},
"coder_1": {
"nct": "NCT03500679",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"e_coli"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ExPEC4V O-antigen conjugate; adjuvant not stated."
},
"coder_2": {
"nct": "NCT03500679",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"e_coli"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ExPEC4V is an O-antigen conjugate; no adjuvant stated."
}
},
{
"trial": {
"nct": "NCT03503058",
"brief_title": "Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria",
"official_title": "Safety, Tolerability, Immunogenicity and Protective Efficacy Against Naturally-Transmitted Malaria in Eastern Indonesia of Two Plasmodium Falciparum Sporozoite Vaccines, Sanaria\u00ae PfSPZ Vaccine and Sanaria\u00ae PfSPZ-CVac: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Healthy Indonesian Adults",
"conditions": [
"Malaria"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"55 Years"
],
"arms": [
{
"label": "Group 1",
"type": "EXPERIMENTAL",
"description": "N=124 will receive PfSPZ Vaccine; three doses of 9x10\\^5 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given on day 1, 8 and 29.",
"interventions": [
"Biological: PfSPZ Vaccine"
]
},
{
"label": "Group 2",
"type": "PLACEBO_COMPARATOR",
"description": "N=62 will receive normal saline; three doses of NS administered by DVI given on day 1, 8 and 29.",
"interventions": [
"Other: Normal Saline"
]
},
{
"label": "Group 3",
"type": "EXPERIMENTAL",
"description": "N=124 will receive PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis; three doses of 2x10\\^5 PfSPZ of PfSPZ Challenge administered by DVI on day 1, 29 and 57, with weekly CQ. Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on PfSPZ-CVac Day -2. Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly [\u2026]",
"interventions": [
"Biological: PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis"
]
},
{
"label": "Group 4",
"type": "PLACEBO_COMPARATOR",
"description": "N=62 will receive normal; three doses of NS administered by DVI given on day 1, 29 and 57, with weekly CQ. Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on PfSPZ-CVac Day -2. Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of PfSPZ  [\u2026]",
"interventions": [
"Other: Normal Saline",
"Drug: Chloroquine chemoprophylaxis alone"
]
}
],
"interventions": [
{
"name": "PfSPZ Vaccine",
"type": "BIOLOGICAL",
"description": "Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)",
"other_names": []
},
{
"name": "PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis",
"type": "BIOLOGICAL",
"description": "Infectious, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Challenge) administered under CQ chemoprophylaxis Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on PfSPZ-CVac Day -2. Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days  [\u2026]",
"other_names": [
"PfSPZ-CVac"
]
},
{
"name": "Normal Saline",
"type": "OTHER",
"description": "0.9% Sodium chloride",
"other_names": [
"NS"
]
},
{
"name": "Chloroquine chemoprophylaxis alone",
"type": "DRUG",
"description": "Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on NS Day -2. Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of NS.",
"other_names": [
"CQ"
]
}
],
"ae_time_frame": "The time frame for data collection is: - PfSPZ Vaccine: 7 days after each vaccination (2 days after each vaccination for local solicited AEs) - PfSPZ-CVac: 14 days after each administration - SAEs for both products: from day of immunization until end of study (24 months). The total period of data co [\u2026]",
"ae_description": "The SAE table below includes the 26 participants who experienced SAEs, all of which were deemed unrelated to investigational product. One participant experienced 3 SAEs and five more each experienced 2 SAEs. Of these 33 SAEs, three had 3 diagnoses and two had 2 diagnoses. Each diagnosis is listed in [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "Group 1 (PfSPZ Vaccine)",
"description": "PfSPZ Vaccine: N=124; three doses of 9x10\\^5 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) on day 1, 8 and 29. PfSPZ Vaccine: Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)."
},
{
"id": "EG001",
"title": "Group 2 (NS Placebo)",
"description": "Normal saline (NS) placebo: N=62; three doses of NS administered by DVI on day 1, 8 and 29. Normal Saline: 0.9% Sodium chloride"
},
{
"id": "EG002",
"title": "Group 3 (PfSPZ Challenge + CQ)",
"description": "PfSPZ-CVac (PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis): N=124; three doses of 2x10\\^5 PfSPZ of PfSPZ Challenge administered by DVI on day 1, 29 and 57, with weekly CQ. Loading Dose: 10 mg/kg of CQ base (orally administered as a single loading dose via directly observed therapy on PfSPZ-CVac Day -2). Weekly Dose: 5 mg/kg of CQ base (subsequent maintenance doses of CQ given weekly as a [\u2026]"
},
{
"id": "EG003",
"title": "Group 4 (NS Placebo + CQ)",
"description": "Normal saline (NS) placebo: N=62; three doses of NS administered by DVI on day 1, 29 and 57, with weekly CQ. Normal Saline: 0.9% Sodium chloride CQ chemoprophylaxis alone: Loading Dose: 10 mg/kg of CQ base (orally administered as a single loading dose via directly observed therapy on NS Day -2). Weekly Dose: 5 mg/kg of CQ base (subsequent maintenance doses of CQ given weekly as a single dose, with [\u2026]"
}
]
},
"coder_1": {
"nct": "NCT03503058",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "chloroquine chemoprophylaxis"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two comparisons: PfSPZ Vaccine vs saline; PfSPZ-CVac vs saline, both with weekly chloroquine. Platform other: radiation-attenuated (non-replicating) whole sporozoites, and infectious sporozoites under chloroquine."
},
"coder_2": {
"nct": "NCT03503058",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "weekly chloroquine chemoprophylaxis"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "PfSPZ Vaccine (radiation-attenuated sporozoites) coded live_attenuated; PfSPZ-CVac (infectious sporozoites under chloroquine) coded other. Chloroquine given to both sides of the second comparison."
}
},
{
"trial": {
"nct": "NCT03510481",
"brief_title": "Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali",
"official_title": "Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali",
"conditions": [
"Malaria"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"18 Years",
"35 Years"
],
"arms": [
{
"label": "Experimental arm 1: Dosing interval 0, 8, 16, and 54 weeks",
"type": "EXPERIMENTAL",
"description": "Participants received 3 doses of PfSPZ Vaccine (9 x 10\\^5) via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.",
"interventions": [
"Biological: PfSPZ Vaccine",
"Drug: artemether 20mg/lumefantrine 120mg (AL)"
]
},
{
"label": "Experimental arm 2: Dosing interval 0, 1, 4, and 42 weeks",
"type": "EXPERIMENTAL",
"description": "Participants received 3 doses of PfSPZ Vaccine (9 x 10\\^5) via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.",
"interventions": [
"Biological: PfSPZ Vaccine",
"Drug: artemether 20mg/lumefantrine 120mg (AL)"
]
},
{
"label": "Placebo comparator 3a: Dosing interval 0, 8, 16, and 54 weeks",
"type": "PLACEBO_COMPARATOR",
"description": "Control for Arm 1. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and [\u2026]",
"interventions": [
"Drug: Normal Saline",
"Drug: artemether 20mg/lumefantrine 120mg (AL)"
]
},
{
"label": "Placebo comparator 3b: Dosing interval 0, 1, 4, and 42 weeks",
"type": "PLACEBO_COMPARATOR",
"description": "Control for Arm 2. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and  [\u2026]",
"interventions": [
"Drug: Normal Saline",
"Drug: artemether 20mg/lumefantrine 120mg (AL)"
]
}
],
"interventions": [
{
"name": "PfSPZ Vaccine",
"type": "BIOLOGICAL",
"description": "PfSPZ Vaccine is Radiation attenuated, aseptic, purified, vialed, cryopreserved, NF54 P. falciparum sporozoites produced by Sanaria, Inc.",
"other_names": []
},
{
"name": "Normal Saline",
"type": "DRUG",
"description": "Clear liquid indistinguishable from the study product will be used as a placebo rather than a comparator vaccine.",
"other_names": []
},
{
"name": "artemether 20mg/lumefantrine 120mg (AL)",
"type": "DRUG",
"description": "Licensed antimalarial in the US and Mali for use for uncomplicated malaria.",
"other_names": [
"Coartem"
]
}
],
"ae_time_frame": "For the primary endpoint, other (non-serious) adverse events were monitored 7 days from time of each vaccination during year one and year two. Deaths and serious AEs were monitored up to 21 months (duration of the study).",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Experimental Arm 1: Dosing Interval 0, 8, 16, and 54 Weeks",
"description": "Participants received 3 doses of PfSPZ Vaccine (9 x10\\^5) via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of  [\u2026]"
},
{
"id": "EG001",
"title": "Experimental Arm 2: Dosing Interval 0, 1, 4, and 42 Weeks",
"description": "Participants received 3 doses of PfSPZ Vaccine (9 x10\\^5) via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 2 [\u2026]"
},
{
"id": "EG002",
"title": "Placebo Comparator 3a: Dosing Interval 0, 8, 16, and 54 Weeks",
"description": "Control for Arm 1. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two day [\u2026]"
},
{
"id": "EG003",
"title": "Placebo Comparator 3b: Dosing Interval 0, 1, 4, and 42 Weeks",
"description": "Control for Arm 2. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days [\u2026]"
}
]
},
"coder_1": {
"nct": "NCT03510481",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "artemether-lumefantrine before doses 3 and 4"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two dosing schedules pooled, each with its saline control. Platform other: radiation-attenuated (non-replicating) whole sporozoites."
},
"coder_2": {
"nct": "NCT03510481",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "artemether-lumefantrine before doses 3 and 4 in all arms"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Radiation-attenuated sporozoites coded live_attenuated."
}
},
{
"trial": {
"nct": "NCT03525119",
"brief_title": "Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine",
"official_title": "A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular Hepatitis A Virus (Inactivated) Vaccine in Healthy Subjects Aged 18 to 60 Years in Non-endemic Country(Ies) for Dengue",
"conditions": [
"Healthy Volunteers"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"18 Years",
"60 Years"
],
"arms": [
{
"label": "HAV Vaccine 1.0 ml + Placebo/ Placebo",
"type": "OTHER",
"description": "HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).",
"interventions": [
"Biological: HAV Vaccine",
"Biological: TDV Placebo"
]
},
{
"label": "TDV 0.5 ml + Placebo/ TDV 0.5 ml",
"type": "EXPERIMENTAL",
"description": "TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).",
"interventions": [
"Biological: TDV",
"Biological: HAV Vaccine Placebo"
]
},
{
"label": "TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml",
"type": "EXPERIMENTAL",
"description": "TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).",
"interventions": [
"Biological: TDV",
"Biological: HAV Vaccine"
]
}
],
"interventions": [
{
"name": "TDV",
"type": "BIOLOGICAL",
"description": "TDV SC injection",
"other_names": []
},
{
"name": "HAV Vaccine",
"type": "BIOLOGICAL",
"description": "HAV Vaccine IM injection.",
"other_names": []
},
{
"name": "TDV Placebo",
"type": "BIOLOGICAL",
"description": "Placebo-matching (normal saline (0.9% NaCl) SC injection.",
"other_names": []
},
{
"name": "HAV Vaccine Placebo",
"type": "BIOLOGICAL",
"description": "Placebo-matching (normal saline (0.9% NaCl) IM injection.",
"other_names": []
}
],
"ae_time_frame": "All-cause mortality and Serious adverse events: From the first vaccination on Day 1 until the end of the trial (Day 270); Other adverse events: Up to 28 days (Day of vaccination+27 subsequent days) after each vaccination.",
"ae_description": "Safety Set included all participants who received at least 1 dose of trial vaccine.",
"ae_groups": [
{
"id": "EG000",
"title": "HAV Vaccine 1.0 ml + Placebo/ Placebo",
"description": "HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose)."
},
{
"id": "EG001",
"title": "TDV 0.5 ml + Placebo/ TDV 0.5 ml",
"description": "TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose)."
},
{
"id": "EG002",
"title": "TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml",
"description": "TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose)."
}
]
},
"coder_1": {
"nct": "NCT03525119",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "hepatitis A vaccine on Day 1"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TDV+HAV/TDV vs HAV+placebo/placebo. EG001 (TDV + HAV placebo) left out: no placebo group without HAV vaccine; its contrast with EG000 is an active control."
},
"coder_2": {
"nct": "NCT03525119",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "TDV dengue vaccine in both"
}
],
"targets": [
"hepatitis_a",
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HAV vs HAV placebo, both with TDV. Group 1 (HAV, TDV placebo) is an active-control mix, left out. Hepatitis A vaccine aluminium from product knowledge."
}
},
{
"trial": {
"nct": "NCT03527173",
"brief_title": "A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults",
"official_title": "Efficacy, Safety and Immunogenicity of GVGH Shigella Sonnei Vaccine (1790GAHB) in a Human Challenge Study of Healthy Non-immune Adults",
"conditions": [
"Dysentery, Bacillary"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"50 Years"
],
"arms": [
{
"label": "S. sonnei Group",
"type": "EXPERIMENTAL",
"description": "Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, received 2 doses of the S. sonnei study vaccine at Day 1 and Day 29 respectively, by intramuscular injection into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects received the challenge dose of S. sonnei 53G strain, orally.",
"interventions": [
"Biological: S.sonnei vaccine",
"Biological: S. sonnei 53G challenge strain"
]
},
{
"label": "Placebo Group",
"type": "PLACEBO_COMPARATOR",
"description": "Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, received 2 doses of the placebo at Day 1 and Day 29 respectively, by intramuscular injection into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects received the challenge dose of S. sonnei 53G strain, orally.",
"interventions": [
"Drug: Placebo",
"Biological: S. sonnei 53G challenge strain"
]
}
],
"interventions": [
{
"name": "S.sonnei vaccine",
"type": "BIOLOGICAL",
"description": "Subjects receiving 2 doses of the study vaccine by intramuscular route, 28 days apart (at Day 1 and Day 29).",
"other_names": [
"GSK3536852A vaccine"
]
},
{
"name": "Placebo",
"type": "DRUG",
"description": "Subjects receiving 2 doses of placebo by intramuscular route, 28 days apart (at Day 1 and Day 29).",
"other_names": [
"GAHB-Placebo"
]
},
{
"name": "S. sonnei 53G challenge strain",
"type": "BIOLOGICAL",
"description": "Subjects receiving the challenge dose of S. sonnei 53G strain, orally, at Day 57.",
"other_names": []
}
],
"ae_time_frame": "Solicited AEs were collected within the 7-day post-vaccination period or 8-day post-challenge period. Unsolicited AEs were collected within the 28-day post-vaccination or post-challenge period. SAEs were collected from Day 1 up to study end at Day 237.",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "S. Sonnei Group",
"description": "Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, received 2 doses of the S. sonnei study vaccine at Day 1 and Day 29 respectively, by intramuscular injection into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects received the challenge dose of S. sonnei 53G strain, orally."
},
{
"id": "EG001",
"title": "Placebo Group",
"description": "Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, received 2 doses of the placebo at Day 1 and Day 29 respectively, by intramuscular injection into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects received the challenge dose of S. sonnei 53G strain, orally."
}
]
},
"coder_1": {
"nct": "NCT03527173",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "oral S. sonnei 53G challenge at Day 57"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Whole-arm groups, vaccination and challenge periods together. Platform other: GVGH 1790GAHB is a GMMA (outer membrane vesicle) vaccine; adjuvant not stated in the record."
},
"coder_2": {
"nct": "NCT03527173",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "oral S. sonnei challenge for all"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "GMMA vaccine (outer membrane vesicles), coded other; adsorbed on aluminium hydroxide per product knowledge."
}
},
{
"trial": {
"nct": "NCT03529773",
"brief_title": "A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults",
"official_title": "A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING, FIRST-IN-HUMAN STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN HEALTHY ADULTS",
"conditions": [
"Respiratory Tract Infections"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"85 Years"
],
"arms": [
{
"label": "Sentinel Arm 1",
"type": "EXPERIMENTAL",
"description": "Low dose formulation A",
"interventions": [
"Biological: Formulation A"
]
},
{
"label": "Sentinel Arm 2",
"type": "EXPERIMENTAL",
"description": "Mid dose formulation A",
"interventions": [
"Biological: Formulation A"
]
},
{
"label": "Sentinel Arm 3",
"type": "EXPERIMENTAL",
"description": "High dose formulation A",
"interventions": [
"Biological: Formulation A"
]
},
{
"label": "Sentinel Arm 4",
"type": "EXPERIMENTAL",
"description": "Low dose formulation B",
"interventions": [
"Biological: Formulation B"
]
},
{
"label": "Sentinel Arm 5",
"type": "EXPERIMENTAL",
"description": "Mid dose formulation B",
"interventions": [
"Biological: Formulation B"
]
},
{
"label": "Sentinel Arm 6",
"type": "EXPERIMENTAL",
"description": "High dose formulation B",
"interventions": [
"Biological: Formulation B"
]
},
{
"label": "Sentinel Arm 7",
"type": "PLACEBO_COMPARATOR",
"description": "Placebo",
"interventions": [
"Biological: Placebo"
]
},
{
"label": "Expanded Arm 8",
"type": "EXPERIMENTAL",
"description": "Low dose formulation A and SIIV",
"interventions": [
"Biological: Formulation A"
]
},
{
"label": "Expanded Arm 9",
"type": "EXPERIMENTAL",
"description": "Mid dose formulation A and SIIV",
"interventions": [
"Biological: Formulation A"
]
},
{
"label": "Expanded Arm 10",
"type": "EXPERIMENTAL",
"description": "High dose formulation A and SIIV",
"interventions": [
"Biological: Formulation A"
]
},
{
"label": "Expanded Arm 11",
"type": "EXPERIMENTAL",
"description": "Low dose formulation B and SIIV",
"interventions": [
"Biological: Formulation B"
]
},
{
"label": "Expanded Arm 12",
"type": "EXPERIMENTAL",
"description": "Mid dose formulation B and SIIV",
"interventions": [
"Biological: Formulation B"
]
},
{
"label": "Expanded Arm 13",
"type": "EXPERIMENTAL",
"description": "High dose formulation B and SIIV",
"interventions": [
"Biological: Formulation B"
]
},
{
"label": "Expanded Arm 14",
"type": "EXPERIMENTAL",
"description": "Low dose formulation A and placebo",
"interventions": [
"Biological: Formulation A"
]
},
{
"label": "Expanded Arm 15",
"type": "EXPERIMENTAL",
"description": "Mid dose formulation A and placebo",
"interventions": [
"Biological: Formulation A"
]
},
{
"label": "Expanded Arm 16",
"type": "EXPERIMENTAL",
"description": "High dose formulation A and placebo",
"interventions": [
"Biological: Formulation A"
]
},
{
"label": "Expanded Arm 17",
"type": "EXPERIMENTAL",
"description": "Low dose formulation B and placebo",
"interventions": [
"Biological: Formulation B"
]
},
{
"label": "Expanded Arm 18",
"type": "EXPERIMENTAL",
"description": "Mid dose formulation B and placebo",
"interventions": [
"Biological: Formulation B"
]
},
{
"label": "Expanded Arm 19",
"type": "EXPERIMENTAL",
"description": "High dose formulation B and placebo",
"interventions": [
"Biological: Formulation B"
]
},
{
"label": "Expanded Arm 20",
"type": "PLACEBO_COMPARATOR",
"description": "placebo and placebo",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "Formulation A",
"type": "BIOLOGICAL",
"description": "RSV vaccine",
"other_names": []
},
{
"name": "Formulation B",
"type": "BIOLOGICAL",
"description": "RSV vaccine",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Placebo",
"other_names": []
}
],
"ae_time_frame": "Local reactions and systemic events collected as Non-SAEs: within 14 days after Vaccination (Vax) 1 and Vax 3 (for revaccination); Other Non-SAEs: Vax 1 up to 1 month after Vax 1, Vax 3 up to 1 month after Vax 3 for revaccination; SAEs: Vax 1 up to 12 months after Vax 1 (approximately up to 378 days [\u2026]",
"ae_description": "Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.",
"ae_groups": [
{
"id": "EG000",
"title": "Sentinel Cohort: RSV Vaccine 60 mcg Age 18-49 Years",
"description": "Participants aged 18-49 years received single 60-mcg dose of RSV vaccine, intramuscularly. Participants were followed up to 12 months after vaccination."
},
{
"id": "EG001",
"title": "Sentinel Cohort: RSV 120 mcg Age 18-49 Years",
"description": "Participants aged 18-49 years received single 120-mcg dose intramuscularly. Participants were followed up to 12 months after vaccination."
},
{
"id": "EG002",
"title": "Sentinel Cohort: RSV 240 mcg Age 18-49 Years",
"description": "Participants aged 18-49 years received single 240-mcg dose intramuscularly. Participants were followed up to 12 months after vaccination."
},
{
"id": "EG003",
"title": "Sentinel Cohort: Placebo Age 18-49 Years",
"description": "Participants aged 18-49 years received placebo matched to RSV vaccine intramuscularly. Participants were followed up to 12 months after vaccination."
},
{
"id": "EG004",
"title": "Sentinel Cohort: RSV 60 mcg With Aluminum Hydroxide Age 50-85 Years",
"description": "Participants aged 50-85 years received single 60-mcg dose with aluminum hydroxide intramuscularly. Participants were followed up to 12 months after vaccination."
},
{
"id": "EG005",
"title": "Sentinel Cohort: RSV 120 mcg With Aluminum Hydroxide Age 50-85 Years",
"description": "Participants aged 50-85 years received single 120-mcg dose with aluminum hydroxide intramuscularly. Participants were followed up to 12 months after vaccination."
},
{
"id": "EG006",
"title": "Sentinel Cohort: RSV 240 mcg With Aluminum Hydroxide Age 50-85 Years",
"description": "Participants aged 50-85 years received single 240-mcg dose with aluminum hydroxide intramuscularly. Participants were followed up to 12 months after vaccination."
},
{
"id": "EG007",
"title": "Sentinel Cohort: RSV 60 mcg With Aluminum Hydroxide Age 18-49 Years",
"description": "Participants aged 18-49 years received single 60-mcg dose with aluminum hydroxide intramuscularly. Participants were followed up to 12 months after vaccination."
},
{
"id": "EG008",
"title": "Sentinel Cohort: RSV 120 mcg With Aluminum Hydroxide Age 18-49 Years",
"description": "Participants aged 18-49 years received single 120-mcg dose with aluminum hydroxide intramuscularly. Participants were followed up to 12 months after vaccination."
},
{
"id": "EG009",
"title": "Sentinel Cohort: RSV 240 mcg With Aluminum Hydroxide Age 18-49 Years",
"description": "Participants aged 18-49 years received single 240-mcg dose with aluminum hydroxide intramuscularly. Participants were followed up to 12 months after vaccination."
},
{
"id": "EG010",
"title": "Sentinel Cohort: RSV Vaccine 60 mcg Age 50-85 Years",
"description": "Participants aged 50-85 years received single 60-mcg dose of RSV vaccine, intramuscularly. Participants were followed up to 12 months after vaccination."
},
{
"id": "EG011",
"title": "Sentinel Cohort: RSV 120 mcg Age 50-85 Years",
"description": "Participants aged 50-85 years received single 120-mcg dose intramuscularly. Participants were followed up to 12 months after vaccination."
},
{
"id": "EG012",
"title": "Sentinel Cohort: RSV 240 mcg Age 50-85 Years",
"description": "Participants aged 50-85 years received single 240-mcg dose intramuscularly. Participants were followed up to 12 months after vaccination."
},
{
"id": "EG013",
"title": "Sentinel Cohort: Placebo Age 50-85 Years",
"description": "Participants aged 50-85 years received placebo matched to RSV vaccine intramuscularly. Participants were followed up to 12 months after vaccination."
},
{
"id": "EG014",
"title": "Expanded Cohort: RSV 60 mcg With SIIV and Placebo Age 18-49 Years",
"description": "Participants aged 18-49 years received RSV vaccine 60 mcg along with 0.5 mL SIIV intramuscularly at Day 1 (Vaccination 1). Participants received placebo (saline control) intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1."
},
{
"id": "EG015",
"title": "Expanded Cohort: RSV 60 mcg With Aluminum Hydroxide and SIIV and Placebo Age 18-49 Years",
"description": "Participants aged 18-49 years received RSV vaccine 60 mcg along with aluminum hydroxide and 0.5 mL SIIV intramuscularly at Day 1 (Vaccination 1). Participants received placebo (saline control) intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1."
},
{
"id": "EG016",
"title": "Expanded Cohort: RSV 120 mcg With SIIV and Placebo Age 18-49 Years:",
"description": "Participants aged 18-49 years received RSV vaccine 120 mcg along with 0.5 mL SIIV intramuscularly at Day 1 (Vaccination 1). Participants received placebo (saline control) intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1."
},
{
"id": "EG017",
"title": "Expanded Cohort: RSV 120 mcg With Aluminum Hydroxide and SIIV and Placebo Age 18-49 Years",
"description": "Participants aged 18-49 years received RSV vaccine 120 mcg along with aluminum hydroxide and 0.5 mL SIIV intramuscularly at Day 1 (Vaccination 1). Participants received placebo (saline control) intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1."
},
{
"id": "EG018",
"title": "Expanded Cohort: RSV 240 mcg With SIIV and Placebo Age 18-49 Years",
"description": "Participants aged 18-49 years received RSV vaccine 240 mcg along with 0.5 mL SIIV intramuscularly at Day 1 (Vaccination 1). Participants received placebo (saline control) intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1. Participants who consented were revaccinated with RSV vaccine 240 mcg along with 0.5 mL SIIV intramuscularly after 12 mont [\u2026]"
},
{
"id": "EG019",
"title": "Expanded Cohort: RSV 240 mcg With Aluminum Hydroxide and SIIV and Placebo Age 18-49 Years",
"description": "Participants aged 18-49 years received RSV vaccine 240 mcg along with aluminum hydroxide and 0.5 mL SIIV intramuscularly at Day 1 (Vaccination 1). Participants received placebo (saline control) intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after vaccination 1. Participants who consented were revaccinated with RSV vaccine 240 mcg along with aluminum hydroxide [\u2026]"
},
{
"id": "EG020",
"title": "Expanded Cohort: Placebo and Placebo and SIIV Age 18-49 Years",
"description": "Participants aged 18-49 years received placebo (saline control) and placebo (saline control) intramuscularly at Day 1 (Vaccination 1). Participants received 0.5 mL SIIV intramuscularly at Day 35 (Vaccination 2). Participants who consented were revaccinated with placebo (saline control) and placebo (saline control) intramuscularly after 12 months of Vaccination 1 (Vaccination 3) and received 0.5 mL [\u2026]"
},
{
"id": "EG021",
"title": "Expanded Cohort: RSV 60 mcg With Placebo and SIIV Age 65-85 Years",
"description": "Participants aged 65-85 years received RSV vaccine 60 mcg along with placebo (saline control) at Day 1 (Vaccination 1). Participants received 0.5 mL SIIV Intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1."
},
{
"id": "EG022",
"title": "Expanded Cohort: RSV 60 mcg With Aluminum Hydroxide and Placebo and SIIV Age 65-85 Years",
"description": "Participants aged 65-85 years received RSV vaccine 60 mcg along with aluminum hydroxide and placebo (saline control) intramuscularly at Day 1 (Vaccination 1). Participants received 0.5 mL SIIV Intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1."
},
{
"id": "EG023",
"title": "Expanded Cohort: RSV 120 mcg With Placebo and SIIV Age 65-85 Years",
"description": "Participants aged 65-85 years received RSV vaccine 120 mcg along with placebo (saline control) at Day 1 (Vaccination 1). Participants received 0.5 mL SIIV Intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1."
},
{
"id": "EG024",
"title": "Expanded Cohort: RSV 120 mcg With Aluminum Hydroxide and Placebo and SIIV Age 65-85 Years",
"description": "Participants aged 65-85 years received RSV vaccine 120 mcg along with aluminum hydroxide and placebo (saline control) intramuscularly at Day 1 (Vaccination 1). Participants received 0.5 mL SIIV Intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1."
},
{
"id": "EG025",
"title": "Expanded Cohort: RSV 240 mcg With Placebo and SIIV Age 65-85 Years",
"description": "Participants aged 65-85 years received RSV vaccine 240 mcg along with placebo (saline control) at Day 1 (Vaccination 1). Participants received 0.5 mL SIIV Intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after vaccination 1. Participants who consented were revaccinated with RSV vaccine 240 mcg along with placebo (saline control) intramuscularly after 12 months  [\u2026]"
},
{
"id": "EG026",
"title": "Expanded Cohort: RSV 240 mcg With Aluminum Hydroxide and Placebo and SIIV Age 65-85 Years",
"description": "Participants aged 65-85 years received RSV vaccine 240 mcg along with aluminum hydroxide and placebo (saline control) intramuscularly at Day 1 (Vaccination 1). Participants received 0.5 mL SIIV Intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after vaccination 1. Participants who consented were revaccinated with RSV vaccine 240 mcg along with aluminum hydroxide [\u2026]"
},
{
"id": "EG027",
"title": "Expanded Cohort: RSV 60 mcg With Placebo and SIIV Age 18-49 Years",
"description": "Participants aged 18-49 years received RSV vaccine 60 mcg along with placebo (saline control) at Day 1 (Vaccination 1). Participants received 0.5 mL SIIV Intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1."
},
{
"id": "EG028",
"title": "Expanded Cohort: RSV 60 mcg With Aluminum Hydroxide and Placebo and SIIV Age 18-49 Years",
"description": "Participants aged 18-49 years received RSV vaccine 60 mcg along with aluminum hydroxide and 0.5 mL SIIV intramuscularly at Day 1 (Vaccination 1). Participants received placebo (saline control) intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1."
},
{
"id": "EG029",
"title": "Expanded Cohort: RSV 120 mcg With Placebo and SIIV Age 18-49 Years",
"description": "Participants aged 18-49 years received RSV vaccine 120 mcg along with placebo (saline control) at Day 1 (Vaccination 1). Participants received 0.5 mL SIIV Intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1."
},
{
"id": "EG030",
"title": "Expanded Cohort: RSV 120 mcg With Aluminum Hydroxide and Placebo and SIIV Age 18-49 Years",
"description": "Participants aged 18-49 years received RSV vaccine 120 mcg along with aluminum hydroxide and placebo (saline control) intramuscularly at Day 1 (Vaccination 1). Participants received 0.5 mL SIIV Intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1."
},
{
"id": "EG031",
"title": "Expanded Cohort: RSV 240 mcg With Placebo and SIIV Age 18-49 Years",
"description": "Participants aged 18-49 years received RSV vaccine 240 mcg along with placebo (saline control) at Day 1 (Vaccination 1). Participants received 0.5 mL SIIV Intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after vaccination 1. Participants who consented were revaccinated with RSV vaccine 240 mcg along with placebo (saline control) intramuscularly after 12 months  [\u2026]"
},
{
"id": "EG032",
"title": "Expanded Cohort: RSV 240 mcg With Aluminum Hydroxide and Placebo and SIIV Age 18-49 Years",
"description": "Participants aged 18-49 years received RSV vaccine 240 mcg along with aluminum hydroxide and placebo (saline control) intramuscularly at Day 1 (Vaccination 1). Participants received 0.5 mL SIIV Intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after vaccination 1. Participants who consented were revaccinated with RSV vaccine 240 mcg along with aluminum hydroxide [\u2026]"
},
{
"id": "EG033",
"title": "Expanded Cohort: RSV 60 mcg With SIIV and Placebo Age 65-85 Years",
"description": "Participants aged 65-85 years received RSV vaccine 60 mcg along with 0.5 mL SIIV intramuscularly at Day 1 (Vaccination 1). Participants received placebo (saline control) intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1."
},
{
"id": "EG034",
"title": "Expanded Cohort: RSV 60 mcg With Aluminum Hydroxide and SIIV and Placebo Age 65-85 Years",
"description": "Participants aged 65-85 years received RSV vaccine 60 mcg along with aluminum hydroxide and 0.5 mL SIIV intramuscularly at Day 1 (Vaccination 1). Participants received placebo (saline control) intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1."
},
{
"id": "EG035",
"title": "Expanded Cohort: RSV 120 mcg With SIIV and Placebo Age 65-85 Years:",
"description": "Participants aged 65-85 years received RSV vaccine 120 mcg along with 0.5 mL SIIV intramuscularly at Day 1 (Vaccination 1). Participants received placebo (saline control) intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1."
},
{
"id": "EG036",
"title": "Expanded Cohort: RSV 120 mcg With Aluminum Hydroxide and SIIV and Placebo Age 65-85 Years",
"description": "Participants aged 65-85 years received RSV vaccine 120 mcg along with aluminum hydroxide and 0.5 mL SIIV intramuscularly at Day 1 (Vaccination 1). Participants received placebo (saline control) intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1."
},
{
"id": "EG037",
"title": "Expanded Cohort: RSV 240 mcg With SIIV and Placebo Age 65-85 Years",
"description": "Participants aged 65-85 years received RSV vaccine 240 mcg along with 0.5 mL SIIV intramuscularly at Day 1 (Vaccination 1). Participants received placebo (saline control) intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after Vaccination 1. Participants who consented were revaccinated with RSV vaccine 240 mcg along with 0.5 mL SIIV intramuscularly after 12 mont [\u2026]"
},
{
"id": "EG038",
"title": "Expanded Cohort: RSV 240 mcg With Aluminum Hydroxide and SIIV and Placebo Age 65-85 Years",
"description": "Participants aged 65-85 years received RSV vaccine 240 mcg along with aluminum hydroxide and 0.5 mL SIIV intramuscularly at Day 1 (Vaccination 1). Participants received placebo (saline control) intramuscularly at Day 35 (Vaccination 2). Participants were followed up to 12 months after vaccination 1. Participants who consented were revaccinated with RSV vaccine 240 mcg along with aluminum hydroxide [\u2026]"
},
{
"id": "EG039",
"title": "Expanded Cohort: Placebo and Placebo and SIIV Age 65-85 Years",
"description": "Participants aged 65-85 years received placebo (saline control) and placebo (saline control) intramuscularly at Day 1 (Vaccination 1). Participants received 0.5 mL SIIV intramuscularly at Day 35 (Vaccination 2). Participants who consented were revaccinated with placebo (saline control) and placebo (saline control) intramuscularly after 12 months of Vaccination 1 (Vaccination 3) and received 0.5 mL [\u2026]"
}
]
},
"coder_1": {
"nct": "NCT03529773",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG011",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG012",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003",
"EG013"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG021",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG023",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG025",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG027",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG029",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG031",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG022",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG024",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG026",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG028",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG030",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG032",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG020",
"EG039"
],
"placebo_content": "inert",
"offspring": false,
"background": "seasonal inactivated influenza vaccine at Day 35"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Sentinel cohort (RSV vaccine with or without Al(OH)3 vs placebo) and expanded cohort (RSV vaccine + placebo then SIIV vs placebo + placebo then SIIV) as two comparisons, ages pooled. Left out the expanded groups given SIIV with the RSV vaccine on Day 1 (EG014-EG019, EG033-EG038): no placebo group got SIIV on Day 1. EG028 taken by its title (its description repeats the SIIV-on-Day-1 schedule). Placebo described as saline control."
},
"coder_2": {
"nct": "NCT03529773",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG010",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG011",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG012",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003",
"EG013"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG021",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG022",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG023",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG024",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG025",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG026",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG027",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG028",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG029",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG030",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG031",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG032",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG020",
"EG039"
],
"placebo_content": "inert",
"offspring": false,
"background": "seasonal influenza vaccine on Day 35"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Sentinel and expanded cohorts have different backgrounds. Expanded: RSV+placebo on Day 1 then SIIV on Day 35 vs placebo+placebo then SIIV; the RSV+SIIV coadministered groups (EG014-EG019, EG033-EG038) left out as the placebo group did not get SIIV on Day 1. EG028's description says SIIV on Day 1 but its title and set place it with the Day 35 groups, so included."
}
},
{
"trial": {
"nct": "NCT03541499",
"brief_title": "Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults",
"official_title": "A Phase 2A Partially-Blind Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Live Attenuated, Intranasal B. Pertussis Vaccine (BPZE1) in Healthy Adults",
"conditions": [
"Pertussis",
"Pertussis Immunisation"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"18 Years",
"49 Years"
],
"arms": [
{
"label": "Group 1",
"type": "EXPERIMENTAL",
"description": "800 microliters (10\\^7 CFU) of B. pertussis vaccine (BPZE1) administered intranasally with the VaxINator device on Day 1, n=15",
"interventions": [
"Biological: BPZE1"
]
},
{
"label": "Group 2",
"type": "EXPERIMENTAL",
"description": "800 microliters (10\\^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1, n=15",
"interventions": [
"Biological: BPZE1"
]
},
{
"label": "Group 3",
"type": "PLACEBO_COMPARATOR",
"description": "800 microliters of Placebo administered intranasally with the VaxINator device on Day 1, n=15",
"interventions": [
"Other: Placebo"
]
},
{
"label": "Group 4",
"type": "EXPERIMENTAL",
"description": "800 microliters (10\\^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1, n=5",
"interventions": [
"Biological: BPZE1"
]
}
],
"interventions": [
{
"name": "BPZE1",
"type": "BIOLOGICAL",
"description": "Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of either 10\\^7 colony forming units (CFU) or 10\\^9 CFU.",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "The placebo consists of the same constituents in the same quantities as the BPZE1 investigational vaccines, absent the attenuated B. pertussis cells, reconstituted with sterile water for injection (SWFI).",
"other_names": []
}
],
"ae_time_frame": "Serious adverse events were collected from the time of vaccination through approximately 6 months after vaccination. Solicited Adverse Events were collected from the time of each study vaccination through 14 days after study vaccination. Unsolicited AEs were collected from the time of study vaccinat [\u2026]",
"ae_description": "Reactogenicity assessments included an assessment of solicited adverse events which includes an assessment of mucosal reactions that include: runny nose, stuffy nose/congestion, nasal pain/irritation, epistaxis, sneezing, sinus pressure/pain, sore throat, cough, and shortness of breath, as well as s [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "BPZE1 10^7 CFU by VaxINator",
"description": "800 microliters (10\\^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1."
},
{
"id": "EG001",
"title": "BPZE1 10^9 CFU by VaxINator",
"description": "800 microliters (10\\^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1."
},
{
"id": "EG002",
"title": "BPZE1 10^9 CFU by Syringe",
"description": "800 microliters (10\\^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1."
},
{
"id": "EG003",
"title": "Placebo by VaxINator",
"description": "800 microliters of Placebo administered intranasally with the VaxINator device on Day 1."
}
]
},
"coder_1": {
"nct": "NCT03541499",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BPZE1 doses by VaxINator vs placebo by VaxINator. Left out EG002 (BPZE1 by syringe, n=5): its delivery differs from the placebo's. Target is pertussis."
},
"coder_2": {
"nct": "NCT03541499",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BPZE1 attenuated B. pertussis."
}
},
{
"trial": {
"nct": "NCT03560258",
"brief_title": "HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study",
"official_title": "HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons With Viral Suppression on Antiretroviral Therapy",
"conditions": [
"HIV Infections"
],
"phases": [
"PHASE1",
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"65 Years"
],
"arms": [
{
"label": "Arm A: p24CE/full-length Gag DNA",
"type": "EXPERIMENTAL",
"description": "Participants received p24CE1/2 pDNA vaccine at Weeks 0 and 4, followed by p24CE1/2 pDNA admixed with full-length p55\\^gag pDNA vaccine at Weeks 12 and 24.",
"interventions": [
"Biological: p24CE1/2 pDNA vaccine",
"Biological: p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine"
]
},
{
"label": "Arm B: Full-length Gag DNA",
"type": "EXPERIMENTAL",
"description": "Participants received full-length p55\\^gag pDNA vaccine at Weeks 0, 4, 12, and 24.",
"interventions": [
"Biological: Full-length p55^gag pDNA vaccine"
]
},
{
"label": "Arm C: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants received placebo at Weeks 0, 4, 12, and 24.",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "p24CE1/2 pDNA vaccine",
"type": "BIOLOGICAL",
"description": "4 mg administered by one injection/electroporation",
"other_names": []
},
{
"name": "p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine",
"type": "BIOLOGICAL",
"description": "2 mg p24CE1/2 pDNA admixed with 2 mg full-length p55\\^gag pDNA administered by one injection/electroporation",
"other_names": []
},
{
"name": "Full-length p55^gag pDNA vaccine",
"type": "BIOLOGICAL",
"description": "4 mg full-length p55\\^gag pDNA vaccine administered by one injection/electroporation",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "1 mL placebo administered by one injection/electroporation",
"other_names": []
}
],
"ae_time_frame": "From treatment initiation to study completion at Week 48 or premature study discontinuation",
"ae_description": "Post-entry, all \u2265 Grade 3 AEs, all AEs that led to a change in treatment regardless of grade, and all AEs meeting SAE definition or EAE reporting requirement, were collected. The DAIDS AE Grading Table (V2.1) and EAE Manual (V2.0) were used. All eligible participants who initiated study treatment we [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "ArmA",
"description": "Participants received p24CE1/2 pDNA vaccine at Weeks 0 and 4, followed by p24CE1/2 pDNA admixed with full-length p55\\^gag pDNA vaccine at Weeks 12 and 24. p24CE1/2 pDNA vaccine: 4 mg administered by one injection/electroporation p24CE1/2 pDNA vaccine admixed with full-length p55\\^gag pDNA vaccine: 2 mg p24CE1/2 pDNA admixed with 2 mg full-length p55\\^gag pDNA administered by one injection/electrop [\u2026]"
},
{
"id": "EG001",
"title": "ArmB",
"description": "Participants received full-length p55\\^gag pDNA vaccine at Weeks 0, 4, 12, and 24. Full-length p55\\^gag pDNA vaccine: 4 mg full-length p55\\^gag pDNA vaccine administered by one injection/electroporation"
},
{
"id": "EG002",
"title": "ArmC",
"description": "Participants received placebo at Weeks 0, 4, 12, and 24. Placebo: 1 mL placebo administered by one injection/electroporation"
}
]
},
"coder_1": {
"nct": "NCT03560258",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HIV DNA vaccine in people with HIV on antiretroviral therapy."
},
"coder_2": {
"nct": "NCT03560258",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"dna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"dna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": ""
}
},
{
"trial": {
"nct": "NCT03576183",
"brief_title": "Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701",
"official_title": "Randomized Double-Blinded Pilot Study Confirming A Human Challenge Model Using LSN03-016011/A Expressing LT And CS17 And Investigating The Safety Of VLA1701 (An Investigational Oral Cholera And ETEC (Enterotoxigenic E Coli) (Vaccine)",
"conditions": [
"Enterotoxigenic Escherichia Coli Infection",
"Diarrhea"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"18 Years",
"49 Years"
],
"arms": [
{
"label": "VLA1701",
"type": "ACTIVE_COMPARATOR",
"description": "VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli) The vaccine is administered orally in 2 doses about 1 week apart.",
"interventions": [
"Biological: VLA1701",
"Other: Challenge Strain"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "The buffer component of VLA1701 will be used as Placebo. The vaccine is administered orally in 2 doses about 1 week apart.",
"interventions": [
"Biological: Placebo",
"Other: Challenge Strain"
]
}
],
"interventions": [
{
"name": "VLA1701",
"type": "BIOLOGICAL",
"description": "VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "buffer component of VLA1701",
"other_names": []
},
{
"name": "Challenge Strain",
"type": "OTHER",
"description": "LSN03-016011/A",
"other_names": []
}
],
"ae_time_frame": "until Month 6",
"ae_description": "solicited and unsolicited AEs",
"ae_groups": [
{
"id": "EG000",
"title": "VLA1701",
"description": "VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli) The vaccine is administered orally in 2 doses about 1 week apart. VLA1701: VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli) Challenge Strain: LSN03-016011/A"
},
{
"id": "EG001",
"title": "Placebo",
"description": "The buffer component of VLA1701 will be used as Placebo. The vaccine is administered orally in 2 doses about 1 week apart. Placebo: buffer component of VLA1701 Challenge Strain: LSN03-016011/A"
}
]
},
"coder_1": {
"nct": "NCT03576183",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "oral ETEC challenge strain"
}
],
"targets": [
"cholera",
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Whole-arm groups including the ETEC challenge both arms got. Platform other: VLA1701 is an investigational oral cholera/ETEC vaccine whose composition the record doesn't give; placebo is its buffer."
},
"coder_2": {
"nct": "NCT03576183",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "oral ETEC challenge for all"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "VLA1701 coded inactivated from product knowledge; adjuvant not stated."
}
},
{
"trial": {
"nct": "NCT03579459",
"brief_title": "Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age",
"official_title": "A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE LOT CONSISTENCY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS 65 TO 85 YEARS OF AGE",
"conditions": [
"Clostridium Difficile Associated Disease"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"65 Years",
"85 Years"
],
"arms": [
{
"label": "Clostridium difficile vaccine Lot 1",
"type": "ACTIVE_COMPARATOR",
"description": "",
"interventions": [
"Biological: Clostridium difficile vaccine"
]
},
{
"label": "Clostridium difficile vaccine Lot 2",
"type": "ACTIVE_COMPARATOR",
"description": "",
"interventions": [
"Biological: Clostridium difficile vaccine"
]
},
{
"label": "Clostridium difficile vaccine Lot 3",
"type": "ACTIVE_COMPARATOR",
"description": "",
"interventions": [
"Biological: Clostridium difficile vaccine"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Normal saline solution (0.9% sodium chloride)",
"interventions": [
"Biological: placebo"
]
}
],
"interventions": [
{
"name": "Clostridium difficile vaccine",
"type": "BIOLOGICAL",
"description": "Toxoid based Clostridium difficile vaccine",
"other_names": []
},
{
"name": "placebo",
"type": "BIOLOGICAL",
"description": "Normal saline solution",
"other_names": [
"0.9% sodium chloride"
]
}
],
"ae_time_frame": "Local reactions and systemic events (systematic assessment): within 7 days after vaccination. SAEs and other AEs: From Day 1 to 1 month after last vaccination (Up to Month 7)",
"ae_description": "Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. Safety analysis population was evaluated.  [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "Clostridium Difficile Vaccine (Pooled Lots)",
"description": "Participants received Clostridium difficile vaccine (200 microgram total toxoid per dose) Lot 1, Lot 2 or Lot 3 intramuscularly at Months 0, 1 and 6."
},
{
"id": "EG001",
"title": "Placebo",
"description": "Participants received placebo (0.9% sodium chloride injection, in a 0.5 mL dose) intramuscularly at Months 0, 1 and 6."
}
]
},
"coder_1": {
"nct": "NCT03579459",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Toxoid vaccine, lots pooled in the tables; adjuvant not stated."
},
"coder_2": {
"nct": "NCT03579459",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Toxoid vaccine; aluminium hydroxide from product knowledge. Lots pooled."
}
},
{
"trial": {
"nct": "NCT03583606",
"brief_title": "A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)",
"official_title": "A Systems Biology Phase 1 Evaluation of the Safety, Reactogenicity, and Immunogenicity of Chimpanzee Adenovirus Type 3- Vectored Zaire Ebolavirus (ChAd3-EBO-Z) and Modified Vaccinia Ankara- Vectored Multivalent Filovirus (MVA-BN(R)-Filo) Vaccine Candidates",
"conditions": [
"Ebola Disease",
"Immunisation"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"45 Years"
],
"arms": [
{
"label": "ChAd3-EBO-Z + ChAd3-EBO-Z",
"type": "EXPERIMENTAL",
"description": "ChAd3-EBO-Z (2 x 10\\^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and ChAd3-EBO-Z (2 x 10\\^11 vp) intramuscularly into the opposite arm on Day 8, n = 20",
"interventions": [
"Biological: ChAd3-EBO-Z"
]
},
{
"label": "ChAd3-EBO-Z + Placebo",
"type": "EXPERIMENTAL",
"description": "ChAd3-EBO-Z (2 x 10\\^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and placebo intramuscularly into the opposite arm on Day 8, n = 20",
"interventions": [
"Biological: ChAd3-EBO-Z",
"Other: Placebo"
]
},
{
"label": "ChAd3-EBO-Z + MVA- BN-Filo",
"type": "EXPERIMENTAL",
"description": "ChAd3-EBO-Z (2 x 10\\^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and MVA-BN-Filo (1 x 10\\^8 Infectious Units (IU)) intramuscularly into the opposite arm on Day 8, n = 20",
"interventions": [
"Biological: ChAd3-EBO-Z",
"Biological: MVA Multi-Filo Ebola Vaccine"
]
}
],
"interventions": [
{
"name": "ChAd3-EBO-Z",
"type": "BIOLOGICAL",
"description": "Zaire ebolavirus vaccine administered by an IM injection into the deltoid as a single dose of 2 x 10\\^11 virus particles (vp)).",
"other_names": []
},
{
"name": "MVA Multi-Filo Ebola Vaccine",
"type": "BIOLOGICAL",
"description": "A booster vaccination of replication defective MVA-BN-Filo administered by an IM injection into the deltoid as a single dose of 1 x 10\\^8 Infectious Units (IU).",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "0.5 mL normal saline administered via IM injection into the deltoid.",
"other_names": []
}
],
"ae_time_frame": "Solicited events were collected from the time of each study vaccination through 7 days post-vaccination. Vaccine-related unsolicited events were collected from the first study vaccination through 28 days post second vaccination. Clinical safety laboratory events were collected from the time of first [\u2026]",
"ae_description": "The solicited and unsolicited adverse events were assessed using MedDRA 23.0.",
"ae_groups": [
{
"id": "EG000",
"title": "ChAd3-EBO-Z + Placebo",
"description": "ChAd3-EBO-Z (2 x 10\\^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and placebo intramuscularly into the opposite arm on Day 8."
},
{
"id": "EG001",
"title": "ChAd3-EBO-Z + ChAd3-EBO-Z",
"description": "ChAd3-EBO-Z (2 x 10\\^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and ChAd3-EBO-Z (2 x 10\\^11 vp) intramuscularly into the opposite arm on Day 8."
},
{
"id": "EG002",
"title": "ChAd3-EBO-Z + MVA- BN-Filo",
"description": "ChAd3-EBO-Z (2 x 10\\^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and MVA-BN-Filo (1 x 10\\^8 Infectious Units (IU)) intramuscularly into the opposite arm on Day 8."
}
]
},
"coder_1": {
"nct": "NCT03583606",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "ChAd3-EBO-Z prime on Day 1"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets ChAd3-EBO-Z on Day 1; took MVA-BN-Filo vs saline on Day 8 (EG002 vs EG000). Left out EG001 (a second ChAd3-EBO-Z dose vs placebo is a dose comparison of the same vaccine)."
},
"coder_2": {
"nct": "NCT03583606",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All arms get ChAd3-EBO-Z."
}
},
{
"trial": {
"nct": "NCT03636906",
"brief_title": "Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV",
"official_title": "A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Infants",
"conditions": [
"Respiratory Syncytial Virus Infections"
],
"phases": [
"PHASE1",
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"6 Months",
"7 Months"
],
"arms": [
{
"label": "RSV1D Pooled Group",
"type": "EXPERIMENTAL",
"description": "Subjects received the interventions as follows: * Either 1 dose of experimental RSV (GSK3389245A) lower dose formulation at Day 1, followed by 1 dose of Placebo at Day 31 and any one the following active comparators: 2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Day 61 and at the end of RSV season 1) or 3 doses of GSK's multicomponent meningococcal B vaccine or Pfizer's meningococcal group A, C, W-135 a [\u2026]",
"interventions": [
"Biological: RSV (GSK3389245A) lower dose formulation vaccine",
"Biological: GSK's multicomponent meningococcal B vaccine",
"Biological: Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine",
"Biological: GSK's pneumococcal polysaccharide conjugate vaccine",
"Biological: GSK's meningococcal group A, C, W-135 and Y conjugate vaccine",
"Drug: Placebo"
]
},
{
"label": "RSV2D Pooled Group",
"type": "EXPERIMENTAL",
"description": "Subjects received the interventions as follows: * Either 2 doses of experimental RSV (GSK3389245A) higher dose formulation (administered at Day 1 and Day 31) and followed by any one the following active comparators: 2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Day 61 and at the end of RSV season 1) or 3 doses of GSK's multicomponent meningococcal B vaccine or Pfizer's meningococcal group A, C, W-135 an [\u2026]",
"interventions": [
"Biological: RSV (GSK3389245A) higher dose formulation vaccine",
"Biological: GSK's multicomponent meningococcal B vaccine",
"Biological: Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine",
"Biological: GSK's pneumococcal polysaccharide conjugate vaccine",
"Biological: GSK's meningococcal group A, C, W-135 and Y conjugate vaccine"
]
},
{
"label": "Comparator_Placebo Pooled Group",
"type": "ACTIVE_COMPARATOR",
"description": "Subjects received either one of interventions schedules as follows: * 3 doses of GSK's multicomponent meningococcal B vaccine (administered at Days 1, 61 and at the end of RSV season 1) and 2 doses of Placebo (administered at Days 31 and 121). * 3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Days 1, 61 and at the end of RSV season 1) and 2 doses of Placebo (administered at Days 31 and 121). * 3 doses  [\u2026]",
"interventions": [
"Biological: GSK's multicomponent meningococcal B vaccine",
"Biological: Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine",
"Biological: GSK's pneumococcal polysaccharide conjugate vaccine",
"Biological: GSK's meningococcal group A, C, W-135 and Y conjugate vaccine",
"Drug: Placebo"
]
}
],
"interventions": [
{
"name": "RSV (GSK3389245A) lower dose formulation vaccine",
"type": "BIOLOGICAL",
"description": "1 dose of RSV (GSK3389245A) lower dose formulation vaccine administered intramuscularly at Day 1.",
"other_names": []
},
{
"name": "RSV (GSK3389245A) higher dose formulation vaccine",
"type": "BIOLOGICAL",
"description": "2 doses of RSV (GSK3389245A) higher dose formulation vaccine administered intramuscularly, at Day 1 and Day 31.",
"other_names": []
},
{
"name": "GSK's multicomponent meningococcal B vaccine",
"type": "BIOLOGICAL",
"description": "3 doses of GSK's multicomponent meningococcal B vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.",
"other_names": [
"Bexsero"
]
},
{
"name": "Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine",
"type": "BIOLOGICAL",
"description": "3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.",
"other_names": [
"Nimenrix"
]
},
{
"name": "GSK's pneumococcal polysaccharide conjugate vaccine",
"type": "BIOLOGICAL",
"description": "3 doses of GSK's pneumococcal polysaccharide conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 31, Day 61 and end of RSV season 1, depending on the vaccination schedule.",
"other_names": [
"Synflorix"
]
},
{
"name": "GSK's meningococcal group A, C, W-135 and Y conjugate vaccine",
"type": "BIOLOGICAL",
"description": "2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61 and at the end of RSV season 1, or at Day 31 and end of RSV season 1, depending on the vaccination schedule.",
"other_names": [
"Menveo"
]
},
{
"name": "Placebo",
"type": "DRUG",
"description": "1 dose or 2 doses of Placebo administered intramuscularly at Day 31, or at Day 1 and Day 31, or at Day 1 and Day 61, or at Day 31 and Day 121, depending on the vaccination schedule.",
"other_names": []
}
],
"ae_time_frame": "Solicited adverse events were collected during the 7-day follow-up period and unsolicited adverse events during the 30-day follow-up period after any vaccination. Serious adverse events were collected from Day 1 up to the end of the second RSV transmission season (up to 2 years).",
"ae_description": "Analysis of adverse events results were reported for the RSV 1D pooled, RSV 2D pooled, and comparator\\_placebo pooled groups as adverse events data collection was based on different standard of care provided at participating countries rather than randomization to each of the individual groups. Accor [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "RSV1D Pooled Group",
"description": "Subjects received the interventions as follows: * Either 1 dose of experimental RSV (GSK3389245A) lower dose formulation at Day 1, followed by 1 dose of Placebo at Day 31 and any one the following active comparators: 2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Day 61 and at the end of RSV season 1) or 3 doses of GSK's multicomponent meningococcal B vac [\u2026]"
},
{
"id": "EG001",
"title": "RSV2D Pooled Group",
"description": "Subjects received the interventions as follows: * Either 2 doses of experimental RSV (GSK3389245A) higher dose formulation (administered at Day 1 and Day 31) and followed by any one the following active comparators: 2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Day 61 and at the end of RSV season 1) or 3 doses of GSK's multicomponent meningococcal B vacc [\u2026]"
},
{
"id": "EG002",
"title": "Comparator_Placebo Pooled Group",
"description": "Subjects received either one of interventions schedules as follows: * 3 doses of GSK's multicomponent meningococcal B vaccine (administered at Days 1, 61 and at the end of RSV season 1) and 2 doses of Placebo (administered at Days 31 and 121). * 3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Days 1, 61 and at the end of RSV season 1) and 2 doses of Pla [\u2026]"
}
]
},
"coder_1": {
"nct": "NCT03636906",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "The control group gets licensed meningococcal or pneumococcal vaccines on Day 1 in place of the first ChAd155-RSV dose (placebo only in the later slots); the RSV groups get the same comparators later, so the control is active for the RSV dose window."
},
"coder_2": {
"nct": "NCT03636906",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "meningococcal and pneumococcal comparator vaccines"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled groups by vaccine received, not individual randomized arms (per the description), but vaccine vs placebo with the same comparator vaccines. Vector platform from product knowledge."
}
},
{
"trial": {
"nct": "NCT03718130",
"brief_title": "Combination HTNV and PUUV DNA Vaccine",
"official_title": "A Phase 1, Randomized Trial to Assess the Safety, Reactogenicity, and Immunogenicity of a Combination HTNV and PUUV DNA Vaccine Candidate Administered by Electroporation",
"conditions": [
"Hantaan Virus Disease, Puumala Virus"
],
"phases": [
"PHASE1"
],
"model": "SINGLE_GROUP",
"masking": "NONE",
"ages": [
"18 Years",
"49 Years"
],
"arms": [
{
"label": "Group 1: 0.6 mg HTNV - Intradermal (ID)",
"type": "EXPERIMENTAL",
"description": "0.1 mL 6.0 mg/mL HTNV DNA + 0.1 mL 0.9% saline (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid\u2122 Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.",
"interventions": [
"Combination Product: Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID)"
]
},
{
"label": "Group 2: 3.0 mg HTNV - Intramuscular (IM)",
"type": "EXPERIMENTAL",
"description": "0.5 mL 6.0 mg/mL HTNV DNA + 0.5 mL 0.9% saline (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid\u2122 Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.",
"interventions": [
"Combination Product: Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)"
]
},
{
"label": "Group 3: 0.6 mg PUUV - Intradermal (ID)",
"type": "EXPERIMENTAL",
"description": "0.1 mL 6.0 mg/mL PUUV DNA + 0.1 mL 0.9% saline (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid\u2122 Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.",
"interventions": [
"Combination Product: Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)"
]
},
{
"label": "Group 4: 3.0 mg PUUV - Intramuscular (IM)",
"type": "EXPERIMENTAL",
"description": "0.5 mL 6.0 mg/mL PUUV DNA + 0.5 mL 0.9% saline (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid\u2122 Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.",
"interventions": [
"Combination Product: Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)"
]
},
{
"label": "Group 5: 1.2 mg HTNV/PUUV (0.6 mg each) - Intradermal (ID)",
"type": "EXPERIMENTAL",
"description": "0.1 mL 6.0 mg/mL HTNV DNA + 0.1 mL 6.0 mg/mL PUUV DNA (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid\u2122 Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.",
"interventions": [
"Combination Product: Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)"
]
},
{
"label": "Group 6: 6.0 mg HTNV/PUUV (3.0 mg each) - Intramuscular (IM)",
"type": "EXPERIMENTAL",
"description": "0.5 mL 6.0 mg/mL HTNV DNA + 0.5 mL 6.0 mg/mL PUUV DNA (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid\u2122 Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.",
"interventions": [
"Combination Product: Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM)"
]
}
],
"interventions": [
{
"name": "Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID)",
"type": "COMBINATION_PRODUCT",
"description": "The HTNV vaccine will be administered using the ID TriGrid\u2122 Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.",
"other_names": [
"HTNV vaccine using TDS ID"
]
},
{
"name": "Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)",
"type": "COMBINATION_PRODUCT",
"description": "The HTNV vaccine will be administered using the IM TriGrid\u2122 Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.",
"other_names": [
"HTNV vaccine using TDS IM"
]
},
{
"name": "Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)",
"type": "COMBINATION_PRODUCT",
"description": "The PUUV vaccine will be administered using the ID TriGrid\u2122 Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.",
"other_names": [
"PUUV vaccine using TDS ID"
]
},
{
"name": "Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)",
"type": "COMBINATION_PRODUCT",
"description": "The PUUV DNA vaccine will be administered using the IM TriGrid\u2122 Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.",
"other_names": [
"PUUV vaccine using the TDS IM"
]
},
{
"name": "Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)",
"type": "COMBINATION_PRODUCT",
"description": "The HTNV and PUUV vaccines will be administered using the ID TriGrid\u2122 Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.",
"other_names": [
"HTNV/PUUV vaccines using the TDS ID"
]
},
{
"name": "Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM)",
"type": "COMBINATION_PRODUCT",
"description": "The HTNV and PUUV vaccines will be administered using the IM TriGrid\u2122 Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.",
"other_names": [
"HTNV/PUUV vaccines using the TDS IM"
]
}
],
"ae_time_frame": "6 months from last vaccination (Day 220)",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Group 1: 0.6 mg HTNV - Intradermal (ID)",
"description": "0.1 mL 6.0 mg/mL HTNV DNA + 0.1 mL 0.9% saline (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid\u2122 Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue. Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intraderma [\u2026]"
},
{
"id": "EG001",
"title": "Group 2: 3.0 mg HTNV - Intramuscular (IM)",
"description": "0.5 mL 6.0 mg/mL HTNV DNA + 0.5 mL 0.9% saline (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid\u2122 Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue. Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscu [\u2026]"
},
{
"id": "EG002",
"title": "Group 3: 0.6 mg PUUV - Intradermal (ID)",
"description": "0.1 mL 6.0 mg/mL PUUV DNA + 0.1 mL 0.9% saline (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid\u2122 Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue. Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intra [\u2026]"
},
{
"id": "EG003",
"title": "Group 4: 3.0 mg PUUV - Intramuscular (IM)",
"description": "0.5 mL 6.0 mg/mL PUUV DNA + 0.5 mL 0.9% saline (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid\u2122 Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue. Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intram [\u2026]"
},
{
"id": "EG004",
"title": "Group 5: 1.2 mg HTNV/PUUV (0.6 mg Each) - Intradermal (ID)",
"description": "0.1 mL 6.0 mg/mL HTNV DNA + 0.1 mL 6.0 mg/mL PUUV DNA (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid\u2122 Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue. Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery S [\u2026]"
},
{
"id": "EG005",
"title": "Group 6: 6.0 mg HTNV/PUUV (3.0 mg Each) - Intramuscular (IM)",
"description": "0.5 mL 6.0 mg/mL HTNV DNA + 0.5 mL 6.0 mg/mL PUUV DNA (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid\u2122 Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue. Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery Sys [\u2026]"
}
]
},
"coder_1": {
"nct": "NCT03718130",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"dna"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"dna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000",
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "HTNV DNA vaccine by electroporation (same dose and route)"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target 'other': hantaviruses (Hantaan and Puumala). No placebo arm as such, but groups 1-2 got HTNV DNA + 0.9% saline in place of the PUUV DNA that groups 5-6 got with the same HTNV dose, route and device, so PUUV DNA vs saline on an HTNV background. ID and IM cohorts pooled. Groups 3-4 (PUUV + saline) left out because groups 5-6 can be used once; pairing them instead would test HTNV on a PUUV background. Open label."
},
"coder_2": {
"nct": "NCT03718130",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Hantavirus (HTNV/PUUV) DNA vaccines; all arms vaccinated, no placebo."
}
},
{
"trial": {
"nct": "NCT03819049",
"brief_title": "A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health",
"official_title": "A Randomized, Observer-blind, First-in-Human Phase 1/2a Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health",
"conditions": [
"Extraintestinal Pathogenic Escherichia Coli Prevention"
],
"phases": [
"PHASE1",
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"60 Years",
null
],
"arms": [
{
"label": "Cohort 1: ExPEC10V (Low Dose)",
"type": "EXPERIMENTAL",
"description": "Participants will be randomized to receive a single intramuscular (IM) injection of low dose ExPEC10V on Day 1.",
"interventions": [
"Biological: ExPEC10V"
]
},
{
"label": "Cohort 1: ExPEC10V (Medium dose)",
"type": "EXPERIMENTAL",
"description": "Participants will be randomized to receive a single IM injection of medium dose ExPEC10V on Day 1.",
"interventions": [
"Biological: ExPEC10V"
]
},
{
"label": "Cohort 1: ExPEC10V (High dose)",
"type": "EXPERIMENTAL",
"description": "Participants will be randomized to receive a single IM injection of high dose ExPEC10V on Day 1.",
"interventions": [
"Biological: ExPEC10V"
]
},
{
"label": "Cohort 1: ExPEC4V",
"type": "EXPERIMENTAL",
"description": "Participants will be randomized to receive a single IM injection of ExPEC4V on Day 1.",
"interventions": [
"Biological: ExPEC4V"
]
},
{
"label": "Cohort 1: Prevnar 13",
"type": "EXPERIMENTAL",
"description": "Participants will be randomized to receive a single IM injection of Prevnar 13 on Day 1.",
"interventions": [
"Biological: Prevnar 13"
]
},
{
"label": "Cohort 2: ExPEC10V",
"type": "EXPERIMENTAL",
"description": "Participants will be randomized to receive a single IM injection of selected dose of ExPEC10V on Day 1. The ExPEC10V dose used in Cohort 2 will be based on the primary analysis (Day 30) results of Cohort 1.",
"interventions": [
"Biological: ExPEC10V"
]
},
{
"label": "Cohort 2: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants will be randomized to receive a single IM injection of matching placebo on Day 1.",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "ExPEC10V",
"type": "BIOLOGICAL",
"description": "Participants will receive a single IM injection of ExPEC10V (1 of 3 doses \\[low or medium or high\\]) in Cohort 1 and ExPEC10V selected dose (based on the primary analysis results of Cohort 1) in Cohort 2 on Day 1.",
"other_names": [
"VAC52416"
]
},
{
"name": "ExPEC4V",
"type": "BIOLOGICAL",
"description": "Participants will receive a single IM injection of ExPEC4V on Day 1.",
"other_names": [
"JNJ-63871860"
]
},
{
"name": "Prevnar 13",
"type": "BIOLOGICAL",
"description": "Participants will receive a single IM injection of Prevnar 13 on Day 1.",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Participants will receive single IM injection of matching placebo on Day 1.",
"other_names": []
}
],
"ae_time_frame": "From Day 1 (post vaccination) up to Day 1826",
"ae_description": "FAS included all randomized participants with a vaccine administration documented.",
"ae_groups": [
{
"id": "EG000",
"title": "Cohort 1: Low Dose ExPEC10V",
"description": "Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection of ExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."
},
{
"id": "EG001",
"title": "Cohort 1: Medium Dose ExPEC10V",
"description": "Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."
},
{
"id": "EG002",
"title": "Cohort 1: High Dose ExPEC10V",
"description": "Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."
},
{
"id": "EG003",
"title": "Cohort 1: ExPEC4V",
"description": "Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."
},
{
"id": "EG004",
"title": "Cohort 1: Prevnar 13",
"description": "Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."
},
{
"id": "EG005",
"title": "Cohort 2: ExPEC10V",
"description": "Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."
},
{
"id": "EG006",
"title": "Cohort 2: Placebo",
"description": "Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."
}
]
},
"coder_1": {
"nct": "NCT03819049",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG005",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"e_coli"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only Cohort 2 has a placebo; Cohort 1 groups (ExPEC10V doses, ExPEC4V, Prevnar 13 active control) left out. ExPEC10V is an O-antigen conjugate; adjuvant not stated. Cohort 2 required a history of UTI but enrolled adults in stable health, so patients false."
},
"coder_2": {
"nct": "NCT03819049",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG005",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"e_coli"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only Cohort 2 has placebo; Cohort 1 groups (dose arms, ExPEC4V, Prevnar 13) have no placebo and are left out. Cohort 2 enrolled people with history of UTI but stable health, patients false."
}
},
{
"trial": {
"nct": "NCT03869333",
"brief_title": "Dose Escalating Study of Intramuscular Invaplex[AR-DETOX]",
"official_title": "A Phase 1 Double-blind, Placebo-controlled, Dose Escalating Study of Intramuscular Detoxified Shigella Flexneri 2a Artificial Invasin Complex (Invaplex[AR-DETOX]) Vaccine",
"conditions": [
"Diarrhea"
],
"phases": [
"PHASE1"
],
"model": "SEQUENTIAL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"50 Years"
],
"arms": [
{
"label": "Invaplex[AR-Detox] 2.5 \u03bcg",
"type": "EXPERIMENTAL",
"description": "Participants received an intramuscular injection of 2.5 \u03bcg Invaplex\\[AR-DETOX\\] vaccine on Days 1, 22, and 43.",
"interventions": [
"Biological: Invaplex[AR-DETOX]"
]
},
{
"label": "Invaplex[AR-Detox] 10 \u03bcg",
"type": "EXPERIMENTAL",
"description": "Participants received an intramuscular injection of 10 \u03bcg Invaplex\\[AR-DETOX\\] vaccine on Days 1, 22, and 43.",
"interventions": [
"Biological: Invaplex[AR-DETOX]"
]
},
{
"label": "Invaplex[AR-Detox] 25 \u03bcg",
"type": "EXPERIMENTAL",
"description": "Participants received an intramuscular injection of 25 \u03bcg Invaplex\\[AR-DETOX\\] vaccine on Days 1, 22, and 43.",
"interventions": [
"Biological: Invaplex[AR-DETOX]"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.",
"interventions": [
"Other: Placebo"
]
}
],
"interventions": [
{
"name": "Invaplex[AR-DETOX]",
"type": "BIOLOGICAL",
"description": "Detoxified Shigella flexneri 2a Artificial Invasin Complex (Invaplex\\[AR-Detox\\]) Vaccine",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "Saline",
"other_names": []
}
],
"ae_time_frame": "From first dose up to 28 days following the third immunization (71 days)",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Invaplex[AR-Detox] 2.5 \u03bcg",
"description": "Participants received an intramuscular injection of 2.5 \u03bcg Invaplex\\[AR-DETOX\\] vaccine on Days 1, 22, and 43."
},
{
"id": "EG001",
"title": "Invaplex[AR-Detox] 10 \u03bcg",
"description": "Participants received an intramuscular injection of 10 \u03bcg Invaplex\\[AR-DETOX\\] vaccine on Days 1, 22, and 43."
},
{
"id": "EG002",
"title": "Invaplex[AR-Detox] 25 \u03bcg",
"description": "Participants received an intramuscular injection of 25 \u03bcg Invaplex\\[AR-DETOX\\] vaccine on Days 1, 22, and 43."
},
{
"id": "EG003",
"title": "Placebo",
"description": "Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43."
}
]
},
"coder_1": {
"nct": "NCT03869333",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Invaplex AR-DETOX, a purified S. flexneri 2a invasin protein complex (with detoxified LPS), coded protein; adjuvant not stated."
},
"coder_2": {
"nct": "NCT03869333",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Invaplex is a Shigella LPS/protein complex; adjuvant not stated"
}
},
{
"trial": {
"nct": "NCT03942406",
"brief_title": "Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults",
"official_title": "Phase 2b Study of BPZE1 Intranasal Pertussis Vaccine in Adults to Assess Immunological Response and Safety Profile of 1-Dose (Prime) and 2-Doses (Prime+Boost) Schedule, Compared to a Boostrix\u2122 Prime Dose With or Without a BPZE1 Boost Dose",
"conditions": [
"Pertussis",
"Whooping Cough"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"50 Years"
],
"arms": [
{
"label": "BPZE1 Intranasal Prime, BPZE1 Boost",
"type": "EXPERIMENTAL",
"description": "Individual will receive an intranasal dose of BPZE1 via the VaxINator atomization device and a dose of intramuscular (I.M.) placebo. Individuals will receive a boost dose of intranasal BPZE1 via the VaxINator\u2122 atomization device.",
"interventions": [
"Combination Product: BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device"
]
},
{
"label": "BPZE1 Intranasal Prime, Placebo Boost",
"type": "EXPERIMENTAL",
"description": "Individual will receive an intranasal dose of BPZE1 via the VaxINator atomization device and a dose of intramuscular (I.M.) placebo. Individuals will receive a boost dose of intranasal placebo via the VaxINator\u2122 atomization device.",
"interventions": [
"Combination Product: BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device"
]
},
{
"label": "Boostrix IM Prime, BPZE1 Boost",
"type": "EXPERIMENTAL",
"description": "Individual will receive an intranasal dose of placebo via the VaxINator atomization device and a dose of intramuscular (I.M.) Boostrix (aP vaccine comparator). Individuals will receive a boost dose of intranasal BPZE1 via the VaxINator\u2122 atomization device.",
"interventions": [
"Combination Product: BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device"
]
},
{
"label": "Boostrix IM Prime, Placebo Boost",
"type": "ACTIVE_COMPARATOR",
"description": "Individual will receive an intranasal dose of placebo via the VaxINator atomization device and a dose of intramuscular (I.M.) Boostrix (aP vaccine comparator). Individuals will receive a boost dose of intranasal placebo via the VaxINator\u2122 atomization device.",
"interventions": [
"Combination Product: BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device"
]
}
],
"interventions": [
{
"name": "BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device",
"type": "COMBINATION_PRODUCT",
"description": "Live attenuated pertussis vaccine administered via the VaxINator(TM) atomization device",
"other_names": []
}
],
"ae_time_frame": "Unsolicited treatment-emergent adverse events (TEAEs) - Days 1 through 29 and Days 85 through 113; All-cause mortality and SAEs - Days 1 through 254 (end of study)",
"ae_description": "10\\^7 and 10\\^9 Safety Analysis Set (includes 10\\^9 Safety Analysis Set \\[n=279\\] and Safety Lead-in Cohort of participants who received BPZE1 10\\^7 CFU \\[n=20\\]). Participants who were randomized to receive BPZE1 as the second vaccination (ie, revaccination/attenuated challenge) but who did not rec [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "BPZE1 Intranasal Prime, BPZE1 Boost",
"description": "Individual will receive an intranasal dose of BPZE1 via the VaxINator atomization device and a dose of IM placebo on Day 1. Individuals will receive a boost dose of intranasal BPZE1 via the VaxINator\u2122 atomization device on Day85. (10\\^9 Safety Analysis Set)"
},
{
"id": "EG001",
"title": "BPZE1 Intranasal Prime, Placebo Boost",
"description": "Individual will receive an intranasal dose of BPZE1 via the VaxINator atomization device and a dose of IM placebo on Day 1. Individuals will receive a boost dose of intranasal placebo via the VaxINator\u2122 atomization device on Day 85. (10\\^9 Safety Analysis Set)"
},
{
"id": "EG002",
"title": "Boostrix IM Prime, BPZE1 Boost",
"description": "Individual will receive an intranasal dose of placebo via the VaxINator atomization device and a dose of IM Boostrix (aP vaccine comparator) on Day 1. Individuals will receive a boost dose of intranasal BPZE1 via the VaxINator\u2122 atomization device on Day 85. (10\\^9 Safety Analysis Set)"
},
{
"id": "EG003",
"title": "Boostrix IM Prime, Placebo Boost",
"description": "Individual will receive an intranasal dose of placebo via the VaxINator atomization device and a dose of IM Boostrix (aP vaccine comparator) on Day 1. Individuals will receive a boost dose of intranasal placebo via the VaxINator\u2122 atomization device on Day 85. (10\\^9 Safety Analysis Set)"
},
{
"id": "EG004",
"title": "BPZE1 (10^7) Intranasal Prime, BPZE1 (10^7) Boost",
"description": "Individual will receive an intranasal dose of BPZE1 via the VaxINator atomization device and a dose of IM placebo on Day 1. Individuals will receive a boost dose of intranasal BPZE1 via the VaxINator\u2122 atomization device on Day 85. (10\\^7 Safety Lead-in Analysis Set)"
},
{
"id": "EG005",
"title": "BPZE1 (10^7) Intranasal Prime, Placebo Boost",
"description": "Individual will receive an intranasal dose of BPZE1 via the VaxINator atomization device and a dose of IM placebo on Day 1. Individuals will receive a boost dose of intranasal placebo via the VaxINator\u2122 atomization device on Day 85. (10\\^7 Safety Lead-in Analysis Set)"
},
{
"id": "EG006",
"title": "Boostrix IM Prime, BPZE1 (10^7) Boost",
"description": "Individual will receive an intranasal dose of placebo via the VaxINator atomization device and a dose of IM Boostrix (aP vaccine comparator) on Day 1. Individuals will receive a boost dose of intranasal BPZE1 via the VaxINator\u2122 atomization device on Day 85. (10\\^7 Safety Lead-in Analysis Set)"
}
]
},
"coder_1": {
"nct": "NCT03942406",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Boostrix (Tdap) IM prime with intranasal placebo on Day 1"
}
],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only clean pair: Boostrix-primed participants randomized to BPZE1 vs intranasal placebo boost at Day 85. BPZE1-primed groups (EG000, EG001) left out: both arms got BPZE1 at prime, and prime BPZE1 vs Boostrix is an active control. Lead-in 10^7 groups (EG004-EG006) left out: their cohort had no placebo-boost group."
},
"coder_2": {
"nct": "NCT03942406",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets BPZE1 or Boostrix; no group is placebo only"
}
},
{
"trial": {
"nct": "NCT03952650",
"brief_title": "Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...",
"official_title": "Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falciparum Infection in Bancoumana and Surrounding Areas, Mali",
"conditions": [
"Malaria"
],
"phases": [
"PHASE1",
"PHASE2"
],
"model": "SEQUENTIAL",
"masking": "DOUBLE",
"ages": [
"18 Years",
"50 Years"
],
"arms": [
{
"label": "1a",
"type": "EXPERIMENTAL",
"description": "Receiving 400,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ",
"interventions": [
"Biological: PfSPZ Challenge",
"Drug: Pyrimethamine",
"Drug: Coartem"
]
},
{
"label": "1b",
"type": "EXPERIMENTAL",
"description": "Receiving 400,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ",
"interventions": [
"Biological: PfSPZ Challenge",
"Drug: Pyrimethamine",
"Drug: Coartem"
]
},
{
"label": "2a",
"type": "EXPERIMENTAL",
"description": "Receiving 400,000 PfSPZ with 75 mg pyrimethamine days 2\\&amp;3 post PfSPZ",
"interventions": [
"Biological: PfSPZ Challenge",
"Drug: Pyrimethamine",
"Drug: Coartem"
]
},
{
"label": "2b",
"type": "EXPERIMENTAL",
"description": "Receiving 400,000 PfSPZ with 75 mg pyrimethamine days 2\\&amp;3 post PfSPZ",
"interventions": [
"Biological: PfSPZ Challenge",
"Drug: Pyrimethamine",
"Drug: Coartem"
]
},
{
"label": "3a",
"type": "EXPERIMENTAL",
"description": "Receiving 400,000 PfSPZ with chloroquine 2 days prior + 5 days post PfSPZibuprofen (if necessary)",
"interventions": [
"Drug: Chloroquine Phosphate",
"Biological: PfSPZ Challenge",
"Drug: Coartem",
"Drug: ibuprofen"
]
},
{
"label": "3b",
"type": "EXPERIMENTAL",
"description": "Receiving 400,000 PfSPZ with weekly chloroquineibuprofen (if necessary)",
"interventions": [
"Drug: Chloroquine Phosphate",
"Biological: PfSPZ Challenge",
"Drug: Coartem",
"Drug: ibuprofen"
]
},
{
"label": "4a",
"type": "PLACEBO_COMPARATOR",
"description": "Receiving normal saline with 75 mg pyrimethamine day 0 post injection",
"interventions": [
"Drug: Pyrimethamine",
"Drug: Coartem"
]
},
{
"label": "4b",
"type": "PLACEBO_COMPARATOR",
"description": "Receiving normal saline with 75 mg pyrimethamine days 2\\&amp;3 post injection",
"interventions": [
"Drug: Pyrimethamine",
"Drug: Coartem"
]
},
{
"label": "4c",
"type": "PLACEBO_COMPARATOR",
"description": "Receiving normal saline with weekly chloroquineibuprofen (if necessary)",
"interventions": [
"Drug: Chloroquine Phosphate",
"Drug: Coartem",
"Drug: ibuprofen"
]
},
{
"label": "5a",
"type": "EXPERIMENTAL",
"description": "Receiving 300,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ (if necessary)",
"interventions": [
"Biological: PfSPZ Challenge",
"Drug: Pyrimethamine",
"Drug: Coartem"
]
},
{
"label": "5b",
"type": "EXPERIMENTAL",
"description": "Receiving 300,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ",
"interventions": [
"Biological: PfSPZ Challenge",
"Drug: Pyrimethamine",
"Drug: Coartem"
]
},
{
"label": "6a",
"type": "EXPERIMENTAL",
"description": "Receiving 300,000 PfSPZ with 75 mg pyrimethamine days 2\\&amp;3 post PfSPZ (if necessary)",
"interventions": [
"Biological: PfSPZ Challenge",
"Drug: Pyrimethamine",
"Drug: Coartem"
]
},
{
"label": "6b",
"type": "EXPERIMENTAL",
"description": "Receiving 300,000 PfSPZ with 75 mg pyrimethamine days 2\\&amp;3 post PfSPZ (if necessary)",
"interventions": [
"Biological: PfSPZ Challenge",
"Drug: Pyrimethamine",
"Drug: Coartem"
]
}
],
"interventions": [
{
"name": "Chloroquine Phosphate",
"type": "DRUG",
"description": "Chloroquine phosphate is approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a blood-stage schizonticide, highly active against replicating forms of blood-stage drug- sensitive parasites. As such, it is routinely employed as first-line prophylaxis against development of patent parasitemia and clinical malaria in non-immune travelers [\u2026]",
"other_names": []
},
{
"name": "PfSPZ Challenge",
"type": "BIOLOGICAL",
"description": "PfSPZ Challenge (NF54) acts as the immunogen in the PfSPZ-CVac approach to vaccinating against malaria. Participants will receive either one (in the pilot phase) or 3 (in the main phase) 400,000 or 300,000 aseptic, purified, cryopreserved, fully infectious PfSPZ injections by DVI (with concurrent administration of antimalarial drugs). Following immunization, participants in the main phase will be followed through the transmission season in order  [\u2026]",
"other_names": []
},
{
"name": "Pyrimethamine",
"type": "DRUG",
"description": "Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia. Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses o [\u2026]",
"other_names": []
},
{
"name": "Coartem",
"type": "DRUG",
"description": "Antimalarial (Coartem ) will be administered to all participants twice during the study, approximately 2 weeks prior to the first vaccination in order to clear pre-existing parasitemia that may interfere with immunity development. The second dose will be given approximately 2 weeks prior to the 3rd vaccination in order to clear any parasitemia infection that may have happened naturally during the vaccination period and prior to the follow up peri [\u2026]",
"other_names": []
},
{
"name": "ibuprofen",
"type": "DRUG",
"description": "Ibuprofen likewise is not a part of the investigational product/regimen, but will be provided to participants in the chloroquine arm (Arm 4) if required to mitigate typical symptoms of malaria infection such as headache, myalgia, fever and chills.",
"other_names": []
}
],
"ae_time_frame": "One month for pilot phase; eight months for main phase; seven months for booster phase",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "1a - Pilot/Safety: Dosing Interval on Days: 1",
"description": "Participants received 1 dose of 4x10\\^5 PfSPZ via direct venus inoculation (DVI) with 75 mg PYR day 0 post PfSPZ"
},
{
"id": "EG001",
"title": "1b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57",
"description": "Participants received 4x10\\^5 PfSPZ via direct venus inoculation (DVI) with 75 mg PYR day 0 post PfSPZ on day 1, day 29 and day 57."
},
{
"id": "EG002",
"title": "2a - Pilot/Safety: Dosing Interval on Days: 1",
"description": "Participants received 1 dose of 4x10\\^5 PfSPZ via direct venus inoculation (DVI) with 75 mg PYR day 2 \\& 3 post PfSPZ"
},
{
"id": "EG003",
"title": "2b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57",
"description": "Participants received 4x10\\^5 PfSPZ via direct venus inoculation (DVI) with 75 mg PYR day 2 \\& 3 post PfSPZ on day 1, day 29 and day 57."
},
{
"id": "EG004",
"title": "3a - Pilot/Safety: Dosing Interval on Days: 1",
"description": "Participants received 1 dose of 4x10\\^5 PfSPZ via direct venus inoculation (DVI) with chloroquine 2 days prior \\& 5 days post PfSPZ"
},
{
"id": "EG005",
"title": "4a - Safety Comparator: Dosing Interval on Days: 1, 29, 57",
"description": "Participants received normal saline (NS) via direct venus inoculation (DVI) with 75 mg PYR day 0 post PfSPZ on day 1, day 29 and day 57."
},
{
"id": "EG006",
"title": "4b - Safety Comparator: Dosing Interval on Days: 1, 29, 57",
"description": "Participants received normal saline (NS) via direct venus inoculation (DVI) with 75 mg PYR day 2 \\& 3 post PfSPZ on day 1, day 29 and day 57."
}
]
},
"coder_1": {
"nct": "NCT03952650",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "pyrimethamine 75 mg on day 0 after each injection; artemether/lumefantrine clearance"
},
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "pyrimethamine 75 mg on days 2 and 3 after each injection; artemether/lumefantrine clearance"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "PfSPZ-CVac: platform other, fully infectious non-attenuated PfSPZ given under antimalarial drug cover. Main-phase groups only, split by the pyrimethamine schedule both sides shared. Single-dose pilot groups (EG000, EG002, EG004) had no placebo group; no chloroquine placebo group was reported."
},
"coder_2": {
"nct": "NCT03952650",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005",
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "pyrimethamine chemoprophylaxis (both sides)"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "PfSPZ Challenge (live infectious sporozoites under drug cover), coded other. Took 3-dose safety/efficacy groups 1b,2b vs saline groups 4a,4b; pilot single-dose groups have no placebo and are left out."
}
},
{
"trial": {
"nct": "NCT03964415",
"brief_title": "A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals",
"official_title": "A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals",
"conditions": [
"Healthy"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"18 Years",
"60 Years"
],
"arms": [
{
"label": "Group1:Ad26.Mos4.HIV,Clade C and Mosaic gp140 bivalent vaccine",
"type": "EXPERIMENTAL",
"description": "Participants will receive adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) via intramuscular (IM) injection into the deltoid muscle at months 0 (Day 1) and 3 (preferably the deltoid of the non-dominant upper arm) and, Ad26.Mos4.HIV together with Clade C and Mosaic gp140 HIV bivalent vaccine IM into the deltoid muscle at Months 6 and 12 (different deltoid for each injection).",
"interventions": [
"Biological: Ad26.Mos4.HIV",
"Biological: Clade C and Mosaic gp140 HIV bivalent vaccine"
]
},
{
"label": "Group 2: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants will receive placebo into the deltoid muscle on Months 0 (Day 1), 3 (1 injection), 6 and 12 (2 injections).",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "Ad26.Mos4.HIV",
"type": "BIOLOGICAL",
"description": "Participants will receive Ad26.Mos4.HIV via IM injection into the deltoid muscle at months 0 (Day 1), 3, 6 and 12.",
"other_names": []
},
{
"name": "Clade C and Mosaic gp140 HIV bivalent vaccine",
"type": "BIOLOGICAL",
"description": "Participants will receive Clade C and Mosaic gp140 HIV bivalent vaccine as IM injection into the deltoid muscle at Months 6 and 12.",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Participants will receive matching placebo.",
"other_names": []
}
],
"ae_time_frame": "Unsolicited AEs: 28 days after each vaccination (up to Day 392); Solicited AEs: 7 days after each vaccination (up to Day 371); All-cause mortality and SAE: From Day 1 up to Month 40",
"ae_description": "The full analysis set (FAS) set included all randomized participants who received at least one vaccine administration.",
"ae_groups": [
{
"id": "EG000",
"title": "Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140",
"description": "Participants received adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) 5\\*10\\^10 viral particles (vp) intramuscular (IM) injection into the deltoid muscle as a monotherapy at Months 0 (Day 1) and 3 (Day 84) (preferably the deltoid of the non-dominant upper arm) along with adjuvanted protein formulation consisting of Clade C protein 80 micrograms (mcg), Mosaic protein 75 [\u2026]"
},
{
"id": "EG001",
"title": "Group 2: Placebo",
"description": "Participants received placebo into the deltoid muscle at Months 0 (Day 1), 3 (Day 84; 1 injection), 6 (Day 168) and 12 (Day 364; 2 injections)."
}
]
},
"coder_1": {
"nct": "NCT03964415",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.Mos4.HIV plus clade C and mosaic gp140 protein; the protein is called adjuvanted but the record (truncated) does not name the adjuvant. Healthy MSM and transgender people."
},
"coder_2": {
"nct": "NCT03964415",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.Mos4.HIV plus aluminium-phosphate-adjuvanted gp140 protein"
}
},
{
"trial": {
"nct": "NCT03982199",
"brief_title": "A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older",
"official_title": "A Randomized, Double-blind, Placebo-controlled Phase 2b Study to Assess the Efficacy, Immunogenicity and Safety of an Ad26.RSV.preF-based Regimen in the Prevention of RT PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older",
"conditions": [
"Respiratory Syncytial Viruses",
"Respiratory Tract Diseases"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"65 Years",
null
],
"arms": [
{
"label": "Group 1: RSV Vaccine",
"type": "EXPERIMENTAL",
"description": "Participants will receive a single intramuscular (IM) injection of an adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV) vaccine at a single dose level on Day 1. Participants will then be divided into revaccination subcohorts: 1A, 1B, and 1C to receive revaccination with Ad26.RSV.preF based vaccine at 1 year, 2 years, and 3 years respectively after the first vaccination.",
"interventions": [
"Biological: RSV Vaccine"
]
},
{
"label": "Group 2: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants will receive a single IM injection of placebo control on Day 1. Participants will then be divided into revaccination subcohorts 2A, 2B, and 2C, and will first receive Ad26.RSV.preF based vaccine at years 1, 2, and 3. In subcohorts 2A and 2B, participants will receive a revaccination one year later with either Ad26.RSV.preF based vaccine, study vaccine A or study vaccine B.",
"interventions": [
"Biological: RSV Vaccine",
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "RSV Vaccine",
"type": "BIOLOGICAL",
"description": "Participants will receive a single IM injection of an Ad26-based RSV vaccine at a single dose level on Day 1 and revaccination after either 1 year, 2 years, or 3 years.",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Participants will receive a single IM injection of placebo control on Day 1.",
"other_names": []
}
],
"ae_time_frame": "All-cause mortality: Day 1 to Day 1095 (Arms 1, 2); Day 365 to Day 730 (Arms 3, 4); Day 730 to Day 1095 (Arms 5 to 9); Day 1095 to Day 1460 (Arms 10 to 14); Serious/other AEs: Day 1 to Day 1095 (Arms 1, 2), 6 months after revacc at Day 365 (Arms 3, 4): up to Day 547, 6 months after revacc at Day 730 [\u2026]",
"ae_description": "All-cause mortality and SAEs analyzed based on FAS population which included all randomized participants with a documented vaccine administration, regardless of occurrence of protocol deviations. Other (not including serious) AEs as solicited and unsolicited AEs were collected and analyzed in safety [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture)",
"description": "Adult participants aged greater than or equal to (\\>=) 65 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) (protein mixture) on Day 1. Participants were divided into revaccination subcohorts: 1A, 1B, and 1C.  [\u2026]"
},
{
"id": "EG001",
"title": "Arm 2: Main Cohort: Group 2: Placebo",
"description": "Adult participants aged \\>=65 years received a single IM injection of placebo on Day 1. Participants were divided into revaccination subcohorts: 2A, 2B, and 2C. Participants further received revaccination with Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 2A), 2 (Subcohort 2B), and 3 (Subcohort 2C) years, respectively after the first vaccination on Day 1 [\u2026]"
},
{
"id": "EG002",
"title": "Arm 3: Revaccination (ReVacc) Subcohort 1A: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)",
"description": "Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort 1A and received IM injection of the protein mixture at the same dose level on Day 365. Participants were then followed up for safety assessments till Day 730."
},
{
"id": "EG003",
"title": "Arm 4: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein Mixture",
"description": "Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365. Participants were then followed up for safety assessments till Day 730."
},
{
"id": "EG004",
"title": "Arm 5: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.PreF Alone",
"description": "Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 in the revaccination subcohort further received Ad26.RSV.preF 1\\*10\\^11 vp alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."
},
{
"id": "EG005",
"title": "Arm 6: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone",
"description": "Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein (protein mixture) on Day 365 in the revaccination subcohort further received RSV preF protein 150 mcg alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."
},
{
"id": "EG006",
"title": "Arm 7: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)",
"description": "Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 and 730. Participants were then followed up for safety assessments till Day 1095."
},
{
"id": "EG007",
"title": "Arm 8: ReVacc Subcohort 1B: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)",
"description": "Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort and received the protein mixture at the same dose level on Day 730. Participants were then followed up for safety assessments till Day 1095."
},
{
"id": "EG008",
"title": "Arm 9: ReVacc Subcohort 2B:Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)",
"description": "Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730. Participants were then followed up for safety assessments till Day 1095."
},
{
"id": "EG009",
"title": "Arm 10: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.preF",
"description": "Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730 followed by Ad26.RSV.preF 1\\*10\\^11 vp alone on Day 1095. Participants were then followed up for safety assessments till Day 1460."
},
{
"id": "EG010",
"title": "Arm 11: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone",
"description": "Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730 followed by RSV preF protein 150 mcg alone on Day 1095. Participants were then followed up for safety assessments till Day 1460."
},
{
"id": "EG011",
"title": "Arm 12: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)",
"description": "Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Days 730 and Day 1095. Participants were then followed up for safety assessments till Day 1460."
},
{
"id": "EG012",
"title": "Arm 13: ReVacc Subcohort 1C: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)",
"description": "Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort and received the protein mixture at the same dose level on Day 1095. Participants were then followed up for safety assessments till Day 1460."
},
{
"id": "EG013",
"title": "Arm 14: ReVacc Subcohort 2C: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)",
"description": "Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1095. Participants were then followed up for safety assessments till Day 1460."
}
]
},
"coder_1": {
"nct": "NCT03982199",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Main cohort groups taken (placebo-controlled until each subcohort's revaccination). Revaccination subcohort groups EG002-EG013 left out: placebo recipients crossed over to vaccine and none has placebo. Adjuvant of the preF protein component not stated."
},
"coder_2": {
"nct": "NCT03982199",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Main cohort arms 1 and 2 (Day 1 to 1095). Revaccination subcohort groups are later re-randomization and mix placebo recipients who got vaccine, left out. Placebo participants were revaccinated from year 1 on, so late follow-up in EG001 may include vaccine."
}
},
{
"trial": {
"nct": "NCT03999554",
"brief_title": "Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines",
"official_title": "Phase 1b Clinical Study to Investigate the Safety and Immunogenicity of the Bris10 (A/Brisbane/10/2007) M2SR and Sing2016 (A/Singapore/INFIMH-16-0019/2016) M2SR H3N2 Monovalent Influenza Vaccines",
"conditions": [
"Influenza A"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"49 Years"
],
"arms": [
{
"label": "Low dose Sing2016 M2SR",
"type": "EXPERIMENTAL",
"description": "Low dose Sing2016 M2SR will be administered intranasally on days 1 and 29",
"interventions": [
"Biological: LD Sing2016 M2SR H3N2 influenza vaccine"
]
},
{
"label": "Medium dose Sing2016 M2SR",
"type": "EXPERIMENTAL",
"description": "Medium dose Sing2016 M2SR will be administered intranasally on days 1 and 29",
"interventions": [
"Biological: MD Sing2016 M2SR H3N2 influenza vaccine"
]
},
{
"label": "High dose Sing2016 M2SR",
"type": "EXPERIMENTAL",
"description": "High dose Sing2016 M2SR will be administered intranasally on days 1 and 29",
"interventions": [
"Biological: HD Sing2016 M2SR H3N2 influenza vaccine"
]
},
{
"label": "Low dose Bris10 M2SR",
"type": "ACTIVE_COMPARATOR",
"description": "Low dose Bris10 M2SR will be administered intranasally on days 1 and 29",
"interventions": [
"Biological: LD Bris10 M2SR H3N2 influenza vaccine"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Saline will be administered intranasally on days 1 and 29",
"interventions": [
"Other: Placebo"
]
}
],
"interventions": [
{
"name": "LD Sing2016 M2SR H3N2 influenza vaccine",
"type": "BIOLOGICAL",
"description": "This group will receive a low dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.",
"other_names": []
},
{
"name": "MD Sing2016 M2SR H3N2 influenza vaccine",
"type": "BIOLOGICAL",
"description": "This group will receive a medium dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.",
"other_names": []
},
{
"name": "HD Sing2016 M2SR H3N2 influenza vaccine",
"type": "BIOLOGICAL",
"description": "This group will receive a high dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.",
"other_names": []
},
{
"name": "LD Bris10 M2SR H3N2 influenza vaccine",
"type": "BIOLOGICAL",
"description": "This group will receive a low dose of the Bris10 M2SR H3N2 monovalent influenza vaccine administered intranasally.",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "This group will receive saline placebo administered intranasally.",
"other_names": []
}
],
"ae_time_frame": "Adverse events were monitored continuously from first administration of IP until study day 57. SAEs were collected until study day 209.",
"ae_description": "Administration site and solicited AEs were recorded through 7 days after each vaccination (Days 8 and 29), unsolicited AEs were recorded through 28 days after the last vaccination (Day 57) and SAEs were recorded until Day 209.",
"ae_groups": [
{
"id": "EG000",
"title": "Low Dose Sing2016 M2SR",
"description": "Low dose Sing2016 M2SR will be administered intranasally on days 1 and 29 LD Sing2016 M2SR H3N2 influenza vaccine: This group will receive a low dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally."
},
{
"id": "EG001",
"title": "Medium Dose Sing2016 M2SR",
"description": "Medium dose Sing2016 M2SR will be administered intranasally on days 1 and 29 MD Sing2016 M2SR H3N2 influenza vaccine: This group will receive a medium dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally."
},
{
"id": "EG002",
"title": "High Dose Sing2016 M2SR",
"description": "High dose Sing2016 M2SR will be administered intranasally on days 1 and 29 HD Sing2016 M2SR H3N2 influenza vaccine: This group will receive a high dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally."
},
{
"id": "EG003",
"title": "Low Dose Bris10 M2SR",
"description": "Low dose Bris10 M2SR will be administered intranasally on days 1 and 29 LD Bris10 M2SR H3N2 influenza vaccine: This group will receive a low dose of the Bris10 M2SR H3N2 monovalent influenza vaccine administered intranasally."
},
{
"id": "EG004",
"title": "Placebo",
"description": "Saline will be administered intranasally on days 1 and 29 Placebo: This group will receive saline placebo administered intranasally."
}
]
},
"coder_1": {
"nct": "NCT03999554",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Platform other: M2SR, an M2-deficient single-replication influenza virus given intranasally (platform not described in the record). Sing2016 and Bris10 M2SR groups all against one saline placebo; Bris10 is a second vaccine, not a control."
},
"coder_2": {
"nct": "NCT03999554",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M2SR single-replication intranasal influenza virus, coded live_attenuated"
}
},
{
"trial": {
"nct": "NCT04078022",
"brief_title": "Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine",
"official_title": "Phase 2b Study of the Safety, Immunogenicity, and Efficacy of a Monovalent Synthetic Carbohydrate-based Conjugate Vaccine (SF2a-TT15) for Protection Against Shigella Flexneri 2a Experimental Infection",
"conditions": [
"Shigella"
],
"phases": [
"PHASE2"
],
"model": "SEQUENTIAL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"45 Years"
],
"arms": [
{
"label": "Cohort 1: Shigella Vaccine or Placebo, Followed by Challenge",
"type": "EXPERIMENTAL",
"description": "1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).",
"interventions": [
"Biological: SF2a-TT15 Shigella Vaccine",
"Other: Placebo",
"Biological: S. flexneri 2a strain 2457T Challenge Agent"
]
},
{
"label": "Cohort 2: Shigella Vaccine or Placebo, Followed by Challenge",
"type": "EXPERIMENTAL",
"description": "1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).",
"interventions": [
"Biological: SF2a-TT15 Shigella Vaccine",
"Other: Placebo",
"Biological: S. flexneri 2a strain 2457T Challenge Agent"
]
},
{
"label": "Cohort 3: Shigella Vaccine or Placebo, Followed by Challenge",
"type": "EXPERIMENTAL",
"description": "1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).",
"interventions": [
"Biological: SF2a-TT15 Shigella Vaccine",
"Other: Placebo",
"Biological: S. flexneri 2a strain 2457T Challenge Agent"
]
},
{
"label": "Cohort 4: Shigella Vaccine Only, No Challenge",
"type": "EXPERIMENTAL",
"description": "All volunteers receive the investigational Shigella vaccine (n=12). No Shigella challenge.",
"interventions": [
"Biological: SF2a-TT15 Shigella Vaccine"
]
}
],
"interventions": [
{
"name": "SF2a-TT15 Shigella Vaccine",
"type": "BIOLOGICAL",
"description": "0.5 mL of the vaccine is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "0.5 mL of normal saline is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.",
"other_names": []
},
{
"name": "S. flexneri 2a strain 2457T Challenge Agent",
"type": "BIOLOGICAL",
"description": "Each participant will drink 120 mL of sodium bicarbonate buffer solution. Approximately 1 to 2 minutes later, the participant will ingest approximately 1500 cfu of S. flexneri 2a strain 2457T suspended in 30 mL of the bicarbonate buffer solution.",
"other_names": []
}
],
"ae_time_frame": "The assessment of the safety of the vaccine was through the detection and documentation of adverse effects, both solicited AEs and unsolicited AEs, and/or clinically significant laboratory abnormalities, from enrollment through 28 days post-vaccination. Only the occurrence of SAEs were reported betw [\u2026]",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Vaccine Enrolled",
"description": "1:1 randomization to investigational Shigella vaccine or placebo (n=29). The majority of participants will then receive the Shigella challenge (n=22). SF2a-TT15 Shigella Vaccine: 0.5 mL of the vaccine is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29. S. flexneri 2a strain 2457T Challenge Agent: Each participant will drink 120 mL of sodium bicar [\u2026]"
},
{
"id": "EG001",
"title": "Placebo Enrolled",
"description": "1:1 randomization to investigational Shigella vaccine or placebo (n=29). The majority of participants will then receive the Shigella challenge (n=22). Placebo: 0.5 mL of normal saline is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29. S. flexneri 2a strain 2457T Challenge Agent: Each participant will drink 120 mL of sodium bicarbonate buffer sol [\u2026]"
},
{
"id": "EG002",
"title": "Vaccine Challenged",
"description": "1:1 randomization to investigational Shigella vaccine or placebo (n=29). The majority of participants will then receive the Shigella challenge (n=22). Placebo: 0.5 mL of normal saline is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29. S. flexneri 2a strain 2457T Challenge Agent: Each participant will drink 120 mL of sodium bicarbonate buffer sol [\u2026]"
},
{
"id": "EG003",
"title": "Placebo Challenged",
"description": "1:1 randomization to investigational Shigella vaccine or placebo (n=29). The majority of participants will then receive the Shigella challenge (n=22). Placebo: 0.5 mL of normal saline is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29. S. flexneri 2a strain 2457T Challenge Agent: Each participant will drink 120 mL of sodium bicarbonate buffer sol [\u2026]"
}
]
},
"coder_1": {
"nct": "NCT04078022",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the Vaccine/Placebo Enrolled groups (all randomized, vaccination period); Challenged groups EG002/EG003 report subsets of the same participants after S. flexneri challenge and are left out. SF2a-TT15 is a synthetic carbohydrate-tetanus toxoid conjugate; adjuvant not stated."
},
"coder_2": {
"nct": "NCT04078022",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the enrolled groups (all randomized); the challenged groups EG002/EG003 are subsets of the same people. Synthetic carbohydrate-tetanus toxoid conjugate, no adjuvant stated. Cohort 4 (vaccine only, no placebo) may sit in EG000."
}
},
{
"trial": {
"nct": "NCT04138056",
"brief_title": "A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women",
"official_title": "A Phase II Study of a Primary Dose of Investigational RSV Maternal Vaccine, Given Alone or With Boostrix, With a 2nd Dose Investigational RSV Maternal Vaccine",
"conditions": [
"Respiratory Syncytial Virus Infections"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"45 Years"
],
"arms": [
{
"label": "RSV120_dTpa_RSV120(Pooled)",
"type": "EXPERIMENTAL",
"description": "Subjects received one dose of 120 \u03bcg RSVPreF3 formulation 3 vaccine and either one dose of 300 \u03bcg or 500 \u03bcg dTpa (Boostrix) vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received a second dose of 120 \u03bcg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.",
"interventions": [
"Biological: RSVPreF3 formulation 3",
"Biological: Boostrix-ex-US",
"Biological: Boostrix-US"
]
},
{
"label": "RSV120_Placebo_RSV120(Pooled)",
"type": "PLACEBO_COMPARATOR",
"description": "Subjects received one dose of 120 \u03bcg RSVPreF3 formulation 3 vaccine and one dose of Placebo on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received a second dose of 120 \u03bcg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.",
"interventions": [
"Biological: RSVPreF3 formulation 3",
"Drug: Placebo"
]
},
{
"label": "RSV60_dTpa_RSV120(Pooled)",
"type": "EXPERIMENTAL",
"description": "Subjects received one dose of 60 \u03bcg RSVPreF3 formulation 2 vaccine and either one dose of 300 \u03bcg or 500 \u03bcg dTpa vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 \u03bcg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.",
"interventions": [
"Biological: RSVPreF3 formulation 3",
"Biological: RSVPreF3 formulation 2",
"Biological: Boostrix-ex-US",
"Biological: Boostrix-US"
]
},
{
"label": "RSV60_Placebo_RSV120(Pooled)",
"type": "PLACEBO_COMPARATOR",
"description": "Subjects received one dose of 60 \u03bcg RSVPreF3 formulation 2 vaccine and one dose of Placebo on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 \u03bcg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.",
"interventions": [
"Biological: RSVPreF3 formulation 3",
"Biological: RSVPreF3 formulation 2",
"Drug: Placebo"
]
},
{
"label": "dTpa_Placebo_RSV120(Pooled)",
"type": "PLACEBO_COMPARATOR",
"description": "Subjects received one dose of Placebo and either one dose of 300 \u03bcg or 500 \u03bcg dTpa vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 \u03bcg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.",
"interventions": [
"Biological: RSVPreF3 formulation 3",
"Biological: Boostrix-ex-US",
"Biological: Boostrix-US",
"Drug: Placebo"
]
}
],
"interventions": [
{
"name": "RSVPreF3 formulation 3",
"type": "BIOLOGICAL",
"description": "One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.",
"other_names": []
},
{
"name": "RSVPreF3 formulation 2",
"type": "BIOLOGICAL",
"description": "One dose of RSVPreF3 formulation 2 vaccine administered intramuscularly in the left arm.",
"other_names": []
},
{
"name": "Boostrix-ex-US",
"type": "BIOLOGICAL",
"description": "One dose of the dTpa (Ex-US formulation) vaccine administered intramuscularly in the right arm.",
"other_names": []
},
{
"name": "Boostrix-US",
"type": "BIOLOGICAL",
"description": "One dose of the dTpa vaccine (US formulation) administered intramuscularly in the right arm.",
"other_names": []
},
{
"name": "Placebo",
"type": "DRUG",
"description": "One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.",
"other_names": []
}
],
"ae_time_frame": "Solicited adverse events were collected during the 7-day follow-up period and unsolicited adverse events during the 30-day follow-up period after any vaccination. Serious adverse events were collected from Day 1 (Primary Study) to the Study End (Day 181 after the second RSVPreF3 vaccination, Extensi [\u2026]",
"ae_description": "As per the analysis plan, AEs were reported for the RSV120\\_dTpa\\_RSV120(Pooled), RSV120\\_Placebo\\_RSV120(Pooled), RSV60\\_dTpa\\_RSV120(Pooled), RSV60\\_Placebo\\_RSV120(Pooled) \\& dTpa\\_Placebo\\_RSV120(Pooled) groups, as the 2 formulations of dTpa vaccine (300 \u03bcg/500 \u03bcg) showed similar safety profiles [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "RSV120_dTpa_RSV120(Pooled)",
"description": "Subjects received one dose of 120 \u03bcg RSVPreF3 formulation 3 vaccine and either one dose of 300 \u03bcg or 500 \u03bcg dTpa (Boostrix) vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received a second dose of 120 \u03bcg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study e [\u2026]"
},
{
"id": "EG001",
"title": "RSV120_Placebo_RSV120(Pooled)",
"description": "Subjects received one dose of 120 \u03bcg RSVPreF3 formulation 3 vaccine and one dose of Placebo on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received a second dose of 120 \u03bcg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end."
},
{
"id": "EG002",
"title": "RSV60_dTpa_RSV120(Pooled)",
"description": "Subjects received one dose of 60 \u03bcg RSVPreF3 formulation 2 vaccine and either one dose of 300 \u03bcg or 500 \u03bcg dTpa vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 \u03bcg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end."
},
{
"id": "EG003",
"title": "RSV60_Placebo_RSV120(Pooled)",
"description": "Subjects received one dose of 60 \u03bcg RSVPreF3 formulation 2 vaccine and one dose of Placebo on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 \u03bcg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end."
},
{
"id": "EG004",
"title": "dTpa_Placebo_RSV120(Pooled)",
"description": "Subjects received one dose of Placebo and either one dose of 300 \u03bcg or 500 \u03bcg dTpa vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 \u03bcg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end."
}
]
},
"coder_1": {
"nct": "NCT04138056",
"eligible": false,
"exclusion_reason": "other",
"comparisons": [],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AE groups run through the extension, in which every group, including placebo+dTpa (EG004), got a second-stage RSVPreF3 dose; no group covers only the placebo-controlled period. Non-pregnant women."
},
"coder_2": {
"nct": "NCT04138056",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "dTpa (Boostrix) on Day 1"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RSV+dTpa vs placebo+dTpa. Groups RSV+placebo (EG001, EG003) have no placebo-placebo match and are left out. Tables pool the primary study with the extension, where the placebo group (EG004) got RSV vaccine, so late follow-up is not purely placebo-controlled and cannot be separated. Placebo content from intervention list (NaCl)."
}
},
{
"trial": {
"nct": "NCT04349553",
"brief_title": "Study to Evaluate the Safety, Tolerability and Immunogenicity of a Potential Enteric Fever Vaccine",
"official_title": "A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Dose Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of a Potential Oral Enteric Fever Vaccine (ZH9 + ZH9PA) in Healthy Participants",
"conditions": [
"Enteric Fever"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"18 Years",
"45 Years"
],
"arms": [
{
"label": "ZH9PA 1x10^9 CFU",
"type": "EXPERIMENTAL",
"description": "1mL ZH9PA 1x10\\^9 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration",
"interventions": [
"Biological: Placebo",
"Biological: ZH9PA"
]
},
{
"label": "ZH9PA 1x10^10 CFU",
"type": "EXPERIMENTAL",
"description": "1mL ZH9PA 1x10\\^10 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration",
"interventions": [
"Biological: Placebo",
"Biological: ZH9PA"
]
},
{
"label": "ZH9PA 1x10^10 CFU plus ZH9 1x10^10 CFU",
"type": "EXPERIMENTAL",
"description": "1mL ZH9PA 1x10\\^10 CFU suspension in normal saline and 1mL ZH9 1x10\\^10 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration",
"interventions": [
"Biological: ZH9PA and ZH9",
"Biological: Placebo"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "1mL (Cohorts 1 and 2) or 2mL (Cohort 3) normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration",
"interventions": [
"Biological: ZH9PA and ZH9",
"Biological: Placebo",
"Biological: ZH9PA"
]
}
],
"interventions": [
{
"name": "ZH9PA and ZH9",
"type": "BIOLOGICAL",
"description": "150mL vaccine for oral administration",
"other_names": [
"Entervax"
]
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "150mL vaccine for oral administration",
"other_names": []
},
{
"name": "ZH9PA",
"type": "BIOLOGICAL",
"description": "150mL vaccine for oral administration",
"other_names": []
}
],
"ae_time_frame": "Up to 12 weeks post-dose (Day 84)",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "ZH9PA 1x10^9 CFU",
"description": "1mL ZH9PA 1x10\\^9 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration Placebo: 150mL vaccine for oral administration ZH9PA: 150mL vaccine for oral administration"
},
{
"id": "EG001",
"title": "ZH9PA 1x10^10 CFU",
"description": "1mL ZH9PA 1x10\\^10 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration Placebo: 150mL vaccine for oral administration ZH9PA: 150mL vaccine for oral administration"
},
{
"id": "EG002",
"title": "ZH9PA 1x10^10 CFU Plus ZH9 1x10^10 CFU",
"description": "1mL ZH9PA 1x10\\^10 CFU suspension in normal saline and 1mL ZH9 1x10\\^10 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration ZH9PA and ZH9: 150mL vaccine for oral administration Placebo: 150mL vaccine for oral administration"
},
{
"id": "EG003",
"title": "Placebo",
"description": "1mL (Cohorts 1 and 2) or 2mL (Cohort 3) normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration ZH9PA and ZH9: 150mL vaccine for oral administration Placebo: 150mL vaccine for oral administration ZH9PA: 150mL vaccine for oral administration"
}
]
},
"coder_1": {
"nct": "NCT04349553",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"typhoid",
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target other: paratyphoid A (ZH9PA, live-attenuated S. Paratyphi A); ZH9 is live-attenuated S. Typhi. Placebo saline in bicarbonate buffer."
},
"coder_2": {
"nct": "NCT04349553",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"typhoid"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Oral live attenuated S. Typhi ZH9 and S. Paratyphi A ZH9PA; typhoid used for enteric fever"
}
},
{
"trial": {
"nct": "NCT04420221",
"brief_title": "Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)",
"official_title": "A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)",
"conditions": [
"Infections, Soft Tissue"
],
"phases": [
"PHASE2"
],
"model": "SEQUENTIAL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"64 Years"
],
"arms": [
{
"label": "Group 1 Dose-escalation Safety Lead-in Epoch: Half dose Non-Adjuvant (Non-Adj)",
"type": "EXPERIMENTAL",
"description": "Participants received 1 dose of the half dose formulation of the vaccine on Day 1.",
"interventions": [
"Biological: Sa-5Ag half dose non-adjuvanted"
]
},
{
"label": "Group 2 Dose-escalation Safety Lead-in Epoch: Full dose Non-Adj",
"type": "EXPERIMENTAL",
"description": "Participants received 1 dose of the full dose formulation of the vaccine on Day 1.",
"interventions": [
"Biological: Sa-5Ag full dose non-adjuvanted"
]
},
{
"label": "Group 3 Dose-escalation Safety Lead-in Epoch: Half dose Adj",
"type": "EXPERIMENTAL",
"description": "Participants received 1 dose of the half dose formulation of the vaccine with adjuvant on Day 1.",
"interventions": [
"Biological: Sa-5Ag half dose adjuvanted"
]
},
{
"label": "Group 4 Dose-escalation Safety Lead-in Epoch: Full dose Adj",
"type": "EXPERIMENTAL",
"description": "Participants received 2 doses of the full dose formulation of the vaccine with adjuvant on Day 1 and Day 61.",
"interventions": [
"Biological: Sa-5Ag full dose adjuvanted"
]
},
{
"label": "Dose-escalation Safety Lead-in Epoch: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants received matching placebo on Day 1 for Group 1, Group 2 and Group 3, and on Day 1 and Day 61 for Group 4 of the escalation epoch.",
"interventions": [
"Biological: Placebo"
]
},
{
"label": "Proof of Principle (PoP): Full dose Adj",
"type": "EXPERIMENTAL",
"description": "Participants were randomized to receive 2 doses of the full dose formulation of the vaccine with adjuvant on Day 1 and Day 61.",
"interventions": [
"Biological: Sa-5Ag full dose adjuvanted"
]
},
{
"label": "PoP: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants were randomized to receive 2 doses of placebo on Day 1 and Day 61.",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "Sa-5Ag half dose non-adjuvanted",
"type": "BIOLOGICAL",
"description": "1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, non-adjuvanted at Day 1, administered intramuscularly.",
"other_names": []
},
{
"name": "Sa-5Ag full dose non-adjuvanted",
"type": "BIOLOGICAL",
"description": "1 dose of Sa-5Ag (5 antigens of S. aureus) full dose, non-adjuvanted at Day 1, administered intramuscularly.",
"other_names": []
},
{
"name": "Sa-5Ag half dose adjuvanted",
"type": "BIOLOGICAL",
"description": "1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, adjuvanted at Day 1, administered intramuscularly.",
"other_names": []
},
{
"name": "Sa-5Ag full dose adjuvanted",
"type": "BIOLOGICAL",
"description": "A series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61), administered intramuscularly.",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "One dose of placebo (saline solution for injection/ vial or prefilled syringe) at Day 1 for placebo Groups 1 to 3 (Dose-escalation epoch) and a series of 2 doses of placebo given approximately 2 months apart (Days 1 and 61) for placebo Group 4 (Dose-escalation epoch) and Group PoP: Placebo, administered intramuscularly.",
"other_names": []
}
],
"ae_time_frame": "Solicited AEs were collected from Day 1 to Day 7 (post vaccination 1) and from Day 61 to Day 67 (post Vaccination 2 only for Group 4 and PoP epoch). Unsolicited AEs were collected from Day 1 to Day 30 (post vaccination 1) and from Day 61 to Day 90 (post vaccination 2 only for Group 4 and PoP epoch). [\u2026]",
"ae_description": "Adverse events are reported on the Exposed Set, who received at least 1 dose of the study treatment.",
"ae_groups": [
{
"id": "EG000",
"title": "Group 1 Dose-escalation Safety Lead-in Epoch: Half Dose Non-Adjuvant (Non-Adj)",
"description": "Participants received 1 dose of the half dose formulation of the vaccine on Day 1."
},
{
"id": "EG001",
"title": "Group 2 Dose-escalation Safety Lead-in Epoch: Full Dose Non-Adj",
"description": "Participants received 1 dose of the full dose formulation of the vaccine on Day 1."
},
{
"id": "EG002",
"title": "Group 3 Dose-escalation Safety Lead-in Epoch: Half Dose Adj",
"description": "Participants received 1 dose of the half dose formulation of the vaccine with adjuvant on Day 1."
},
{
"id": "EG003",
"title": "Group 4 Dose-escalation Safety Lead-in Epoch: Full Dose Adj",
"description": "Participants received 2 doses of the full dose formulation of the vaccine with adjuvant on Day 1 and Day 61."
},
{
"id": "EG004",
"title": "Dose-escalation Safety Lead-in Epoch: Placebo",
"description": "Participants received matching placebo on Day 1 for Group 1, Group 2 and Group 3, and on Day 1 and Day 61 for Group 4 of the escalation epoch."
},
{
"id": "EG005",
"title": "Proof of Principle (PoP): Full Dose Adj",
"description": "Participants were randomized to receive 2 doses of the full dose formulation of the vaccine with adjuvant on Day 1 and Day 61."
},
{
"id": "EG006",
"title": "PoP: Placebo",
"description": "Participants were randomized to receive 2 doses of placebo on Day 1 and Day 61."
}
]
},
"coder_1": {
"nct": "NCT04420221",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG005",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG004",
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Dose-escalation epoch (healthy adults, pooled placebo) and proof-of-principle epoch (adults with a recent S. aureus SSTI) pooled. Platform other: Sa-5Ag, five S. aureus antigens not described further. Adjuvanted groups' adjuvant not named. patients true for the recent-SSTI epoch."
},
"coder_2": {
"nct": "NCT04420221",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG004",
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Dose-escalation epoch and proof-of-principle epoch pooled. Sa-5Ag has conjugated polysaccharide and protein antigens (product knowledge); the adjuvant is unnamed in the record, coded other as not aluminium by product knowledge (AS03)."
}
},
{
"trial": {
"nct": "NCT04436276",
"brief_title": "A Study of Ad26.COV2.S in Adults (COVID-19)",
"official_title": "A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older",
"conditions": [
"Covid-19 Prevention"
],
"phases": [
"PHASE1",
"PHASE2"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"18 Years",
null
],
"arms": [
{
"label": "Cohort 1a",
"type": "EXPERIMENTAL",
"description": "Participants (healthy adults aged greater than or equal to (\\>=)18 to less than or equal to (\\<=) 55 years) will receive Ad26.COV2.S at 2 dose levels, as a single dose or 2 dose schedule with an 8-week interval or matching Placebo on Day 1 and Day 57. At unblinding visit, post Emergency Use Authorization (EUA), conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be o [\u2026]",
"interventions": [
"Biological: Ad26.COV2.S",
"Biological: Placebo"
]
},
{
"label": "Cohort 1b",
"type": "EXPERIMENTAL",
"description": "Participants (healthy adults aged \\>=18 to \\<= 55 years) will receive Ad26.COV2.S as a single vaccination in the primary regimen or matching Placebo on Day 1 and Day 57. At unblinding visit, post EUA, conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S. If they choose not to receive Ad26.COV2.S they will be asked to  [\u2026]",
"interventions": [
"Biological: Ad26.COV2.S",
"Biological: Placebo"
]
},
{
"label": "Cohort 2a",
"type": "EXPERIMENTAL",
"description": "Participants (healthy adults aged \\>=18 to \\<=55 years) will receive Ad26.COV2.S as single vaccination in the primary regimen or matching Placebo on Day 1, followed by booster vaccination at 6 or 12 months with same dose or matching Placebo. At unblinding visit, post EUA, conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26. [\u2026]",
"interventions": [
"Biological: Ad26.COV2.S",
"Biological: Placebo"
]
},
{
"label": "Cohort 2b",
"type": "EXPERIMENTAL",
"description": "Participants(healthy adults aged \\>=18 to \\<=55 years)will receive Ad26.COV2.S in primary regimen or matching Placebo on Day 1 and 57,followed by booster vaccination at 8 or 14 months (that is, 6 or 12 months after completion of primary regimen)with same dose or matching Placebo.At unblinding visit,post EUA,conditional licensure,or approval for single dose regimen of Ad26.COV2.S vaccine,participants initially receiving placebo will be offered to  [\u2026]",
"interventions": [
"Biological: Ad26.COV2.S",
"Biological: Placebo"
]
},
{
"label": "Cohort 3",
"type": "EXPERIMENTAL",
"description": "Participants (good or stable health adults aged \\>=65 years) will receive Ad26.COV2.S at 2 dose levels, as a single dose or 2 dose schedule with an 8-week interval or matching Placebo on Day 1 and Day 57. At unblinding visit, post EUA, conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S. If they choose not to receive [\u2026]",
"interventions": [
"Biological: Ad26.COV2.S",
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "Ad26.COV2.S",
"type": "BIOLOGICAL",
"description": "Participants will receive intramuscular (IM) injection of Ad26.COV2.S.",
"other_names": [
"JNJ-78436735",
"Ad26COVS1"
]
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Participants will receive Placebo.",
"other_names": []
}
],
"ae_time_frame": "Cohorts 1, 2a and 3: From Day 1 up to 808 days; Cohort 2b: Day 1 up to 752 days",
"ae_description": "FAS included all subjects with at least one vaccine administration documented.",
"ae_groups": [
{
"id": "EG000",
"title": "COHORT 1A: Ad26 5e10, Ad26 5e10(AHBV: Ad26 5e10)",
"description": "Healthy adult participants aged greater than or equal to (\\>=) 18 to less than or equal to (\\<=) 55 received a single intramuscular (IM) injection of Ad26.COV2.S 5\\*10\\^10 vp on Day 1 (Vaccination 1) and Day 57 (Vaccination 2). As per protocol amendment 15, all eligible participants who had previously received 1 or more doses of any COVID-19 vaccine were offered a single ad hoc booster vaccination [\u2026]"
},
{
"id": "EG001",
"title": "COHORT 1A: Ad26 5e10, PL(AHBV: Ad26 5e10)",
"description": "Healthy adult participants aged \\>=18 to \\<=55 received a single IM injection of Ad26.COV2.S 5\\*10\\^10 vp on Day 1 (Vaccination 1) and matching placebo on Day 57 (Vaccination 2). As per protocol amendment 15, all eligible participants who had previously received 1 or more doses of any COVID-19 vaccine were offered a single AHBV of Ad26.COV2.S at the dose of 5\\*10\\^10 vp \\>=6 months after Vaccinati [\u2026]"
},
{
"id": "EG002",
"title": "COHORT 1A: Ad26 1e11, Ad26 1e11(AHBV: Ad26 5e10)",
"description": "Healthy adult participants aged \\>=18 to \\<=55 received a single IM injection of Ad26.COV2.S 1\\*10\\^11 vp on Day 1 (Vaccination 1) and Day 57 (Vaccination 2). As per protocol amendment 15, all eligible participants who had previously received 1 or more doses of any COVID-19 vaccine were offered a single ad AHBV of Ad26.COV2.S at the dose of 5\\*10\\^10 vp Ad26.COV2.S. \\>=6 months after Vaccination 2 [\u2026]"
},
{
"id": "EG003",
"title": "COHORT 1A: Ad26 1e11, PL(AHBV: Ad26 5e10)",
"description": "Healthy adult participants aged \\>=18 to \\<=55 received a single IM injection of Ad26.COV2.S 1\\*10\\^11 vp on Day 1 (Vaccination 1) and matching placebo on Day 57 (Vaccination 2). As per protocol amendment 15, all eligible participants who had previously received 1 or more doses of any COVID-19 vaccine were offered a single AHBV of Ad26.COV2.S at the dose of 5\\*10\\^10 vp \\>=6 months after Vaccinati [\u2026]"
},
{
"id": "EG004",
"title": "COHORT 1A: Placebo, Placebo",
"description": "Healthy adult participants aged \\>=18 to \\<=55 received a single IM injection of placebo matching to Ad26.COV2.S vaccine on Day 1 (vaccination1) and 57 (Vaccination2). As per protocol amendment 10, after unblinding, enrolled participants who had initially received placebo were offered a single dose of 5\\*10\\^10 vp Ad26.COV2.S."
},
{
"id": "EG005",
"title": "COHORT 1B: Ad26 5e10, Ad26 5e10(AHBV: Ad26 5e10)",
"description": "Healthy adult participants aged \\>=18 to \\<=55 received a single IM injection of Ad26.COV2.S 5\\*10\\^10 vp on Day 1 (Vaccination 1) and Day 57 (Vaccination 2). As per protocol amendment 15, all eligible participants who had previously received 1 or more doses of any COVID-19 vaccine were offered a single AHBV of Ad26.COV2.S at the dose of 5\\*10\\^10 vp \\>=6 months after Vaccination 2."
},
{
"id": "EG006",
"title": "COHORT 1B: Ad26 5e10, PL(AHBV: Ad26 5e10)",
"description": "Healthy adult participants aged \\>=18 to \\<=55 received a single IM injection of Ad26.COV2.S 5\\*10\\^10 vp on Day 1 (Vaccination 1) and a matching placebo on Day 57 (Vaccination 2). As per protocol amendment 15, all eligible participants who had previously received 1 or more doses of any COVID-19 vaccine were offered a single AHBV of Ad26.COV2.S at the dose of 5\\*10\\^10 vp \\>=6 months after Vaccina [\u2026]"
},
{
"id": "EG007",
"title": "COHORT 1B: Ad26 1e11, Ad26 1e11(AHBV: Ad26 5e10)",
"description": "Healthy adult participants aged \\>=18 to \\<=55 received a single IM injection of Ad26.COV2.S 1\\*10\\^11 vp on Day 1 (Vaccination 1) and Day 57 (Vaccination 2). As per protocol amendment 15, all eligible participants who had previously received 1 or more doses of any COVID-19 vaccine were offered a single AHBV of Ad26.COV2.S at the dose of 5\\*10\\^10 vp \\>=6 months after Vaccination 2."
},
{
"id": "EG008",
"title": "COHORT 1B: Ad26 1e11, PL(AHBV: Ad26 5e10)",
"description": "Healthy adult participants aged \\>=18 to \\<=55 received a single IM injection of Ad26.COV2.S 1\\*10\\^11 vp on Day 1 (Vaccination 1) and matching placebo on Day 57 (Vaccination 2). As per protocol amendment 15, all eligible participants who had previously received 1 or more doses of any COVID-19 vaccine were offered a single AHBV of Ad26.COV2.S at the dose of 5\\*10\\^10 vp \\>=6 months after Vaccinati [\u2026]"
},
{
"id": "EG009",
"title": "COHORT 1B: Placebo, Placebo",
"description": "Healthy adult participants aged \\>=18 to \\<=55 received a single IM injection of placebo matching to Ad26.COV2.S vaccine on Day 1 (vaccination1) and 57 (Vaccination2). As per protocol amendment 10, after unblinding, enrolled participants who had initially received placebo were offered a single dose of 5\\*10\\^10 vp Ad26.COV2.S."
},
{
"id": "EG010",
"title": "COHORT 2A: Ad26 5e10, B: PL(PL/AHBV: Ad26 5e10)",
"description": "Group 1 and Group 4 healthy adult participants aged \\>=18 to \\<=55 received a single IM injection of Ad26.COV2.S 5\\*10\\^10 vp on Day 1 (Vaccination 1) followed by matching placebo at 6 and 12 months as matching Booster (B) 1 and Booster 2 vaccination. As per protocol amendment 15, all eligible participants who had previously received 1 or more doses of any COVID-19 vaccine were offered a single AH [\u2026]"
},
{
"id": "EG011",
"title": "COHORT 2A: Ad26 5e10, B: Ad26 5e10, PL",
"description": "Group 2 healthy adult participants aged \\>=18 to \\<=55 received a single IM injection of Ad26.COV2.S 5\\*10\\^10 vp on Day 1 (Vaccination 1) followed by first booster vaccination with single IM injection of Ad26.COV2.S 5\\*10\\^10 vp booster 1 at 6 months and a matching placebo at 12 months to match second Booster vaccination."
},
{
"id": "EG012",
"title": "COHORT 2A: Ad26 5e10, B: PL, Ad26 5e10",
"description": "Group 3 healthy adult participants aged \\>=18 to \\<=55 received a single IM injection of Ad26.COV2.S 5\\*10\\^10 vp on Day 1 (Vaccination 1) followed by a matching placebo booster 1 injection after 6 months and Ad26.COV2.S 5\\*10\\^10 vp after 12 months as Booster 2."
},
{
"id": "EG013",
"title": "COHORT 2A: Placebo, B: Placebo",
"description": "Group 5 subjects received a single IM injection of placebo matching to Ad26.COV2.S vaccine on Day 1 (Vaccination 1), 6 months (Booster 1) and 12 months (Booster 2). Subjects who had previously received 1 or more doses of any COVID-19 vaccine received a single ad hoc booster dose of 5\\*10\\^10 vp Ad26.COV2.S. 6 months after Booster 2 Vaccination."
},
{
"id": "EG014",
"title": "COHORT 2B: Ad26 5e10, Ad26 5e10, B: PL(PL/AHBV: Ad26 5e10)",
"description": "Group 1 and 4 healthy adult participants aged \\>=18 to \\<=55 received a single IM injection of Ad26.COV2.S 5\\*10\\^10 vp on Day 1 (Vaccination 1) and Day 57 (Vaccination 2) and matching placebo at 6 and 12 months after vaccination 2 as Booster 1 and Booster 2 vaccines. As per protocol amendment 15, all eligible participants who had previously received 1 or more doses of any COVID-19 vaccine were of [\u2026]"
},
{
"id": "EG015",
"title": "COHORT 2B: Ad26 5e10, Ad26 5e10, B: Ad26 5e10, PL",
"description": "Group 2 healthy adult participants aged \\>=18 to \\<=55 received a single IM injection of Ad26.COV2.S 5\\*10\\^10 vp on Day 1 (Vaccination 1), Day 57 (Vaccination 2) and 6 months after Vaccination 2(Booster 1). At 12 months after vaccination 2, participants received placebo matching to Ad26.COV2.S vaccine (Booster 2)."
},
{
"id": "EG016",
"title": "COHORT 2B: Ad26 5e10, Ad26 5e10, B: PL, Ad26 5e10",
"description": "Group 3 healthy adult participants aged \\>=18 to \\<=55 received a single IM injection of Ad26.COV2.S 5\\*10\\^10 vp on Day 1 (Vaccination 1) and Day 57 (Vaccination 2) and matching placebo at 6 months after vaccination 2 as Booster 1 vaccination and Ad26.COV2.S 5\\*10\\^10 vp at 12 months after vaccination 2 as Booster 2 vaccination."
},
{
"id": "EG017",
"title": "COHORT 2B: Placebo, B: PL",
"description": "Group 5 healthy adult participants aged \\>=18 to \\<=55 received a single IM injection of placebo matching to Ad26.COV2.S vaccine on Day 1 (Vaccination 1), Day 57 (Vaccination 2), 8 Month (Booster 1) and 14 months (Booster 2). As per protocol amendment 10, after unblinding, enrolled participants who had initially received placebo were offered a single dose of 5\\*10\\^10 vp Ad26.COV2.S."
},
{
"id": "EG018",
"title": "COHORT 3: Ad26 5e10, Ad26 5e10(AHBV: Ad26 5e10)",
"description": "Adult participants (with good or stable health) aged \\>=65 years received a single IM injection of Ad26.COV2.S 5\\*10\\^10 vp on Day 1 (Vaccination 1) and Day 57 (Vaccination 2). As per protocol amendment 15, all eligible participants who had previously received 1 or more doses of any COVID-19 vaccine were offered a single ad hoc booster dose of 5\\*10\\^10 vp Ad26.COV2.S. \\>=6 months after Vaccinatio [\u2026]"
},
{
"id": "EG019",
"title": "COHORT 3: Ad26 5e10, PL(AHBV: Ad26 5e10)",
"description": "Adult participants (with good or stable health) aged \\>=65 years received a single IM injection of Ad26.COV2.S 5\\*10\\^10 vp on Day 1 (Vaccination 1) and matching placebo on Day 57 (Vaccination 2). As per protocol amendment 15, all eligible participants who had previously received 1 or more doses of any COVID-19 vaccine were offered a single ad hoc booster dose of 5\\*10\\^10 vp Ad26.COV2.S. \\>=6 mon [\u2026]"
},
{
"id": "EG020",
"title": "COHORT 3: Ad26 1e11, Ad26 1e11(AHBV: Ad26 5e10)",
"description": "Adult participants (with good or stable health) aged \\>=65 years received a single IM injection of Ad26.COV2.S 1\\*10\\^11 vp on Day 1 (Vaccination 1) and Day 57 (Vaccination 2). As per protocol amendment 15, all eligible participants who had previously received 1 or more doses of any COVID-19 vaccine were offered a single ad hoc booster dose of 5\\*10\\^10 vp Ad26.COV2.S. \\>=6 months after Vaccinatio [\u2026]"
},
{
"id": "EG021",
"title": "COHORT 3: Ad26 1e11, PL(AHBV: Ad26 5e10)",
"description": "Adult participants (with good or stable health) aged \\>=65 years received a single IM injection of Ad26.COV2.S 1\\*10\\^11 vp on Day 1 (Vaccination 1) and matching placebo on Day 57 (Vaccination 2). As per protocol amendment 15, all eligible participants who had previously received 1 or more doses of any COVID-19 vaccine were offered a single ad hoc booster dose of 5\\*10\\^10 vp Ad26.COV2.S. \\>=6 mon [\u2026]"
},
{
"id": "EG022",
"title": "COHORT 3: Placebo, Placebo",
"description": "Adult participants (with good or stable health) aged \\>=65 years received a single IM injection of placebo matching to Ad26.COV2.S vaccine on Day 1 (vaccination1) and 57 (Vaccination2). As per protocol amendment 10, after unblinding, enrolled participants who had initially received placebo were offered a single dose of 5\\*10\\^10 vp Ad26.COV2.S."
}
]
},
"coder_1": {
"nct": "NCT04436276",
"eligible": false,
"exclusion_reason": "other",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AE groups run to Day 808 and, by their descriptions, include placebo recipients' Ad26.COV2.S dose after unblinding (and ad hoc boosters); no group covers only the placebo-controlled period."
},
"coder_2": {
"nct": "NCT04436276",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG011",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG012",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG014",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG015",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG016",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG018",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG019",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG020",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG021",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004",
"EG009",
"EG013",
"EG017",
"EG022"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All cohorts pooled (1a, 1b, 2a, 2b, 3). Groups follow to about 2 years and include post-unblinding vaccination and boosters (AHBV), which the tables do not separate."
}
},
{
"trial": {
"nct": "NCT04475081",
"brief_title": "Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis",
"official_title": "Use of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis/Inflammation",
"conditions": [
"Sepsis Syndrome"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "SINGLE",
"ages": [
"18 Years",
"70 Years"
],
"arms": [
{
"label": "MMR vaccination",
"type": "EXPERIMENTAL",
"description": "Subjects will be randomized to receive the MMR Vaccine subcutaneously",
"interventions": [
"Biological: MMR vaccine"
]
},
{
"label": "Placebo control",
"type": "PLACEBO_COMPARATOR",
"description": "Subjects will be randomized to receive sterile saline given subcutaneously",
"interventions": [
"Biological: MMR vaccine"
]
}
],
"interventions": [
{
"name": "MMR vaccine",
"type": "BIOLOGICAL",
"description": "Merck MMR-II vaccine",
"other_names": []
}
],
"ae_time_frame": "up to 72 h post-vaccination for any allergic responses. After 72 h allergic responses would not be evident. Any other monitoring for adverse events and conditions were monitored monthly through a 12-month enrollment period in the study",
"ae_description": "allergic reactions to the vaccine were monitored by calls by nursing staff or reported back to nursing staff over a 72 h period post-vaccination. Any other adverse events, treatment or non-treatment, were monitored by the nursing staff via monthly phone calls. Adverse events could have been any type [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "MMR Vaccination",
"description": "Subjects will be randomized to receive the MMR Vaccine subcutaneously MMR vaccine: Merck MMR-II vaccine"
},
{
"id": "EG001",
"title": "Placebo Control",
"description": "Subjects will be randomized to receive sterile saline given subcutaneously MMR vaccine: Merck MMR-II vaccine"
}
]
},
"coder_1": {
"nct": "NCT04475081",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": true,
"pregnant": false,
"patients": false,
"note": "MMR-II given against COVID-19-associated sepsis (off-target); placebo sterile saline."
},
"coder_2": {
"nct": "NCT04475081",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"measles_mumps_rubella"
],
"off_target": true,
"pregnant": false,
"patients": false,
"note": "MMR given against COVID-19 sepsis; placebo arm is saline though interventions list MMR."
}
},
{
"trial": {
"nct": "NCT04520659",
"brief_title": "Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/\u0394M2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age",
"official_title": "Phase Ib Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/\u0394M2-2/1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age",
"conditions": [
"RSV Infection"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"6 Months",
"24 Months"
],
"arms": [
{
"label": "Group 1: RSV LID/\u0394M2-2/1030s",
"type": "EXPERIMENTAL",
"description": "Participants will receive a single dose of RSV LID/\u0394M2-2/1030s vaccine at study entry (Day 0).",
"interventions": [
"Biological: RSV LID/\u0394M2-2/1030s"
]
},
{
"label": "Group 1: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants will receive a single dose of placebo at study entry (Day 0).",
"interventions": [
"Biological: Placebo"
]
},
{
"label": "Group 2: RSV LID/\u0394M2-2/1030s",
"type": "EXPERIMENTAL",
"description": "Participants will receive a single dose of RSV LID/\u0394M2-2/1030s vaccine at study entry (Day 0).",
"interventions": [
"Biological: RSV LID/\u0394M2-2/1030s"
]
},
{
"label": "Group 2: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants will receive a single dose of placebo at study entry (Day 0).",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "RSV LID/\u0394M2-2/1030s",
"type": "BIOLOGICAL",
"description": "10\\^5 plaque-forming units (PFU); administered as nose drops",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Administered as nose drops",
"other_names": []
}
],
"ae_time_frame": "From study entry to end of study. The duration of follow-up for a given participant was between 6 and 13 months for both Groups 1 & 2 depending on time of enrollment.",
"ae_description": "For days 0-28, all SAEs, solicited and unsolicited AEs, with exceptions per protocol section 7. SAEs and LRIs were reported according to Sections 7 \\& 8 in the Protocol Document. For days 29-56, SAEs were collected. After day 56, from Nov. 1 - March 31 of the following year, medically attended fever [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "Group 1: RSV LID/\u0394M2-2/1030s",
"description": "Participants will receive a single dose of RSV LID/\u0394M2-2/1030s vaccine at study entry (Day 0). RSV LID/\u0394M2-2/1030s: 10\\^5 plaque-forming units (PFU); administered as nose drops"
},
{
"id": "EG001",
"title": "Group 1: Placebo",
"description": "Participants will receive a single dose of placebo at study entry (Day 0). Placebo: Administered as nose drops"
},
{
"id": "EG002",
"title": "Group 2: RSV LID/\u0394M2-2/1030s",
"description": "Participants will receive a single dose of RSV LID/\u0394M2-2/1030s vaccine at study entry (Day 0). RSV LID/\u0394M2-2/1030s: 10\\^5 plaque-forming units (PFU); administered as nose drops"
},
{
"id": "EG003",
"title": "Group 2: Placebo",
"description": "Participants will receive a single dose of placebo at study entry (Day 0). Placebo: Administered as nose drops"
},
{
"id": "EG004",
"title": "Groups 1 and 2 Combined: RSV LID/\u0394M2-2/1030s",
"description": "Participants will receive a single dose of RSV LID/\u0394M2-2/1030s vaccine at study entry (Day 0). RSV LID/\u0394M2-2/1030s: 10\\^5 plaque-forming units (PFU); administered as nose drops"
},
{
"id": "EG005",
"title": "Groups 1 and 2 Combined: Placebo",
"description": "Participants will receive a single dose of placebo at study entry (Day 0). Placebo: Administered as nose drops"
}
]
},
"coder_1": {
"nct": "NCT04520659",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the combined Groups 1+2 (EG004, EG005); the per-group EG000-EG003 report the same participants. Placebo nose drops, composition not given."
},
"coder_2": {
"nct": "NCT04520659",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Groups 1 and 2 separately; combined groups EG004/EG005 duplicate them."
}
},
{
"trial": {
"nct": "NCT04544787",
"brief_title": "A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates",
"official_title": "A Phase 2, Partial Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of Two Novel Live Attenuated Serotype 2 Oral Poliovirus Vaccines Candidates, in Healthy Adults Previously Vaccinated With Oral Polio Vaccine (OPV) or Inactivated Polio Vaccine (IPV), Compared With Historical Controls Given Sabin OPV2 or Placebo",
"conditions": [
"Poliomyelitis"
],
"phases": [
"PHASE2"
],
"model": "SEQUENTIAL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"50 Years"
],
"arms": [
{
"label": "Group 1: One Dose of Novel OPV2 Candidate 1",
"type": "EXPERIMENTAL",
"description": "Participants previously vaccinated with oral polio vaccine (OPV) received one dose of novel OPV2 candidate 1 on Day 0, administered orally as six drops (0.3 mL total; approximately 10\u2076 50% cell culture infectious dose units \\[CCID50\\]).",
"interventions": [
"Biological: Novel OPV2 candidate 1"
]
},
{
"label": "Group 2: Two Doses of Novel OPV2 Candidate 1",
"type": "EXPERIMENTAL",
"description": "Participants previously vaccinated with OPV received two doses of novel OPV2 candidate 1 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10\u2076 CCID50).",
"interventions": [
"Biological: Novel OPV2 candidate 1"
]
},
{
"label": "Group 3: One Dose of Novel OPV2 Candidate 2",
"type": "EXPERIMENTAL",
"description": "Participants previously vaccinated with OPV received one dose of novel OPV2 candidate 2 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10\u2076 CCID50).",
"interventions": [
"Biological: Novel OPV2 candidate 2"
]
},
{
"label": "Group 4: Two Doses of Novel OPV2 Candidate 2",
"type": "EXPERIMENTAL",
"description": "Participants previously vaccinated OPV received two doses novel OPV2 candidate 2 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10\u2076 CCID50).",
"interventions": [
"Biological: Novel OPV2 candidate 2"
]
},
{
"label": "Group 5: Two Doses of Novel OPV2 Candidate 1",
"type": "EXPERIMENTAL",
"description": "Participants previously vaccinated with inactivated polio vaccine (IPV) received two doses of novel OPV2 candidate 1 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10\u2076 CCID50).",
"interventions": [
"Biological: Novel OPV2 candidate 1"
]
},
{
"label": "Group 6: Two Doses of Novel OPV2 Candidate 2",
"type": "EXPERIMENTAL",
"description": "Participants previously vaccinated with IPV received two doses of novel OPV2 candidate 2 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10\u2076 CCID50).",
"interventions": [
"Biological: Novel OPV2 candidate 2"
]
},
{
"label": "Group 7: Two Doses of Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants previously vaccinated with IPV received two doses of placebo 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total).",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "Novel OPV2 candidate 1",
"type": "BIOLOGICAL",
"description": "Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 1 (S2/cre5/S15domV/rec1/hifi3). Modifications included the following: * Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes. * Two modifications in the [\u2026]",
"other_names": []
},
{
"name": "Novel OPV2 candidate 2",
"type": "BIOLOGICAL",
"description": "Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 2 (S2/S15domV/CpG40). Modifications included the following: * Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes. * silent non-coding modifications en [\u2026]",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "sugar syrup, propylene glycol (Sirupus simplex, Propylenglycolum, European Pharmacopoeia)",
"other_names": []
}
],
"ae_time_frame": "Up to 42 days after each vaccination (42 days in Groups 1 and 3 and 70 days for all other Groups).",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Group 1: OPV-vaccinated - One Dose of Novel OPV2 Candidate 1",
"description": "Participants previously vaccinated with OPV received one dose of novel OPV2 candidate 1 on study Day 0."
},
{
"id": "EG001",
"title": "Group 2: OPV-vaccinated - Two Doses of Novel OPV2 Candidate 1",
"description": "Participants previously vaccinated with OPV received two doses of novel OPV2 candidate 1 28 days apart (Day 0 and Day 28)."
},
{
"id": "EG002",
"title": "Group 3: OPV-vaccinated - One Dose of Novel OPV2 Candidate 2",
"description": "Participants previously vaccinated with OPV received one dose of novel OPV2 candidate 2 on study Day 0."
},
{
"id": "EG003",
"title": "Group 4: OPV-vaccinated - Two Doses of Novel OPV2 Candidate 2",
"description": "Participants previously vaccinated OPV received two doses of novel OPV2 candidate 2 28 days apart (Day 0 and Day 28)."
},
{
"id": "EG004",
"title": "Group 5: IPV-vaccinated - Two Doses of Novel OPV2 Candidate 1",
"description": "Participants previously vaccinated with only IPV received two doses of novel OPV2 candidate 1 28 days apart (Day 0 and Day 28)."
},
{
"id": "EG005",
"title": "Group 6: IPV-vaccinated - Two Doses of Novel OPV2 Candidate 2",
"description": "Participants previously vaccinated with only IPV received two doses of novel OPV2 candidate 2 28 days apart (Day 0 and Day 28)."
},
{
"id": "EG006",
"title": "Group 7: IPV-vaccinated - Two Doses of Placebo",
"description": "Participants previously vaccinated with only IPV received two doses of placebo 28 days apart (Day 0 and Day 28)."
}
]
},
"coder_1": {
"nct": "NCT04544787",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"polio"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo was randomized only in the IPV-primed stratum, so took its groups (two nOPV2 candidates vs placebo). Left out the OPV-primed groups EG000-EG003, which have no placebo. Placebo sugar syrup and propylene glycol."
},
"coder_2": {
"nct": "NCT04544787",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "IPV-primed adults"
}
],
"targets": [
"polio"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only IPV-primed groups have a placebo; OPV-primed groups EG000-003 left out (no placebo)."
}
},
{
"trial": {
"nct": "NCT04614948",
"brief_title": "A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults",
"official_title": "A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older",
"conditions": [
"Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"18 Years",
null
],
"arms": [
{
"label": "Ad26.COV2.S",
"type": "EXPERIMENTAL",
"description": "Participants will receive intramuscular (IM) injection of Ad26.COV2.S vaccine on Day 1 and Day 57 in the double-blind phase. At unblinding visit (open-label phase), participants who have not yet received second vaccination will receive second dose of Ad26.COV2.S vaccine on Day 57, if applicable and newly enrolled participants will either receive IM injection of one dose of Ad26.COV2.S vaccine on Day 1 or two doses of Ad26.COV2.S vaccine on Day 1  [\u2026]",
"interventions": [
"Biological: Ad26.COV2.S"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants will receive IM injection of placebo on Day 1 and Day 57 in the double-blind phase. At unblinding visit (open-label phase), participants initially receiving placebo will be offered to receive IM injection of a single dose of Ad26.COV2.S vaccine. All ongoing participants who only received a single vaccination with Ad26.COV2.S in the study will be offered to receive single booster dose of Ad26.COV2.S in the open label phase preferably  [\u2026]",
"interventions": [
"Biological: Ad26.COV2.S",
"Other: Placebo"
]
}
],
"interventions": [
{
"name": "Ad26.COV2.S",
"type": "BIOLOGICAL",
"description": "Ad26.COV2.S vaccine will be administered on Day 1 and Day 57 in the double-blind phase. At unblinding visit Ad26.COV2.S vaccine will be administered to participants at Day 57 who have not yet received second vaccination and in newly enrolled participants as either single dose on Day 1 or two doses on Day 1 and Day 57. Single dose of Ad26.COV2.S vaccine will also be administered to participants initially receiving placebo. Single booster dose of A [\u2026]",
"other_names": [
"JNJ-78436735",
"Ad26COVS1",
"VAC31518"
]
},
{
"name": "Placebo",
"type": "OTHER",
"description": "Placebo will be administered as IM injection on Day 1 and Day 57.",
"other_names": []
}
],
"ae_time_frame": "DB phase: All-cause mortality and SAEs: From Day 1 till end of DB phase (up to 7.2 months), Solicited AEs: 7 days after first vaccination on Day 1 (up to Day 8), 7 days after second vaccination on Day 57 (up to Day 64) ; All participants arm: All-cause mortality and SAEs: Day 1 up to end of study (u [\u2026]",
"ae_description": "All-cause mortality/SAE: Per change in planned analysis, due to complex vaccination schedules, combined data for DB and OL was analyzed in the 'All Participant' arm after unblinding. As pre-specified: (a) only deaths/SAEs were planned to be collected in OL phase, (b) safety subset of FAS was used to [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "Double Blind Phase: Ad26.COV2.S",
"description": "Participants received a single dose of 0.5 milliliter (mL) adenovirus type 26 vector coronavirus-2 spike protein (Ad26.COV2.S) 5\\*10\\^10 viral particles (vp) vaccine intramuscularly on Day 1 and Day 57."
},
{
"id": "EG001",
"title": "Double Blind Phase: Placebo",
"description": "Participants received a single dose of placebo matching to Ad26.COV2.S 5\\*10\\^10 vp vaccine intramuscularly on Day 1 and Day 57."
},
{
"id": "EG002",
"title": "Combined Double-blind and Open-label Phase: All Participants",
"description": "Each participant was initially randomized to receive 1 dose of 0.5 mL Ad26.COV2.S 5\\*10\\^10 vp vaccine intramuscularly on Day 1 and on Day 57 or 1 dose of placebo vaccine intramuscularly on Day 1 and on Day 57 during the DB phase (up to 7.2 months). Following authorization of COVID-19 vaccine(s) in their country, participants could request to be unblinded to receive a different authorized/licensed [\u2026]"
},
{
"id": "EG003",
"title": "Double Blind Phase: Non-FAS Post-Dose 1: Ad26.COV2.S",
"description": "Participants who received a COVID-19 vaccination outside of the study prior to first study vaccination were randomized to receive a single dose of 0.5 mL Ad26.COV2.S 5\\*10\\^10 vp vaccine intramuscularly on Day 1."
},
{
"id": "EG004",
"title": "Double Blind Phase: Non-FAS Post-Dose 1: Placebo",
"description": "Participants who received a COVID-19 vaccination outside of the study prior to first study vaccination were randomized to receive a single dose of placebo matching to Ad26.COV2.S 5\\*10\\^10 vp vaccine intramuscularly on Day 1."
}
]
},
"coder_1": {
"nct": "NCT04614948",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the double-blind groups, including the non-FAS post-dose-1 groups (randomized participants vaccinated against COVID-19 outside the study beforehand); left out the combined all-participants group."
},
"coder_2": {
"nct": "NCT04614948",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "prior outside COVID-19 vaccination"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Double-blind groups only; All Participants group (includes open label) left out. Non-FAS participants had prior outside vaccination, so own comparison."
}
},
{
"trial": {
"nct": "NCT04673149",
"brief_title": "GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)",
"official_title": "Multicenter, Randomized, Combined Phase I Dose-escalation and Phase IIa Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Immunogenicity of GLS-5310 DNA Vaccine, Administered Intradermally Against SARS-CoV-2 in Healthy Adults",
"conditions": [
"SARS-CoV-2"
],
"phases": [
"PHASE1",
"PHASE2"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"19 Years",
"85 Years"
],
"arms": [
{
"label": "GLS-5310 0.6mg [Group 1a]",
"type": "EXPERIMENTAL",
"description": "0.6mg of GLS-5310 will be intradermally administered on Day 0 and Week 8.",
"interventions": [
"Biological: GLS-5310"
]
},
{
"label": "GLS-5310 1.2mg [Group 1b]",
"type": "EXPERIMENTAL",
"description": "1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 8.",
"interventions": [
"Biological: GLS-5310"
]
},
{
"label": "GLS-5310 1.2mg [Group 1c]",
"type": "EXPERIMENTAL",
"description": "1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 12.",
"interventions": [
"Biological: GLS-5310"
]
},
{
"label": "Placebo [Group 2a]",
"type": "PLACEBO_COMPARATOR",
"description": "Placebo will be intradermally administered on Day 0 and Week 8 (or Week 12).",
"interventions": [
"Biological: Placebo"
]
},
{
"label": "GLS-5310 1.2mg [Group 2b]",
"type": "EXPERIMENTAL",
"description": "1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 8 (or Week 12).",
"interventions": [
"Biological: GLS-5310"
]
}
],
"interventions": [
{
"name": "GLS-5310",
"type": "BIOLOGICAL",
"description": "GLS-5310 DNA plasmid vaccine",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Placebo",
"other_names": []
}
],
"ae_time_frame": "Adverse Event data were collected from Week 0 through Week 48.",
"ae_description": "Adverse events were graded according to the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials guidelines that were issued by the Food and Drug Administration in September 2007.",
"ae_groups": [
{
"id": "EG000",
"title": "GLS-5310 0.6mg [Group 1a]",
"description": "0.6mg of GLS-5310 will be intradermally administered on Day 0 and Week 8. GLS-5310: GLS-5310 DNA plasmid vaccine"
},
{
"id": "EG001",
"title": "GLS-5310 1.2mg [Group 1b]",
"description": "1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 8. GLS-5310: GLS-5310 DNA plasmid vaccine"
},
{
"id": "EG002",
"title": "GLS-5310 1.2mg [Group 1c]",
"description": "1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 12. GLS-5310: GLS-5310 DNA plasmid vaccine"
},
{
"id": "EG003",
"title": "Placebo [Group 2a]",
"description": "Placebo will be intradermally administered on Day 0 and Week 8 (or Week 12). Placebo: Placebo"
},
{
"id": "EG004",
"title": "GLS-5310 1.2mg [Group 2b]",
"description": "1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 8 (or Week 12). GLS-5310: GLS-5310 DNA plasmid vaccine"
}
]
},
"coder_1": {
"nct": "NCT04673149",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"dna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo only in the Phase IIa part, so took Group 2b vs Group 2a; left out Phase I dose-escalation groups 1a-1c, which had no placebo."
},
"coder_2": {
"nct": "NCT04673149",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"dna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"dna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"dna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"dna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": ""
}
},
{
"trial": {
"nct": "NCT04722003",
"brief_title": "Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination",
"official_title": "Mucosal Immune Responses Against Neisseria Gonorrhoeae Following Meningococcal Immunization in Healthy Young Adults",
"conditions": [
"Gonorrhoea"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"18 Years",
"49 Years"
],
"arms": [
{
"label": "4CMenB",
"type": "EXPERIMENTAL",
"description": "Participants will receive two doses (0.5 mL each) of 4CMenB vaccine on Day 1 and Day 29. Each single dose of vaccine will be administered via intramuscular (IM) injection into the deltoid muscle of the preferred arm. N=40",
"interventions": [
"Biological: Meningococcal Group B Vaccine"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants will receive two doses (0.5 mL each) of placebo injections (saline) on Day 1 and Day 29. Each single dose of placebo will be administered via intramuscular (IM) injection into the deltoid muscle of the preferred arm. N=10",
"interventions": [
"Other: Placebo"
]
}
],
"interventions": [
{
"name": "Meningococcal Group B Vaccine",
"type": "BIOLOGICAL",
"description": "A combination vaccine consisting of recombinant proteins Neisserial adhesin A (NadA), Neisserial Heparin Binding Antigen (NHBA), and factor H binding protein (fHbp), Outer Membrane Vesicles (OMV), aluminum hydroxide, sodium chloride, histidine, and sucrose.",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "0.9% Sodium Chloride, USP injection.",
"other_names": []
}
],
"ae_time_frame": "Solicited injection site and systemic reactogenicity events were documented and reported from Day 1 through Day 8 and Day 29 through Day 36. Unsolicited AEs were collected and assessed through the end of the protocol-defined follow up period (181 days post first vaccination)",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "4CMenB",
"description": "Participants will receive two doses (0.5 mL each) of 4CMenB vaccine on Day 1 and Day 29. Each single dose of vaccine will be administered via intramuscular (IM) injection into the deltoid muscle of the preferred arm. Meningococcal Group B Vaccine: A combination vaccine consisting of recombinant proteins Neisserial adhesin A (NadA), Neisserial Heparin Binding Antigen (NHBA), and factor H binding pr [\u2026]"
},
{
"id": "EG001",
"title": "Placebo",
"description": "Participants will receive two doses (0.5 mL each) of placebo injections (saline) on Day 1 and Day 29. Each single dose of placebo will be administered via intramuscular (IM) injection into the deltoid muscle of the preferred arm. Placebo: 0.9% Sodium Chloride, USP injection."
}
]
},
"coder_1": {
"nct": "NCT04722003",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": true,
"pregnant": false,
"patients": false,
"note": "4CMenB (recombinant proteins + OMV, aluminium hydroxide) given to study protection against gonorrhoea (off-target; 'other' target = gonorrhoea); placebo saline."
},
"coder_2": {
"nct": "NCT04722003",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"meningococcal"
],
"off_target": true,
"pregnant": false,
"patients": false,
"note": "4CMenB (protein plus outer membrane vesicles) given to study mucosal effects on gonorrhoea."
}
},
{
"trial": {
"nct": "NCT04785612",
"brief_title": "Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults",
"official_title": "A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Immunogenicity and Efficacy of A Respiratory Syncytial Virus Vaccine (RSVpreF) in A Virus Challenge Model in Healthy Adults",
"conditions": [
"Respiratory Syncytial Virus Infections"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"50 Years"
],
"arms": [
{
"label": "RSVPreF",
"type": "EXPERIMENTAL",
"description": "A single intramuscular injection at a dose of 120 mcg reconstituted with sterile water for an 0.5 mL injection volume",
"interventions": [
"Biological: RSVPreF"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "A single intramuscular injection of Placebo to match active vaccine",
"interventions": [
"Other: Placebo"
]
}
],
"interventions": [
{
"name": "RSVPreF",
"type": "BIOLOGICAL",
"description": "A single dose of 120 mcg RSVpreF for intramuscular injection",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "A single Placebo dose for intramuscular injection to match experimental vaccine",
"other_names": []
}
],
"ae_time_frame": "Adverse events (AEs) were recorded from vaccination (Day -28) up until viral challenge (Day 0 pre-challenge), following viral challenge (Day 0 post-challenge) until Day 28, and from Day 28 until Day 155. Medically attended AEs and SAEs were recorded from vaccination (Day -28) up until viral challeng [\u2026]",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "RSVPreF (From Vaccination Until Viral Challenge)",
"description": "A single intramuscular injection at a dose of 120 mcg reconstituted with sterile water for an 0.5 mL injection volume RSVPreF: A single dose of 120 mcg RSVpreF for intramuscular injection on Day -28"
},
{
"id": "EG001",
"title": "Placebo (From Vaccination Until Viral Challenge)",
"description": "A single intramuscular injection of Placebo to match active vaccine Placebo: A single Placebo dose for intramuscular injection to match experimental vaccine on Day -28"
},
{
"id": "EG002",
"title": "RSVPreF (From Viral Challenge Until Day 28)",
"description": "Participants undergone intranasal challenge with RSV-A Memphis 37b virus on Day 0, after receiving a single intramuscular dose of of 120 mcg RSVpreF on Day -28"
},
{
"id": "EG003",
"title": "Placebo (From Viral Challenge Until Day 28)",
"description": "Participants undergone intranasal challenge with RSV-A Memphis 37b virus on Day 0, after receiving a single intramuscular dose of placebo on Day -28."
},
{
"id": "EG004",
"title": "RSVPreF (From Day 28 Until Day155)",
"description": "Participants completed 6 months post challenge follow up visit after receiving a single intramuscular dose of of 120 mcg RSVpreF on Day -28 and RSV-A Memphis 37b virus on Day 0"
},
{
"id": "EG005",
"title": "Placebo (From Day 28 Until Day155)",
"description": "Participants completed 6 months post challenge follow up visit after receiving a single intramuscular dose of of Placebo on Day -28 and RSV-A Memphis 37b virus on Day 0"
}
]
},
"coder_1": {
"nct": "NCT04785612",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Same participants reported in three periods; took vaccination-until-challenge (EG000, EG001), the only period before the RSV challenge both arms got, though Day 28-155 is longer. RSVpreF is unadjuvanted; placebo composition not given."
},
"coder_2": {
"nct": "NCT04785612",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Same participants appear in three time-split group pairs; took the longest period (Day 28 to 155, after viral challenge). Alternative: EG000/EG001 before challenge."
}
},
{
"trial": {
"nct": "NCT04785794",
"brief_title": "Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old",
"official_title": "Phase 1b Clinical Study to Investigate the Safety and Immunogenicity of the Sing2016 (A/Singapore/INFIMH-16-0019/2016) M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old.",
"conditions": [
"Influenza Vaccine"
],
"phases": [
"PHASE1"
],
"model": "SEQUENTIAL",
"masking": "QUADRUPLE",
"ages": [
"50 Years",
"85 Years"
],
"arms": [
{
"label": "M2SR dose, 50-64 years of age",
"type": "EXPERIMENTAL",
"description": "Intranasal M2SR vaccine followed by standard, licensed IIV",
"interventions": [
"Biological: Sing2016 M2SR H3N2 influenza vaccine"
]
},
{
"label": "Placebo dose, 50-64 years of age",
"type": "PLACEBO_COMPARATOR",
"description": "Intranasal physiological saline followed by standard, licensed IIV",
"interventions": [
"Other: Placebo"
]
},
{
"label": "M2SR dose, 65-85 years of age",
"type": "EXPERIMENTAL",
"description": "Intranasal M2SR vaccine followed by licensed IIV recommended for people 65 years and older",
"interventions": [
"Biological: Sing2016 M2SR H3N2 influenza vaccine"
]
},
{
"label": "Placebo dose, 65-85 years of age",
"type": "PLACEBO_COMPARATOR",
"description": "Intranasal physiological saline followed by licensed IIV recommended for people 65 years and older",
"interventions": [
"Other: Placebo"
]
}
],
"interventions": [
{
"name": "Sing2016 M2SR H3N2 influenza vaccine",
"type": "BIOLOGICAL",
"description": "This group will receive a dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally on Day 1 followed by IIV at least 28 days later.",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "This group will receive saline placebo administered intranasally on Day 1 followed by IIV at least 28 days later.",
"other_names": []
}
],
"ae_time_frame": "IP administration until 28 days post-IIV (where interval between IP and IIV was up to 91 days with an average span of 49 days)",
"ae_description": "Includes treatment emergent AEs",
"ae_groups": [
{
"id": "EG000",
"title": "M2SR Dose, 50-64 Years of Age",
"description": "Intranasal M2SR vaccine followed by standard, licensed IIV Sing2016 M2SR H3N2 influenza vaccine: This group will receive a dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally on Day 1 followed by IIV at least 28 days later."
},
{
"id": "EG001",
"title": "Placebo Dose, 50-64 Years of Age",
"description": "Intranasal physiological saline followed by standard, licensed IIV Placebo: This group will receive saline placebo administered intranasally on Day 1 followed by IIV at least 28 days later."
},
{
"id": "EG002",
"title": "M2SR Dose, 65-85 Years of Age",
"description": "Intranasal M2SR vaccine followed by licensed IIV recommended for people 65 years and older Sing2016 M2SR H3N2 influenza vaccine: This group will receive a dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally on Day 1 followed by IIV at least 28 days later."
},
{
"id": "EG003",
"title": "Placebo Dose, 65-85 Years of Age",
"description": "Intranasal physiological saline followed by licensed IIV recommended for people 65 years and older Placebo: This group will receive saline placebo administered intranasally on Day 1 followed by IIV at least 28 days later."
}
]
},
"coder_1": {
"nct": "NCT04785794",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "licensed inactivated influenza vaccine at least 28 days later"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M2SR is a single-replication (M2-deficient) intranasal live influenza virus, coded live_attenuated; both age cohorts pooled though their IIV differed by age. Placebo saline."
},
"coder_2": {
"nct": "NCT04785794",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "licensed inactivated influenza vaccine after the study product"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M2SR is a single-replication intranasal influenza vaccine; platform other."
}
},
{
"trial": {
"nct": "NCT04798027",
"brief_title": "Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older",
"official_title": "Immunogenicity and Safety of the First-in-Human SARS-CoV-2 mRNA Vaccine Formulation in Healthy Adults 18 Years of Age and Older",
"conditions": [
"COVID-19"
],
"phases": [
"PHASE1",
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
null
],
"arms": [
{
"label": "Sentinel Cohort: SARS-CoV-2 Vaccine Ultra Low dose",
"type": "EXPERIMENTAL",
"description": "Participants received two intramuscular (IM) injections of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Vaccine ultra-low dose on Day 1 and at Day 22, respectively.",
"interventions": [
"Biological: SARS-CoV-2 mRNA vaccine formulation 1"
]
},
{
"label": "Sentinel Cohort: SARS-CoV-2 Vaccine Low dose",
"type": "EXPERIMENTAL",
"description": "Participants received two IM injections of SARS-CoV-2 Vaccine low dose on Day 1 and at Day 22, respectively.",
"interventions": [
"Biological: SARS-CoV-2 mRNA vaccine formulation 2"
]
},
{
"label": "Sentinel Cohort: SARS-CoV-2 Vaccine Medium dose",
"type": "EXPERIMENTAL",
"description": "Participants received two IM injections of SARS-CoV-2 Vaccine medium dose on Day 1 and at Day 22, respectively.",
"interventions": [
"Biological: SARS-CoV-2 mRNA vaccine formulation 3"
]
},
{
"label": "FEC Cohort 1: SARS-CoV-2 Vaccine Ultra Low dose",
"type": "EXPERIMENTAL",
"description": "Participants received a single IM injection of SARS-CoV-2 Vaccine ultra-low dose on Day 1.",
"interventions": [
"Biological: SARS-CoV-2 mRNA vaccine formulation 1"
]
},
{
"label": "FEC Cohort 1: SARS-CoV-2 Vaccine Low dose",
"type": "EXPERIMENTAL",
"description": "Participants received a single IM injection of SARS-CoV-2 Vaccine low dose on Day 1.",
"interventions": [
"Biological: SARS-CoV-2 mRNA vaccine formulation 2"
]
},
{
"label": "FEC Cohort 1: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants received a single IM injection of placebo matched to SARS-CoV-2 Vaccine on Day 1.",
"interventions": [
"Biological: Placebo (0.9% normal saline)"
]
},
{
"label": "FEC Cohort 2: SARS-CoV-2 Vaccine Ultra Low dose",
"type": "EXPERIMENTAL",
"description": "Participants received two IM injections of SARS-CoV-2 Vaccine ultra-low dose on Day 1 and at Day 22, respectively.",
"interventions": [
"Biological: SARS-CoV-2 mRNA vaccine formulation 1"
]
},
{
"label": "FEC Cohort 2: SARS-CoV-2 Vaccine Low dose",
"type": "EXPERIMENTAL",
"description": "Participants received two IM injections of SARS-CoV-2 Vaccine low dose on Day 1 and at Day 22, respectively.",
"interventions": [
"Biological: SARS-CoV-2 mRNA vaccine formulation 2"
]
},
{
"label": "FEC Cohort 2: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants received two IM injections of placebo matched to SARS-CoV-2 Vaccine on Day 1 and at Day 22, respectively.",
"interventions": [
"Biological: Placebo (0.9% normal saline)"
]
}
],
"interventions": [
{
"name": "SARS-CoV-2 mRNA vaccine formulation 1",
"type": "BIOLOGICAL",
"description": "Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection",
"other_names": []
},
{
"name": "SARS-CoV-2 mRNA vaccine formulation 2",
"type": "BIOLOGICAL",
"description": "Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection",
"other_names": []
},
{
"name": "SARS-CoV-2 mRNA vaccine formulation 3",
"type": "BIOLOGICAL",
"description": "Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection",
"other_names": []
},
{
"name": "Placebo (0.9% normal saline)",
"type": "BIOLOGICAL",
"description": "Pharmaceutical form: Liquid Route of administration: Intramuscular injection",
"other_names": []
}
],
"ae_time_frame": "Unsolicited AEs were collected within 21 days post-vaccination. Solicited reaction data were collected within 7 days post any vaccination. SAE data were collected from Day 1 up to 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 groups and up to Day 387 for Cohort 2 groups)",
"ae_description": "SafAS population. In AE section, SR, Fever was reported as Pyrexia. AEs were planned to be collected \\& analyzed for combined population in which the same dose-level groups in Sentinel \\& FEC were pooled for analysis. One participant of Sentinel Cohort (ultra-low dose) who was supposed to receive 2  [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "Cohort 1: SARS-CoV-2 Vaccine Ultra Low Dose",
"description": "Participants received a single IM injection of SARS-CoV-2 Vaccine ultra-low dose on Day 1."
},
{
"id": "EG001",
"title": "Cohort 1: SARS-CoV-2 Vaccine Low Dose",
"description": "Participants received a single IM injection of SARS-CoV-2 Vaccine low dose on Day 1."
},
{
"id": "EG002",
"title": "Cohort 1: Placebo",
"description": "Participants received a single IM injection of placebo matched to SARS-CoV-2 Vaccine on Day 1."
},
{
"id": "EG003",
"title": "Cohort 2: SARS-CoV-2 Vaccine Ultra Low Dose",
"description": "Participants received two IM injections of SARS-CoV-2 Vaccine ultra-low dose on Day 1 and at Day 22, respectively."
},
{
"id": "EG004",
"title": "Cohort 2: SARS-CoV-2 Vaccine Low Dose",
"description": "Participants received two IM injections of SARS-CoV-2 Vaccine low dose on Day 1 and at Day 22, respectively."
},
{
"id": "EG005",
"title": "Cohort 2: SARS-CoV-2 Vaccine Medium Dose",
"description": "Participants received two IM injections of SARS-CoV-2 Vaccine medium dose on Day 1 and at Day 22, respectively."
},
{
"id": "EG006",
"title": "Cohort 2: Placebo",
"description": "Participants received two IM injections of placebo matched to SARS-CoV-2 Vaccine on Day 1 and at Day 22, respectively."
}
]
},
"coder_1": {
"nct": "NCT04798027",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cohort 1 and 2 groups pooled; left out medium dose (EG005), given only in the sentinel cohort, which had no placebo. EG003/EG004 include sentinel participants, as the record pooled them. Placebo 0.9% saline."
},
"coder_2": {
"nct": "NCT04798027",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cohorts 1 and 2 pooled."
}
},
{
"trial": {
"nct": "NCT04801420",
"brief_title": "Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population",
"official_title": "SAFETY AND IMMUNOGENICITY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS: A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY IN A HEALTHY PEDIATRIC AND ADULT STUDY POPULATION",
"conditions": [
"Lyme Borreliosis"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"5 Years",
"65 Years"
],
"arms": [
{
"label": "Part A+B - Group 1",
"type": "EXPERIMENTAL",
"description": "Part A: VLA15 at Month 0, 2 and 6 Part B: VLA15 at Month 18, 30 and 42",
"interventions": [
"Biological: VLA15"
]
},
{
"label": "Part A+B - Group 2",
"type": "EXPERIMENTAL",
"description": "Part A: VLA15 at Month 0 and 6, placebo at Month 2 Part B: VLA15 at Month 18, 30 and 42",
"interventions": [
"Biological: VLA15",
"Biological: Placebo"
]
},
{
"label": "Part A+B - Group 3",
"type": "PLACEBO_COMPARATOR",
"description": "Part A: Placebo at Month 0, 2 and 6 Part B: Placebo at Month 18, 30 and 42",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "VLA15",
"type": "BIOLOGICAL",
"description": "a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "PBS (Phosphate Buffered Saline)",
"other_names": []
}
],
"ae_time_frame": "Systematic assessment: local reactions and systemic events were assessed for up to 7 Days after each vaccination; non- systematic assessment: all-cause mortality, SAEs, AESIs were assessed up to Month 48 and other AEs (including non-SAEs) were assessed up to 28 days after each vaccination",
"ae_description": "Same event may appear as non-SAE and SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another or a participant may have experienced both SAE and non-SAE. SAS included all participants who entered the study, and received at least one vaccination  [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "Group 1: VLA15",
"description": "Participants aged 5 to 65 years were allocated to receive three IM vaccinations of 180 mcg VLA15 at Months 0, 2 and 6 during the main study phase and received three IM vaccinations of 180 mcg VLA15 at Months 18, 30 and 42 during the booster phase."
},
{
"id": "EG001",
"title": "Group 2: VLA15 + Placebo",
"description": "Participants aged 5 to 65 years were allocated to receive two IM vaccinations of 180 mcg VLA15 at Months 0 and 6 and a placebo injection at Month 2 during the main study phase and received three IM vaccinations of 180 mcg VLA15 at Months 18, 30 and 42 during the booster phase."
},
{
"id": "EG002",
"title": "Group 3: Placebo",
"description": "Participants aged 5 to 65 years were allocated to receive three IM injections of placebo at Months 0, 2 and 6 during the main study phase and received three IM injections of placebo at Months 18, 30 and 42 during the booster phase."
},
{
"id": "EG003",
"title": "Received Any VLA15 Including Wrong/Missed Vaccination",
"description": "Participants aged 5 to 65 years who received any IM vaccination of 180 mcg VLA15 in Group 1 and 2 including participants that received VLA15 at least once but cannot be assigned to one of the study groups because of wrong/missed vaccination(s)."
},
{
"id": "EG004",
"title": "All Participants",
"description": "All study participants aged 5 to 65 years who received either IM vaccination of 180 mcg VLA15 or placebo injections during the study were included."
}
]
},
"coder_1": {
"nct": "NCT04801420",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"lyme"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took per-arm groups EG000-EG002 (placebo arm got placebo in the booster phase too); left out EG003 (any VLA15, overlaps) and EG004 (all participants). VLA15 adjuvant not stated in the record (investigational)."
},
"coder_2": {
"nct": "NCT04801420",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"lyme"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took EG000-EG002 (randomized arms, main plus booster phase, placebo arm placebo throughout); EG003 and EG004 repeat the same participants. VLA15 alum adjuvant from product knowledge."
}
},
{
"trial": {
"nct": "NCT04830800",
"brief_title": "A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)",
"official_title": "A Phase 1/2 Randomized, Placebo-controlled, Observer-blind Trial to Assess the Safety and Immunogenicity of COVIVAC Vaccine Produced by IVAC in Adults Aged 18-60 Years in Vietnam",
"conditions": [
"COVID-19 Disease",
"SARS Pneumonia",
"Pneumonia, Viral",
"COVID-19 Vaccine"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"60 Years"
],
"arms": [
{
"label": "COVIVAC 1mcg",
"type": "EXPERIMENTAL",
"description": "1mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.",
"interventions": [
"Biological: COVIVAC"
]
},
{
"label": "COVIVAC 3mcg",
"type": "EXPERIMENTAL",
"description": "3mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.",
"interventions": [
"Biological: COVIVAC"
]
},
{
"label": "COVIVAC 10mcg",
"type": "EXPERIMENTAL",
"description": "10mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.",
"interventions": [
"Biological: COVIVAC"
]
},
{
"label": "COVIVAC 1mcg + CpG1018 1.5mg",
"type": "EXPERIMENTAL",
"description": "1mcg + CpG1018 IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.",
"interventions": [
"Biological: COVIVAC"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Phosphate buffered saline (pH 7.2) for intramuscular injection administered as two doses (0.5mL each) 28 days apart.",
"interventions": [
"Biological: Phosphate-buffered saline"
]
}
],
"interventions": [
{
"name": "COVIVAC",
"type": "BIOLOGICAL",
"description": "COVIVAC vaccine, manufactured by IVAC with or without adjuvant CpG1018 for prevention of COVID-19",
"other_names": []
},
{
"name": "Phosphate-buffered saline",
"type": "BIOLOGICAL",
"description": "Phosphate buffer solution (pH 7.2), manufactured by IVAC",
"other_names": []
}
],
"ae_time_frame": "- Solicited AEs were collected during the 7 days after each vaccination - Unsolicited AEs were collected during the 28 days after each vaccination - MAAEs, AESIs and SAEs were collected from first vaccination until Day 197",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "COVIVAC 1 mcg",
"description": "Participants receiving 2 doses with 28 days apart reporting solicited AEs"
},
{
"id": "EG001",
"title": "COVIVAC 3 mcg",
"description": "Participants receiving 2 doses with 28 days apart reporting solicited AEs"
},
{
"id": "EG002",
"title": "COVIVAC 10 mcg",
"description": "Participants receiving 2 doses with 28 days apart reporting solicited AEs"
},
{
"id": "EG003",
"title": "COVIVAC 1mcg + CpG",
"description": "Participants receiving 2 doses with 28 days apart reporting solicited AEs"
},
{
"id": "EG004",
"title": "Placebo",
"description": "Participants receiving 2 doses with 28 days apart reporting solicited AEs"
}
]
},
"coder_1": {
"nct": "NCT04830800",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "COVIVAC platform not stated in the record (platform other); EG003 adds CpG1018, the other doses are without adjuvant."
},
"coder_2": {
"nct": "NCT04830800",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "COVIVAC is NDV-HXP-S (egg-grown, inactivated Newcastle disease virus displaying spike); platform chosen as inactivated from product knowledge. EG003 has CpG1018."
}
},
{
"trial": {
"nct": "NCT04886154",
"brief_title": "A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults",
"official_title": "A Phase I/II, Randomised, Controlled Study to Assess the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Adults (Phase I) and to Healthy Adolescents and Adults (Phase II)",
"conditions": [
"Infections, Meningococcal"
],
"phases": [
"PHASE1",
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"10 Years",
"50 Years"
],
"arms": [
{
"label": "ABCWY low dose Group",
"type": "EXPERIMENTAL",
"description": "Participants received two doses of the MenABCWY-2Gen low-dose vaccine on Day 1 and Day 31, following a 0, 1-month schedule during Study Phase I (Safety Lead-In).",
"interventions": [
"Combination Product: MenABCWY-2Gen low dose vaccine"
]
},
{
"label": "Placebo low dose Group",
"type": "PLACEBO_COMPARATOR",
"description": "Participants received two doses of a placebo on Day 1 and Day 31, following a 0, 1-month schedule during Study Phase I (Safety Lead-In), as the control group for the ABCWY low-dose group.",
"interventions": [
"Combination Product: Placebo"
]
},
{
"label": "ABCWY high dose Group",
"type": "EXPERIMENTAL",
"description": "Participants received two doses of the MenABCWY-2Gen high-dose vaccine on Day 1 and Day 31, following a 0, 1-month schedule during Study Phase I (Safety Lead-In).",
"interventions": [
"Combination Product: MenABCWY-2Gen high dose vaccine"
]
},
{
"label": "Placebo high dose Group",
"type": "PLACEBO_COMPARATOR",
"description": "Participants received two doses of a placebo on Day 1 and Day 31, following a 0, 1-month schedule during Study Phase I (Safety Lead-In), as the control group for the ABCWY high-dose group.",
"interventions": [
"Combination Product: Placebo"
]
},
{
"label": "ABCWY low dose_06 Group",
"type": "EXPERIMENTAL",
"description": "Participants received two doses of the MenABCWY-2Gen low-dose vaccine on Day 1 and Day 181, following a 0, 6-month schedule, along with one dose of a placebo on Day 121 during Phase II (Formulation and Schedule-Finding).",
"interventions": [
"Combination Product: MenABCWY-2Gen low dose vaccine",
"Combination Product: Placebo"
]
},
{
"label": "ABCWY low dose_02 Group",
"type": "EXPERIMENTAL",
"description": "Participants received two doses of the MenABCWY-2Gen low-dose vaccine on Day 121 and Day 181, following a 0, 2-month schedule, along with one dose of a placebo on Day 1 during Phase II (Formulation and Schedule-Finding).",
"interventions": [
"Combination Product: MenABCWY-2Gen low dose vaccine",
"Combination Product: Placebo"
]
},
{
"label": "ABCWY high dose_06 Group",
"type": "EXPERIMENTAL",
"description": "Participants received two doses of the MenABCWY-2Gen high-dose vaccine on Day 1 and Day 181, following a 0, 6-month schedule, along with one dose of a placebo on Day 121 during Phase II (Formulation and Schedule-Finding).",
"interventions": [
"Combination Product: MenABCWY-2Gen high dose vaccine",
"Combination Product: Placebo"
]
},
{
"label": "ABCWY high dose_02 Group",
"type": "EXPERIMENTAL",
"description": "Participants received two doses of the MenABCWY-2Gen high-dose vaccine on Day 121 and Day 181, following a 0, 2-month schedule, along with one dose of a placebo on Day 1 during Phase II (Formulation and Schedule-Finding).",
"interventions": [
"Combination Product: MenABCWY-2Gen high dose vaccine",
"Combination Product: Placebo"
]
},
{
"label": "Control Group",
"type": "ACTIVE_COMPARATOR",
"description": "Participants randomized to the control group received two doses of the Bexsero (MenB) vaccine on Day 1 and Day 181, following a 0, 6-month schedule, and one dose of Menveo (MenACWY) on Day 1 during Study Phase II (Formulation and Schedule-Finding).",
"interventions": [
"Combination Product: MenB vaccine",
"Biological: MenACWY vaccine"
]
},
{
"label": "ABCWY low dose_01 Group",
"type": "EXPERIMENTAL",
"description": "Participants received two doses of MenABCWY-2Gen low dose vaccine on Day 1 and Day 31, following a 0, 1-month schedule during study Phase II (Sourcing).",
"interventions": [
"Combination Product: MenABCWY-2Gen low dose vaccine"
]
},
{
"label": "ABCWY high dose_01 Group",
"type": "EXPERIMENTAL",
"description": "Participants received two doses of MenABCWY-2Gen high dose vaccine on Day 1 and Day 31, following a 0, 1-month schedule during study Phase II (Sourcing).",
"interventions": [
"Combination Product: MenABCWY-2Gen high dose vaccine"
]
},
{
"label": "ABCWY low doseS_02 Group",
"type": "EXPERIMENTAL",
"description": "Participants received two doses of MenABCWY-2Gen low dose vaccine on Day 1 and day 61 following a 0, 2-month schedule during study Phase II (Sourcing).",
"interventions": [
"Combination Product: MenABCWY-2Gen low dose vaccine"
]
},
{
"label": "ABCWY high doseS_02 Group",
"type": "EXPERIMENTAL",
"description": "Participants received two doses of MenABCWY-2Gen high dose vaccine on Day 1 and day 61 following a 0, 2-month schedule during study Phase II (Sourcing).",
"interventions": [
"Combination Product: MenABCWY-2Gen high dose vaccine"
]
},
{
"label": "ABCWY low doseS_06 Group",
"type": "EXPERIMENTAL",
"description": "Participants received two doses of MenABCWY-2Gen low dose vaccine on Day 1 and day 181 following a 0, 6-month schedule during study Phase II (Sourcing).",
"interventions": [
"Combination Product: MenABCWY-2Gen low dose vaccine"
]
},
{
"label": "ABCWY high doseS_06 Group",
"type": "EXPERIMENTAL",
"description": "Participants received two doses of MenABCWY-2Gen high dose vaccine on Day 1 and day 181 following a 0, 6-month schedule during study Phase II (Sourcing).",
"interventions": [
"Combination Product: MenABCWY-2Gen high dose vaccine"
]
}
],
"interventions": [
{
"name": "MenABCWY-2Gen low dose vaccine",
"type": "COMBINATION_PRODUCT",
"description": "MenABCWY-2Gen low dose vaccine is administered intramuscularly as 2 doses to participants in the ABCWY low dose Group in study Phase I, ABCWY low dose\\_06 Group and ABCWY low dose\\_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY low dose\\_01 Group, ABCWY low doseS\\_02 Group and ABCWY low doseS\\_06 Group in study Phase II (Sourcing).",
"other_names": []
},
{
"name": "MenABCWY-2Gen high dose vaccine",
"type": "COMBINATION_PRODUCT",
"description": "MenABCWY-2Gen high dose vaccine is administered intramuscularly 2 doses to participants in the ABCWY high dose Group in study Phase I, ABCWY high dose\\_06 Group and ABCWY high dose\\_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY high dose\\_01 Group, ABCWY high doseS\\_02 Group and ABCWY high doseS\\_06 Group in study Phase II (Sourcing).",
"other_names": []
},
{
"name": "Placebo",
"type": "COMBINATION_PRODUCT",
"description": "Placebo is administered intramuscularly as 2 doses to participants in the Placebo low dose Group, Placebo high dose Group in study Phase I and as 1 dose to participants in the ABCWY low dose\\_06 Group, ABCWY low dose\\_02 Group, ABCWY high dose\\_06 Group, ABCWY high dose\\_02 Group in study Phase II (Formulation and Schedule-finding).",
"other_names": [
"NaCl, saline solution"
]
},
{
"name": "MenB vaccine",
"type": "COMBINATION_PRODUCT",
"description": "MenB vaccine is administered intramuscularly as 2 doses in a 0,6-months schedule to participants in the Control Group in study Phase II (Formulation and Schedule-finding).",
"other_names": [
"GSK's meningococcal group B vaccine, Bexsero"
]
},
{
"name": "MenACWY vaccine",
"type": "BIOLOGICAL",
"description": "MenACWY vaccine is administered intramuscularly as 1 dose to participants in the Control Group in study Phase II (Formulation and Schedule-finding).",
"other_names": [
"GSK's combined meningococcal groups A, C, Y and W-135 conjugate vaccine, Menveo"
]
}
],
"ae_time_frame": "Solicited AEs: during the 7-day follow-up period after any vaccination and Unsolicited AEs: during the 30-day follow-up period after any vaccination in all the 3 phases. SAEs, AEs leading to withdrawal & AESIs were collected throughout the study period: from Day 1 up to study end [Day 211] in Phase  [\u2026]",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "ABCWY Low Dose Group",
"description": "Participants received two doses of the MenABCWY-2Gen low-dose vaccine on Day 1 and Day 31, following a 0, 1-month schedule during Study Phase I (Safety Lead-In)."
},
{
"id": "EG001",
"title": "Placebo Low Dose Group",
"description": "Participants received two doses of a placebo on Day 1 and Day 31, following a 0, 1-month schedule during Study Phase I (Safety Lead-In), as the control group for the ABCWY low-dose group."
},
{
"id": "EG002",
"title": "ABCWY High Dose Group",
"description": "Participants received two doses of the MenABCWY-2Gen high-dose vaccine on Day 1 and Day 31, following a 0, 1-month schedule during Study Phase I (Safety Lead-In)."
},
{
"id": "EG003",
"title": "Placebo High Dose Group",
"description": "Participants received two doses of a placebo on Day 1 and Day 31, following a 0, 1-month schedule during Study Phase I (Safety Lead-In), as the control group for the ABCWY high-dose group."
},
{
"id": "EG004",
"title": "ABCWY Low dose_06 Group",
"description": "Participants received two doses of the MenABCWY-2Gen low-dose vaccine on Day 1 and Day 181, following a 0, 6-month schedule, along with one dose of a placebo on Day 121 during Phase II (Formulation and Schedule-Finding)."
},
{
"id": "EG005",
"title": "ABCWY Low dose_02 Group",
"description": "Participants received two doses of the MenABCWY-2Gen low-dose vaccine on Day 121 and Day 181, following a 0, 2-month schedule, along with one dose of a placebo on Day 1 during Phase II (Formulation and Schedule-Finding)."
},
{
"id": "EG006",
"title": "ABCWY High dose_06 Group",
"description": "Participants received two doses of the MenABCWY-2Gen high-dose vaccine on Day 1 and Day 181, following a 0, 6-month schedule, along with one dose of a placebo on Day 121 during Phase II (Formulation and Schedule-Finding)."
},
{
"id": "EG007",
"title": "ABCWY High dose_02 Group",
"description": "Participants received two doses of the MenABCWY-2Gen high-dose vaccine on Day 121 and Day 181, following a 0, 2-month schedule, along with one dose of a placebo on Day 1 during Phase II (Formulation and Schedule-Finding)."
},
{
"id": "EG008",
"title": "Control Group",
"description": "Participants randomized to the control group received two doses of the Bexsero (MenB) vaccine on Day 1 and Day 181, following a 0, 6-month schedule, and one dose of Menveo (MenACWY) on Day 1 during Study Phase II (Formulation and Schedule-Finding)."
},
{
"id": "EG009",
"title": "ABCWY Low dose_01 Group",
"description": "Participants received two doses of MenABCWY-2Gen low dose vaccine on Day 1 and Day 31, following a 0, 1-month schedule during study Phase II (Sourcing)."
},
{
"id": "EG010",
"title": "ABCWY High dose_01 Group",
"description": "Participants received two doses of MenABCWY-2Gen high dose vaccine on Day 1 and Day 31, following a 0, 1-month schedule during study Phase II (Sourcing)."
},
{
"id": "EG011",
"title": "ABCWY Low doseS_02 Group",
"description": "Participants received two doses of MenABCWY-2Gen low dose vaccine on Day 1 and day 61 following a 0, 2-month schedule during study Phase II (Sourcing)."
},
{
"id": "EG012",
"title": "ABCWY High doseS_02 Group",
"description": "Participants received two doses of MenABCWY-2Gen high dose vaccine on Day 1 and day 61 following a 0, 2-month schedule during study Phase II (Sourcing)."
},
{
"id": "EG013",
"title": "ABCWY Low doseS_06 Group",
"description": "Participants received two doses of MenABCWY-2Gen low dose vaccine on Day 1 and day 181 following a 0, 6-month schedule during study Phase II (Sourcing)."
},
{
"id": "EG014",
"title": "ABCWY High doseS_06 Group",
"description": "Participants received two doses of MenABCWY-2Gen high dose vaccine on Day 1 and day 181 following a 0, 6-month schedule during study Phase II (Sourcing)."
}
]
},
"coder_1": {
"nct": "NCT04886154",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only Phase I (safety lead-in) has placebo arms; Phase II groups all get MenABCWY or the active Bexsero+Menveo control and are left out. MenABCWY-2Gen (MenB proteins plus ACWY conjugates) adjuvant not stated."
},
"coder_2": {
"nct": "NCT04886154",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only Phase I safety lead-in has placebo groups (saline, 2 doses); Phase II groups all got vaccine or Bexsero/Menveo control. Adjuvant for MenABCWY-2Gen (alum on the MenB part) from product knowledge, moderately sure."
}
},
{
"trial": {
"nct": "NCT04887948",
"brief_title": "Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2",
"official_title": "A PHASE 3, RANDOMIZED, DOUBLE BLIND TRIAL TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF 20 VALENT PNEUMOCOCCAL CONJUGATE VACCINE WHEN COADMINISTERED WITH A BOOSTER DOSE OF BNT162b2 IN ADULTS 65 YEARS OF AGE AND OLDER",
"conditions": [
"Pneumococcal Disease",
"COVID-19",
"SARS-CoV-2 Infection"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"65 Years",
null
],
"arms": [
{
"label": "Coadministration Group",
"type": "EXPERIMENTAL",
"description": "Participants receive an injection of pneumococcal vaccine (20vPnC) and of COVID-19 vaccine (BNT162b2) at the same visit.",
"interventions": [
"Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)",
"Biological: BNT162b2"
]
},
{
"label": "20vPnC-only Group",
"type": "ACTIVE_COMPARATOR",
"description": "Participants receive an injection of pneumococcal vaccine (20vPnC) and of saline at the same visit.",
"interventions": [
"Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)",
"Other: Saline"
]
},
{
"label": "BNT162b2-only Group",
"type": "ACTIVE_COMPARATOR",
"description": "Participants receive an injection of COVID-19 vaccine (BNT162b2) and of saline at the same visit.",
"interventions": [
"Biological: BNT162b2",
"Other: Saline"
]
}
],
"interventions": [
{
"name": "20-valent pneumococcal conjugate vaccine (20vPnC)",
"type": "BIOLOGICAL",
"description": "20-valent pneumococcal conjugate vaccine (20vPnC)",
"other_names": []
},
{
"name": "BNT162b2",
"type": "BIOLOGICAL",
"description": "RNA-based SARS-CoV-2 vaccine (BNT162b2)",
"other_names": []
},
{
"name": "Saline",
"type": "OTHER",
"description": "Normal saline for injection",
"other_names": []
}
],
"ae_time_frame": "Systematic assessment: local reactions recorded within 10 days after vaccination, and systemic events recorded within 7 days after vaccination; Non-systematic assessment: SAEs recorded from day of vaccination (Day 1) up to 6 months after vaccination and other AEs recorded from Day 1 up to 1 month af [\u2026]",
"ae_description": "Same event may appear as AE and SAE but what is presented are distinct events. Event may be categorized as serious in 1 participant and as non-serious in another participant or 1 participant may have experienced both serious and non-serious event during study.",
"ae_groups": [
{
"id": "EG000",
"title": "Coadministration Group: 20vPnC+BNT162b2",
"description": "On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."
},
{
"id": "EG001",
"title": "20vPnC Only Group: 20vPnC+Saline",
"description": "On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid and a single dose of 0.3 mL saline intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."
},
{
"id": "EG002",
"title": "BNT162b2 Only Group: BNT162b2+Saline",
"description": "On Day 1, participants were randomized to receive a single dose of 0.5 mL saline intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."
}
]
},
"coder_1": {
"nct": "NCT04887948",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "BNT162b2 COVID-19 booster"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "20vPnC+BNT162b2 vs saline+BNT162b2. EG001 (20vPnC+saline) left out: it could only be a placebo for BNT162b2 against EG000, which is already used. 20vPnC holds aluminium phosphate."
},
"coder_2": {
"nct": "NCT04887948",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "20vPnC"
}
],
"targets": [
"covid19",
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Compared BNT162b2 with saline, both with 20vPnC (EG000 vs EG001). EG002 (BNT162b2 plus saline) has a different background and no matching placebo group, left out. 20vPnC is the background vaccine here."
}
},
{
"trial": {
"nct": "NCT04899336",
"brief_title": "A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years",
"official_title": "Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years",
"conditions": [
"Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"60 Years",
null
],
"arms": [
{
"label": "ExPEC9V",
"type": "EXPERIMENTAL",
"description": "Participants will receive a single intramuscular (IM) injection of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) on Day 1.",
"interventions": [
"Biological: ExPEC9V"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants will receive a single IM injection of matching placebo on Day 1.",
"interventions": [
"Other: Placebo"
]
}
],
"interventions": [
{
"name": "ExPEC9V",
"type": "BIOLOGICAL",
"description": "ExPEC9V will be administered as an IM injection.",
"other_names": [
"VAC52416,",
"JNJ-78901563"
]
},
{
"name": "Placebo",
"type": "OTHER",
"description": "Matching placebo will be administered as an IM injection.",
"other_names": []
}
],
"ae_time_frame": "All-cause mortality: From Day 1 up to end of study (Up to 4 year 1 month); SAEs: From Day 1 (post vaccination) up to Day 181; unsolicited AEs (other AEs): From Day 1 (post vaccination) up to Day 30; Solicited AEs: From Day 1 (post vaccination) up to Day 15",
"ae_description": "FAS included all participants with documented vaccine administration, regardless of the occurrence of protocol deviations and excluding the participants of a site with serious documented misconduct.",
"ae_groups": [
{
"id": "EG000",
"title": "Arm 1: Placebo",
"description": "Participants received a single intramuscular (IM) injection of placebo 0.5 milliliter (mL) (sodium chloride 0.9% w/v) matching to ExPEC9V vaccine on Day 1."
},
{
"id": "EG001",
"title": "Arm 2: ExPEC9V Vaccine",
"description": "Participants received a single IM injection of 0.5 mL of ExPEC9V (176 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."
}
]
},
"coder_1": {
"nct": "NCT04899336",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"e_coli"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ExPEC9V O-antigen conjugate, adjuvant not stated. Enrolled for a history of UTI in the past 2 years (patients true)."
},
"coder_2": {
"nct": "NCT04899336",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"e_coli"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Conjugate of E. coli O-antigen polysaccharides; enrolled adults with recent urinary tract infection history."
}
},
{
"trial": {
"nct": "NCT04908683",
"brief_title": "A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older",
"official_title": "A Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of an Ad26.RSV.preF-based Vaccine in the Prevention of Lower Respiratory Tract Disease Caused by RSV in Adults Aged 60 Years and Older",
"conditions": [
"Respiratory Syncytial Viruses",
"Lower Respiratory Tract Disease"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"60 Years",
null
],
"arms": [
{
"label": "Group 1: Respiratory Syncytial Virus (RSV) vaccine",
"type": "EXPERIMENTAL",
"description": "All participants in the active group will receive a single dose intramuscular (IM) injection of study vaccine on Day 1.",
"interventions": [
"Biological: Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF"
]
},
{
"label": "Group 2: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "All participants in the placebo group will receive a single IM injection of matching placebo on Day 1.",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF",
"type": "BIOLOGICAL",
"description": "Participants will receive a single IM injection of an RSV vaccine.",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Participants will receive a single IM injection of matching placebo.",
"other_names": []
}
],
"ae_time_frame": "From Day 1 up to 24 months post-vaccination on Day 1 (Day 731).",
"ae_description": "All-cause mortality and serious adverse events (SAEs) were analyzed on Full Analysis Set (FAS) population. Other (not including serious) AEs as solicited and unsolicited AEs were collected and analyzed on a subset of FAS that is called safety subset. The safety subset included all participants that  [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "Group 1: Ad26.RSV.preF and RSV preF Protein",
"description": "Participants received a single intramuscular (IM) injection containing a mixture of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) at a dose of 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) on Day 1."
},
{
"id": "EG001",
"title": "Group 2: Placebo",
"description": "Participants received a single IM injection of matching placebo on Day 1."
}
]
},
"coder_1": {
"nct": "NCT04908683",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.RSV.preF mixed with RSV preF protein; whether the protein is adjuvanted is not stated."
},
"coder_2": {
"nct": "NCT04908683",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.RSV.preF plus RSV preF protein, unadjuvanted."
}
},
{
"trial": {
"nct": "NCT04940130",
"brief_title": "PfSPZ Vaccine Trial in Malian Children",
"official_title": "Phase 2 Trial of Safety, Immunogenicity, and Efficacy Against Plasmodium Falciparum Malaria of PfSPZ Vaccine in Children in Mali",
"conditions": [
"Malaria",
"Malaria,Falciparum"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"6 Years",
"10 Years"
],
"arms": [
{
"label": "Arm 1 (PfSPZ Vaccine)",
"type": "EXPERIMENTAL",
"description": "134 children ages 6 - 10 will receive three doses of PfSPZ Vaccine (9.0x10\\^5 PfSPZ) via DVI at 1, 8, and 29 days",
"interventions": [
"Biological: Sanaria\u00ae PfSPZ Vaccine"
]
},
{
"label": "Arm 2 (normal saline)",
"type": "PLACEBO_COMPARATOR",
"description": "134 children ages 6 - 10 will receive normal saline via DVI at 1, 8, and 29 days",
"interventions": [
"Other: Normal Saline"
]
}
],
"interventions": [
{
"name": "Sanaria\u00ae PfSPZ Vaccine",
"type": "BIOLOGICAL",
"description": "non-adjuvanted, live (metabolically active), radiation-attenuated, non-replicating, whole sporozoite (SPZ) vaccine designed to prevent malaria infection caused by Plasmodium falciparum (Pf).",
"other_names": []
},
{
"name": "Normal Saline",
"type": "OTHER",
"description": "placebo control- saline",
"other_names": []
}
],
"ae_time_frame": "Receipt of AL treatment to 26 weeks post 3rd vaccination (study day -17 to study day 211) = ~8 months",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Arm 1 (PfSPZ Vaccine)",
"description": "Children ages 6 - 10 will receive three doses of PfSPZ Vaccine (9.0x10\\^5 PfSPZ) via direct venous inoculation (DVI) at 1, 8, and 29 days Sanaria\u00ae PfSPZ Vaccine: non-adjuvanted, live (metabolically active), radiation-attenuated, non-replicating, whole sporozoite (SPZ) vaccine designed to prevent malaria infection caused by Plasmodium falciparum (Pf)."
},
{
"id": "EG001",
"title": "Arm 2 (Normal Saline)",
"description": "Children ages 6 - 10 will receive normal saline via DVI at 1, 8, and 29 days Normal Saline: placebo control- saline"
},
{
"id": "EG002",
"title": "Enrolled With no Arm Assignment",
"description": "Children ages 6 -10 were enrolled upon administration of AL treatment, but not assigned to a treatment arm (did not receive PfSPZ Vaccine nor Normal saline)"
}
]
},
"coder_1": {
"nct": "NCT04940130",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "artemether-lumefantrine before vaccination"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "PfSPZ: radiation-attenuated, metabolically active but non-replicating whole sporozoites; coded live_attenuated. EG002 (enrolled, no arm) left out."
},
"coder_2": {
"nct": "NCT04940130",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "PfSPZ is radiation-attenuated, non-replicating whole sporozoites (not a replicating organism, so other). EG002 was never assigned an arm."
}
},
{
"trial": {
"nct": "NCT04977479",
"brief_title": "The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose",
"official_title": "A Randomized, Placebo-controlled Crossover Study to Assess the Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose",
"conditions": [
"Systemic Allergic Reaction"
],
"phases": [
"PHASE2"
],
"model": "CROSSOVER",
"masking": "QUADRUPLE",
"ages": [
"16 Years",
"69 Years"
],
"arms": [
{
"label": "Blinded Active Vaccine 2",
"type": "ACTIVE_COMPARATOR",
"description": "Participants who experienced a systemic allergic reaction after receiving their first full dose of the Pfizer-BioNTech or Moderna COVID-19 vaccine receives one dose of the active mRNA COVID-19 vaccine (0.3mL) intramuscularly followed by a wash out period of 24 hours then crossover to receive placebo (0.3 mL normal saline) intramuscularly.",
"interventions": [
"Biological: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)",
"Other: Placebo"
]
},
{
"label": "Blinded Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants who experienced a systemic allergic reaction after receiving their first full dose of the Pfizer-BioNTech or Moderna COVID-19 vaccine receives one dose of the placebo (0.3 mL normal saline) intramuscularly followed by a wash out period of 24 hours then crossover to receive the active mRNA COVID-19 vaccine (0.3mL) intramuscularly.",
"interventions": [
"Biological: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)",
"Other: Placebo"
]
},
{
"label": "Open-Label Booster Vaccine",
"type": "EXPERIMENTAL",
"description": "Participants who did not suffer from a COFAR grade 3 or higher reaction after blinded active vaccine 2 were offered to receive booster dose of the active mRNA COVID-19 vaccine (0.3 mL) intramuscularly 5 months later.",
"interventions": [
"Biological: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)",
"Biological: Pfizer-BioNTech COVID-19 Vaccine, Bivalent"
]
}
],
"interventions": [
{
"name": "Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)",
"type": "BIOLOGICAL",
"description": "mRNA vaccine for the prevention of COVID-19. Single dose (0.3mL) via IM.",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "Commercially available sterile, preservative-free 0.9% Sodium Chloride Injection, USP. Volume to match active vaccine controlling for and delivered as a single dose via IM.",
"other_names": []
},
{
"name": "Pfizer-BioNTech COVID-19 Vaccine, Bivalent",
"type": "BIOLOGICAL",
"description": "mRNA vaccine booster bivalent (Original and Omicron BA.4/BA.5) for the prevention of COVID-19. Single dose (0.3mL) via IM.",
"other_names": []
}
],
"ae_time_frame": "Blinded Active Vaccine 2 & Placebo - Within 3-hour post-vaccination Overall Study - up to 17 months post intervention in the crossover phase Open-Label Booster Vaccine - up to 11 months post vaccine administration",
"ae_description": "Adverse events associated with the crossover phase have been grouped under 'Overall Study' due to the brief washout period between the active vaccine and the placebo.",
"ae_groups": [
{
"id": "EG000",
"title": "Blinded Active Vaccine 2",
"description": "Participants who experienced a systemic allergic reaction after receiving their first full dose of the Pfizer-BioNTech or Moderna COVID-19 vaccine receives one dose of the active mRNA COVID-19 vaccine (0.3mL) intramuscularly"
},
{
"id": "EG001",
"title": "Placebo",
"description": "Participants who experienced a systemic allergic reaction after receiving their first full dose of the Pfizer-BioNTech or Moderna COVID-19 vaccine receives one dose of placebo (0.3 mL normal saline) intramuscularly."
},
{
"id": "EG002",
"title": "Open-Label Booster Vaccine",
"description": "Participants who did not suffer from a COFAR grade 3 or higher reaction after blinded active vaccine 2 were offered to receive booster dose of the active mRNA COVID-19 vaccine (0.3 mL) intramuscularly 5 months later."
},
{
"id": "EG003",
"title": "Overall Study",
"description": "Participants who experienced a systemic allergic reaction after receiving their first full dose of the Pfizer-BioNTech or Moderna COVID-19 vaccine receives one dose of the active mRNA COVID-19 vaccine (0.3mL) intramuscularly or placebo (0.3 mL normal saline) intramuscularly in the crossover phase of study."
}
]
},
"coder_1": {
"nct": "NCT04977479",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Crossover with 24-hour washout: every participant got vaccine and placebo; the vaccine and placebo groups (3-hour windows) are by injection received, not first-period randomized arms."
},
"coder_2": {
"nct": "NCT04977479",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Crossover; EG000 and EG001 are the blinded dose groups (within 3 hours after each dose). Participants had a prior allergic reaction to an mRNA dose. EG002 open-label booster and EG003 overall left out. Uncertain whether EG000/EG001 hold the same people in different periods."
}
},
{
"trial": {
"nct": "NCT05027932",
"brief_title": "Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine",
"official_title": "Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of the Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine",
"conditions": [
"Influenza"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"18 Years",
"55 Years"
],
"arms": [
{
"label": "Group A",
"type": "EXPERIMENTAL",
"description": "15 participants receiving IM BPL1357 \\&amp; IN Placebo",
"interventions": [
"Other: IN Placebo",
"Drug: BPL-1357"
]
},
{
"label": "Group B",
"type": "EXPERIMENTAL",
"description": "15 participants receiving IN BPL1357 \\&amp; IM Placebo",
"interventions": [
"Other: IM Placebo",
"Drug: BPL-1357"
]
},
{
"label": "Group C",
"type": "SHAM_COMPARATOR",
"description": "15 participants receiving IM and IN placebo",
"interventions": [
"Other: IN Placebo",
"Other: IM Placebo"
]
}
],
"interventions": [
{
"name": "IN Placebo",
"type": "OTHER",
"description": "The placebo is normal saline in two syringes administered IN.",
"other_names": []
},
{
"name": "IM Placebo",
"type": "OTHER",
"description": "The placebo is normal saline in a syringe administered IM.",
"other_names": []
},
{
"name": "BPL-1357",
"type": "DRUG",
"description": "BPL-1357 contains 4 whole inactivated avian influenza viruses: A /Environment /Maryland/261/2006 H7N3, A/Mallard /Maryland/802/2007 H5N1, A/Pintail/Ohio /339/1987 H3N8, and A/Mallard/Ohio /265/1987 H1N9. It is administered either IM or IN depending on the assigned treatment group.",
"other_names": []
}
],
"ae_time_frame": "7 months",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Group A",
"description": "15 participants receiving IM BPL1357 and IN Placebo"
},
{
"id": "EG001",
"title": "Group B",
"description": "15 participants receiving IN BPL1357 and IM Placebo"
},
{
"id": "EG002",
"title": "Group C",
"description": "15 participants receiving IM and IN placebo"
}
]
},
"coder_1": {
"nct": "NCT05027932",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "IM and IN routes pooled; each vaccine group got saline by the other route as the placebo group did. BPL-1357 adjuvant not stated."
},
"coder_2": {
"nct": "NCT05027932",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Whole inactivated avian influenza viruses, IM or intranasal; adjuvant not stated, taken as none."
}
},
{
"trial": {
"nct": "NCT05045144",
"brief_title": "A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.",
"official_title": "A Phase III, Randomized, Multi-country Study to Evaluate the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response, Safety and Reactogenicity of RSV Maternal Vaccine When Co-administered With GSK's Quadrivalent Influenza D-QIV Vaccine in Healthy Non-pregnant Women 18-49 Years of Age.",
"conditions": [
"Respiratory Syncytial Virus Infections"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
"49 Years"
],
"arms": [
{
"label": "RSV lot1 Group",
"type": "EXPERIMENTAL",
"description": "Participants randomized to the RSV lot1 Group received one dose of RSV MAT Lot 1 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.",
"interventions": [
"Combination Product: RSVPreF3(120 \u03bcg)"
]
},
{
"label": "RSV lot2 Group",
"type": "EXPERIMENTAL",
"description": "Participants randomized to the RSV lot2 Group received one dose of RSV MAT Lot 2 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.",
"interventions": [
"Combination Product: RSVPreF3(120 \u03bcg)"
]
},
{
"label": "RSV lot3 Group",
"type": "EXPERIMENTAL",
"description": "Participants randomized to the RSV lot3 Group received one dose of RSV MAT Lot 3 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.",
"interventions": [
"Combination Product: RSVPreF3(120 \u03bcg)"
]
},
{
"label": "RSV+Flu pooled Group",
"type": "EXPERIMENTAL",
"description": "Participants randomized in this group received one dose of RSVPreF3 vaccine (RSV MAT vaccine) from one of the three lots used (Lot 1, Lot 2 or Lot 3 of same formulation of RSVPreF3 vaccine) and one dose of the Flu D-QIV vaccine on Day 1, and were followed up until the end of the study (Day 181). The participants in this group were considered for the immunogenicity and safety analyses of the RSV MAT and Flu D-QIV vaccines.",
"interventions": [
"Combination Product: Flu Quadrivalent influenza vaccine (15 \u03bcg HA)"
]
},
{
"label": "Flu+Placebo Group",
"type": "ACTIVE_COMPARATOR",
"description": "Participants randomized in this group received one dose of Flu D-QIV vaccine co-administered with one dose of placebo at Day 1, and were followed up until the end of the study (Day 181). This group was considered comparator for immunogenicity and safety analyses for RSV+ Flu Pooled group.",
"interventions": [
"Combination Product: Flu Quadrivalent influenza vaccine (15 \u03bcg HA)",
"Combination Product: Placebo"
]
}
],
"interventions": [
{
"name": "RSVPreF3(120 \u03bcg)",
"type": "COMBINATION_PRODUCT",
"description": "A single dose of RSVPreF3(120 \u03bcg) combined with Sodium Chloride (NaCl) was administrated intramuscular (IM). There were used 3 different lots of RSVPreF3(120 \u03bcg), one for each individual group (RSV lot1 Group, RSV lot2 Group and RSV lot3 Group) considered under RSV pooled Group.",
"other_names": []
},
{
"name": "Flu Quadrivalent influenza vaccine (15 \u03bcg HA)",
"type": "COMBINATION_PRODUCT",
"description": "A single dose of Flu Quadrivalent influenza (15 \u03bcg HA) vaccine was administrated intramuscular (IM).",
"other_names": []
},
{
"name": "Placebo",
"type": "COMBINATION_PRODUCT",
"description": "One dose of placebo, administered intramuscularly in the deltoid region of the right arm, at Day 1.",
"other_names": []
}
],
"ae_time_frame": "Serious Adverse Events (SAEs) were collected through the entire period of the study (from Day 1 up to study end [Day 181]). Solicited AEs were collected from Day 1 to Day 7 included and unsolicited AEs were collected from Day 1 to Day 30 included.",
"ae_description": "As pre-specified in protocol, adverse events were presented for individual RSV lot groups, RSV+Flu pooled Group (since minimal differences were expected in adverse events between participants who received different lots of the vaccine) and Flu+Placebo group. Participants that received the Flu vaccin [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "RSV lot1 Group",
"description": "Participants randomized to the RSV lot1 Group received one dose of RSV MAT Lot 1 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care."
},
{
"id": "EG001",
"title": "RSV lot2 Group",
"description": "Participants randomized to the RSV lot2 Group received one dose of RSV MAT Lot 2 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care."
},
{
"id": "EG002",
"title": "RSV lot3 Group",
"description": "Participants randomized to the RSV lot3 Group received one dose of RSV MAT Lot 3 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care."
},
{
"id": "EG003",
"title": "RSV+Flu Pooled Group",
"description": "Participants randomized in this group received one dose of RSVPreF3 vaccine (RSV MAT vaccine) from one of the three lots used (Lot 1, Lot 2 or Lot 3 of same formulation of RSVPreF3 vaccine) and one dose of the Flu D-QIV vaccine on Day 1, and were followed up until the end of the study (Day 181). The participants in this group were considered for the immunogenicity and safety analyses of the RSV MA [\u2026]"
},
{
"id": "EG004",
"title": "Flu+Placebo Group",
"description": "Participants randomized in this group received one dose of Flu D-QIV vaccine co-administered with one dose of placebo at Day 1, and were followed up until the end of the study (Day 181). This group was considered comparator for immunogenicity and safety analyses for RSV+ Flu Pooled group."
}
]
},
"coder_1": {
"nct": "NCT05045144",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Flu D-QIV influenza vaccine"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RSV+Flu vs Flu+placebo. Lot groups EG000-EG002 (RSV alone) have no placebo-alone group and are left out. RSV MAT adjuvant not stated in this record. Non-pregnant women."
},
"coder_2": {
"nct": "NCT05045144",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Flu D-QIV vaccine"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RSV vaccine plus flu vs flu plus placebo on Day 1. RSV-only lot groups EG000-EG002 have no matching placebo group, left out."
}
},
{
"trial": {
"nct": "NCT05070546",
"brief_title": "A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection",
"official_title": "A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Adults Aged 18 to 59 Years, Including Those at High-risk for Severe RSV",
"conditions": [
"Respiratory Syncytial Virus Infection Prevention"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"18 Years",
null
],
"arms": [
{
"label": "Cohort (C)1 Group (G)1: Healthy Adults, 18-59 Years (Respiratory Syncytial Virus [RSV] vaccine)",
"type": "EXPERIMENTAL",
"description": "Participants will receive a single intramuscular (IM) injection of study vaccine on Day 1.",
"interventions": [
"Biological: Ad26.RSV.preF-based Vaccine"
]
},
{
"label": "C1 G2: Healthy Adults, 18-59 Years (Placebo)",
"type": "PLACEBO_COMPARATOR",
"description": "Participants will receive a single IM injection of matching placebo on Day 1.",
"interventions": [
"Other: Placebo"
]
},
{
"label": "C2 G3: High Risk Adult, 18-59 Years (RSV Vaccine)",
"type": "EXPERIMENTAL",
"description": "Participants will receive a single IM injection of study vaccine on Day 1.",
"interventions": [
"Biological: Ad26.RSV.preF-based Vaccine"
]
},
{
"label": "C2 G4: High Risk Adult, 18-59 Years (Placebo)",
"type": "PLACEBO_COMPARATOR",
"description": "Participants will receive a single IM injection of matching placebo on Day 1.",
"interventions": [
"Other: Placebo"
]
},
{
"label": "C3 G5: Adults, 65 Years and Older (RSV Vaccine)",
"type": "EXPERIMENTAL",
"description": "Participants will receive a single IM injection of study vaccine on Day 1.",
"interventions": [
"Biological: Ad26.RSV.preF-based Vaccine"
]
},
{
"label": "C3 G6: Adults, 65 Years and Older (Placebo)",
"type": "PLACEBO_COMPARATOR",
"description": "Participants will receive a single IM injection of matching placebo on Day 1.",
"interventions": [
"Other: Placebo"
]
}
],
"interventions": [
{
"name": "Ad26.RSV.preF-based Vaccine",
"type": "BIOLOGICAL",
"description": "Participants will receive a single IM injection of an RSV vaccine.",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "Participants will receive a single IM injection of matching placebo.",
"other_names": []
}
],
"ae_time_frame": "Up to Day 183",
"ae_description": "Full analysis set included all participants who received study vaccine, regardless of the occurrence of protocol deviations and vaccine type (study vaccine or placebo).",
"ae_groups": [
{
"id": "EG000",
"title": "Group 1 (Cohort 1): Ad26.RSV.preF and RSV preF Protein",
"description": "Healthy adult participants aged 18 to 59 years received a single intramuscular (IM) injection containing mixture of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation-stabilized F protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) on Day 1."
},
{
"id": "EG001",
"title": "Group 2 (Cohort 1): Placebo",
"description": "Healthy adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1."
},
{
"id": "EG002",
"title": "Group 3 (Cohort 2): Ad26.RSV.preF and RSV preF Protein",
"description": "High-risk adult participants aged 18 to 59 years received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1."
},
{
"id": "EG003",
"title": "Group 4 (Cohort 2): Placebo",
"description": "High-risk adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1."
},
{
"id": "EG004",
"title": "Group 5 (Cohort 3): Ad26.RSV.preF and RSV preF Protein",
"description": "Adult participants aged 65 years and older received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1."
},
{
"id": "EG005",
"title": "Group 6 (Cohort 3): Placebo",
"description": "Adult participants aged 65 years and older received a single IM injection of matching placebo on Day 1."
}
]
},
"coder_1": {
"nct": "NCT05070546",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG004",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Three cohorts pooled (healthy 18-59, high-risk 18-59, 65+); patients true for the high-risk cohort. Protein adjuvant not stated."
},
"coder_2": {
"nct": "NCT05070546",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Three cohorts pooled: healthy adults 18-59, high-risk adults 18-59, adults 65+. Patients true because one cohort enrolled high-risk adults."
}
},
{
"trial": {
"nct": "NCT05071313",
"brief_title": "A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older",
"official_title": "A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older",
"conditions": [
"Influenza, Human Prevention",
"Respiratory Syncytial Viruses Prevention"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"65 Years",
null
],
"arms": [
{
"label": "Group 1: Coadministration (CoAd) Group",
"type": "EXPERIMENTAL",
"description": "Participants will receive Ad26.RSV.preF-based vaccine and quadrivalent high dose influenza vaccine concomitantly on Day 1 and placebo on Day 29.",
"interventions": [
"Biological: Ad26.RSV.preF-based vaccine",
"Biological: Quadrivalent High-dose Influenza Vaccine",
"Biological: Placebo"
]
},
{
"label": "Group 2: Control Group",
"type": "EXPERIMENTAL",
"description": "Participants will receive placebo and quadrivalent high-dose influenza vaccine on Day 1 and Ad26.RSV.preF-based vaccine on Day 29.",
"interventions": [
"Biological: Ad26.RSV.preF-based vaccine",
"Biological: Quadrivalent High-dose Influenza Vaccine",
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "Ad26.RSV.preF-based vaccine",
"type": "BIOLOGICAL",
"description": "Ad26.RSV.preF-based vaccine will be administered as single IM injection.",
"other_names": []
},
{
"name": "Quadrivalent High-dose Influenza Vaccine",
"type": "BIOLOGICAL",
"description": "Quadrivalent High-dose Influenza Vaccine will be administered as IM injection.",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Placebo will be administered as IM injection to Ad26.RSV.preF-based vaccine.",
"other_names": []
}
],
"ae_time_frame": "From Day 1 up to 7 months",
"ae_description": "The full analysis set (FAS) included all participants who received at least 1 study vaccination, regardless of the occurrence of protocol deviations and vaccine type (seasonal influenza, Ad26/protein preF RSV vaccine, or placebo).",
"ae_groups": [
{
"id": "EG000",
"title": "Group 1: Ad26/Protein preF RSV Vaccine With Fluzone HD QIV (CoAd Group)",
"description": "Participants received intramuscular (IM) injection containing both Ad26. RSV. preF; 1\\*10\\^11 viral particles (vp) and RSV preF protein; 150 micrograms (mcg) coadministered with Fluzone high-dose (HD) quadrivalent (QIV) 240 mcg IM injection on Day 1."
},
{
"id": "EG001",
"title": "Group 2: Fluzone HD QIV With Placebo (Control Group)",
"description": "Participants received Fluzone HD QIV 240 mcg IM injection coadministered with placebo IM injection on Day 1."
},
{
"id": "EG002",
"title": "Group 1: Placebo (CoAd Group)",
"description": "Participants received placebo IM injection on Day 29."
},
{
"id": "EG003",
"title": "Group 2: Ad26/Protein preF RSV Vaccine (Control Group)",
"description": "Participants received IM injection containing both Ad26. RSV. preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 29."
}
]
},
"coder_1": {
"nct": "NCT05071313",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Fluzone High-Dose quadrivalent influenza vaccine"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took Day 1 groups (before the control group got RSV vaccine on Day 29); Day 29 groups EG002-EG003 are the same participants and left out."
},
"coder_2": {
"nct": "NCT05071313",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "high-dose seasonal influenza vaccine"
}
],
"targets": [
"rsv",
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Day 1 groups: RSV plus flu vs placebo plus flu (EG000 vs EG001). Day 29 groups EG002/EG003 are the same participants later."
}
},
{
"trial": {
"nct": "NCT05073003",
"brief_title": "A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants",
"official_title": "A Staged Phase I/II Observer-blind, Randomised, Controlled, Multi-country Study to Evaluate the Safety, Reactogenicity, and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against S. Sonnei and S. Flexneri, Serotypes 1b, 2a, and 3a, in Adults in Europe (Stage 1) Followed by Age De-escalation From Adults to Children and Infants, and Dose-finding in Infants in Africa (Stage 2)",
"conditions": [
"Diarrhoea"
],
"phases": [
"PHASE1",
"PHASE2"
],
"model": "SEQUENTIAL",
"masking": "QUADRUPLE",
"ages": [
"9 Months",
"50 Years"
],
"arms": [
{
"label": "Stage 1 Adults: altSonflex1-2-3 High Dose Group 1",
"type": "EXPERIMENTAL",
"description": "European participants 18-50 years of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1 and Day 85. High dose of altSonflex1-2-3 contained 15 micrograms (\u00b5g) of O-antigen (OAg) each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).",
"interventions": [
"Biological: AltSonflex1-2-3 High Dose"
]
},
{
"label": "Stage 1 Adults: altSonflex1-2-3 High Dose Group 2",
"type": "EXPERIMENTAL",
"description": "European participants 18-50 years of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1 and Day 169. High dose of altSonflex1-2-3 contained 15 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).",
"interventions": [
"Biological: AltSonflex1-2-3 High Dose"
]
},
{
"label": "Stage 1 Adults: Placebo Group",
"type": "PLACEBO_COMPARATOR",
"description": "European participants 18-50 years of age were randomized to receive 1 dose of Placebo on Day 1 and on Day 85 or 169. All participants in Step 1 that received placebo were pooled, as pre-specified in Statistical Analysis Plan.",
"interventions": [
"Drug: altSonflex Placebo"
]
},
{
"label": "Stage 2 Adults: altSonflex1-2-3 High Dose",
"type": "EXPERIMENTAL",
"description": "African participants 18-50 years of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1 and Day 85. High dose of altSonflex1-2-3 contained of 15 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).",
"interventions": [
"Biological: AltSonflex1-2-3 High Dose"
]
},
{
"label": "Stage 2 Adults: Control",
"type": "ACTIVE_COMPARATOR",
"description": "African participants 18-50 years of age were randomized to receive 1 dose of MENVEO as comparator on Day 1 and 1 dose of BOOSTRIX as comparator Day 85.",
"interventions": [
"Biological: Menveo",
"Combination Product: Boostrix"
]
},
{
"label": "Stage 2 Children: altSonflex1-2-3 Medium Dose",
"type": "EXPERIMENTAL",
"description": "African participants 24-59 months of age were randomized to receive a medium dose of altSonflex1-2-3 on Day 1 and Day 85. Medium dose of altSonflex1-2-3 contained 7.5 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).",
"interventions": [
"Biological: AltSonflex1-2-3 Medium Dose"
]
},
{
"label": "Stage 2 Children: altSonflex1-2-3 High Dose",
"type": "EXPERIMENTAL",
"description": "African participants 24-59 months of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1 and Day 85. High dose of altSonflex1-2-3 contained 15 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).",
"interventions": [
"Biological: AltSonflex1-2-3 High Dose"
]
},
{
"label": "Stage 2 Children: Control",
"type": "ACTIVE_COMPARATOR",
"description": "African participants 24-59 months of age were randomized to receive 1 dose of MENVEO as comparator on Day 1 and 1 dose of TYPHIM VI as comparator on Day 85.",
"interventions": [
"Biological: Menveo",
"Combination Product: Typhim-Vi"
]
},
{
"label": "Stage 2 Infants safety cohort: altSonflex1-2-3 Low Dose",
"type": "EXPERIMENTAL",
"description": "African participants 9 months of age were randomized to receive a low dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. The measles-rubella vaccine (MR-VAC) was administered on Day 29 and Day 281. Low dose of altSonflex1-2-3 contained 3.75 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).",
"interventions": [
"Biological: AltSonflex1-2-3 Low Dose",
"Biological: MR-Vac"
]
},
{
"label": "Stage 2 Infants safety cohort: altSonflex1-2-3 Medium Dose",
"type": "EXPERIMENTAL",
"description": "African participants 9 months of age were randomized to receive a medium dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was administered on Day 29 and Day 281. Medium dose of altSonflex1-2-3 contained 7.5 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).",
"interventions": [
"Biological: AltSonflex1-2-3 Medium Dose",
"Biological: MR-Vac"
]
},
{
"label": "Stage 2 Infants safety cohort: altSonflex1-2-3 High Dose",
"type": "EXPERIMENTAL",
"description": "African participants 9 months of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was administered on Day 29 and Day 281. High dose of altSonflex1-2-3 contained 15 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).",
"interventions": [
"Biological: AltSonflex1-2-3 High Dose",
"Biological: MR-Vac"
]
},
{
"label": "Stage 2 Infants safety cohort: Control",
"type": "ACTIVE_COMPARATOR",
"description": "African participants 9 months of age were randomized to receive a dose of MENVEO as comparator on Day 1 and Day 85 and INFRANRIX HEXA as comparator on Day 253. MR-VAC was administered on Day 29 and Day 281.",
"interventions": [
"Biological: Menveo",
"Combination Product: INFANRIX HEXA",
"Biological: MR-Vac"
]
},
{
"label": "Stage 2 Infants dose-finding cohort: altSonflex1-2-3 Low Dose",
"type": "EXPERIMENTAL",
"description": "African participants 9 months of age were randomized to receive a low dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was co-administered on Day 1 and Day 253. This cohort was created to identify the preferred dose among low, medium and high doses. Low dose of altSonflex1-2-3 contained 3.75 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).",
"interventions": [
"Biological: AltSonflex1-2-3 Low Dose",
"Biological: MR-Vac"
]
},
{
"label": "Stage 2 Infants dose-finding cohort: altSonflex1-2-3 Medium Dose",
"type": "EXPERIMENTAL",
"description": "African participants 9 months of age were randomized to receive a medium dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was co-administered on Day 1 and Day 253. This cohort was created to identify the preferred dose among low, medium and high doses. Medium dose of altSonflex1-2-3 contained 7.5 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).",
"interventions": [
"Biological: AltSonflex1-2-3 Medium Dose",
"Biological: MR-Vac"
]
},
{
"label": "Stage 2 Infants dose-finding cohort: altSonflex1-2-3 High Dose",
"type": "EXPERIMENTAL",
"description": "African participants 9 months of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was co-administered on Day 1 and Day 253. This cohort was created to identify the preferred dose among low, medium and high doses. High dose of altSonflex1-2-3 contained 15 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).",
"interventions": [
"Biological: AltSonflex1-2-3 High Dose",
"Biological: MR-Vac"
]
},
{
"label": "Stage 2 Infants dose-finding cohort: Control",
"type": "ACTIVE_COMPARATOR",
"description": "African participants 9 months of age were randomized to receive a dose of MENVEO as comparator on Day 1 and Day 85 and INFRANRIX HEXA as comparator on Day 253. MR-VAC was co-administered on Day 1 and Day 253. This cohort was created to identify the preferred dose among low, medium and high doses.",
"interventions": [
"Biological: Menveo",
"Combination Product: INFANRIX HEXA",
"Biological: MR-Vac"
]
}
],
"interventions": [
{
"name": "AltSonflex1-2-3 High Dose",
"type": "BIOLOGICAL",
"description": "2 doses in adults 18-50 years of age and children 24-59 months of age, 3 doses in infants 9 months of age",
"other_names": []
},
{
"name": "AltSonflex1-2-3 Medium Dose",
"type": "BIOLOGICAL",
"description": "2 doses in children 24-59 months of age, 3 doses in infants 9 months of age",
"other_names": []
},
{
"name": "AltSonflex1-2-3 Low Dose",
"type": "BIOLOGICAL",
"description": "3 doses in infants 9 months of age",
"other_names": []
},
{
"name": "Menveo",
"type": "BIOLOGICAL",
"description": "1 dose in adults 18-50 years of age (stage 2) and children 24-59 months of age and 2 doses in infants 9 months of age",
"other_names": []
},
{
"name": "Boostrix",
"type": "COMBINATION_PRODUCT",
"description": "1 dose in adults 18-50 years of age (stage 2)",
"other_names": []
},
{
"name": "INFANRIX HEXA",
"type": "COMBINATION_PRODUCT",
"description": "1 dose in infants 9 months of age",
"other_names": []
},
{
"name": "Typhim-Vi",
"type": "COMBINATION_PRODUCT",
"description": "1 dose in children 24-59 months of age",
"other_names": []
},
{
"name": "MR-Vac",
"type": "BIOLOGICAL",
"description": "2 doses in children 24-59 months of age",
"other_names": []
},
{
"name": "altSonflex Placebo",
"type": "DRUG",
"description": "2 doses in adults 18-50 years of age (stage 1)",
"other_names": []
}
],
"ae_time_frame": "Solicited AEs were collected within 7 days and unsolicited AEs within 28 days after any intervention (administered on Day (D) 1 and D85 for Stage 1 adults, Stage 2 adults and children and D1, D85 and D253 for Stage 2 infants). SAEs and all-cause mortality: from Day (D) 1 to D113/D197 for stage 1, fr [\u2026]",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Stage 1 Adults: altSonflex1-2-3 High Dose Group 1",
"description": "European participants 18-50 years of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1 and Day 85. High dose of altSonflex1-2-3 contained 15 micrograms (\u00b5g) O-antigen (OAg) of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a)."
},
{
"id": "EG001",
"title": "Stage 1 Adults: altSonflex1-2-3 High Dose Group 2",
"description": "European participants 18-50 years of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1 and Day 169. High dose of altSonflex1-2-3 contained 15 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a)."
},
{
"id": "EG002",
"title": "Stage 1 Adults: Placebo Group",
"description": "European participants 18-50 years of age were randomized to receive 1 dose of Placebo on Day 1 and on Day 85 or 169. All participants in Step 1 that received placebo were pooled, as pre-specified in Statistical Analysis Plan."
},
{
"id": "EG003",
"title": "Stage 2 Adults: altSonflex1-2-3 High Dose",
"description": "African participants 18-50 years of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1 and Day 85. High dose of altSonflex1-2-3 contained of 15 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a)."
},
{
"id": "EG004",
"title": "Stage 2 Adults: Control",
"description": "African participants 18-50 years of age were randomized to receive 1 dose of MENVEO as comparator on Day 1 and 1 dose of BOOSTRIX as comparator Day 85."
},
{
"id": "EG005",
"title": "Stage 2 Children: altSonflex1-2-3 Medium Dose",
"description": "African participants 24-59 months of age were randomized to receive a medium dose of altSonflex1-2-3 on Day 1 and Day 85. Medium dose of altSonflex1-2-3 contained 7.5 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a)."
},
{
"id": "EG006",
"title": "Stage 2 Children: altSonflex1-2-3 High Dose",
"description": "African participants 24-59 months of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1 and Day 85. High dose of altSonflex1-2-3 contained 15 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a)."
},
{
"id": "EG007",
"title": "Stage 2 Children: Control",
"description": "African participants 24-59 months of age were randomized to receive 1 dose of MENVEO as comparator on Day 1 and 1 dose of TYPHIM VI as comparator on Day 85."
},
{
"id": "EG008",
"title": "Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose",
"description": "African participants 9 months of age were randomized to receive a low dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. The measles-rubella vaccine (MR-VAC) was administered on Day 29 and Day 281. Low dose of altSonflex1-2-3 contained 3.75 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a)."
},
{
"id": "EG009",
"title": "Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose",
"description": "African participants 9 months of age were randomized to receive a medium dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was administered on Day 29 and Day 281. Medium dose of altSonflex1-2-3 contained 7.5 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a)."
},
{
"id": "EG010",
"title": "Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose",
"description": "African participants 9 months of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was administered on Day 29 and Day 281. High dose of altSonflex1-2-3 contained 15 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a)."
},
{
"id": "EG011",
"title": "Stage 2 Infants Safety Cohort: Control",
"description": "African participants 9 months of age were randomized to receive a dose of MENVEO as comparator on Day 1 and Day 85 and INFRANRIX HEXA as comparator on Day 253. MR-VAC was administered on Day 29 and Day 281."
},
{
"id": "EG012",
"title": "Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose",
"description": "African participants 9 months of age were randomized to receive a low dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was co-administered on Day 1 and Day 253. This cohort was created to identify the preferred dose among low, medium and high doses. Low dose of altSonflex1-2-3 contained 3.75 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a)."
},
{
"id": "EG013",
"title": "Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose",
"description": "African participants 9 months of age were randomized to receive a medium dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was co-administered on Day 1 and Day 253. This cohort was created to identify the preferred dose among low, medium and high doses. Medium dose of altSonflex1-2-3 contained 7.5 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3 [\u2026]"
},
{
"id": "EG014",
"title": "Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose",
"description": "African participants 9 months of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was co-administered on Day 1 and Day 253. This cohort was created to identify the preferred dose among low, medium and high doses. High dose of altSonflex1-2-3 contained 15 \u00b5g OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a)."
},
{
"id": "EG015",
"title": "Stage 2 Infants Dose-finding Cohort: Control",
"description": "African participants 9 months of age were randomized to receive a dose of MENVEO as comparator on Day 1 and Day 85 and INFRANRIX HEXA as comparator on Day 253. MR-VAC was co-administered on Day 1 and Day 253. This cohort was created to identify the preferred dose among low, medium and high doses."
}
]
},
"coder_1": {
"nct": "NCT05073003",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Stage 1 adults only; Stage 2 controls are active vaccines (Menveo, Boostrix, Typhim Vi, Infanrix hexa). altSonflex1-2-3 platform not stated (dosed by O-antigen; GMMA-type), adjuvant not stated."
},
"coder_2": {
"nct": "NCT05073003",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Stage 1 adults in Europe only. GMMA-based (outer membrane vesicle) vaccine, platform other; alum adjuvant from product knowledge. Stage 2 groups use Menveo/Boostrix/Typhim Vi/Infanrix hexa controls, left out."
}
},
{
"trial": {
"nct": "NCT05099965",
"brief_title": "Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex\u00ae)",
"official_title": "Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex\u00ae), in Adults With Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART With Conserved Immune Function",
"conditions": [
"Cytomegalovirus Infections",
"HIV Infections",
"Vaccine"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"18 Years",
"65 Years"
],
"arms": [
{
"label": "CMV-MVA Triplex",
"type": "ACTIVE_COMPARATOR",
"description": "CMV-MVA Triplex\u00ae containing 5 x 10\\^8 plaque-forming unit (pfu) \u00b10.5 x 10\\^8 pfu of MVA Vaccine Encoding CMV Antigens by intramuscular (IM) deltoid injections at Entry/Day 0 and week 4.",
"interventions": [
"Biological: CMV-MVA Triplex"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Placebo (7.5% lactose in phosphate-buffered saline) that matched the volume of the active vaccine injection by IM deltoid injections at Entry/Day 0 and week 4.",
"interventions": [
"Biological: Placebo"
]
}
],
"interventions": [
{
"name": "CMV-MVA Triplex",
"type": "BIOLOGICAL",
"description": "5 x 10\\^8 plaque-forming unit (pfu) \u00b10.5 x 10\\^8 pfu of MVA Vaccine",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "7.5% lactose in phosphate-buffered saline",
"other_names": []
}
],
"ae_time_frame": "From Day 0 to Week 96, or premature study discontinuation",
"ae_description": "The DAIDS AE Grading Table, Corrected Version 2.1, was used for grading adverse events (AE): * Grade \u22653 AEs * Vaccine-related AEs regardless of grade * AEs that led to a change in study treatment/intervention regardless of grade * AEs meeting the Serious Adverse Event (SAE) definition or Expedited A [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "CMV-MVA Triplex",
"description": "CMV-MVA Triplex\u00ae containing 5 x 10\\^8 plaque-forming unit (pfu) \u00b10.5 x 10\\^8 pfu of MVA Vaccine Encoding CMV Antigens by intramuscular (IM) deltoid injections at Entry/Day 0 and week 4. CMV-MVA Triplex: 5 x 10\\^8 plaque-forming unit (pfu) \u00b10.5 x 10\\^8 pfu of MVA Vaccine"
},
{
"id": "EG001",
"title": "Placebo",
"description": "Placebo (7.5% lactose in phosphate-buffered saline) that matched the volume of the active vaccine injection by IM deltoid injections at Entry/Day 0 and week 4. Placebo: 7.5% lactose in phosphate-buffered saline"
}
]
},
"coder_1": {
"nct": "NCT05099965",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Triplex given to adults who already have CMV (and HIV); treats an existing infection."
},
"coder_2": {
"nct": "NCT05099965",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "CMV-MVA Triplex in people with HIV and CMV on ART. Participants already have CMV, so preventive vs therapeutic is borderline; coded preventive (aims to prevent CMV complications). Placebo 7.5% lactose in PBS."
}
},
{
"trial": {
"nct": "NCT05172544",
"brief_title": "Trial of an Inactivated Yellow Fever Virus Vaccine",
"official_title": "A Double Blind, Randomized, Placebo-Controlled, Phase 1 Dose Escalation Trial to Evaluate the Safety and Immunogenicity of an Inactivated Yellow Fever Virus Vaccine, HydroVax-002 YFV, in Healthy Adults",
"conditions": [
"Yellow Fever"
],
"phases": [
"PHASE1"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"18 Years",
"49 Years"
],
"arms": [
{
"label": "Low Dose Sentinel",
"type": "EXPERIMENTAL",
"description": "3 subjects will receive 1 mcg intramuscularly (IM) of HydroVax-002 YFV and 1 subject will receive placebo IM on Days 1 and 29.",
"interventions": [
"Biological: HydroVax-002 YFV",
"Other: Placebo"
]
},
{
"label": "Low Dose Expanded",
"type": "EXPERIMENTAL",
"description": "7 subjects will receive 1 mcg intramuscularly (IM) of HydroVax-002 YFV and 2 subject will receive placebo IM on Days 1 and 29.",
"interventions": [
"Biological: HydroVax-002 YFV",
"Other: Placebo"
]
},
{
"label": "High Dose Sentinel",
"type": "EXPERIMENTAL",
"description": "3 subjects will receive 5 mcg intramuscularly (IM) of HydroVax-002 YFV and 1 subject will receive placebo IM on Days 1 and 29.",
"interventions": [
"Biological: HydroVax-002 YFV",
"Other: Placebo"
]
},
{
"label": "High Dose Expanded",
"type": "EXPERIMENTAL",
"description": "7 subjects will receive 5 mcg intramuscularly (IM) of HydroVax-002 YFV and 1 subject will receive placebo IM on Days 1 and 29.",
"interventions": [
"Biological: HydroVax-002 YFV",
"Other: Placebo"
]
}
],
"interventions": [
{
"name": "HydroVax-002 YFV",
"type": "BIOLOGICAL",
"description": "Inactivated YFV vaccine",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "NaCl 0.9%, Normal Saline",
"other_names": []
}
],
"ae_time_frame": "7 months",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "Low Dose",
"description": "1 mcg intramuscularly (IM) of HydroVax-002 YFV on Days 1 and 29."
},
{
"id": "EG001",
"title": "High Dose",
"description": "5 mcg intramuscularly (IM) of HydroVax-002 YFV on Days 1 and 29."
},
{
"id": "EG002",
"title": "Placebo",
"description": "Placebo intramuscularly (IM) on Days 1 and 29."
}
]
},
"coder_1": {
"nct": "NCT05172544",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"yellow_fever"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HydroVax-002 adjuvant not stated."
},
"coder_2": {
"nct": "NCT05172544",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"yellow_fever"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HydroVax-002 YFV; alum adjuvant from product knowledge."
}
},
{
"trial": {
"nct": "NCT05281094",
"brief_title": "Efficacy and Safety of Two Doses of HIL-214 in Children",
"official_title": "A Phase 2b, Double-blind, Randomized, Multi-site, Placebo-controlled Trial to Evaluate the Efficacy, Safety and Immunogenicity of Intramuscular HIL-214 Norovirus Vaccine in Healthy Children 5 Months of Age at Initial Vaccination",
"conditions": [
"Gastroenteritis"
],
"phases": [
"PHASE2",
"PHASE3"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"5 Months",
"5 Months"
],
"arms": [
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "One dose of placebo on Day 1 and one dose of placebo between Day 28 and Day 56.",
"interventions": [
"Biological: Placebo"
]
},
{
"label": "Experimental",
"type": "EXPERIMENTAL",
"description": "One dose of HIL-214 on Day 1 and one dose of HIL-214 between Day 28 and Day 56.",
"interventions": [
"Biological: HIL-214"
]
}
],
"interventions": [
{
"name": "HIL-214",
"type": "BIOLOGICAL",
"description": "2 injections - given on Day 1 and the second given between Day 29 - Day 57",
"other_names": []
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "2 injections - given on Day 1 and the second given between Day 29 - Day 57",
"other_names": []
}
],
"ae_time_frame": "Deaths from Day 1 to the end of 6 month observation period; Serious adverse events from Day 1 to the end of the trial; Unsolicited adverse events for up to 28 days after any dose of trial vaccine.",
"ae_description": "Serious adverse events that occurred are reported at the preferred term level in the safety analysis set.",
"ae_groups": [
{
"id": "EG000",
"title": "Placebo",
"description": "One dose of placebo on Day 1 and one dose of placebo between Day 28 and Day 56."
},
{
"id": "EG001",
"title": "Experimental",
"description": "One dose of HIL-214 on Day 1 and one dose of HIL-214 between Day 28 and Day 56."
}
]
},
"coder_1": {
"nct": "NCT05281094",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HIL-214 norovirus VLP vaccine; adjuvant not stated."
},
"coder_2": {
"nct": "NCT05281094",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HIL-214 norovirus VLP vaccine; alum adjuvant from product knowledge."
}
},
{
"trial": {
"nct": "NCT05327816",
"brief_title": "A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older",
"official_title": "A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of Various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older",
"conditions": [
"Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention"
],
"phases": [
"PHASE1",
"PHASE2"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"60 Years",
null
],
"arms": [
{
"label": "Arm 1a: Respiratory Syncytial Virus (RSV) preFusion (preF) Based Vaccine",
"type": "EXPERIMENTAL",
"description": "Participants will receive single dose of mixture of RSV preF-based vaccine in cohort (C) 1 (Group \\[G\\] 1) and C 2 through intramuscular injection on Day 1.",
"interventions": [
"Biological: RSV preF-based Vaccine"
]
},
{
"label": "Arm 1b: RSV preF Based Vaccine",
"type": "EXPERIMENTAL",
"description": "Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 1-4) and C 2 through intramuscular injection on Day 1.",
"interventions": [
"Biological: RSV preF-based Vaccine"
]
},
{
"label": "Arm 1c: Placebo",
"type": "EXPERIMENTAL",
"description": "Participants will receive single dose of placebo in C 1 (G 1-4) and C 2 through intramuscular injection on Day 1.",
"interventions": [
"Drug: Placebo"
]
},
{
"label": "Arm 2: RSV preF Based Vaccine",
"type": "EXPERIMENTAL",
"description": "Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.",
"interventions": [
"Biological: RSV preF-based Vaccine"
]
},
{
"label": "Arm 3: RSV preF Based Vaccine",
"type": "EXPERIMENTAL",
"description": "Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.",
"interventions": [
"Biological: RSV preF-based Vaccine"
]
},
{
"label": "Arm 4: RSV preF Based Vaccine",
"type": "EXPERIMENTAL",
"description": "Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.",
"interventions": [
"Biological: RSV preF-based Vaccine"
]
},
{
"label": "Arm 5: RSV preF Based Vaccine",
"type": "EXPERIMENTAL",
"description": "Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.",
"interventions": [
"Biological: RSV preF-based Vaccine"
]
},
{
"label": "Arm 6: RSV preF Based Vaccine",
"type": "EXPERIMENTAL",
"description": "Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.",
"interventions": [
"Biological: RSV preF-based Vaccine"
]
},
{
"label": "Arm 7: RSV preF Based Vaccine",
"type": "EXPERIMENTAL",
"description": "Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 3) and C 2 through intramuscular injection on Day 1.",
"interventions": [
"Biological: RSV preF-based Vaccine"
]
},
{
"label": "Arm 8: RSV preF Based Vaccine",
"type": "EXPERIMENTAL",
"description": "Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 3) and C 2 through intramuscular injection on Day 1.",
"interventions": [
"Biological: RSV preF-based Vaccine"
]
},
{
"label": "Arm 9: RSV preF Based Vaccine",
"type": "EXPERIMENTAL",
"description": "Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 4) and C 2 through intramuscular injection on Day 1.",
"interventions": [
"Biological: RSV preF-based Vaccine"
]
},
{
"label": "Arm 10: RSV preF Based Vaccine",
"type": "EXPERIMENTAL",
"description": "Participants will receive a single dose of selected formulation (based on C 1 and 2 results) in C 3 through intramuscular injection on Day 1.",
"interventions": [
"Biological: RSV preF-based Vaccine"
]
},
{
"label": "Arm 11a: RSV preF Based Vaccine and Placebo",
"type": "EXPERIMENTAL",
"description": "Participants in C 3 will receive a single dose of first vaccination with selected formulation (as per data C1 and 2) plus placebo on Day 1 and re-vaccination with selected formulation whenever revaccination would be needed through intramuscular injection.",
"interventions": [
"Biological: RSV preF-based Vaccine",
"Drug: Placebo"
]
},
{
"label": "Arm 11b: RSV preF Based Vaccine and Placebo",
"type": "EXPERIMENTAL",
"description": "Participants in C 3 will receive a single dose of first vaccination with selected formulation (as per data from C 1 and 2) plus placebo on Day 1 and re-vaccination with placebo whenever revaccination would be needed through intramuscular injection.",
"interventions": [
"Biological: RSV preF-based Vaccine",
"Drug: Placebo"
]
},
{
"label": "Arm 12: RSV preF Based Vaccine and Placebo",
"type": "EXPERIMENTAL",
"description": "Participants in C 3 will receive first vaccination with placebo on Day 1 and re-vaccination with selected formulation (as per data from C 1 and 2) whenever revaccination would be needed through intramuscular injection.",
"interventions": [
"Biological: RSV preF-based Vaccine",
"Drug: Placebo"
]
},
{
"label": "Arm 13: RSV preF Based Vaccine",
"type": "EXPERIMENTAL",
"description": "Participants in C 3 will receive the mixture of RSV preF-based vaccine plus placebo on Day 1 through intramuscular injection.",
"interventions": [
"Biological: RSV preF-based Vaccine",
"Drug: Placebo"
]
},
{
"label": "Arm 14: RSV preF Based Vaccine",
"type": "EXPERIMENTAL",
"description": "Participants in C 4 will receive first vaccination with selected formulation (as per data from C 1 and 2) on Day 1 and re-vaccination with selected formulation whenever revaccination would be needed through intramuscular injection.",
"interventions": [
"Biological: RSV preF-based Vaccine"
]
},
{
"label": "Arm 15: RSV preF Based Vaccine and Placebo",
"type": "EXPERIMENTAL",
"description": "Participants in C 4 will receive first vaccination with selected formulation (as per data from C 1 and 2) on Day 1 and re-vaccination with placebo whenever revaccination would be needed through intramuscular injection.",
"interventions": [
"Biological: RSV preF-based Vaccine",
"Drug: Placebo"
]
},
{
"label": "Arm 16: RSV preF Based Vaccine and Placebo",
"type": "EXPERIMENTAL",
"description": "Participants in C 4 will receive first vaccination with placebo on Day 1 and re-vaccination with selected formulation (as per data from C 1 and 2) whenever revaccination would be needed through intramuscular injection.",
"interventions": [
"Biological: RSV preF-based Vaccine",
"Drug: Placebo"
]
}
],
"interventions": [
{
"name": "RSV preF-based Vaccine",
"type": "BIOLOGICAL",
"description": "RSV preF-based vaccine will be administered as intramuscular injection.",
"other_names": []
},
{
"name": "Placebo",
"type": "DRUG",
"description": "Placebo will be administered as intramuscular injection.",
"other_names": []
}
],
"ae_time_frame": "From Day 1 up to 6 months post vaccination (up to Day 183)",
"ae_description": "The full analysis set (FAS) included all participants who received the study vaccine, regardless of the occurrence of protocol deviations.",
"ae_groups": [
{
"id": "EG000",
"title": "Arm 1a (Cohort 1): Ad26.RSV-B.PreF2 1*10^11 vp + RSV-B.PreF Protein 150 mcg",
"description": "Participants received single intramuscular (IM) injections of adenovirus serotype 26 respiratory syncytial virus-B prefusion-F2 protein (Ad26.RSV-B.preF2) 1\\*10\\^11 viral particles (vp) and RSV-B.preF protein 150 micrograms (mcg) on Day 1."
},
{
"id": "EG001",
"title": "Arm 1b (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF Protein 150 mcg",
"description": "Participants received single IM injections of adenovirus serotype 26 respiratory syncytial virus-A prefusion-F protein (Ad26.RSV-A.preF) 1\\*10\\^11 vp and RSV-A.preF protein 150 mcg on Day 1."
},
{
"id": "EG002",
"title": "Arm 1c (Cohort 1): Pooled Placebo",
"description": "Participants received a single IM injection of placebo on Day 1."
},
{
"id": "EG003",
"title": "Arm 2 (Cohort 1): RSV-A.PreF Protein 150 mcg + RSV-B.PreF Protein 150 mcg",
"description": "Participants received single IM injections of RSV-A.preF protein 150 mcg and RSV-B.preF protein 150 mcg on Day 1."
},
{
"id": "EG004",
"title": "Arm 3 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 2.5*10^10 vp + RSV-A.PreF/RSV-B.PreF 150 mcg",
"description": "Participants received single IM injections of Ad26.RSV-A.preF 2.5\\*10\\^10 vp, Ad26.RSV-B.preF2 2.5 \\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."
},
{
"id": "EG005",
"title": "Arm 4 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 5*10^10 vp + RSV-A.PreF /RSV-B.PreF 150 mcg",
"description": "Participants received single IM injections of Ad26.RSV-A.preF 5\\*10\\^10 vp, Ad26.RSV-B.preF2 5 \\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."
},
{
"id": "EG006",
"title": "Arm 5 (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF Protein 300 mcg",
"description": "Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp and RSV-A.preF protein 300 mcg on Day 1."
},
{
"id": "EG007",
"title": "Arm 6 (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF and RSV-B.PreF at 150 mcg",
"description": "Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."
},
{
"id": "EG008",
"title": "Arm 7 (Cohort 1):Ad26.RSV-A.PreF 1*10^11vp/Ad26.RSV-B.preF2 5*10^10vp + RSV-A.Pre/RSV-B.PreF 150 mcg",
"description": "Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, Ad26.RSV-B.preF2 5\\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."
},
{
"id": "EG009",
"title": "Arm 8 (Cohort 1): Ad26.RSV-A.PreF 1.5*10^11 vp +RSV-A.PreF Protein 300 mcg",
"description": "Participants received single IM injections of Ad26.RSV-A.preF 1.5\\*10\\^11 vp and RSV-A.preF protein 300 mcg on Day 1."
},
{
"id": "EG010",
"title": "Arm 9 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 1*10^11 vp + RSV-A.PreF/RSV-B.PreF 150 mcg",
"description": "Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, Ad26.RSV-B.preF2 1\\*10\\^11 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."
}
]
},
"coder_1": {
"nct": "NCT05327816",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG004",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG005",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG006",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG007",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG008",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG009",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG010",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AE tables report Cohort 1 only. Ad26 RSV preF vectors plus RSV preF protein; whether the protein is adjuvanted is not stated, so adjuvant unknown."
},
"coder_2": {
"nct": "NCT05327816",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG009",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cohort 1 groups only; adjuvant taken as none (unadjuvanted Ad26/protein candidate, not stated). Cohort 3 and 4 not in tables."
}
},
{
"trial": {
"nct": "NCT05590403",
"brief_title": "A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above",
"official_title": "A Phase 3, Observer-blind, Randomized, Placebo-controlled Study to Evaluate the Non-inferiority of the Immune Response and Safety of the RSVPreF3 OA Investigational Vaccine in Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults \u226560 Years of Age",
"conditions": [
"Respiratory Syncytial Virus Infections"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"50 Years",
null
],
"arms": [
{
"label": "Adults HA-RSV Group",
"type": "EXPERIMENTAL",
"description": "Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-Lower respiratory tract disease (RSV-LRTD), aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.",
"interventions": [
"Biological: RSVPreF3 OA investigational vaccine"
]
},
{
"label": "Adults HA-Placebo Group",
"type": "PLACEBO_COMPARATOR",
"description": "Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-LRTD, aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.",
"interventions": [
"Drug: Placebo"
]
},
{
"label": "Adults AIR-RSV Group",
"type": "EXPERIMENTAL",
"description": "Adults at increased risk of RSV-Lower respiratory tract disease (RSV-LRTD) aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.",
"interventions": [
"Biological: RSVPreF3 OA investigational vaccine"
]
},
{
"label": "Adults AIR-Placebo Group",
"type": "PLACEBO_COMPARATOR",
"description": "Adults at increased risk of RSV-LRTD aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.",
"interventions": [
"Drug: Placebo"
]
},
{
"label": "OA-RSV Group",
"type": "EXPERIMENTAL",
"description": "Older adults aged 60 years old and above received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.",
"interventions": [
"Biological: RSVPreF3 OA investigational vaccine"
]
}
],
"interventions": [
{
"name": "RSVPreF3 OA investigational vaccine",
"type": "BIOLOGICAL",
"description": "One dose administered intramuscularly at Day 1.",
"other_names": []
},
{
"name": "Placebo",
"type": "DRUG",
"description": "One dose administered intramuscularly at Day 1.",
"other_names": []
}
],
"ae_time_frame": "Solicited AEs were collected from Day 1 (day of vaccination) up to Day 4 post-dose. Unsolicited AEs were collected from Day 1 up to Day 30 post-dose. SAEs and pIMDs were collected from Day 1 up to Month 6 post dose-administration. Related SAEs, related pIMDs and fatal SAEs were collected from Day 1  [\u2026]",
"ae_description": "Solicited and unsolicited events were reported per participant at any dose for the assessed timeframe (within 30 days after any vaccine dose administration) according to occurence of each event, as pre-specified in Statistical Analysis Plan.",
"ae_groups": [
{
"id": "EG000",
"title": "Adults HA-RSV Group",
"description": "Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-LRTD, aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end."
},
{
"id": "EG001",
"title": "Adults HA-Placebo Group",
"description": "Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-LRTD, aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end."
},
{
"id": "EG002",
"title": "Adults AIR-RSV Group",
"description": "Adults at increased risk of RSV-Lower respiratory tract disease (RSV-LRTD) aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end."
},
{
"id": "EG003",
"title": "Adults AIR-Placebo Group",
"description": "Adults at increased risk of RSV-LRTD aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end."
},
{
"id": "EG004",
"title": "OA-RSV Group",
"description": "Older adults aged 60 years old and above received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end."
}
]
},
"coder_1": {
"nct": "NCT05590403",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Pooled healthy and at-increased-risk 50-59 strata. EG004 (adults 60+, RSVPreF3 OA only) left out: no placebo group of its own. RSVPreF3 OA (Arexvy) is AS01E-adjuvanted. patients true because one randomized stratum was enrolled for chronic conditions raising RSV risk."
},
"coder_2": {
"nct": "NCT05590403",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RSVPreF3 OA is AS01E adjuvanted. Healthy 50-59 and at-increased-risk 50-59 pooled. Left out EG004 (60+ vaccine only, no placebo)."
}
},
{
"trial": {
"nct": "NCT05639894",
"brief_title": "Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older",
"official_title": "A Phase I/IIa, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV Vaccine Candidate in Adult Participants 18 to 50 Years of Age in Phase I, and 60 Years and Older in Phase IIa",
"conditions": [
"Respiratory Syncytial Virus Immunization"
],
"phases": [
"PHASE1",
"PHASE2"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"18 Years",
null
],
"arms": [
{
"label": "Stage 1: Sentinel Cohort: RSV Vaccine Dose A1",
"type": "EXPERIMENTAL",
"description": "Participants enrolled in the Sentinel Cohort received 0.5 mL RSV vaccine dose A1 as an IM injection on Day 1 of Stage 1.",
"interventions": [
"Biological: RSV vaccine candidate"
]
},
{
"label": "Stage 1: Sentinel Cohort: RSV Vaccine Dose A2",
"type": "EXPERIMENTAL",
"description": "Participants enrolled in the Sentinel Cohort received 0.5 mL RSV vaccine dose A2 as an IM injection on Day 1 of Stage 1.",
"interventions": [
"Biological: RSV vaccine candidate"
]
},
{
"label": "Stage 1: Sentinel Cohort: RSV Vaccine Dose B1",
"type": "EXPERIMENTAL",
"description": "Participants enrolled in the Sentinel Cohort received 0.5 mL RSV vaccine dose B1 as an IM injection on Day 1 of Stage 1.",
"interventions": [
"Biological: RSV vaccine candidate"
]
},
{
"label": "Stage 1: Sentinel Cohort: RSV Vaccine Dose B2",
"type": "EXPERIMENTAL",
"description": "Participants enrolled in the Sentinel Cohort received 0.5 mL RSV vaccine dose B2 as an IM injection on Day 1 of Stage 1.",
"interventions": [
"Biological: RSV vaccine candidate"
]
},
{
"label": "Stage 1: Sentinel Cohort: RSV Vaccine Dose C1",
"type": "EXPERIMENTAL",
"description": "Participants enrolled in the Sentinel Cohort received 0.5 mL RSV vaccine dose C1 as an IM injection on Day 1 of Stage 1.",
"interventions": [
"Biological: RSV vaccine candidate"
]
},
{
"label": "Stage 1: Sentinel Cohort: RSV Vaccine Dose C2",
"type": "EXPERIMENTAL",
"description": "Participants enrolled in the Sentinel Cohort received 0.5 mL RSV vaccine dose C2 as an IM injection on Day 1 of Stage 1.",
"interventions": [
"Biological: RSV vaccine candidate"
]
},
{
"label": "Stage 1: Sentinel Cohort: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants enrolled in the Sentinel Cohort received 0.5 mL placebo matched to RSV vaccine as an IM injection on Day 1 of Stage 1.",
"interventions": [
"Other: Placebo"
]
},
{
"label": "Stage 1: Main Cohort: RSV Vaccine Dose A1",
"type": "EXPERIMENTAL",
"description": "Participants enrolled in the Main Cohort received 0.5 mL RSV vaccine dose A1 as an IM injection on Day 1 of Stage 1.",
"interventions": [
"Biological: RSV vaccine candidate"
]
},
{
"label": "Stage 1: Main Cohort: RSV Vaccine Dose A2",
"type": "EXPERIMENTAL",
"description": "Participants enrolled in the Main Cohort received 0.5 mL RSV vaccine dose A2 as an IM injection on Day 1 of Stage 1.",
"interventions": [
"Biological: RSV vaccine candidate"
]
},
{
"label": "Stage 1: Main Cohort: RSV Vaccine Dose B1",
"type": "EXPERIMENTAL",
"description": "Participants enrolled in the Main Cohort received 0.5 mL RSV vaccine dose B1 as an IM injection on Day 1 of Stage 1.",
"interventions": [
"Biological: RSV vaccine candidate"
]
},
{
"label": "Stage 1: Main Cohort: RSV Vaccine Dose B2",
"type": "EXPERIMENTAL",
"description": "Participants enrolled in the Main Cohort received 0.5 mL RSV vaccine dose B2 as an IM injection on Day 1 of Stage 1.",
"interventions": [
"Biological: RSV vaccine candidate"
]
},
{
"label": "Stage 1: Main Cohort: RSV Vaccine Dose C1",
"type": "EXPERIMENTAL",
"description": "Participants enrolled in the Main Cohort received 0.5 mL RSV vaccine dose C1 as an IM injection on Day 1 of Stage 1.",
"interventions": [
"Biological: RSV vaccine candidate"
]
},
{
"label": "Stage 1: Main Cohort: RSV Vaccine Dose C2",
"type": "EXPERIMENTAL",
"description": "Participants enrolled in the Main Cohort received 0.5 mL RSV vaccine dose C2 as an IM injection on Day 1 of Stage 1.",
"interventions": [
"Biological: RSV vaccine candidate"
]
},
{
"label": "Stage 1: Main Cohort: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants enrolled in the Main Cohort received 0.5 mL placebo matched to RSV vaccine as an IM injection on Day 1 of Stage 1.",
"interventions": [
"Other: Placebo"
]
},
{
"label": "Stage 2: RSV Vaccine Dose C2",
"type": "EXPERIMENTAL",
"description": "Participants received 0.5 mL RSV vaccine dose C2 as an IM injection on Day 1 of Stage 2.",
"interventions": [
"Biological: RSV vaccine candidate"
]
},
{
"label": "Stage 2: RSV Vaccine Dose D",
"type": "EXPERIMENTAL",
"description": "Participants received 0.5 mL RSV vaccine dose D as an IM injection on Day 1 of Stage 2.",
"interventions": [
"Biological: RSV vaccine candidate"
]
},
{
"label": "Stage 2: Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants received 0.5 mL placebo matched to RSV vaccine as an IM injection on Day 1 of Stage 2.",
"interventions": [
"Other: Placebo"
]
}
],
"interventions": [
{
"name": "RSV vaccine candidate",
"type": "BIOLOGICAL",
"description": "Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "Pharmaceutical Form: Liquid Route of Administration: Intramuscular injection",
"other_names": []
}
],
"ae_time_frame": "AEs and deaths were collected from Day 1 (first dose of primary vaccination) to Day 365 (Stage 1 Sentinel and Main Cohort); from Month 12 (first dose of booster vaccination) to Month 24 (Stage 1 Booster Cohort); from Day 1 (first dose of primary vaccination) to Day 180 (Stage 2).",
"ae_description": "Analysis was performed on SafAS 1 for Stage 1 Sentinel and Main Cohort, SafAS2 for Stage 1 Booster Cohort and SafAS3 for Stage 2.",
"ae_groups": [
{
"id": "EG000",
"title": "Stage 1: Sentinel Cohort: RSV Vaccine Dose A1",
"description": "Participants enrolled in the Sentinel Cohort received 0.5 mL RSV vaccine dose A1 as an IM injection on Day 1 of Stage 1."
},
{
"id": "EG001",
"title": "Stage 1: Sentinel Cohort: RSV Vaccine Dose A2",
"description": "Participants enrolled in the Sentinel Cohort received 0.5 mL RSV vaccine dose A2 as an IM injection on Day 1 of Stage 1."
},
{
"id": "EG002",
"title": "Stage 1: Sentinel Cohort: RSV Vaccine Dose B1",
"description": "Participants enrolled in the Sentinel Cohort received 0.5 mL RSV vaccine dose B1 as an IM injection on Day 1 of Stage 1."
},
{
"id": "EG003",
"title": "Stage 1: Sentinel Cohort: RSV Vaccine Dose B2",
"description": "Participants enrolled in the Sentinel Cohort received 0.5 mL RSV vaccine dose B2 as an IM injection on Day 1 of Stage 1."
},
{
"id": "EG004",
"title": "Stage 1: Sentinel Cohort: RSV Vaccine Dose C1",
"description": "Participants enrolled in the Sentinel Cohort received 0.5 mL RSV vaccine dose C1 as an IM injection on Day 1 of Stage 1."
},
{
"id": "EG005",
"title": "Stage 1: Sentinel Cohort: RSV Vaccine Dose C2",
"description": "Participants enrolled in the Sentinel Cohort received 0.5 mL RSV vaccine dose C2 as an IM injection on Day 1 of Stage 1."
},
{
"id": "EG006",
"title": "Stage 1: Sentinel Cohort: Placebo",
"description": "Participants enrolled in the Sentinel Cohort received 0.5 mL placebo matched to RSV vaccine as an IM injection on Day 1 of Stage 1."
},
{
"id": "EG007",
"title": "Stage 1: Main Cohort: RSV Vaccine Dose A1",
"description": "Participants enrolled in the Main Cohort received 0.5 mL RSV vaccine dose A1 as an IM injection on Day 1 of Stage 1."
},
{
"id": "EG008",
"title": "Stage 1: Main Cohort: RSV Vaccine Dose A2",
"description": "Participants enrolled in the Main Cohort received 0.5 mL RSV vaccine dose A2 as an IM injection on Day 1 of Stage 1."
},
{
"id": "EG009",
"title": "Stage 1: Main Cohort: RSV Vaccine Dose B1",
"description": "Participants enrolled in the Main Cohort received 0.5 mL RSV vaccine dose B1 as an IM injection on Day 1 of Stage 1."
},
{
"id": "EG010",
"title": "Stage 1: Main Cohort: RSV Vaccine Dose B2",
"description": "Participants enrolled in the Main Cohort received 0.5 mL RSV vaccine dose B2 as an IM injection on Day 1 of Stage 1."
},
{
"id": "EG011",
"title": "Stage 1: Main Cohort: RSV Vaccine Dose C1",
"description": "Participants enrolled in the Main Cohort received 0.5 mL RSV vaccine dose C1 as an IM injection on Day 1 of Stage 1."
},
{
"id": "EG012",
"title": "Stage 1: Main Cohort: RSV Vaccine Dose C2",
"description": "Participants enrolled in the Main Cohort received 0.5 mL RSV vaccine dose C2 as an IM injection on Day 1 of Stage 1."
},
{
"id": "EG013",
"title": "Stage 1: Main Cohort: Placebo",
"description": "Participants enrolled in the Main Cohort received 0.5 mL placebo matched to RSV vaccine as an IM injection on Day 1 of Stage 1."
},
{
"id": "EG014",
"title": "Stage 1: Booster Cohort: RSV Vaccine Dose C2 at V01 and V08",
"description": "Participants who received RSV vaccine dose C2 at Day1/V01 as primary injection in the Main Cohort received 0.5 mL RSV vaccine dose C2 as an IM injection (booster injection) at Month 12/V08 of Stage 1 in the Booster Cohort."
},
{
"id": "EG015",
"title": "Stage 1: Booster Cohort: RSV Vaccine Dose C2 at V01 and Placebo at V08",
"description": "Participants who received RSV vaccine dose C2 at Day1/V01 as primary injection in the Main Cohort received 0.5 mL placebo matched to RSV vaccine as an IM injection (booster injection) at Month 12/V08 of Stage 1 in the Booster Cohort."
},
{
"id": "EG016",
"title": "Stage 1: Booster Cohort: Placebo at V01 and RSV Vaccine Dose C2 at V08",
"description": "Participants who received placebo matched to RSV vaccine at Day1/V01 as primary injection in the Main Cohort received 0.5 mL RSV vaccine dose C2 as an IM injection (booster injection) at Month 12/V08 of Stage 1 in the Booster Cohort."
},
{
"id": "EG017",
"title": "Stage 1: Booster Cohort: Placebo at V01 and V08",
"description": "Participants who received placebo matched to RSV vaccine at Day1/V01 as primary injection in the Main Cohort received 0.5 mL placebo matched to RSV vaccine as an IM injection (booster injection) at Month 12/V08 of Stage 1 in the Booster Cohort."
},
{
"id": "EG018",
"title": "Stage 2: RSV Vaccine Dose C2",
"description": "Participants received 0.5 mL RSV vaccine dose C2 as an IM injection on Day 1 of Stage 2."
},
{
"id": "EG019",
"title": "Stage 2: RSV Vaccine Dose D",
"description": "Participants received 0.5 mL RSV vaccine dose D as an IM injection on Day 1 of Stage 2."
},
{
"id": "EG020",
"title": "Stage 2: Placebo",
"description": "Participants received 0.5 mL placebo matched to RSV vaccine as an IM injection on Day 1 of Stage 2."
}
]
},
"coder_1": {
"nct": "NCT05639894",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG004",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG005",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG007",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG008",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG009",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG010",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG011",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG012",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG018",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG019",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG006",
"EG013",
"EG020"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled Stage 1 sentinel and main cohorts (18-50) and Stage 2 (60+) primary-vaccination groups. Booster cohort groups EG014-EG017 left out: later re-randomization of Main Cohort participants already counted. Platform other: an LNP-encapsulated candidate whose nucleic acid or antigen the record doesn't name (probably mRNA)."
},
"coder_2": {
"nct": "NCT05639894",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG009",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG011",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG012",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG018",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG019",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006",
"EG013",
"EG020"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Stage 1 sentinel and main cohorts and Stage 2 pooled, each with its own placebo group. Left out the booster cohort groups (EG014-017), which re-randomize subsets of the main cohort already counted."
}
},
{
"trial": {
"nct": "NCT05842967",
"brief_title": "A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease",
"official_title": "A PHASE 3 PROTOCOL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE",
"conditions": [
"RESPIRATORY SYNCYTIAL VIRUS (RSV)"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"18 Years",
null
],
"arms": [
{
"label": "Substudy A - RSVpreF",
"type": "EXPERIMENTAL",
"description": "Participants will receive a single 120-\u00b5g dose of RSVpreF at Visit 1",
"interventions": [
"Biological: RSVpreF"
]
},
{
"label": "Substudy A - Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Participants will receive placebo at Visit 1",
"interventions": [
"Other: Placebo"
]
},
{
"label": "Substudy B - RSVpreF",
"type": "EXPERIMENTAL",
"description": "Participants will receive 120-\u00b5g doses of RSVpreF at Visit 1 and Visit 2 (open label, single arm only)",
"interventions": [
"Biological: RSVpreF"
]
}
],
"interventions": [
{
"name": "RSVpreF",
"type": "BIOLOGICAL",
"description": "120-\u00b5g",
"other_names": []
},
{
"name": "Placebo",
"type": "OTHER",
"description": "Placebo",
"other_names": []
}
],
"ae_time_frame": "SSA- LR/SE: Within 7Days after Vaccination (Vacc on Day1);AEs: Within 1 Month (M) after Vacc (Vacc on Day1), including any events reported up to 6 months; SAEs: Any events reported up to 6 months; SSB- LR/SE: Within 7 Days after Vacc1 (Day1 of SSB) Within 7 Days after Vacc 2 (second dose on 1M post- [\u2026]",
"ae_description": "Same event may appear as both SAE and non-SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study. Safety po [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "SSA: RSVpreF",
"description": "Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly on Day 1 of SSA."
},
{
"id": "EG001",
"title": "SSA: Placebo",
"description": "Participants aged \\>=18 to \\<60 years received placebo (lyophile matched to RSVpreF) intramuscularly on Day 1 of SSA."
},
{
"id": "EG002",
"title": "SSB: RSVpreF, >= 18 to < 60 Years",
"description": "Participants aged \\>=18 to \\<60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."
},
{
"id": "EG003",
"title": "SSB: RSVpreF, >= 60 Years",
"description": "Participants aged \\>=60 years received RSVpreF 120 mcg intramuscularly first dose on Day 1 of SSB (Vaccination 1) and second dose on 1-month post-vaccination 1 (Vaccination 2)."
}
]
},
"coder_1": {
"nct": "NCT05842967",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Substudy A (18-59, high risk) RSVpreF vs placebo (lyophile matched to RSVpreF, composition not given). Substudy B groups (EG002, EG003) left out: open-label single arm. RSVpreF (Abrysvo) is unadjuvanted."
},
"coder_2": {
"nct": "NCT05842967",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Substudy A only. Left out Substudy B (open-label, no placebo). Placebo is lyophile matched to RSVpreF, i.e. its excipients."
}
},
{
"trial": {
"nct": "NCT05886777",
"brief_title": "A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).",
"official_title": "A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATE(S) AGAINST INFECTIOUS RESPIRATORY ILLNESSES, INCLUDING COVID-19 AND RSV, IN HEALTHY INDIVIDUALS",
"conditions": [
"Healthy Participants"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "TRIPLE",
"ages": [
"65 Years",
null
],
"arms": [
{
"label": "Group 1",
"type": "EXPERIMENTAL",
"description": "Combination \\[RSVpreF+BNT162b2\\] + Quadrivalent influenza vaccine (QIV)",
"interventions": [
"Biological: Combination [RSVpreF+BNTb162b2]",
"Biological: QIV"
]
},
{
"label": "Group 2",
"type": "EXPERIMENTAL",
"description": "Combination \\[RSVpreF+BNT162b2\\] + placebo",
"interventions": [
"Biological: Combination [RSVpreF+BNTb162b2]",
"Biological: Normal Saline Placebo"
]
},
{
"label": "Group 3",
"type": "ACTIVE_COMPARATOR",
"description": "BNT162b2 + placebo",
"interventions": [
"Biological: Bivalent BNT162b2 (original/Omi BA.4/BA.5)",
"Biological: Normal Saline Placebo"
]
},
{
"label": "Group 4",
"type": "ACTIVE_COMPARATOR",
"description": "RSVpreF + placebo",
"interventions": [
"Biological: RSVpreF",
"Biological: Normal Saline Placebo"
]
},
{
"label": "Group 5",
"type": "ACTIVE_COMPARATOR",
"description": "QIV + placebo",
"interventions": [
"Biological: QIV",
"Biological: Normal Saline Placebo"
]
},
{
"label": "Group 6",
"type": "EXPERIMENTAL",
"description": "Coadministration RSVpreF + bivalent BNT162b2 + placebo",
"interventions": [
"Biological: Bivalent BNT162b2 (original/Omi BA.4/BA.5)",
"Biological: RSVpreF",
"Biological: Normal Saline Placebo"
]
},
{
"label": "Group 7",
"type": "EXPERIMENTAL",
"description": "Coadministration RSVpreF + bivalent BNT162b2 + QIV",
"interventions": [
"Biological: Bivalent BNT162b2 (original/Omi BA.4/BA.5)",
"Biological: RSVpreF",
"Biological: QIV"
]
}
],
"interventions": [
{
"name": "Combination [RSVpreF+BNTb162b2]",
"type": "BIOLOGICAL",
"description": "Combination of RSVpreF and Bivalent BNT162b2 given as a single intramuscular injection",
"other_names": []
},
{
"name": "Bivalent BNT162b2 (original/Omi BA.4/BA.5)",
"type": "BIOLOGICAL",
"description": "Bivalent BNT162b2 given as an intramuscular injection",
"other_names": []
},
{
"name": "RSVpreF",
"type": "BIOLOGICAL",
"description": "RSVpreF given as an intramuscular injection",
"other_names": []
},
{
"name": "QIV",
"type": "BIOLOGICAL",
"description": "Licensed QIV given as an intramuscular injection",
"other_names": []
},
{
"name": "Normal Saline Placebo",
"type": "BIOLOGICAL",
"description": "Normal saline (0.9% sodium chloride solution for injection)",
"other_names": []
}
],
"ae_time_frame": "Local reactions and systemic events: From Day 1 to Day 7 after Vaccination 1; Non serious AEs: up to 1 month after Vaccination 1, SAEs: up to 6 months after Vaccination 1",
"ae_description": "Same event may appear as both an AE and an SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study. Safety p [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "Group 1: [RSVpreF + BNT162b2] + QIV",
"description": "Participants were randomized to receive combination of RSVpreF and Bivalent BNT162b2 as a single intramuscular injection along with concomitant QIV as intramuscular injection on Day 1."
},
{
"id": "EG001",
"title": "Group 2: [RSVpreF+BNT162b2] + Placebo",
"description": "Participants were randomized to receive combination of RSVpreF and Bivalent BNT162b2 as a single intramuscular injection along with placebo as intramuscular injection on Day 1."
},
{
"id": "EG002",
"title": "Group 3: BNT162b2 + Placebo",
"description": "Participants were randomized to receive BNT162b2 as a single intramuscular injection along with placebo as intramuscular injection on Day 1."
},
{
"id": "EG003",
"title": "Group 4: RSVpreF + Placebo",
"description": "Participants were randomized to receive RSVpreF as a single intramuscular injection along with placebo as intramuscular injection on Day 1."
},
{
"id": "EG004",
"title": "Group 5: QIV + Placebo",
"description": "Participants were randomized to receive QIV as a single intramuscular injection along with placebo as intramuscular injection on Day 1."
},
{
"id": "EG005",
"title": "Group 6: RSVpreF + BNT162b2 + Placebo",
"description": "Participants were randomized to receive RSVpreF + BNT162b2 + Placebo as a single intramuscular injection on Day 1."
},
{
"id": "EG006",
"title": "Group 7: RSVpreF + BNT162b2 + QIV",
"description": "Participants were randomized to receive RSVpreF + BNT162b2 + QIV as a single intramuscular injection on Day 1."
}
]
},
"coder_1": {
"nct": "NCT05886777",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "licensed quadrivalent influenza vaccine"
},
{
"vaccine_groups": [
{
"id": "EG006",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "RSVpreF and bivalent BNT162b2 coadministered"
}
],
"targets": [
"rsv",
"covid19",
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "1: combination RSVpreF+BNT162b2 with QIV (G1) vs QIV+saline (G5). 2: RSVpreF+BNT162b2+QIV (G7) vs RSVpreF+BNT162b2+saline (G6), a QIV comparison; QIV type not named, so platform other and adjuvant unknown. G1 could instead pair with G2 as a QIV comparison. Left out G2, G3, G4 (no matching placebo group)."
},
"coder_2": {
"nct": "NCT05886777",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "RSVpreF+BNT162b2 combination injection in both"
},
{
"vaccine_groups": [
{
"id": "EG006",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "RSVpreF and BNT162b2 coadministered in both"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "QIV vs placebo, two backgrounds. Licensed QIV not named, adjuvant unknown. Left out groups 3, 4, 5 (single vaccine plus placebo) since pairing them differs by other vaccines."
}
},
{
"trial": {
"nct": "NCT06134804",
"brief_title": "A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older",
"official_title": "A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older",
"conditions": [
"Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "DOUBLE",
"ages": [
"65 Years",
null
],
"arms": [
{
"label": "Group 1: Coadministration (CoAd) Group",
"type": "EXPERIMENTAL",
"description": "Participants will receive intramuscular (IM) injection of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) along with high-dose (HD) quadrivalent influenza vaccine, concomitantly, on Day 1 and placebo on Day 30.",
"interventions": [
"Biological: ExPEC9V",
"Biological: Placebo",
"Biological: HD quadrivalent influenza vaccine"
]
},
{
"label": "Group 2: Control Group",
"type": "EXPERIMENTAL",
"description": "Participants will receive IM injection of matching placebo along with HD quadrivalent influenza vaccine, concomitantly, on Day 1 and ExPEC9V on Day 30.",
"interventions": [
"Biological: ExPEC9V",
"Biological: Placebo",
"Biological: HD quadrivalent influenza vaccine"
]
}
],
"interventions": [
{
"name": "ExPEC9V",
"type": "BIOLOGICAL",
"description": "ExPEC9V will be administered as an IM injection.",
"other_names": [
"VAC52416; JNJ-78901563"
]
},
{
"name": "Placebo",
"type": "BIOLOGICAL",
"description": "Placebo will be administered as an IM injection.",
"other_names": []
},
{
"name": "HD quadrivalent influenza vaccine",
"type": "BIOLOGICAL",
"description": "HD quadrivalent influenza vaccine will be administered as IM injection.",
"other_names": []
}
],
"ae_time_frame": "All-Cause Mortality: CoAd/control group post dose-1:Day 1 to Day 30, CoAd/control group post dose-2:Day 30 to Day 210; SAEs: CoAd/control group post dose-1: Day 1 to Day 30, CoAd/control group post dose-2:Day 30 to Day 210; Unsolicited AEs (other AEs): Up to 29 days post-dose 1 (Day 1 to Day 30), Up [\u2026]",
"ae_description": "Full analysis set included all participants who received at least one study vaccination, regardless of the occurrence of protocol deviations and vaccine type (HD quadrivalent seasonal influenza vaccine, ExPEC9V, or placebo).",
"ae_groups": [
{
"id": "EG000",
"title": "CoAd: Post-dose 1",
"description": "Participants received a single blinded intramuscular injection of 176 micrograms (mcg) polysaccharide per milliliter (PS/mL) ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1."
},
{
"id": "EG001",
"title": "CoAd: Post-dose 2",
"description": "Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine on Day 30."
},
{
"id": "EG002",
"title": "Control: Post-dose 1",
"description": "Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1."
},
{
"id": "EG003",
"title": "Control: Post-dose 2",
"description": "Participants received a single blinded intramuscular injection of 176 mcg PS/mL ExPEC9V vaccine on Day 30."
}
]
},
"coder_1": {
"nct": "NCT06134804",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "high-dose quadrivalent influenza vaccine"
}
],
"targets": [
"e_coli"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Planned crossover: took the post-dose 1 groups (ExPEC9V+HD-QIV vs placebo+HD-QIV). Post-dose 2 groups left out. ExPEC9V is an O-antigen conjugate; adjuvant not stated."
},
"coder_2": {
"nct": "NCT06134804",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "high-dose quadrivalent influenza vaccine on Day 1"
}
],
"targets": [
"e_coli"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Post-dose 1 groups only (Day 1 to 30); the placebo group received ExPEC9V on Day 30, so post-dose 2 groups are left out. ExPEC9V is a polysaccharide-protein bioconjugate."
}
},
{
"trial": {
"nct": "NCT06237049",
"brief_title": "A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults",
"official_title": "A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA COVID-19 Vaccine and a Recombinant Influenza Vaccine Administered as a Single Injection in Healthy Adults 50 Years of Age or Older",
"conditions": [
"Influenza, Human",
"SARS-CoV-2 Infection",
"COVID-19"
],
"phases": [
"PHASE2"
],
"model": "PARALLEL",
"masking": "SINGLE",
"ages": [
"50 Years",
null
],
"arms": [
{
"label": "BNT162b2 (Omi XBB.1.5)/RIV and placebo",
"type": "EXPERIMENTAL",
"description": "Participants will receive a single injection combination of BNT162b2 (Omi XBB.1.5) and RIV and normal saline placebo",
"interventions": [
"Biological: BNT162b2 (Omi XBB.1.5)/RIV",
"Other: Normal saline placebo"
]
},
{
"label": "BNT162b2 (Omi XBB.1.5) and RIV",
"type": "EXPERIMENTAL",
"description": "Participants will receive BNT162b2 (Omi XBB.1.5) and RIV",
"interventions": [
"Biological: BNT162b2 (Omi XBB.1.5)",
"Biological: RIV"
]
},
{
"label": "BNT162b2 (Omi XBB.1.5) and placebo",
"type": "ACTIVE_COMPARATOR",
"description": "Participants will receive BNT162b2 (Omi XBB.1.5) and normal saline placebo",
"interventions": [
"Biological: BNT162b2 (Omi XBB.1.5)",
"Other: Normal saline placebo"
]
},
{
"label": "RIV and placebo",
"type": "ACTIVE_COMPARATOR",
"description": "Participants will receive RIV and normal saline placebo",
"interventions": [
"Biological: RIV",
"Other: Normal saline placebo"
]
}
],
"interventions": [
{
"name": "BNT162b2 (Omi XBB.1.5)/RIV",
"type": "BIOLOGICAL",
"description": "Combination of BNT162b2 (Omi XBB.1.5) and RIV",
"other_names": []
},
{
"name": "BNT162b2 (Omi XBB.1.5)",
"type": "BIOLOGICAL",
"description": "Licensed COVID-19 vaccine",
"other_names": []
},
{
"name": "RIV",
"type": "BIOLOGICAL",
"description": "Licensed recombinant influenza vaccine",
"other_names": []
},
{
"name": "Normal saline placebo",
"type": "OTHER",
"description": "Normal saline (solution for injection)",
"other_names": []
}
],
"ae_time_frame": "AEs by systematic assessment: Day 1 up to 7 Days following Vaccination; AEs by Non-systematic assessment: a) Serious AEs- Day 1 of Vaccination up to 6 months of follow-up after Vaccination, b) Other AEs- Day 1 of Vaccination up to 4 weeks of follow-up after Vaccination; All-cause mortality: Day 1 of [\u2026]",
"ae_description": "Same event may appear as both an AE and an SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study. Safety p [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo",
"description": "Participants were randomized to receive BNT162b2 (Omi XBB.1.5)//RIV together as a single IM injection in the left deltoid and normal saline placebo IM injection in the right deltoid on Day 1."
},
{
"id": "EG001",
"title": "Group 2: BNT162b2 (Omi XBB.1.5) + RIV",
"description": "Participants were randomized to receive BNT162b2 (Omi XBB.1.5) IM injection in the left deltoid and RIV IM injection in the right deltoid on Day 1."
},
{
"id": "EG002",
"title": "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo",
"description": "Participants were randomized to receive BNT162b2 (Omi XBB.1.5) IM injection in the left deltoid and normal saline placebo IM injection in the right deltoid on Day 1."
},
{
"id": "EG003",
"title": "Group 4: RIV + Placebo",
"description": "Participants were randomized to receive RIV IM injection in the left deltoid and normal saline placebo IM injection in the right deltoid on Day 1."
}
]
},
"coder_1": {
"nct": "NCT06237049",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "licensed recombinant influenza vaccine (RIV)"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BNT162b2+RIV (G2) vs RIV+saline (G4). G2 could instead pair with G3 (BNT162b2+saline) as an RIV comparison. Left out G1 (combination+saline: no group with saline in place of the combination) and G3."
},
"coder_2": {
"nct": "NCT06237049",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna",
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "BNT162b2 (Omi XBB.1.5) in both"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RIV (recombinant influenza vaccine) given with BNT162b2 vs placebo with BNT162b2. EG001 could also be paired with EG003 for the COVID vaccine but is used once. Left out the combination group EG000 and EG003."
}
},
{
"trial": {
"nct": "NCT06325657",
"brief_title": "A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants",
"official_title": "A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN PREGNANT PARTICIPANTS LIVING WITH HIV AND THEIR INFANTS",
"conditions": [
"Respiratory Syncytial Virus"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"0 Years",
"49 Years"
],
"arms": [
{
"label": "RSVpreF vaccine",
"type": "EXPERIMENTAL",
"description": "RSV vaccine (RSVpreF)",
"interventions": [
"Biological: RSVpreF vaccine"
]
},
{
"label": "Placebo",
"type": "PLACEBO_COMPARATOR",
"description": "Placebo",
"interventions": [
"Biological: Placebp"
]
}
],
"interventions": [
{
"name": "RSVpreF vaccine",
"type": "BIOLOGICAL",
"description": "RSVpreF vaccine",
"other_names": []
},
{
"name": "Placebp",
"type": "BIOLOGICAL",
"description": "Placebo",
"other_names": []
}
],
"ae_time_frame": "Maternal participants: Local reactions and systemic events: From Day 1 to Day 7 after vaccination; SAEs and AESIs: From vaccination on Day 1 up to 6 months after delivery (maximum up to 10 months); Other AEs: From vaccination on Day 1 up to 1 month after vaccination; Infant participants: SAEs, AESIs [\u2026]",
"ae_description": "Local reactions and systemic events were assessed by systematic assessment; AEs by non-systematic assessment. Same event may appear as both an SAE and non-SAE. But what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a par [\u2026]",
"ae_groups": [
{
"id": "EG000",
"title": "Maternal Participants: RSVpreF",
"description": "Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive a single dose of 120 mcg RSVpreF, IM on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."
},
{
"id": "EG001",
"title": "Maternal Participants: Placebo",
"description": "Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive placebo (matching to RSVpreF without active vaccine) IM as a single dose on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."
},
{
"id": "EG002",
"title": "Infant Participants: RSVpreF",
"description": "Infant participants born to maternal participants living with HIV who were vaccinated with a single dose of 120 mcg RSVpreF were included. Infant participants were followed from birth up to 6 months of age."
},
{
"id": "EG003",
"title": "Infant Participants: Placebo",
"description": "Infant participants born to maternal participants living with HIV who received placebo (matching RSVpreF without active vaccine) were included. Infant participants were followed from birth up to 6 months of age."
}
]
},
"coder_1": {
"nct": "NCT06325657",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": true,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": true,
"patients": true,
"note": "Pregnant women living with HIV, and their infants as the offspring comparison. RSVpreF (Abrysvo) unadjuvanted; placebo is matched with no composition given."
},
"coder_2": {
"nct": "NCT06325657",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": true,
"patients": true,
"note": "Maternal groups and infant groups (maternal vaccine). Placebo matches RSVpreF without active vaccine."
}
},
{
"trial": {
"nct": "NCT06614725",
"brief_title": "A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)",
"official_title": "A Phase 3, Randomized, Placebo-controlled, Observer-blind Study in India to Evaluate Immune Response, Reactogenicity and Safety of a Single Intramuscular Dose of RSVPreF3 OA Investigational Vaccine When Administered to Older Adults >=60 Years of Age and Adults 50-59 Years of Age at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease",
"conditions": [
"Respiratory Syncytial Virus Infections"
],
"phases": [
"PHASE3"
],
"model": "PARALLEL",
"masking": "QUADRUPLE",
"ages": [
"50 Years",
null
],
"arms": [
{
"label": "OA-RSV group",
"type": "EXPERIMENTAL",
"description": "Older adult (OA) participants, greater than or equal to (\u2265) 60 years of age (YOA), received a single dose of RSVPreF3 OA investigational vaccine at Day 1.",
"interventions": [
"Biological: RSVPreF3 OA investigational vaccine"
]
},
{
"label": "OA-Placebo group",
"type": "PLACEBO_COMPARATOR",
"description": "OA participants, \u2265 60 YOA, received a single dose of placebo at Day 1.",
"interventions": [
"Combination Product: Placebo"
]
},
{
"label": "Adults-AIR-RSV group",
"type": "EXPERIMENTAL",
"description": "Adult participants, 50-59 YOA, at increased risk (AIR) of Respiratory Syncytial Virus - Lower Respiratory Tract Disease (RSV-LRTD), received a single dose of RSVPreF3 OA investigational vaccine at Day 1.",
"interventions": [
"Biological: RSVPreF3 OA investigational vaccine"
]
},
{
"label": "Adults-AIR-Placebo group",
"type": "PLACEBO_COMPARATOR",
"description": "Adult participants, 50-59 YOA, at increased risk (AIR) of RSV-LRTD, received a single dose of placebo at Day 1.",
"interventions": [
"Combination Product: Placebo"
]
}
],
"interventions": [
{
"name": "RSVPreF3 OA investigational vaccine",
"type": "BIOLOGICAL",
"description": "1 dose of RSVPreF3 OA investigational vaccine administered intramuscularly on Day 1 to participants in OA-RSV and Adults-AIR-RSV groups.",
"other_names": []
},
{
"name": "Placebo",
"type": "COMBINATION_PRODUCT",
"description": "1 dose of placebo (saline solution) administered intramuscularly on Day 1 to participants in OA-Placebo and Adults-AIR-Placebo groups.",
"other_names": []
}
],
"ae_time_frame": "Solicited AEs were collected from Day 1 (day of administration) up to Day 4 post-dose. Unsolicited AEs were collected from Day 1 up to Day 30 post-dose. All-cause mortality, SAEs, and pIMDs were collected throughout the study (from Day 1 to Month 6).",
"ae_description": "",
"ae_groups": [
{
"id": "EG000",
"title": "OA-RSV Group",
"description": "Older adult (OA) participants, greater than or equal to (\u2265) 60 years of age (YOA), received a single dose of RSVPreF3 OA investigational vaccine at Day 1."
},
{
"id": "EG001",
"title": "OA-Placebo Group",
"description": "OA participants, \u2265 60 YOA, received a single dose of placebo at Day 1."
},
{
"id": "EG002",
"title": "Adults-AIR-RSV Group",
"description": "Adult participants, 50-59 YOA, at increased risk (AIR) of Respiratory Syncytial Virus - Lower Respiratory Tract Disease (RSV-LRTD), received a single dose of RSVPreF3 OA investigational vaccine at Day 1."
},
{
"id": "EG003",
"title": "Adults-AIR-Placebo Group",
"description": "Adult participants, 50-59 YOA, at increased risk (AIR) of RSV-LRTD, received a single dose of placebo at Day 1."
}
]
},
"coder_1": {
"nct": "NCT06614725",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Pooled the two age cohorts (>=60 years, and 50-59 at increased risk of RSV-LRTD) into one comparison; placebo is saline. patients true because the 50-59 cohort was enrolled for conditions raising RSV risk; the >=60 cohort is general population. RSVPreF3 OA is adjuvanted with AS01E."
},
"coder_2": {
"nct": "NCT06614725",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled older adults and adults 50-59 at increased risk (AS01-adjuvanted RSVPreF3); patients set false because the at-risk adults are a minority and not clearly enrolled for a condition."
}
}
]